The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
of O
augmenting O
trabeculectomy O
with O
subconjunctival O
mitomycin O
C O
( O
TMMC O
) O
versus O
5-fluorouracil O
( O
T5-FU O
) O
in O
lowering O
intraocular O
pressure O
( O
IOP O
) O
. O

Forty O
eyes O
from O
40 O
patients O
referred O
to O
the O
Nikoukari O
Ophthalmology O
University O
Hospital O
, O
Tabriz O
University O
of O
Medical O
Sciences O
, O
Tabriz O
, O
Iran O
, O
were O
enrolled O
in O
a O
randomized O
clinical O
trial O
. O

Patients O
with O
high-risk O
open O
angle O
glaucoma O
were O
allocated O
to O
receive O
either O
subconjunctival O
TMMC O
or O
T5-FU O
. O

Mean O
overall O
preoperative O
IOP O
was O
30.8 O
mmHg O
. O

Mean B-Premise
preoperative I-Premise
IOPs I-Premise
in I-Premise
the I-Premise
TMMC I-Premise
and I-Premise
T5-FU I-Premise
groups I-Premise
were I-Premise
31.2 I-Premise
± I-Premise
9.8 I-Premise
and I-Premise
30.6 I-Premise
± I-Premise
9.9 I-Premise
mmHg I-Premise
, I-Premise
respectively I-Premise
. I-Premise
Postoperatively I-Premise
, I-Premise
mean I-Premise
IOPs I-Premise
were I-Premise
11.4 I-Premise
± I-Premise
4.9 I-Premise
and I-Premise
13.6 I-Premise
± I-Premise
3.9 I-Premise
mmHg I-Premise
, I-Premise
respectively I-Premise
for I-Premise
TMMC I-Premise
and I-Premise
T5-FU I-Premise
groups I-Premise
after I-Premise
6 I-Premise
months I-Premise
. I-Premise

In O
spite O
of O
some O
existing O
descriptive O
differences O
in O
IOP O
between O
the O
groups O
, O
statistical B-Premise
tests I-Premise
showed I-Premise
no I-Premise
difference I-Premise
in I-Premise
mean I-Premise
and I-Premise
median I-Premise
IOP I-Premise
. I-Premise

Three B-Premise
cases I-Premise
of I-Premise
hypotonia I-Premise
( I-Premise
IOP I-Premise
< I-Premise
6 I-Premise
mmHg I-Premise
) I-Premise
and I-Premise
1 I-Premise
case I-Premise
of I-Premise
epithelial I-Premise
keratitis I-Premise
were I-Premise
detected I-Premise
. I-Premise

TMMC B-Claim
and I-Claim
T5-FU I-Claim
appeared I-Claim
to I-Claim
have I-Claim
similar I-Claim
efficacy I-Claim
in I-Claim
lowering I-Claim
IOP I-Claim
. I-Claim

The O
purpose O
of O
this O
study O
was O
to O
establish O
the O
efficacy O
and O
safety O
of O
the O
Ex-PRESS O
( O
Optonol O
Ltd. O
, O
Neve O
Ilan O
, O
Israel O
) O
mini O
glaucoma O
shunt O
in O
open-angle O
glaucoma O
. O

This O
was O
a O
prospective O
, O
randomized O
trial O
. O

Eyes O
from O
enrolled O
patients O
were O
randomly O
assigned O
to O
either O
Ex-PRESS O
implantation O
under O
a O
scleral O
flap O
, O
or O
trabeculectomy O
. O

The O
main O
outcome O
measures O
were O
: O
mean O
intraocular O
pressure O
( O
IOP O
) O
, O
postoperative O
medication O
use O
, O
visual O
acuity O
, O
and O
incidence O
of O
complications O
. O

Complete O
success O
was O
defined O
as O
an O
IOP O
of O
> O
4 O
mmHg O
and O
< O
or=18 O
mmHg O
without O
the O
use O
of O
antiglaucoma O
medications O
. O

A O
more O
stringent O
target O
of O
IOP O
> O
4 O
mmHg O
and O
< O
or=15 O
mmHg O
was O
also O
noted O
. O

There O
were O
78 O
patients O
( O
80 O
eyes O
) O
with O
primary O
open-angle O
, O
pseudoexfoliative O
, O
or O
pigmentary O
glaucoma O
enrolled O
in O
the O
study O
. O

A O
total O
of O
84.6 O
% O
of O
patients O
receiving O
Ex-PRESS O
and O
60.0 O
% O
of O
patients O
receiving O
trabeculectomy O
( O
P=0.0230 O
) O
achieved O
complete O
success O
. O

The O
respective O
proportions O
of O
patients O
achieving O
an O
IOP O
> O
4 O
mmHg O
and O
< O
or=15 O
mmHg O
were O
76.9 O
% O
and O
50.0 O
% O
( O
P=0.0193 O
) O
. O

At B-Premise
1-year I-Premise
follow-up I-Premise
, I-Premise
complete I-Premise
success I-Premise
rates I-Premise
were I-Premise
81.8 I-Premise
% I-Premise
for I-Premise
Ex-PRESS I-Premise
and I-Premise
47.5 I-Premise
% I-Premise
for I-Premise
trabeculectomy I-Premise
( I-Premise
P=0.0020 I-Premise
) I-Premise
, I-Premise
and I-Premise
71.7 I-Premise
% I-Premise
and I-Premise
37.5 I-Premise
% I-Premise
( I-Premise
P=0.0070 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
the I-Premise
more I-Premise
stringent I-Premise
target I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
similar I-Premise
level I-Premise
of I-Premise
postoperative I-Premise
interventions I-Premise
and I-Premise
complications I-Premise
for I-Premise
each I-Premise
group I-Premise
. I-Premise

In B-Claim
open-angle I-Claim
glaucoma I-Claim
, I-Claim
the I-Claim
Ex-PRESS I-Claim
mini I-Claim
glaucoma I-Claim
shunt I-Claim
implanted I-Claim
under I-Claim
a I-Claim
superficial I-Claim
scleral I-Claim
flap I-Claim
produces I-Claim
significantly I-Claim
higher I-Claim
success I-Claim
rates I-Claim
, I-Claim
and I-Claim
a I-Claim
similar I-Claim
complication I-Claim
rate I-Claim
, I-Claim
compared I-Claim
with I-Claim
trabeculectomy I-Claim
. I-Claim

The B-Claim
Ex-PRESS I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
device I-Claim
for I-Claim
treating I-Claim
open-angle I-Claim
glaucoma I-Claim
. I-Claim

To O
compare O
the O
effects O
on O
intraocular O
pressure O
( O
IOP O
) O
and O
side O
effects O
of O
monotherapy O
with O
either O
latanoprost O
or O
dorzolamide O
in O
patients O
with O
glaucoma O
or O
ocular O
hypertension O
. O

224 O
patients O
with O
open O
angle O
glaucoma O
or O
ocular O
hypertension O
were O
recruited O
to O
a O
3 O
month O
open O
labelled O
study O
. O

Previous O
glaucoma O
medications O
were O
washed O
out O
and O
the O
patients O
were O
randomised O
to O
receive O
either O
latanoprost O
0.005 O
% O
once O
daily O
or O
dorzolamide O
2 O
% O
three O
times O
daily O
. O

Of O
224 O
patients O
213 O
were O
included O
in O
the O
analysis O
of O
efficacy O
. O

After B-Premise
3 I-Premise
months I-Premise
, I-Premise
latanoprost I-Premise
reduced I-Premise
mean I-Premise
baseline I-Premise
diurnal I-Premise
IOP I-Premise
from I-Premise
27.2 I-Premise
( I-Premise
SD I-Premise
3.0 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
by I-Premise
8.5 I-Premise
( I-Premise
3.3 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
. I-Premise

The B-Premise
corresponding I-Premise
figures I-Premise
for I-Premise
dorzolamide I-Premise
were I-Premise
27.2 I-Premise
( I-Premise
3.4 I-Premise
) I-Premise
and I-Premise
5.6 I-Premise
( I-Premise
2.6 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
. I-Premise

The B-Premise
difference I-Premise
of I-Premise
2.9 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
2.3-3.6 I-Premise
) I-Premise
was I-Premise
highly I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
, I-Premise
ANCOVA I-Premise
) I-Premise
. I-Premise

Latanoprost B-Premise
reduced I-Premise
IOP I-Premise
at I-Premise
peak I-Premise
by I-Premise
8.6 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
32 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
6.2 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
23 I-Premise
% I-Premise
) I-Premise
for I-Premise
dorzolamide I-Premise
, I-Premise
and I-Premise
the I-Premise
difference I-Premise
of I-Premise
2.4 I-Premise
mm I-Premise
Hg I-Premise
was I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
, I-Premise
ANCOVA I-Premise
) I-Premise
. I-Premise

The B-Premise
corresponding I-Premise
figures I-Premise
at I-Premise
trough I-Premise
were I-Premise
8.1 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
31 I-Premise
% I-Premise
) I-Premise
for I-Premise
latanoprost I-Premise
and I-Premise
4.7 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
17 I-Premise
% I-Premise
) I-Premise
for I-Premise
dorzolamide I-Premise
, I-Premise
a I-Premise
significant I-Premise
difference I-Premise
of I-Premise
3.4 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
, I-Premise
ANCOVA I-Premise
) I-Premise
. I-Premise

Both B-Claim
drugs I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
systemically I-Claim
and I-Claim
locally I-Claim
. I-Claim

Latanoprost B-Claim
was I-Claim
superior I-Claim
to I-Claim
dorzolamide I-Claim
in I-Claim
reducing I-Claim
the I-Claim
IOP I-Claim
, I-Claim
judged I-Claim
both I-Claim
from I-Claim
the I-Claim
effect I-Claim
on I-Claim
IOP I-Claim
at I-Claim
peak I-Claim
and I-Claim
trough I-Claim
and I-Claim
by I-Claim
the I-Claim
effect I-Claim
on I-Claim
diurnal I-Claim
IOP I-Claim
. I-Claim

Approximately O
40 O
% O
of O
patients O
with O
glaucoma O
are O
concomitantly O
prescribed O
> O
or=2 O
different O
intraocular O
pressure O
( O
IOP O
) O
-lowering O
medications O
. O

An O
effective O
and O
well-tolerated O
fixed O
combination O
of O
agents O
requiring O
once-daily O
instillation O
may O
improve O
patient O
compliance O
. O

The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
and O
safety O
profile O
of O
the O
fixed O
combination O
latanoprost O
0.005 O
% O
+ O
timolol O
maleate O
0.5 O
% O
QD O
with O
those O
of O
latanoprost O
0.005 O
% O
monotherapy O
QD O
in O
patients O
whose O
elevated O
IOP O
( O
> O
or=21 O
mm O
Hg O
) O
was O
inadequately O
controlled O
by O
latanoprost O
. O

This O
21-day O
, O
randomized O
, O
double-masked O
, O
active-control O
study O
was O
conducted O
at O
49 O
study O
sites O
in O
Argentina O
, O
Brazil O
, O
Colombia O
, O
Mexico O
, O
Peru O
, O
the O
United O
States O
, O
and O
Venezuela O
. O

Adults O
with O
glaucoma O
or O
ocular O
hypertension O
who O
had O
failed O
to O
reach O
an O
IOP O
of O
< O
21 O
mm O
Hg O
while O
receiving O
latanoprost O
for O
at O
least O
28 O
days O
were O
enrolled O
. O

After O
an O
additional O
28 O
days O
of O
latanoprost O
run-in O
, O
patients O
were O
randomly O
assigned O
to O
continue O
latanoprost O
monotherapy O
or O
to O
switch O
to O
the O
fixed O
combination O
for O
21 O
days O
. O

The O
intent-to-treat O
( O
ITT O
) O
population O
included O
all O
patients O
who O
received O
at O
least O
1 O
dose O
of O
double-masked O
study O
medication O
";" O
the O
per-protocol O
( O
PP O
) O
analysis O
included O
patients O
who O
completed O
the O
study O
without O
a O
major O
protocol O
violation O
and O
who O
had O
IOP O
measurements O
both O
at O
baseline O
and O
at O
day O
21 O
. O

The O
primary O
end O
point O
was O
the O
proportion O
of O
patients O
whose O
IOP O
was O
decreased O
> O
or=2 O
mm O
Hg O
from O
the O
baseline O
level O
on O
day O
21 O
. O

Proportions O
of O
patients O
demonstrating O
IOP O
decreases O
> O
or=3 O
, O
> O
or=4 O
, O
or O
> O
or=5 O
mm O
Hg O
from O
the O
baseline O
level O
and O
of O
patients O
reaching O
an O
10P O
< O
or=18 O
mm O
Hg O
were O
evaluated O
. O

Adverse O
events O
( O
AEs O
) O
were O
also O
assessed O
. O

A O
total O
of O
350 O
patients O
were O
enrolled O
. O

In O
all O
, O
348 O
patients O
were O
included O
in O
the O
ITT O
and O
tolerability O
analyses O
( O
fixed O
combination O
, O
n O
= O
175 O
";" O
latanoprost O
, O
n O
= O
173 O
";" O
mean O
[ O
SD O
] O
age O
, O
64.4 O
[ O
13.2 O
] O
and O
63.2 O
[ O
14.0 O
] O
years O
, O
respectively O
";" O
103 O
women O
in O
each O
group O
) O
. O

Baseline O
demographic O
and O
clinical O
characteristics O
were O
similar O
between O
groups O
. O

A B-Premise
higher I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
the I-Premise
fixed I-Premise
combination I-Premise
had I-Premise
IOP I-Premise
decreases I-Premise
of I-Premise
2 I-Premise
mm I-Premise
Hg I-Premise
on I-Premise
day I-Premise
21 I-Premise
relative I-Premise
to I-Premise
baseline I-Premise
compared I-Premise
with I-Premise
latanoprost-treated I-Premise
patients I-Premise
( I-Premise
79.4 I-Premise
% I-Premise
vs I-Premise
51.4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

PP B-Premise
analyses I-Premise
found I-Premise
that I-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
fixed-combination I-Premise
group I-Premise
had I-Premise
IOP I-Premise
decreases I-Premise
> I-Premise
or=3 I-Premise
, I-Premise
> I-Premise
or=4 I-Premise
, I-Premise
or I-Premise
> I-Premise
or=5 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
for I-Premise
each I-Premise
target I-Premise
level I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
vs I-Premise
latanoprost I-Premise
group I-Premise
) I-Premise
or I-Premise
final I-Premise
IOP I-Premise
18 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
fixed I-Premise
-combination I-Premise
, I-Premise
35.1 I-Premise
% I-Premise
";" I-Premise
latanoprost I-Premise
, I-Premise
17.8 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Both B-Claim
treatments I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Similar B-Premise
proportions I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
fixed-combination I-Premise
and I-Premise
latanoprost I-Premise
groups I-Premise
reported I-Premise
at I-Premise
least I-Premise
1 I-Premise
treatment-emergent I-Premise
AE I-Premise
( I-Premise
10.9 I-Premise
% I-Premise
and I-Premise
12.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

In O
this O
selected O
population O
of O
patients B-Claim
with I-Claim
an I-Claim
inadequate I-Claim
initial I-Claim
IOP I-Claim
response I-Claim
to I-Claim
latanoprost I-Claim
, I-Claim
switching I-Claim
to I-Claim
fixed-combination I-Claim
latanoprosttimolol I-Claim
resulted I-Claim
in I-Claim
a I-Claim
greater I-Claim
decrease I-Claim
in I-Claim
IOP I-Claim
and I-Claim
similar I-Claim
tolerability I-Claim
compared I-Claim
with I-Claim
continuing I-Claim
latanoprost I-Claim
therapy I-Claim
. I-Claim

To O
verify O
the O
safety O
and O
efficacy O
of O
Ologen O
( O
OLO O
) O
implant O
as O
adjuvant O
compared O
with O
low-dosage O
mitomycin-C O
( O
MMC O
) O
in O
trabeculectomy O
. O

This O
was O
a O
prospective O
randomized O
clinical O
trial O
with O
a O
24-month O
follow-up O
. O

Forty O
glaucoma O
patients O
( O
40 O
eyes O
) O
were O
assigned O
to O
trabeculectomy O
with O
MMC O
or O
OLO O
. O

Primary O
outcome O
includes O
target O
IOP O
at O
<=21 O
, O
<=17 O
, O
and O
<=15 O
mmHg O
";" O
complete O
( O
target O
IOP O
without O
medications O
) O
, O
and O
qualified O
success O
( O
target O
IOP O
regardless O
of O
medications O
) O
. O

Secondary O
outcomes O
include O
bleb O
evaluation O
, O
according O
to O
Moorfields O
Bleb O
Grading O
System O
( O
MBGS O
) O
";" O
spectral O
domain O
optical O
coherence O
tomography O
( O
SD-OCT O
) O
examination O
";" O
number O
of O
glaucoma O
medications O
";" O
and O
frequency O
of O
postoperative O
adjunctive O
procedures O
and O
complications O
. O

The O
mean O
preoperative O
IOP O
was O
26.5 O
( O
±5.2 O
) O
in O
MMC O
and O
27.3 O
( O
±6.0 O
) O
in O
OLO O
eyes O
, O
without O
statistical O
significance O
. O

One-day B-Premise
postoperatively I-Premise
, I-Premise
the I-Premise
IOP I-Premise
dropped I-Premise
to I-Premise
5.2 I-Premise
( I-Premise
±3.5 I-Premise
) I-Premise
and I-Premise
9.2 I-Premise
( I-Premise
±5.5 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P=0.009 I-Premise
) I-Premise
. I-Premise

The B-Premise
IOP I-Premise
reduction I-Premise
was I-Premise
significant I-Premise
at I-Premise
end I-Premise
point I-Premise
in I-Premise
all I-Premise
groups I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
, I-Premise
with I-Premise
a I-Premise
mean I-Premise
IOP I-Premise
of I-Premise
16.0 I-Premise
( I-Premise
±2.9 I-Premise
) I-Premise
and I-Premise
16.5 I-Premise
( I-Premise
±2.1 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
MMC I-Premise
and I-Premise
OLO I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
rates I-Premise
and I-Premise
Kaplan-Meier I-Premise
curves I-Premise
did I-Premise
not I-Premise
differ I-Premise
for I-Premise
both I-Premise
complete I-Premise
and I-Premise
qualified I-Premise
success I-Premise
at I-Premise
any I-Premise
target I-Premise
IOP I-Premise
. I-Premise

The B-Premise
bleb I-Premise
height I-Premise
in I-Premise
OLO I-Premise
group I-Premise
was I-Premise
higher I-Premise
than I-Premise
MMC I-Premise
one I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

SD-OCT B-Premise
analysis I-Premise
of I-Premise
successful/unsuccessful I-Premise
bleb I-Premise
in I-Premise
patients I-Premise
with I-Premise
or I-Premise
without I-Premise
complete I-Premise
success I-Premise
at I-Premise
IOP I-Premise
17 I-Premise
mm I-Premise
Hg I-Premise
indicated I-Premise
a I-Premise
sensitivity I-Premise
of I-Premise
83 I-Premise
% I-Premise
and I-Premise
73 I-Premise
% I-Premise
and I-Premise
a I-Premise
specificity I-Premise
of I-Premise
75 I-Premise
% I-Premise
and I-Premise
67 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
MMC I-Premise
and I-Premise
OLO I-Premise
groups I-Premise
. I-Premise

No B-Premise
adverse I-Premise
reaction I-Premise
to I-Premise
OLO I-Premise
was I-Premise
noted I-Premise
. I-Premise

Our B-Claim
results I-Claim
suggest I-Claim
that I-Claim
OLO I-Claim
implant I-Claim
could I-Claim
be I-Claim
a I-Claim
new I-Claim
, I-Claim
safe I-Claim
, I-Claim
and I-Claim
effective I-Claim
alternative I-Claim
to I-Claim
MMC I-Claim
, I-Claim
with I-Claim
similar I-Claim
long-term I-Claim
success I-Claim
rate I-Claim
. I-Claim

To O
compare O
the O
intraocular O
pressure-lowering O
effect O
of O
latanoprost O
with O
that O
of O
dorzolamide O
when O
added O
to O
timolol O
. O

This O
randomized O
, O
open-label O
study O
with O
two O
parallel O
groups O
was O
conducted O
in O
five O
centers O
in O
Greece O
. O

The O
study O
enrolled O
148 O
patients O
with O
inadequately O
controlled O
open-angle O
or O
pseudoexfoliation O
glaucoma O
( O
intraocular O
pressure O
of O
at O
least O
22 O
mm O
Hg O
) O
or O
ocular O
hypertension O
( O
intraocular O
pressure O
of O
at O
least O
27 O
mm O
Hg O
) O
who O
were O
receiving O
monotherapy O
with O
a O
beta-blocker O
or O
dual O
therapy O
in O
which O
one O
of O
the O
agents O
was O
a O
beta-blocker O
. O

The O
patients O
were O
switched O
to O
timolol O
0.5 O
% O
twice O
daily O
for O
2 O
to O
4 O
weeks O
( O
run-in O
period O
) O
before O
the O
start O
of O
the O
study O
( O
baseline O
) O
. O

At O
baseline O
, O
the O
patients O
were O
randomized O
to O
receive O
latanoprost O
0.005 O
% O
once O
daily O
or O
dorzolamide O
2 O
% O
twice O
daily O
as O
add-on O
therapy O
to O
timolol O
. O

The O
intraocular O
pressure O
was O
recorded O
at O
9:30 O
AM O
, O
12:30 O
PM O
, O
and O
3:30 O
PM O
at O
baseline O
and O
at O
3 O
months O
. O

Safety O
was O
followed O
throughout O
the O
study O
. O

The B-Premise
diurnal I-Premise
intraocular I-Premise
pressure I-Premise
reduction I-Premise
was I-Premise
significant I-Premise
in I-Premise
both I-Premise
groups I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
intraocular I-Premise
pressure I-Premise
reduction I-Premise
from I-Premise
baseline I-Premise
was I-Premise
32 I-Premise
% I-Premise
for I-Premise
the I-Premise
latanoprost I-Premise
plus I-Premise
timolol I-Premise
group I-Premise
and I-Premise
20 I-Premise
% I-Premise
for I-Premise
the I-Premise
dorzolamide I-Premise
plus I-Premise
timolol I-Premise
group I-Premise
. I-Premise

The B-Premise
least I-Premise
square I-Premise
estimate I-Premise
of I-Premise
the I-Premise
mean I-Premise
diurnal I-Premise
intraocular I-Premise
pressure I-Premise
reduction I-Premise
after I-Premise
3 I-Premise
months I-Premise
was I-Premise
-7.06 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
latanoprost I-Premise
plus I-Premise
timolol I-Premise
group I-Premise
and I-Premise
-4.44 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
dorzolamide I-Premise
plus I-Premise
timolol I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Drugs B-Claim
administered I-Claim
in I-Claim
both I-Claim
treatment I-Claim
groups I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

This B-Claim
study I-Claim
clearly I-Claim
showed I-Claim
that I-Claim
the I-Claim
additive I-Claim
diurnal I-Claim
intraocular I-Claim
pressure-lowering I-Claim
effect I-Claim
of I-Claim
latanoprost I-Claim
is I-Claim
superior I-Claim
to I-Claim
that I-Claim
of I-Claim
dorzolamide I-Claim
in I-Claim
patients I-Claim
treated I-Claim
with I-Claim
timolol I-Claim
. I-Claim

To O
compare O
the O
efficacy O
and O
tolerability O
of O
latanoprost O
or O
brimonidine O
in O
patients O
with O
elevated O
intraocular O
pressure O
( O
IOP O
) O
. O

This O
prospective O
, O
randomized O
, O
masked-evaluator O
, O
parallel-group O
, O
multicenter O
study O
in O
the O
United O
States O
included O
patients O
with O
primary O
open O
angle O
glaucoma O
or O
ocular O
hypertension O
. O

Patients O
received O
latanoprost O
0.005 O
% O
once O
daily O
( O
8:00 O
AM O
";" O
n O
= O
152 O
) O
or O
brimonidine O
tartrate O
0.2 O
% O
twice O
daily O
( O
8:00 O
AM O
and O
8:00 O
PM O
";" O
n O
= O
151 O
) O
. O

Patients O
underwent O
evaluation O
at O
screening O
, O
baseline O
( O
randomization O
) O
, O
and O
after O
0.5 O
, O
3 O
, O
and O
6 O
months O
of O
treatment O
. O

IOP O
was O
measured O
at O
8:00 O
AM O
, O
10:00 O
AM O
, O
noon O
, O
and O
4:00 O
PM O
at O
baseline O
and O
the O
months O
3 O
and O
6 O
visits O
, O
and O
at O
8:00 O
AM O
only O
at O
week O
2 O
. O

The O
main O
outcome O
measure O
was O
the O
difference O
in O
diurnal O
IOP O
change O
from O
baseline O
to O
month O
6 O
between O
treatment O
groups O
. O

Adverse O
events O
were O
recorded O
at O
each O
visit O
. O

Baseline O
mean O
diurnal O
IOP O
levels O
were O
similar O
between O
groups O
. O

At B-Premise
month I-Premise
6 I-Premise
, I-Premise
the I-Premise
adjusted I-Premise
mean I-Premise
( I-Premise
+/- I-Premise
SEM I-Premise
) I-Premise
diurnal I-Premise
IOP I-Premise
reduction I-Premise
was I-Premise
5.7 I-Premise
+/- I-Premise
0.3 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
and I-Premise
3.1 I-Premise
+/- I-Premise
0.3 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
brimonidine I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
difference I-Premise
in I-Premise
diurnal I-Premise
IOP I-Premise
reduction I-Premise
was I-Premise
2.5 I-Premise
+/- I-Premise
0.3 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
1.9 I-Premise
, I-Premise
3.2 I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Five B-Premise
times I-Premise
more I-Premise
patients I-Premise
receiving I-Premise
brimonidine I-Premise
than I-Premise
latanoprost I-Premise
were I-Premise
withdrawn I-Premise
from I-Premise
the I-Premise
study I-Premise
due I-Premise
to I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Latanoprost B-Claim
instilled I-Claim
once I-Claim
daily I-Claim
is I-Claim
more I-Claim
effective I-Claim
and I-Claim
better I-Claim
tolerated I-Claim
than I-Claim
brimonidine I-Claim
administered I-Claim
twice I-Claim
daily I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
patients I-Claim
with I-Claim
glaucoma I-Claim
or I-Claim
ocular I-Claim
hypertension I-Claim
. I-Claim

During B-Claim
therapy I-Claim
, I-Claim
the I-Claim
range I-Claim
of I-Claim
daily I-Claim
fluctuation I-Claim
of I-Claim
IOP I-Claim
is I-Claim
less I-Claim
for I-Claim
latanoprost I-Claim
compared I-Claim
with I-Claim
brimonidine I-Claim
. I-Claim

Brimonidin O
tartrate O
is O
a O
highly O
selective O
alpha O
2-agonist O
. O

This O
study O
investigates O
the O
safety O
and O
efficacy O
of O
0.2 O
% O
brimonidine O
administered O
twice O
daily O
for O
1 O
year O
in O
patients O
with O
glaucoma O
or O
ocular O
hypertension O
. O

The O
study O
design O
was O
a O
multicenter O
, O
double-masked O
, O
randomized O
, O
parallel-group O
, O
active-controlled O
comparison O
clinical O
trial O
. O

Subjects O
instilled O
0.2 O
% O
brimonidine O
or O
0.5 O
% O
timolol O
maleate O
twice O
daily O
for O
12 O
months O
. O

Subjects O
were O
examined O
at O
baseline O
, O
week O
1 O
, O
and O
months O
1 O
, O
2 O
, O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
. O

A O
subset O
of O
subjects O
was O
examined O
at O
week O
2 O
. O

Of O
443 O
subjects O
enrolled O
in O
this O
study O
, O
374 O
met O
the O
entry O
criteria O
";" O
186 O
received O
brimonidine O
and O
188 O
received O
timolol O
. O

Brimonidine-treated B-Premise
subjects I-Premise
showed I-Premise
an I-Premise
overall I-Premise
mean I-Premise
peak I-Premise
reduction I-Premise
in I-Premise
intraocular I-Premise
pressure I-Premise
( I-Premise
IOP I-Premise
) I-Premise
of I-Premise
6.5 I-Premise
mm I-Premise
Hg I-Premise
";" I-Premise
timolol-treated I-Premise
subjects I-Premise
had I-Premise
a I-Premise
mean I-Premise
peak I-Premise
reduction I-Premise
in I-Premise
IOP I-Premise
of I-Premise
6.1 I-Premise
mm I-Premise
Hg I-Premise
. I-Premise

Brimonidine B-Premise
lowered I-Premise
mean I-Premise
peak I-Premise
IOP I-Premise
significantly I-Premise
more I-Premise
than I-Premise
timolol I-Premise
at I-Premise
week I-Premise
2 I-Premise
and I-Premise
month I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
.03 I-Premise
) I-Premise
";" O
no O
significant O
difference O
was O
observed O
between O
the O
groups O
for O
this O
variable O
at O
other O
visits O
throughout O
the O
1-year O
course O
of O
the O
study O
. O

No B-Premise
evidence I-Premise
of I-Premise
tachyphylaxis I-Premise
was I-Premise
seen I-Premise
in I-Premise
either I-Premise
group I-Premise
. I-Premise

Allergy B-Premise
was I-Premise
seen I-Premise
in I-Premise
9 I-Premise
% I-Premise
of I-Premise
subjects I-Premise
treated I-Premise
with I-Premise
brimonidine I-Premise
. I-Premise

Dry B-Premise
mouth I-Premise
was I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
brimonidine-treated I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
timolol-treated I-Premise
group I-Premise
( I-Premise
33.0 I-Premise
% I-Premise
vs I-Premise
19.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
but O
complaints B-Premise
of I-Premise
burning I-Premise
and I-Premise
stinging I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
timolol-treated I-Premise
group I-Premise
( I-Premise
41.9 I-Premise
% I-Premise
) I-Premise
than I-Premise
in I-Premise
the I-Premise
brimonidine-treated I-Premise
patients I-Premise
( I-Premise
28.1 I-Premise
% I-Premise
) I-Premise
. I-Premise

Headache B-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
drowsiness I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
2 I-Premise
groups I-Premise
. I-Premise

In O
general O
, O
the O
tolerance O
to O
medication O
was O
acceptable O
. O

Brimonidine B-Claim
is I-Claim
safe I-Claim
and I-Claim
effective I-Claim
in I-Claim
lowering I-Claim
IOP I-Claim
in I-Claim
glaucomatous I-Claim
eyes I-Claim
. I-Claim

Brimonidine B-Claim
provides I-Claim
a I-Claim
sustained I-Claim
long-term I-Claim
ocular I-Claim
hypotensive I-Claim
effect I-Claim
, I-Claim
is I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
and I-Claim
has I-Claim
a I-Claim
low I-Claim
rate I-Claim
of I-Claim
allergic I-Claim
response I-Claim
. I-Claim

To O
compare O
phacoemulsification O
versus O
trabeculectomy O
with O
adjunctive O
mitomycin O
C O
in O
medically O
uncontrolled O
chronic O
angle-closure O
glaucoma O
( O
CACG O
) O
without O
cataract O
. O

Prospective O
, O
randomized O
clinical O
trial O
. O

Fifty O
medically O
uncontrolled O
CACG O
eyes O
without O
cataract O
of O
50 O
patients O
. O

Patients O
were O
randomized O
into O
undergoing O
either O
phacoemulsification O
or O
trabeculectomy O
with O
adjunctive O
mitomycin O
C. O
After O
surgery O
, O
patients O
were O
followed O
up O
every O
3 O
months O
for O
2 O
years O
. O

Intraocular O
pressure O
( O
IOP O
) O
and O
requirement O
for O
glaucoma O
drugs O
. O

Twenty-six O
CACG O
eyes O
were O
randomized O
to O
receive O
phacoemulsification O
, O
and O
24 O
eyes O
underwent O
trabeculectomy O
with O
mitomycin O
C. O
Phacoemulsification B-Premise
and I-Premise
trabeculectomy I-Premise
resulted I-Premise
in I-Premise
significant I-Premise
and I-Premise
comparable I-Premise
IOP I-Premise
reduction I-Premise
at I-Premise
24 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
( I-Premise
reduction I-Premise
of I-Premise
8.4 I-Premise
mmHg I-Premise
or I-Premise
34 I-Premise
% I-Premise
for I-Premise
phacoemulsification I-Premise
vs I-Premise
8.9 I-Premise
mmHg I-Premise
or I-Premise
36 I-Premise
% I-Premise
for I-Premise
trabeculectomy I-Premise
";" I-Premise
P=0.76 I-Premise
) I-Premise
. I-Premise

Over B-Premise
first I-Premise
24 I-Premise
months I-Premise
, I-Premise
trabeculectomy-treated I-Premise
eyes I-Premise
required I-Premise
on I-Premise
average I-Premise
1.1 I-Premise
fewer I-Premise
drugs I-Premise
than I-Premise
phacoemulsification-treated I-Premise
eyes I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

However O
, O
trabeculectomy B-Premise
was I-Premise
associated I-Premise
with I-Premise
significantly I-Premise
more I-Premise
surgical I-Premise
complications I-Premise
than I-Premise
phacoemulsification I-Premise
( I-Premise
46 I-Premise
% I-Premise
vs I-Premise
4 I-Premise
% I-Premise
";" I-Premise
P=0.001 I-Premise
) I-Premise
. I-Premise

Eight B-Premise
( I-Premise
33 I-Premise
% I-Premise
) I-Premise
of I-Premise
24 I-Premise
trabeculectomy I-Premise
eyes I-Premise
demonstrated I-Premise
cataract I-Premise
during I-Premise
follow-up I-Premise
. I-Premise

Both B-Claim
phacoemulsification I-Claim
and I-Claim
trabeculectomy I-Claim
are I-Claim
effective I-Claim
in I-Claim
reducing I-Claim
IOP I-Claim
in I-Claim
medically I-Claim
uncontrolled I-Claim
CACG I-Claim
eyes I-Claim
without I-Claim
cataract I-Claim
. I-Claim

Trabeculectomy B-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
phacoemulsification I-Claim
in I-Claim
reducing I-Claim
dependence I-Claim
on I-Claim
glaucoma I-Claim
drugs I-Claim
, I-Claim
but I-Claim
is I-Claim
associated I-Claim
with I-Claim
more I-Claim
complications I-Claim
. I-Claim

To O
compare O
phacoemulsification O
alone O
and O
phacoemulsification O
with O
micro-bypass O
stent O
implantation O
in O
eyes O
with O
primary O
open-angle O
glaucoma O
. O

Instituto O
di O
Fisiopatologia O
Clinica O
, O
Clinica O
Oculistica O
, O
Universita O
' O
di O
Torino O
, O
Torino O
, O
Italy O
. O

In O
this O
prospective O
double-masked O
randomized O
clinical O
trial O
, O
patients O
had O
phacoemulsification O
alone O
( O
control O
group O
) O
or O
phacoemulsification O
with O
iStent O
implantation O
( O
combined O
group O
) O
. O

Primary O
outcomes O
were O
intraocular O
pressure O
( O
IOP O
) O
and O
reduction O
in O
medication O
use O
over O
15 O
months O
and O
IOP O
after O
a O
1-month O
washout O
of O
ocular O
hypotensive O
agents O
( O
ie O
, O
16 O
months O
postoperatively O
) O
. O

The O
baseline O
IOP O
was O
similar O
between O
groups O
( O
combined O
group O
: O
17.9 O
mm O
Hg O
+/- O
2.6 O
[ O
SD O
] O
";" O
control O
group O
: O
17.3 O
+/- O
3.0 O
mm O
Hg O
) O
( O
P O
= O
.512 O
) O
. O

Three O
patients O
in O
the O
control O
group O
were O
lost O
to O
follow-up O
. O

The B-Premise
mean I-Premise
IOP I-Premise
was I-Premise
14.8 I-Premise
+/- I-Premise
1.2 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
combined I-Premise
group I-Premise
and I-Premise
15.7 I-Premise
+/- I-Premise
1.1 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
at I-Premise
15 I-Premise
months I-Premise
and I-Premise
16.6 I-Premise
+/- I-Premise
3.1 I-Premise
mm I-Premise
Hg I-Premise
and I-Premise
19.2 I-Premise
+/- I-Premise
3.5 I-Premise
mm I-Premise
Hg I-Premise
, I-Premise
respectively I-Premise
, I-Premise
after I-Premise
washout I-Premise
";" I-Premise
the B-Premise
IOP I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
combined I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
at I-Premise
both I-Premise
time I-Premise
points I-Premise
( I-Premise
P I-Premise
= I-Premise
.031 I-Premise
and I-Premise
P I-Premise
= I-Premise
.042 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

At B-Premise
15 I-Premise
months I-Premise
, I-Premise
the I-Premise
mean I-Premise
number I-Premise
of I-Premise
medications I-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
combined I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
0.4 I-Premise
+/- I-Premise
0.7 I-Premise
and I-Premise
1.3 I-Premise
+/- I-Premise
1.0 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.007 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
the I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
on I-Premise
ocular I-Premise
hypotensive I-Premise
medication I-Premise
( I-Premise
33 I-Premise
% I-Premise
and I-Premise
76 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Phacoemulsification B-Claim
with I-Claim
stent I-Claim
implantation I-Claim
was I-Claim
more I-Claim
effective I-Claim
in I-Claim
controlling I-Claim
IOP I-Claim
than I-Claim
phacoemulsification I-Claim
alone I-Claim
";" I-Claim
the O
safety O
profiles O
were O
similar O
. O

To O
compare O
the O
intraocular O
pressure O
( O
IOP O
) O
lowering O
efficacy O
and O
side O
effects O
of O
latanoprost O
0.005 O
% O
and O
bimatoprost O
0.03 O
% O
in O
subjects O
with O
chronic O
primary O
angle O
closure O
glaucoma O
( O
PACG O
) O
. O

This O
was O
an O
observer-masked O
randomised O
crossover O
study O
of O
60 O
PACG O
subjects O
who O
received O
either O
latanoprost O
or O
bimatoprost O
for O
6 O
weeks O
, O
after O
which O
they O
were O
crossed O
over O
to O
the O
other O
medication O
for O
another O
6 O
weeks O
. O

The O
IOP-reducing O
effect O
of O
the O
medications O
was O
assessed O
by O
the O
reduction O
in O
IOP O
after O
6 O
weeks O
of O
treatment O
compared O
with O
baseline O
. O

Fifty-four O
subjects O
( O
80 O
eyes O
) O
completed O
the O
study O
. O

Latanoprost B-Premise
reduced I-Premise
IOP I-Premise
( I-Premise
mean I-Premise
( I-Premise
SD I-Premise
) I-Premise
) I-Premise
by I-Premise
8.4 I-Premise
( I-Premise
3.8 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
and I-Premise
bimatoprost I-Premise
by I-Premise
8.9 I-Premise
( I-Premise
3.9 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
from I-Premise
a I-Premise
baseline I-Premise
of I-Premise
25.2 I-Premise
( I-Premise
3.6 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
and I-Premise
25.2 I-Premise
( I-Premise
3.6 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.23 I-Premise
) I-Premise
. I-Premise

Adverse B-Premise
events I-Premise
were I-Premise
mild I-Premise
in I-Premise
both I-Premise
groups I-Premise
";" I-Premise
however B-Premise
there I-Premise
were I-Premise
twice I-Premise
as I-Premise
many I-Premise
reports I-Premise
of I-Premise
an I-Premise
adverse I-Premise
event I-Premise
in I-Premise
the I-Premise
bimatoprost I-Premise
group I-Premise
( I-Premise
81 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
( I-Premise
40 I-Premise
% I-Premise
, I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Ocular O
irritation O
was O
the O
most O
frequently O
reported O
adverse O
event O
in O
both O
groups O
";" O
22 B-Premise
subjects I-Premise
( I-Premise
37.9 I-Premise
% I-Premise
) I-Premise
treated I-Premise
with I-Premise
bimatoprost I-Premise
experienced I-Premise
ocular I-Premise
hyperaemia I-Premise
as I-Premise
compared I-Premise
with I-Premise
13 I-Premise
subjects I-Premise
( I-Premise
22.4 I-Premise
% I-Premise
) I-Premise
treated I-Premise
with I-Premise
latanoprost I-Premise
( I-Premise
p I-Premise
= I-Premise
0.11 I-Premise
) I-Premise
. I-Premise

Bimatoprost B-Claim
once I-Claim
daily I-Claim
was I-Claim
similarly I-Claim
effective I-Claim
in I-Claim
reducing I-Claim
IOP I-Claim
compared I-Claim
with I-Claim
latanoprost I-Claim
once I-Claim
daily I-Claim
in I-Claim
subjects I-Claim
with I-Claim
chronic I-Claim
PACG I-Claim
. I-Claim

Both B-Claim
drugs I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
with I-Claim
mild I-Claim
ocular I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Latanoprost O
, O
a O
new O
prostaglandin O
analogue O
, O
was O
compared O
with O
timolol O
for O
ocular O
hypotensive O
efficacy O
and O
side O
effects O
. O

In O
a O
multicenter O
, O
randomized O
, O
double-masked O
, O
parallel O
group O
study O
, O
268 O
patients O
with O
ocular O
hypertension O
or O
early O
primary O
open-angle O
glaucoma O
received O
either O
0.005 O
% O
latanoprost O
once O
daily O
or O
0.5 O
% O
timolol O
twice O
daily O
for O
6 O
months O
. O

All O
except O
ten O
patients O
from O
each O
group O
successfully O
completed O
the O
study O
. O

Intraocular B-Premise
pressure I-Premise
( I-Premise
IOP I-Premise
) I-Premise
was I-Premise
significantly I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
reduced I-Premise
and I-Premise
maintained I-Premise
by I-Premise
both I-Premise
medications I-Premise
without I-Premise
evidence I-Premise
of I-Premise
a I-Premise
long-term I-Premise
drift I-Premise
over I-Premise
6 I-Premise
months I-Premise
. I-Premise

Comparing B-Premise
6-month I-Premise
with I-Premise
baseline I-Premise
diurnal I-Premise
IOP I-Premise
values I-Premise
, I-Premise
the I-Premise
IOP I-Premise
reduction I-Premise
( I-Premise
mean I-Premise
+/- I-Premise
standard I-Premise
deviation I-Premise
) I-Premise
achieved I-Premise
with I-Premise
latanoprost I-Premise
( I-Premise
-6.7 I-Premise
+/- I-Premise
3.4 I-Premise
mmHg I-Premise
) I-Premise
was I-Premise
significantly I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
greater I-Premise
than I-Premise
that I-Premise
produced I-Premise
with I-Premise
timolol I-Premise
( I-Premise
4.9 I-Premise
+/- I-Premise
2.9 I-Premise
mmHg I-Premise
) I-Premise
. I-Premise

Four O
patients O
treated O
with O
timolol O
and O
none O
treated O
with O
latanoprost O
were O
withdrawn O
from O
the O
study O
because O
of O
inadequate O
IOP O
control O
. O

Pulse B-Premise
rate I-Premise
was I-Premise
significantly I-Premise
reduced I-Premise
with I-Premise
timolol I-Premise
, I-Premise
but I-Premise
not I-Premise
with I-Premise
latanoprost I-Premise
. I-Premise

Slightly B-Premise
more I-Premise
conjunctival I-Premise
hyperemia I-Premise
appeared I-Premise
in I-Premise
latanoprost-treated I-Premise
compared I-Premise
with I-Premise
timolol-treated I-Premise
eyes I-Premise
. I-Premise

Fewer B-Claim
subjective I-Claim
side I-Claim
effects I-Claim
occurred I-Claim
in I-Claim
latanoprost-treated I-Claim
eyes I-Claim
. I-Claim

Both B-Premise
eyes I-Premise
of I-Premise
a I-Premise
patient I-Premise
with I-Premise
a I-Premise
characteristic I-Premise
, I-Premise
concentric I-Premise
iris I-Premise
heterochromia I-Premise
( I-Premise
darker I-Premise
centrally I-Premise
) I-Premise
at I-Premise
baseline I-Premise
showed I-Premise
a I-Premise
definite I-Premise
, I-Premise
photographically I-Premise
documented I-Premise
increase I-Premise
in I-Premise
pigmentation I-Premise
during I-Premise
latanoprost I-Premise
treatment I-Premise
, I-Premise
making I-Premise
the I-Premise
irides I-Premise
uniformly I-Premise
darker I-Premise
. I-Premise

Three O
additional O
patients O
treated O
with O
latanoprost O
were O
suspects O
for O
this O
color O
change O
. O

Otherwise O
, O
no B-Claim
significant I-Claim
difference I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
occurred I-Claim
visual I-Claim
acuity I-Claim
, I-Claim
slit-lamp I-Claim
examination I-Claim
, I-Claim
blood I-Claim
pressure I-Claim
, I-Claim
and I-Claim
laboratory I-Claim
values I-Claim
. I-Claim

Latanoprost B-Claim
has I-Claim
the I-Claim
potential I-Claim
for I-Claim
becoming I-Claim
a I-Claim
new I-Claim
first-line I-Claim
treatment I-Claim
for I-Claim
glaucoma I-Claim
. I-Claim

Efficacy O
of O
the O
latanoprost O
versus O
timolol/dorzolamide O
combination O
therapy O
in O
patients O
with O
primary O
open O
angle O
glaucoma O
. O

The O
study O
was O
designed O
as O
a O
6 O
months O
randomized O
, O
observer-masked O
study O
comprising O
120 O
patients O
with O
primary O
open-angle O
glaucoma O
in O
Feiz O
Hospital O
, O
Isfahan O
, O
Iran O
, O
from O
2006 O
to O
2007 O
. O

The O
patients O
were O
randomized O
( O
latanoprost O
, O
n O
= O
60 O
";" O
dorzolamide/timolol O
, O
n O
= O
60 O
) O
to O
treatment O
with O
either O
latanoprost O
, O
0.005 O
% O
once O
daily O
, O
or O
the O
combination O
of O
timolol O
0.5 O
% O
twice O
daily O
, O
and O
dorzolamide O
2 O
% O
3 O
times O
daily O
. O

The O
mean O
intraocular O
pressure O
( O
IOP O
) O
after O
one O
, O
3 O
, O
and O
6 O
months O
of O
treatment O
was O
compared O
with O
baseline O
in O
the O
2 O
groups O
. O

A O
total O
of O
120 O
patients O
were O
randomized O
to O
2 O
equal O
treatment O
groups O
. O

The O
mean O
baseline O
IOP O
values O
were O
similar O
between O
the O
2 O
groups O
. O

The B-Premise
mean I-Premise
( I-Premise
standard I-Premise
error I-Premise
of I-Premise
mean I-Premise
[ I-Premise
SE I-Premise
] I-Premise
) I-Premise
IOP I-Premise
reductions I-Premise
at I-Premise
months I-Premise
one I-Premise
was I-Premise
7.2 I-Premise
( I-Premise
0.4 I-Premise
) I-Premise
, I-Premise
at I-Premise
month I-Premise
3 I-Premise
was I-Premise
7.3 I-Premise
( I-Premise
0.4 I-Premise
) I-Premise
, I-Premise
and I-Premise
at I-Premise
month I-Premise
6 I-Premise
was I-Premise
7.1 I-Premise
( I-Premise
0.3 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
for I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
and I-Premise
7.5 I-Premise
( I-Premise
0.3 I-Premise
) I-Premise
, I-Premise
7.8 I-Premise
( I-Premise
0.3 I-Premise
) I-Premise
, I-Premise
and I-Premise
7.4 I-Premise
( I-Premise
0.3 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
for I-Premise
the I-Premise
dorzolamide/timolol I-Premise
group I-Premise
. I-Premise

The B-Claim
2 I-Claim
therapies I-Claim
were I-Claim
similarly I-Claim
effective I-Claim
. I-Claim

The B-Claim
latanoprost I-Claim
and I-Claim
dorzolamide/timolol I-Claim
combination I-Claim
were I-Claim
equally I-Claim
effective I-Claim
at I-Claim
lowering I-Claim
IOP I-Claim
compared I-Claim
to I-Claim
untreated I-Claim
baseline I-Claim
. I-Claim

To O
compare O
the O
effectiveness O
and O
safety O
of O
excimer O
laser O
trabeculotomy O
( O
ELT O
) O
ab O
interno O
vs O
selective O
laser O
trabeculoplasty O
( O
SLT O
) O
over O
24 O
months O
of O
follow-up O
in O
patients O
with O
primary O
open-angle O
glaucoma O
( O
POAG O
) O
refractory O
to O
medical O
therapy O
. O

This O
prospective O
, O
randomized O
study O
included O
30 O
consecutive O
eyes O
assigned O
randomly O
to O
either O
ELT O
or O
SLT O
group O
. O

ELT O
was O
carried O
out O
using O
a O
XeCl O
Excimer O
Laser O
with O
an O
emission O
wavelength O
of O
308 O
nm O
. O

Eight O
spots O
were O
equally O
distributed O
at O
a O
distance O
of O
500 O
microm O
from O
one O
another O
over O
the O
anterior O
trabeculum O
. O

The O
SLT O
patients O
were O
treated O
with O
a O
frequency-doubled O
q-switched O
neodymium O
: O
yytrium-aluminum-garnet O
laser O
( O
wavelength O
532 O
nm O
) O
. O

Approximately O
50 O
adjacent O
, O
but O
not O
overlapping O
, O
laser O
spots O
were O
distributed O
over O
180 O
degrees O
of O
the O
trabecular O
meshwork O
, O
using O
an O
energy O
level O
ranging O
from O
0.7 O
to O
1.0 O
mJ O
per O
pulse O
. O

The O
main O
outcome O
measure O
was O
intraocular O
pressure O
( O
IOP O
) O
lowering O
after O
ELT O
and O
SLT O
. O

Success O
was O
defined O
as O
> O
or=20 O
% O
reduction O
in O
IOP O
without O
further O
glaucoma O
intervention O
. O

At B-Premise
24 I-Premise
months I-Premise
, I-Premise
complete I-Premise
success I-Premise
rates I-Premise
were I-Premise
53.3 I-Premise
% I-Premise
for I-Premise
the I-Premise
ELT I-Premise
group I-Premise
and I-Premise
40 I-Premise
% I-Premise
for I-Premise
the I-Premise
SLT I-Premise
group I-Premise
( I-Premise
P=0.35 I-Premise
, I-Premise
Fisher I-Premise
's I-Premise
exact I-Premise
test I-Premise
) I-Premise
";" I-Premise
qualified B-Premise
success I-Premise
rates I-Premise
were I-Premise
33.3 I-Premise
% I-Premise
for I-Premise
the I-Premise
ELT I-Premise
and I-Premise
26.6 I-Premise
% I-Premise
for I-Premise
the I-Premise
SLT I-Premise
group I-Premise
( I-Premise
P=0.5 I-Premise
, I-Premise
Fisher I-Premise
's I-Premise
exact I-Premise
test I-Premise
) I-Premise
. I-Premise

Mean B-Premise
IOP I-Premise
decreased I-Premise
from I-Premise
25.0+/-1.9 I-Premise
to I-Premise
17.6+/-2.2 I-Premise
mmHg I-Premise
( I-Premise
-29.6 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
in I-Premise
the I-Premise
ELT I-Premise
group I-Premise
and I-Premise
from I-Premise
23.9+/-0.9 I-Premise
to I-Premise
19.1+/-1.8 I-Premise
mmHg I-Premise
( I-Premise
-21 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
in I-Premise
the I-Premise
SLT I-Premise
group I-Premise
. I-Premise

Both B-Claim
ELT I-Claim
and I-Claim
SLT I-Claim
proved I-Claim
to I-Claim
be I-Claim
effective I-Claim
techniques I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
POAG I-Claim
refractory I-Claim
to I-Claim
medical I-Claim
therapy I-Claim
. I-Claim

To O
compare O
the O
ocular O
hypotensive O
activity O
and O
safety O
profile O
of O
long-acting O
1 O
% O
carteolol O
hydrochloride O
eye O
drops O
( O
long-acting O
formulation O
) O
to O
those O
of O
1 O
% O
carteolol O
hydrochloride O
eye O
drops O
( O
currently O
prescribed O
drug O
) O
for O
reduction O
of O
intraocular O
pressure O
. O

Patients O
with O
primary O
open-angle O
glaucoma O
or O
ocular O
hypertension O
( O
146 O
cases O
) O
were O
assigned O
randomly O
to O
the O
long-acting O
drug O
group O
( O
74 O
cases O
) O
and O
the O
currently-prescribed O
drug O
group O
( O
72 O
cases O
) O
. O

Long-acting O
eye O
drops O
were O
instilled O
once O
a O
day O
in O
the O
morning O
( O
along O
with O
one O
drop O
of O
placebo O
at O
night O
) O
, O
and O
currently-prescribed O
eye O
drops O
were O
instilled O
twice O
a O
day O
in O
the O
morning O
and O
at O
night O
. O

Eye O
drops O
were O
administered O
for O
8 O
weeks O
. O

Intraocular O
pressure O
was O
monitored O
at O
2 O
, O
4 O
, O
and O
8 O
weeks O
after O
the O
initiation O
of O
drug O
instillation O
for O
evaluation O
of O
equivalence O
. O

Intraocular B-Premise
pressure I-Premise
was I-Premise
significantly I-Premise
reduced I-Premise
during I-Premise
the I-Premise
entire I-Premise
follow-up I-Premise
period I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

In B-Premise
the I-Premise
long-acting I-Premise
drug I-Premise
group I-Premise
, I-Premise
the I-Premise
reduction I-Premise
of I-Premise
intraocular I-Premise
pressure I-Premise
was I-Premise
-3.5 I-Premise
+/- I-Premise
0.2 I-Premise
, I-Premise
-4.3 I-Premise
+/- I-Premise
0.2 I-Premise
and I-Premise
-4.6 I-Premise
+/- I-Premise
0.3 I-Premise
mmHg I-Premise
at I-Premise
2 I-Premise
, I-Premise
4 I-Premise
, I-Premise
and I-Premise
8 I-Premise
weeks I-Premise
, I-Premise
respectively I-Premise
( I-Premise
paired I-Premise
t I-Premise
test I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
currently-prescribed I-Premise
drug I-Premise
group I-Premise
, I-Premise
the I-Premise
reduction I-Premise
of I-Premise
intraocular I-Premise
pressure I-Premise
was I-Premise
-4.1 I-Premise
+/- I-Premise
0.2 I-Premise
, I-Premise
-4.4 I-Premise
+/- I-Premise
0.3 I-Premise
and I-Premise
-- I-Premise
4.6 I-Premise
+/- I-Premise
0.2 I-Premise
mmHg I-Premise
at I-Premise
2 I-Premise
, I-Premise
4 I-Premise
, I-Premise
and I-Premise
8 I-Premise
weeks I-Premise
( I-Premise
paired I-Premise
t I-Premise
test I-Premise
) I-Premise
. I-Premise

The B-Claim
safety I-Claim
profile I-Claim
was I-Claim
similar I-Claim
in I-Claim
both I-Claim
groups I-Claim
, I-Claim
and I-Claim
the I-Claim
tolerance I-Claim
for I-Claim
the I-Claim
long-acting I-Claim
eye I-Claim
drops I-Claim
was I-Claim
as I-Claim
good I-Claim
as I-Claim
for I-Claim
the I-Claim
currently-prescribed I-Claim
eye I-Claim
drops I-Claim
. I-Claim

Because B-Claim
the I-Claim
efficacy I-Claim
of I-Claim
both I-Claim
drugs I-Claim
was I-Claim
equivalent I-Claim
, I-Claim
with I-Claim
an I-Claim
identical I-Claim
safety I-Claim
profile I-Claim
, I-Claim
the B-Claim
long-acting I-Claim
eye I-Claim
drops I-Claim
seem I-Claim
to I-Claim
be I-Claim
an I-Claim
efficacious I-Claim
formulation I-Claim
for I-Claim
clinical I-Claim
use I-Claim
in I-Claim
Japanese I-Claim
glaucoma I-Claim
patients I-Claim
. I-Claim

The O
newer O
ocular O
hypotensive O
agents O
available O
to O
treat O
glaucoma O
and O
ocular O
hypertension O
( O
OHT O
) O
include O
latanoprost O
, O
a O
prostaglandin O
F O
( O
2alpha O
) O
analogue O
, O
and O
the O
fixed O
combination O
of O
dorzolamide O
hydrochloride O
, O
a O
carbonic O
anhydrase O
inhibitor O
, O
and O
timolol O
maleate O
, O
a O
beta-blocker O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
and O
tolerability O
of O
latanoprost O
with O
that O
of O
the O
fixed O
combination O
of O
dorzolamide O
and O
timolol O
over O
8 O
weeks O
. O

This O
interventional O
, O
8-week O
, O
randomized O
, O
open-label O
, O
parallel-group O
study O
was O
conducted O
at O
18 O
centers O
in O
6 O
Latin O
American O
countries O
. O

Patients O
with O
unilateral O
or O
bilateral O
primary O
open-angle O
, O
pigmentary O
, O
or O
exfoliative O
glaucoma O
or O
OHT O
were O
randomized O
to O
receive O
latanoprost O
, O
1 O
drop O
in O
the O
affected O
eye O
QD O
( O
evening O
) O
, O
or O
fixed O
combination O
dorzolamide/timolol O
, O
1 O
drop O
in O
the O
affected O
eye O
BID O
( O
morning O
and O
evening O
) O
. O

Medications O
were O
self-administered O
, O
1 O
drop O
per O
affected O
eye O
. O

At O
baseline O
and O
week O
8 O
, O
intraocular O
pressure O
( O
IOP O
) O
was O
measured O
3 O
times O
each O
at O
8:30 O
am O
, O
10:00 O
am O
, O
2:00 O
pm O
, O
and O
5:00 O
pm O
and O
after O
the O
water-drinking O
test O
, O
which O
estimates O
the O
IOP O
peak O
of O
diurnal O
tension O
curve O
, O
performed O
following O
the O
5:00 O
pm O
IOP O
assessment O
. O

The O
primary O
efficacy O
outcome O
was O
change O
in O
diurnal O
IOP O
( O
the O
mean O
of O
IOP O
measurements O
) O
from O
baseline O
to O
week O
8 O
. O

Adverse O
effect O
( O
AE O
) O
data O
were O
recorded O
at O
each O
visit O
. O

A O
total O
of O
229 O
patients O
were O
randomized O
( O
latanoprost O
, O
n O
= O
112 O
";" O
dorzolamide/timolol O
, O
n O
= O
117 O
) O
. O

Mean B-Premise
baseline I-Premise
diurnal I-Premise
IOP I-Premise
values I-Premise
were I-Premise
similar I-Premise
between I-Premise
the I-Premise
2 I-Premise
groups I-Premise
. I-Premise

Mean B-Premise
( I-Premise
SD I-Premise
) I-Premise
diurnal I-Premise
IOP I-Premise
reductions I-Premise
at I-Premise
week I-Premise
8 I-Premise
before I-Premise
the I-Premise
water-drinking I-Premise
test I-Premise
were I-Premise
6.9 I-Premise
( I-Premise
3.0 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
for I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
and I-Premise
6.4 I-Premise
( I-Premise
3.2 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
for I-Premise
the I-Premise
dorzolamide/timolol I-Premise
group I-Premise
. I-Premise

Mean B-Premise
IOP I-Premise
values I-Premise
were I-Premise
similar I-Premise
at I-Premise
all I-Premise
time I-Premise
points I-Premise
except I-Premise
at I-Premise
5:00 I-Premise
pm I-Premise
, I-Premise
when I-Premise
levels I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
latanoprost-treated I-Premise
patients I-Premise
( I-Premise
P I-Premise
= I-Premise
0.025 I-Premise
) I-Premise
. I-Premise

After B-Premise
the I-Premise
water-drinking I-Premise
test I-Premise
, I-Premise
the I-Premise
increase I-Premise
in I-Premise
IOP I-Premise
values I-Premise
was I-Premise
similar I-Premise
between I-Premise
groups I-Premise
at I-Premise
baseline I-Premise
but I-Premise
lower I-Premise
in I-Premise
latanoprost-treated I-Premise
patients I-Premise
at I-Premise
week I-Premise
8 I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
, I-Premise
1.08 I-Premise
mm I-Premise
Hg I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.012 I-Premise
) I-Premise
. I-Premise

Fewer B-Premise
patients I-Premise
treated I-Premise
with I-Premise
latanoprost I-Premise
reported I-Premise
ocular I-Premise
or I-Premise
systemic I-Premise
AEs I-Premise
( I-Premise
P I-Premise
= I-Premise
0.025 I-Premise
and I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

In B-Claim
this I-Claim
study I-Claim
of I-Claim
patients I-Claim
with I-Claim
unilateral I-Claim
or I-Claim
bilateral I-Claim
primary I-Claim
open-angle I-Claim
, I-Claim
pigmentary I-Claim
, I-Claim
or I-Claim
exfoliative I-Claim
glaucoma I-Claim
or I-Claim
OHT I-Claim
IOP I-Claim
reductions I-Claim
generally I-Claim
were I-Claim
similar I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
, I-Claim
except B-Claim
at I-Claim
5:00 I-Claim
pm I-Claim
, I-Claim
when I-Claim
the I-Claim
mean I-Claim
IOP I-Claim
level I-Claim
was I-Claim
significantly I-Claim
lower I-Claim
in I-Claim
latanoprost-treated I-Claim
patients I-Claim
. I-Claim

Latanoprost B-Claim
was I-Claim
better I-Claim
tolerated I-Claim
than I-Claim
fixed-combination I-Claim
dorzolamide I-Claim
and I-Claim
timolol I-Claim
. I-Claim

To O
compare O
the O
clinical O
success O
rates O
and O
quality O
of O
life O
impact O
of O
brimonidine O
0.2 O
% O
with O
timolol O
0.5 O
% O
in O
newly O
diagnosed O
patients O
naive O
to O
glaucoma O
therapy O
. O

A O
prospective O
, O
multicenter O
, O
randomized O
, O
double-masked O
, O
clinical O
effectiveness O
trial O
in O
which O
the O
clinical O
outcomes O
of O
twice O
daily O
brimonidine O
tartrate O
0.2 O
% O
were O
compared O
with O
those O
of O
timolol O
maleate O
0.5 O
% O
in O
patients O
with O
glaucoma O
and O
ocular O
hypertension O
was O
conducted O
. O

Two O
hundred O
nineteen O
patients O
were O
enrolled O
-- O
111 O
in O
the O
brimonidine O
group O
and O
108 O
in O
the O
timolol O
group O
. O

Patients O
instilled O
their O
study O
medications O
twice O
daily O
for O
4 O
months O
. O

Factors O
for O
determining O
clinical O
success O
were O
reduction O
of O
intraocular O
pressure O
( O
IOP O
) O
, O
safety O
, O
and O
adverse O
events O
. O

Quality O
of O
life O
effects O
were O
assessed O
with O
the O
SF-36 O
Health O
Survey O
and O
Glaucoma O
Disability O
Index O
questionnaires O
. O

Clinical B-Premise
success I-Premise
was I-Premise
71 I-Premise
% I-Premise
( I-Premise
75/106 I-Premise
) I-Premise
with I-Premise
brimonidine I-Premise
and I-Premise
70 I-Premise
% I-Premise
( I-Premise
73/105 I-Premise
) I-Premise
with I-Premise
timolol I-Premise
as I-Premise
initial I-Premise
treatment I-Premise
. I-Premise

The B-Premise
overall I-Premise
mean I-Premise
decrease I-Premise
in I-Premise
IOP I-Premise
was I-Premise
6.5 I-Premise
mm I-Premise
Hg I-Premise
with I-Premise
brimonidine I-Premise
and I-Premise
6.2 I-Premise
mm I-Premise
Hg I-Premise
with I-Premise
timolol I-Premise
. I-Premise

Few B-Premise
patients I-Premise
reported I-Premise
a I-Premise
specific I-Premise
adverse I-Premise
event I-Premise
and O
, O
with B-Premise
the I-Premise
exception I-Premise
of I-Premise
a I-Premise
slightly I-Premise
higher I-Premise
rate I-Premise
of I-Premise
ocular I-Premise
burning I-Premise
and I-Premise
stinging I-Premise
in I-Premise
the I-Premise
brimonidine I-Premise
group I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
between-group I-Premise
differences I-Premise
. I-Premise

No B-Premise
significant I-Premise
chronotropic I-Premise
effects I-Premise
on I-Premise
the I-Premise
heart I-Premise
were I-Premise
seen I-Premise
with I-Premise
brimonidine I-Premise
, O
while O
small B-Premise
but I-Premise
significant I-Premise
mean I-Premise
decreases I-Premise
in I-Premise
heart I-Premise
rate I-Premise
were I-Premise
seen I-Premise
at I-Premise
months I-Premise
1 I-Premise
and I-Premise
4 I-Premise
with I-Premise
timolol I-Premise
. I-Premise

Mean B-Premise
systolic I-Premise
and I-Premise
diastolic I-Premise
blood I-Premise
pressure I-Premise
remained I-Premise
relatively I-Premise
stable I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
remained I-Premise
stable I-Premise
, I-Premise
with I-Premise
no I-Premise
significant I-Premise
between-group I-Premise
differences I-Premise
. I-Premise

As B-Claim
a I-Claim
first-line I-Claim
agent I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
glaucoma I-Claim
and I-Claim
ocular I-Claim
hypertension I-Claim
, I-Claim
brimonidine I-Claim
has I-Claim
clinical I-Claim
effectiveness I-Claim
equivalent I-Claim
to I-Claim
timolol I-Claim
, I-Claim
but I-Claim
with I-Claim
less I-Claim
chronotropic I-Claim
effect I-Claim
on I-Claim
the I-Claim
heart I-Claim
. I-Claim

Brimonidine B-Claim
is I-Claim
a I-Claim
viable I-Claim
alternative I-Claim
to I-Claim
timolol I-Claim
for I-Claim
first-line I-Claim
therapy I-Claim
in I-Claim
glaucoma I-Claim
and I-Claim
ocular I-Claim
hypertension I-Claim
. I-Claim

To O
compare O
the O
alpha2-adrenergic O
agonist O
brimonidine O
tartrate O
0.2 O
% O
to O
the O
beta-adrenergic O
antagonist O
timolol O
maleate O
0.5 O
% O
in O
preserving O
visual O
function O
in O
low-pressure O
glaucoma O
. O

Randomized O
, O
double-masked O
, O
multicenter O
clinical O
trial O
. O

Exclusion O
criteria O
included O
untreated O
intraocular O
pressure O
( O
IOP O
) O
> O
21 O
mm O
Hg O
, O
visual O
field O
mean O
deviation O
worse O
than O
-16 O
decibels O
, O
or O
contraindications O
to O
study O
medications O
. O

Both O
eyes O
received O
twice-daily O
monotherapy O
randomized O
in O
blocks O
of O
7 O
( O
4 O
brimonidine O
to O
3 O
timolol O
) O
. O

Standard O
automated O
perimetry O
and O
tonometry O
were O
performed O
at O
4-month O
intervals O
. O

Main O
outcome O
measure O
was O
field O
progression O
in O
either O
eye O
, O
defined O
as O
the O
same O
3 O
or O
more O
points O
with O
a O
negative O
slope O
-1 O
dB/year O
at O
P O
< O
5 O
% O
, O
on O
3 O
consecutive O
tests O
, O
assessed O
by O
pointwise O
linear O
regression O
. O

Secondary O
outcome O
measures O
were O
progression O
based O
on O
glaucoma O
change O
probability O
maps O
( O
GCPM O
) O
of O
pattern O
deviation O
and O
the O
3-omitting O
method O
for O
pointwise O
linear O
regression O
. O

Ninety-nine O
patients O
were O
randomized O
to O
brimonidine O
and O
79 O
to O
timolol O
. O

Mean O
( O
+/- O
SE O
) O
months O
of O
follow-up O
for O
all O
patients O
was O
30.0 O
+/- O
2 O
. O

Statistically B-Premise
fewer I-Premise
brimonidine-treated I-Premise
patients I-Premise
( I-Premise
9 I-Premise
, I-Premise
9.1 I-Premise
% I-Premise
) I-Premise
had I-Premise
visual I-Premise
field I-Premise
progression I-Premise
by I-Premise
pointwise I-Premise
linear I-Premise
regression I-Premise
than I-Premise
timolol-treated I-Premise
patients I-Premise
( I-Premise
31 I-Premise
, I-Premise
39.2 I-Premise
% I-Premise
, I-Premise
log-rank I-Premise
12.4 I-Premise
, I-Premise
P=.001 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
treated I-Premise
IOP I-Premise
was I-Premise
similar I-Premise
for I-Premise
brimonidine- I-Premise
and I-Premise
timolol-treated I-Premise
patients I-Premise
at I-Premise
all I-Premise
time I-Premise
points I-Premise
. I-Premise

More B-Premise
brimonidine-treated I-Premise
( I-Premise
28 I-Premise
, I-Premise
28.3 I-Premise
% I-Premise
) I-Premise
than I-Premise
timolol-treated I-Premise
( I-Premise
9 I-Premise
, I-Premise
11.4 I-Premise
% I-Premise
) I-Premise
patients I-Premise
discontinued I-Premise
study I-Premise
participation I-Premise
because I-Premise
of I-Premise
drug-related I-Premise
adverse I-Premise
events I-Premise
( I-Premise
P=.008 I-Premise
) I-Premise
. I-Premise

Similar B-Claim
differences I-Claim
in I-Claim
progression I-Claim
were I-Claim
observed I-Claim
when I-Claim
analyzed I-Claim
by I-Claim
GCPM I-Claim
and I-Claim
the I-Claim
3-omitting I-Claim
method I-Claim
. I-Claim

Low-pressure B-Claim
glaucoma I-Claim
patients I-Claim
treated I-Claim
with I-Claim
brimonidine I-Claim
0.2 I-Claim
% I-Claim
who I-Claim
do I-Claim
not I-Claim
develop I-Claim
ocular I-Claim
allergy I-Claim
are I-Claim
less I-Claim
likely I-Claim
to I-Claim
have I-Claim
field I-Claim
progression I-Claim
than I-Claim
patients I-Claim
treated I-Claim
with I-Claim
timolol I-Claim
0.5 I-Claim
% I-Claim
. I-Claim

To O
compare O
two O
intraocular O
irrigating O
solutions O
, O
Balanced O
Salt O
Solution O
Plus O
( O
BSS O
Plus O
) O
versus O
Lactated O
Ringer O
's O
( O
Ringer O
) O
, O
for O
the O
preservation O
of O
corneal O
integrity O
after O
phacoemulsification O
. O

110 O
patients O
undergoing O
phacoemulsification O
were O
randomised O
to O
either O
BSS O
Plus O
( O
n=55 O
) O
or O
Ringer O
( O
n=55 O
) O
as O
the O
irrigating O
solution O
. O

Patients O
were O
examined O
at O
baseline O
and O
at O
1 O
, O
8 O
, O
15 O
, O
30 O
and O
60 O
days O
postoperatively O
. O

Evaluations O
included O
specular O
microscopy O
to O
evaluate O
endothelial O
cell O
density O
( O
ECD O
) O
and O
endothelial O
cell O
size O
variability O
( O
CV O
) O
, O
and O
corneal O
pachymetry O
for O
central O
corneal O
thickness O
( O
CCT O
) O
measurement O
. O

Groups O
were O
well O
balanced O
regarding O
baseline O
ECD O
, O
CV O
and O
CCT O
( O
p O
> O
0.05 O
) O
. O

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
between I-Premise
ECD I-Premise
reduction I-Premise
in I-Premise
group I-Premise
BSS I-Premise
Plus I-Premise
13.1 I-Premise
± I-Premise
2.0 I-Premise
% I-Premise
and I-Premise
Ringer I-Premise
9.2 I-Premise
± I-Premise
1.9 I-Premise
% I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
at I-Premise
day I-Premise
60 I-Premise
or I-Premise
in I-Premise
any I-Premise
study I-Premise
visit I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
between I-Premise
CV I-Premise
increase I-Premise
in I-Premise
group I-Premise
BSS I-Premise
Plus I-Premise
23.0 I-Premise
± I-Premise
3.0 I-Premise
% I-Premise
and I-Premise
Ringer I-Premise
20.2 I-Premise
± I-Premise
4.0 I-Premise
% I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
at I-Premise
day I-Premise
60 I-Premise
or I-Premise
in I-Premise
any I-Premise
study I-Premise
visit I-Premise
. I-Premise

CCT B-Premise
was I-Premise
significantly I-Premise
increased I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
at I-Premise
1 I-Premise
, I-Premise
8 I-Premise
, I-Premise
15 I-Premise
and I-Premise
30 I-Premise
days I-Premise
postoperatively I-Premise
, I-Premise
returning I-Premise
to I-Premise
baseline I-Premise
at I-Premise
60 I-Premise
days I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
CCT I-Premise
increase I-Premise
in I-Premise
both I-Premise
groups I-Premise
at I-Premise
any I-Premise
visit I-Premise
. I-Premise

Interestingly O
, O
there B-Premise
were I-Premise
statistically I-Premise
significant I-Premise
correlations I-Premise
between I-Premise
ECD I-Premise
loss I-Premise
and I-Premise
phacoemulsification I-Premise
time I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
ECD I-Premise
loss I-Premise
and I-Premise
irrigation I-Premise
solution I-Premise
volume I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
in I-Premise
the I-Premise
Ringer I-Premise
group I-Premise
, I-Premise
but I-Premise
not I-Premise
in I-Premise
the I-Premise
BSS I-Premise
Plus I-Premise
group I-Premise
. I-Premise

Ringers B-Claim
solution I-Claim
was I-Claim
similar I-Claim
to I-Claim
BSS I-Claim
Plus I-Claim
for I-Claim
corneal I-Claim
preservation I-Claim
in I-Claim
atraumatic I-Claim
cataract I-Claim
surgery I-Claim
. I-Claim

However B-Claim
, I-Claim
our I-Claim
study I-Claim
demonstrates I-Claim
that I-Claim
there I-Claim
is I-Claim
a I-Claim
trend I-Claim
towards I-Claim
lower I-Claim
postoperative I-Claim
endothelial I-Claim
cell I-Claim
density I-Claim
for I-Claim
surgeries I-Claim
with I-Claim
longer I-Claim
phacoemulsification I-Claim
time I-Claim
and I-Claim
higher I-Claim
irrigation I-Claim
volumes I-Claim
if I-Claim
Ringer I-Claim
is I-Claim
used I-Claim
. I-Claim

To O
compare O
the O
efficacy O
and O
tolerability O
of O
the O
fixed O
combination O
of O
timolol O
maleate O
0.5 O
% O
/brimonidine O
tartrate O
0.2 O
% O
versus O
fixed O
combination O
of O
timolol O
maleate O
0.5 O
% O
/dorzolamide O
2 O
% O
in O
patients O
with O
elevated O
intraocular O
pressure O
( O
IOP O
) O
over O
8 O
weeks O
. O

This O
8-week O
, O
multicentric O
, O
interventional O
, O
randomized O
, O
open-label O
, O
parallel O
group O
study O
was O
conducted O
at O
4 O
centers O
in O
Brazil O
and O
1 O
center O
in O
Argentina O
. O

Patients O
with O
open-angle O
glaucoma O
or O
ocular O
hypertension O
were O
randomized O
to O
receive O
bilaterally O
fixed O
combination O
of O
brimonidine/timolol O
maleate O
0.5 O
% O
or O
fixed O
combination O
of O
dorzolamide O
2 O
% O
/timolol O
0.5 O
% O
twice O
daily O
at O
8:00 O
AM O
and O
8:00 O
PM O
. O

A O
modified O
diurnal O
tension O
curve O
( O
8:00 O
AM O
, O
10:30 O
AM O
, O
02:00 O
PM O
, O
and O
4:00 O
PM O
) O
followed O
by O
the O
water O
drinking O
test O
( O
WDT O
) O
, O
which O
estimates O
IOP O
peak O
of O
diurnal O
tension O
curve O
, O
were O
performed O
in O
the O
baseline O
and O
week-8 O
visits O
. O

Adverse O
events O
data O
were O
recorded O
at O
each O
visit O
. O

A O
total O
of O
210 O
patients O
were O
randomized O
( O
brimonidine/timolol O
, O
n=111 O
";" O
dorzolamide/timolol O
, O
n=99 O
) O
. O

Mean O
baseline O
IOP O
was O
23.43+/-3.22 O
mm O
Hg O
and O
23.43+/-4.06 O
mm O
Hg O
in O
the O
patients O
treated O
with O
brimonidine/timolol O
and O
dorzolamide/timolol O
, O
respectively O
( O
P=0.993 O
) O
. O

Mean B-Premise
diurnal I-Premise
IOP I-Premise
reduction I-Premise
after I-Premise
8 I-Premise
weeks I-Premise
were I-Premise
7.02+/-3.06 I-Premise
mm I-Premise
Hg I-Premise
and I-Premise
6.91+/-3.67 I-Premise
mm I-Premise
Hg I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P=0.811 I-Premise
) I-Premise
. I-Premise

The B-Premise
adjusted I-Premise
difference I-Premise
between I-Premise
groups I-Premise
( I-Premise
analysis I-Premise
of I-Premise
covariance I-Premise
) I-Premise
at I-Premise
week I-Premise
8 I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P=0.847 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
baseline I-Premise
WDT I-Premise
peak I-Premise
was I-Premise
27.79+/-4.29 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
brimonidine/timolol I-Premise
group I-Premise
and I-Premise
27.68+/-5.46 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
dorzolamide/timolol I-Premise
group I-Premise
. I-Premise

After B-Premise
8 I-Premise
weeks I-Premise
of I-Premise
treatment I-Premise
, I-Premise
mean I-Premise
WDT I-Premise
peaks I-Premise
were I-Premise
20.94+/-3.76 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
20.98+/-4.19 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The O
adjusted O
difference O
between O
groups O
( O
analysis O
of O
covariance O
) O
was O
not O
statistically O
significant O
( O
P=0.469 O
) O
. O

No B-Premise
statistical I-Premise
difference I-Premise
in I-Premise
terms I-Premise
of I-Premise
adverse I-Premise
events I-Premise
was I-Premise
found I-Premise
between I-Premise
groups I-Premise
. I-Premise

Both B-Claim
fixed I-Claim
combinations I-Claim
were I-Claim
capable I-Claim
of I-Claim
significantly I-Claim
reducing I-Claim
the I-Claim
mean I-Claim
diurnal I-Claim
IOP I-Claim
, I-Claim
mean I-Claim
diurnal I-Claim
peak I-Claim
, I-Claim
and I-Claim
mean I-Claim
WDT I-Claim
peak I-Claim
after I-Claim
8 I-Claim
weeks I-Claim
of I-Claim
treatment I-Claim
. I-Claim

Also O
, O
both B-Claim
fixed I-Claim
combinations I-Claim
are I-Claim
well I-Claim
tolerated I-Claim
with I-Claim
few I-Claim
side I-Claim
effects I-Claim
. I-Claim

To O
compare O
the O
intraocular O
pressure O
) O
-lowering O
effect O
and O
side O
effects O
of O
latanoprost O
0.005 O
% O
once O
daily O
with O
unoprostone O
0.12 O
% O
twice O
daily O
. O

Sixty O
patients O
with O
primary O
open-angle O
glaucoma O
or O
ocular O
hypertension O
were O
randomized O
to O
receive O
either O
latanoprost O
once O
daily O
in O
the O
evening O
and O
placebo O
once O
daily O
in O
the O
morning O
, O
or O
unoprostone O
twice O
daily O
in O
the O
morning O
and O
evening O
. O

The O
study O
was O
double O
masked O
and O
followed O
a O
crossover O
design O
with O
two O
treatment O
periods O
of O
1 O
month O
separated O
by O
a O
3-week O
washout O
period O
. O

The O
intraocular O
pressure O
was O
measured O
at O
9 O
AM O
and O
5 O
PM O
on O
the O
baseline O
and O
day O
28 O
visits O
, O
and O
at O
9 O
AM O
on O
day O
2 O
and O
day O
14 O
visits O
of O
each O
treatment O
period O
. O

The O
9 O
AM O
measurement O
was O
taken O
2 O
hours O
and O
13 O
hours O
after O
the O
last O
drop O
of O
unoprostone O
and O
latanoprost O
, O
and O
the O
5 O
PM O
measurement O
was O
at O
10 O
and O
21 O
hours O
, O
respectively O
. O

The O
mean O
of O
the O
measurements O
was O
calculated O
. O

Safety O
parameters O
were O
also O
recorded O
. O

Fifty-six O
patients O
completed O
both O
treatment O
periods O
and O
had O
intraocular O
pressure O
data O
available O
for O
evaluation O
. O

After B-Premise
1 I-Premise
month I-Premise
of I-Premise
treatment I-Premise
, I-Premise
latanoprost I-Premise
significantly I-Premise
reduced I-Premise
intraocular I-Premise
pressure I-Premise
( I-Premise
mean I-Premise
+/- I-Premise
SEM I-Premise
) I-Premise
by I-Premise
6.1 I-Premise
+/- I-Premise
0.5 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
unoprostone I-Premise
by I-Premise
4.2 I-Premise
+/- I-Premise
0.4 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
adjusted I-Premise
from I-Premise
an I-Premise
overall I-Premise
baseline I-Premise
of I-Premise
22.3 I-Premise
+/- I-Premise
0.5 I-Premise
mm I-Premise
Hg I-Premise
and I-Premise
23.2 I-Premise
+/- I-Premise
0.4 I-Premise
mm I-Premise
Hg I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
difference I-Premise
of I-Premise
1.9 I-Premise
mm I-Premise
Hg I-Premise
between I-Premise
treatments I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
in I-Premise
favor I-Premise
of I-Premise
latanoprost I-Premise
[ I-Premise
P I-Premise
=.003 I-Premise
, I-Premise
analysis I-Premise
of I-Premise
covariance I-Premise
( I-Premise
ANCOVA I-Premise
) I-Premise
] I-Premise
. I-Premise

Unadjusted B-Premise
analysis I-Premise
of I-Premise
responders I-Premise
using I-Premise
the I-Premise
percentage I-Premise
decrease I-Premise
in I-Premise
intraocular I-Premise
pressure I-Premise
showed I-Premise
that I-Premise
the I-Premise
proportion I-Premise
of I-Premise
responders I-Premise
in I-Premise
the I-Premise
latanoprost-treated I-Premise
group I-Premise
was I-Premise
greater I-Premise
than I-Premise
in I-Premise
the I-Premise
unoprostone-treated I-Premise
group I-Premise
. I-Premise

Adverse B-Premise
ocular I-Premise
symptoms I-Premise
and I-Premise
findings I-Premise
were I-Premise
mild I-Premise
in I-Premise
both I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Eye B-Premise
redness I-Premise
and I-Premise
ocular I-Premise
irritation I-Premise
were I-Premise
the I-Premise
most I-Premise
frequently I-Premise
reported I-Premise
events I-Premise
. I-Premise

Latanoprost B-Claim
once I-Claim
daily I-Claim
was I-Claim
significantly I-Claim
more I-Claim
effective I-Claim
in I-Claim
reducing I-Claim
intraocular I-Claim
pressure I-Claim
compared I-Claim
with I-Claim
unoprostone I-Claim
twice I-Claim
daily I-Claim
after I-Claim
1 I-Claim
month I-Claim
of I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
primary I-Claim
open-angle I-Claim
glaucoma I-Claim
and I-Claim
ocular I-Claim
hypertension I-Claim
. I-Claim

Both B-Claim
drugs I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
with I-Claim
few I-Claim
ocular I-Claim
adverse I-Claim
events I-Claim
. I-Claim

To O
compare O
latanoprost O
and O
timolol O
with O
regard O
to O
changes O
in O
the O
intervisit O
intraocular O
pressure O
( O
IOP O
) O
range O
, O
a O
measure O
of O
long-term O
IOP O
fluctuation O
. O

Post O
hoc O
analysis O
of O
three O
6-month O
, O
multicenter O
, O
randomized O
( O
1:1 O
) O
, O
double-masked O
registration O
trials O
of O
latanoprost O
( O
n O
= O
313 O
) O
vs O
timolol O
( O
n O
= O
318 O
) O
. O

Analyses O
included O
patients O
with O
glaucoma O
or O
ocular O
hypertension O
who O
instilled O
latanoprost O
once O
daily O
in O
the O
evening O
and O
vehicle O
in O
the O
morning O
and O
those O
instilling O
timolol O
twice O
daily O
. O

Pretreatment O
intervisit O
IOP O
range O
: O
highest O
IOP O
minus O
lowest O
IOP O
of O
4 O
measurements O
obtained O
at O
screening O
and O
baseline O
. O

Posttreatment O
intervisit O
IOP O
range O
: O
highest O
IOP O
minus O
lowest O
IOP O
of O
4 O
measurements O
obtained O
at O
weeks O
18 O
and O
26 O
. O

Ranges O
were O
dichotomized O
to O
high O
( O
> O
6 O
mm O
Hg O
) O
and O
low O
( O
< O
or O
= O
6 O
mm O
Hg O
) O
. O

Both B-Claim
treatments I-Claim
resulted I-Claim
in I-Claim
significant I-Claim
reductions I-Claim
in I-Claim
mean I-Claim
intervisit I-Claim
IOP I-Claim
range I-Claim
during I-Claim
26 I-Claim
weeks I-Claim
. I-Claim

Pretreatment O
, O
comparable O
proportions O
of O
patients O
treated O
with O
latanoprost O
and O
timolol O
had O
high O
intervisit O
IOP O
ranges O
( O
22 O
% O
[ O
70/313 O
] O
and O
23 O
% O
[ O
72/318 O
] O
, O
respectively O
";" O
P O
= O
.934 O
) O
. O

After B-Premise
treatment I-Premise
, I-Premise
6 I-Premise
% I-Premise
( I-Premise
19/313 I-Premise
) I-Premise
and I-Premise
11 I-Premise
% I-Premise
( I-Premise
35/318 I-Premise
) I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
latanoprost I-Premise
and I-Premise
timolol I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
, I-Premise
had I-Premise
high I-Premise
intervisit I-Premise
IOP I-Premise
ranges I-Premise
( I-Premise
P I-Premise
= I-Premise
.026 I-Premise
) I-Premise
. I-Premise

Significant B-Premise
risk I-Premise
factors I-Premise
for I-Premise
high I-Premise
posttreatment I-Premise
intervisit I-Premise
range I-Premise
( I-Premise
multivariate I-Premise
logistic I-Premise
regression I-Premise
) I-Premise
were I-Premise
high I-Premise
pretreatment I-Premise
intervisit I-Premise
IOP I-Premise
range I-Premise
, I-Premise
treatment I-Premise
with I-Premise
timolol I-Premise
, I-Premise
Black I-Premise
race I-Premise
, I-Premise
longer I-Premise
time I-Premise
since I-Premise
diagnosis I-Premise
, I-Premise
and I-Premise
higher I-Premise
mean I-Premise
pretreatment I-Premise
IOP I-Premise
. I-Premise

Compared B-Claim
with I-Claim
timolol I-Claim
, I-Claim
treatment I-Claim
with I-Claim
latanoprost I-Claim
results I-Claim
in I-Claim
significantly I-Claim
fewer I-Claim
patients I-Claim
with I-Claim
a I-Claim
high I-Claim
IOP I-Claim
fluctuation I-Claim
. I-Claim

The O
impact O
of O
reducing O
high O
IOP O
fluctuation O
on O
progressive O
glaucomatous O
damage O
deserves O
further O
investigation O
in O
prospective O
studies O
. O

To O
report O
a O
randomized O
clinical O
trial O
of O
postoperative O
subconjunctival O
injections O
of O
low-dose O
5-fluorouracil O
in O
patients O
undergoing O
primary O
trabeculectomy O
. O

In O
a O
prospective O
, O
randomized O
clinical O
trial O
, O
40 O
eyes O
of O
40 O
patients O
were O
randomized O
to O
the O
low-dose O
5-fluorouracil O
group O
and O
received O
three O
subconjunctival O
injections O
of O
5 O
mg O
each O
over O
11 O
postoperative O
days O
, O
and O
40 O
eyes O
of O
40 O
patients O
were O
randomized O
to O
trabeculectomy O
without O
5-fluorouracil O
. O

Mean B-Premise
( I-Premise
+/-SD I-Premise
) I-Premise
preoperative I-Premise
and I-Premise
1-year I-Premise
postoperative I-Premise
intraocular I-Premise
pressures I-Premise
in I-Premise
the I-Premise
5-fluorouracil I-Premise
group I-Premise
were I-Premise
26.9 I-Premise
( I-Premise
+/-9.5 I-Premise
) I-Premise
and I-Premise
15.3 I-Premise
( I-Premise
+/-5.8 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Premise
the I-Premise
control I-Premise
group I-Premise
these I-Premise
were I-Premise
25.9 I-Premise
( I-Premise
+/-8.1 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
, I-Premise
and I-Premise
15.8 I-Premise
( I-Premise
+/-5.1 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
patients I-Premise
who I-Premise
received I-Premise
5-fluorouracil I-Premise
had I-Premise
a I-Premise
mean I-Premise
reduction I-Premise
in I-Premise
intraocular I-Premise
pressure I-Premise
of I-Premise
11.5 I-Premise
( I-Premise
+/-9.1 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
at I-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
52.3 I-Premise
weeks I-Premise
. I-Premise

The B-Premise
control I-Premise
group I-Premise
had I-Premise
a I-Premise
mean I-Premise
reduction I-Premise
in I-Premise
intraocular I-Premise
pressure I-Premise
of I-Premise
10.2 I-Premise
( I-Premise
+/-8.7 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
at I-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
52.6 I-Premise
weeks I-Premise
. I-Premise

These B-Premise
differences I-Premise
were I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

Three B-Premise
postoperative I-Premise
subconjunctival I-Premise
5-fluorouracil I-Premise
injections I-Premise
of I-Premise
5 I-Premise
mg I-Premise
each I-Premise
after I-Premise
trabeculectomy I-Premise
in I-Premise
eyes I-Premise
at I-Premise
low I-Premise
risk I-Premise
for I-Premise
failure I-Premise
had I-Premise
no I-Premise
statistically I-Premise
or I-Premise
clinically I-Premise
significant I-Premise
effect I-Premise
on I-Premise
reduction I-Premise
of I-Premise
intraocular I-Premise
pressure I-Premise
with I-Premise
1-year I-Premise
follow-up I-Premise
. I-Premise

Enhancement B-Claim
of I-Claim
success I-Claim
in I-Claim
this I-Claim
group I-Claim
of I-Claim
patients I-Claim
may I-Claim
require I-Claim
a I-Claim
larger I-Claim
total I-Claim
dose I-Claim
of I-Claim
5-fluorouracil I-Claim
. I-Claim

To O
compare O
the O
longitudinal O
effects O
of O
treatment O
on O
intraocular O
pressure O
( O
IOP O
) O
and O
visual O
field O
performance O
in O
Japanese O
normal-tension O
glaucoma O
( O
NTG O
) O
between O
latanoprost O
and O
timolol O
. O

This O
is O
an O
open-label O
, O
randomized O
, O
study O
. O

A O
total O
of O
62 O
NTG O
patients O
were O
prospectively O
, O
consecutively O
enrolled O
. O

All O
study O
subjects O
were O
randomly O
assigned O
to O
0.005 O
% O
latanoprost O
instillation O
once O
daily O
in O
the O
morning O
or O
0.5 O
% O
timolol O
instillation O
twice O
daily O
for O
a O
prospective O
3-year O
follow-up O
, O
and O
underwent O
a O
routine O
ocular O
examination O
every O
month O
. O

Automated O
perimetry O
was O
performed O
every O
6 O
months O
using O
Humphrey O
field O
analysers O
. O

Stereophotographs O
of O
optic O
discs O
were O
also O
obtained O
every O
6 O
months O
. O

Percentage B-Premise
of I-Premise
IOP I-Premise
reduction I-Premise
or I-Premise
the I-Premise
magnitude I-Premise
of I-Premise
IOP I-Premise
reduction I-Premise
showed I-Premise
no I-Premise
intergroup I-Premise
differences I-Premise
either I-Premise
at I-Premise
any I-Premise
time I-Premise
point I-Premise
( I-Premise
13-15 I-Premise
% I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
visual I-Premise
field I-Premise
, I-Premise
the I-Premise
estimated I-Premise
rate I-Premise
of I-Premise
change I-Premise
in I-Premise
the I-Premise
MD I-Premise
value I-Premise
( I-Premise
dB/year I-Premise
) I-Premise
was I-Premise
-0.34+/-0.17 I-Premise
( I-Premise
SE I-Premise
) I-Premise
for I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
, I-Premise
and I-Premise
-0.10+/-0.18 I-Premise
( I-Premise
SE I-Premise
) I-Premise
for I-Premise
the I-Premise
timolol I-Premise
group I-Premise
. I-Premise

The B-Premise
estimated I-Premise
rate I-Premise
of I-Premise
change I-Premise
in I-Premise
MD I-Premise
showed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
from I-Premise
zero I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
and I-Premise
there I-Premise
were I-Premise
no I-Premise
statistical I-Premise
intergroup I-Premise
differences I-Premise
. I-Premise

No B-Premise
changes I-Premise
in I-Premise
the I-Premise
optic I-Premise
nerve I-Premise
head I-Premise
topography I-Premise
in I-Premise
the I-Premise
vertical I-Premise
cup-to-disc I-Premise
ratio I-Premise
and I-Premise
rim I-Premise
area I-Premise
measured I-Premise
by I-Premise
image-analysis I-Premise
techniques I-Premise
were I-Premise
observed I-Premise
in I-Premise
either I-Premise
group I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
patients I-Premise
who I-Premise
dropped I-Premise
out I-Premise
due I-Premise
to I-Premise
the I-Premise
side I-Premise
effects I-Premise
of I-Premise
treatment I-Premise
regimens I-Premise
. I-Premise

Both B-Claim
latanoprost I-Claim
and I-Claim
timolol I-Claim
single I-Claim
treatments I-Claim
reduced I-Claim
IOP I-Claim
by I-Claim
13-15 I-Claim
% I-Claim
at I-Claim
their I-Claim
trough I-Claim
effects I-Claim
for I-Claim
3 I-Claim
years I-Claim
in I-Claim
Japanese I-Claim
NTG I-Claim
patients I-Claim
";" O
both B-Claim
showed I-Claim
similar I-Claim
effects I-Claim
on I-Claim
visual I-Claim
field I-Claim
performance I-Claim
. I-Claim

Latanoprost O
is O
a O
PGF2 O
alpha O
analogue O
which O
reduces O
the O
intraocular O
pressure O
( O
IOP O
) O
by O
increasing O
the O
uveoscleral O
outflow O
. O

The O
objective O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
two O
different O
regimens O
of O
latanoprost O
on O
the O
diurnal O
IOP O
and O
also O
the O
effect O
of O
latanoprost O
on O
the O
blood-aqueous O
barrier O
measured O
with O
a O
laser O
flare O
cell O
meter O
( O
Kowa O
FM-500 O
) O
. O

Moreover O
, O
the O
safety O
aspects O
of O
the O
two O
regimens O
regarding O
hyperemia O
were O
studied O
. O

A O
double-masked O
, O
randomized O
study O
was O
performed O
in O
30 O
patients O
( O
9 O
males O
, O
21 O
females O
";" O
mean O
age O
61.9 O
years O
) O
with O
primary O
open-angle O
glaucoma O
or O
pseudoexfoliation O
glaucoma O
. O

Twenty O
patients O
were O
treated O
with O
latanoprost O
0.0015 O
% O
twice O
daily O
or O
0.005 O
% O
once O
daily O
for O
3 O
weeks O
in O
a O
cross-over O
design O
. O

Ten O
patients O
received O
timolol O
0.5 O
% O
twice O
daily O
as O
control O
. O

Latanoprost B-Premise
0.005 I-Premise
% I-Premise
once I-Premise
daily I-Premise
reduced I-Premise
IOP I-Premise
( I-Premise
+/- I-Premise
SEM I-Premise
) I-Premise
more I-Premise
effectively I-Premise
than I-Premise
latanoprost I-Premise
0.0015 I-Premise
% I-Premise
twice I-Premise
daily I-Premise
( I-Premise
9.8 I-Premise
+/- I-Premise
0.9 I-Premise
mm I-Premise
Hg I-Premise
and I-Premise
6.7 I-Premise
+/- I-Premise
0.9 I-Premise
mm I-Premise
Hg I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
increase I-Premise
in I-Premise
the I-Premise
aqueous I-Premise
humour I-Premise
protein I-Premise
concentration I-Premise
within I-Premise
the I-Premise
timolol I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
, I-Premise
but I-Premise
not I-Premise
within I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.97 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
change I-Premise
in I-Premise
aqueous I-Premise
humour I-Premise
protein I-Premise
concentration I-Premise
from I-Premise
baseline I-Premise
between I-Premise
latanoprost I-Premise
and I-Premise
timolol I-Premise
groups I-Premise
( I-Premise
P I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
conjunctival I-Premise
hyperemia I-Premise
between I-Premise
the I-Premise
two I-Premise
latanoprost I-Premise
regimens I-Premise
was I-Premise
found I-Premise
( I-Premise
P I-Premise
= I-Premise
0.37 I-Premise
) I-Premise
. I-Premise

Latanoprost B-Premise
0.005 I-Premise
% I-Premise
once I-Premise
daily I-Premise
reduced I-Premise
IOP I-Premise
more I-Premise
effectively I-Premise
than I-Premise
latanoprost I-Premise
0.0015 I-Premise
% I-Premise
twice I-Premise
daily I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Latanoprost B-Claim
had I-Claim
no I-Claim
statistically I-Claim
or I-Claim
clinically I-Claim
significant I-Claim
effect I-Claim
on I-Claim
the I-Claim
blood-aqueous I-Claim
barrier I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
difference I-Claim
in I-Claim
hyperemia I-Claim
between I-Claim
the I-Claim
two I-Claim
regimens I-Claim
. I-Claim

Both B-Claim
concentrations I-Claim
of I-Claim
latanoprost I-Claim
reduced I-Claim
IOP I-Claim
at I-Claim
least I-Claim
as I-Claim
well I-Claim
as I-Claim
timolol I-Claim
0.5 I-Claim
% I-Claim
eye I-Claim
drops I-Claim
. I-Claim

We O
conducted O
a O
prospective O
, O
randomized O
study O
to O
compare O
mitomycin O
with O
fluorouracil O
for O
efficacy O
and O
safety O
as O
an O
adjunct O
to O
trabeculectomy O
in O
eyes O
with O
glaucoma O
with O
poor O
surgical O
prognosis O
. O

Thirty-two O
eyes O
of O
32 O
patients O
were O
randomly O
allocated O
to O
either O
mitomycin O
( O
17 O
eyes O
) O
or O
fluorouracil O
therapy O
( O
15 O
eyes O
) O
. O

Mitomycin O
( O
0.2 O
mg O
) O
was O
applied O
only O
once O
during O
trabeculectomy O
, O
and O
fluorouracil O
( O
5 O
mg O
) O
was O
subconjunctivally O
injected O
10 O
times O
in O
the O
2 O
weeks O
after O
surgery O
. O

Fifteen B-Premise
eyes I-Premise
( I-Premise
88 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
mitomycin I-Premise
group I-Premise
and I-Premise
seven I-Premise
( I-Premise
47 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
fluorouracil I-Premise
group I-Premise
achieved I-Premise
an I-Premise
intraocular I-Premise
pressure I-Premise
of I-Premise
less I-Premise
than I-Premise
or I-Premise
equal I-Premise
to I-Premise
20 I-Premise
mm I-Premise
Hg I-Premise
without I-Premise
antiglaucoma I-Premise
medication I-Premise
. I-Premise

The O
follow-up O
period O
was O
7 O
to O
12 O
months O
. O

Corneal B-Premise
complications I-Premise
were I-Premise
less I-Premise
common I-Premise
in I-Premise
the I-Premise
group I-Premise
given I-Premise
mitomycin I-Premise
than I-Premise
in I-Premise
that I-Premise
given I-Premise
fluorouracil I-Premise
( I-Premise
12 I-Premise
% I-Premise
vs I-Premise
53 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Claim
incidence I-Claim
of I-Claim
other I-Claim
complications I-Claim
was I-Claim
similar I-Claim
between I-Claim
the I-Claim
two I-Claim
groups I-Claim
. I-Claim

trabeculectomy O
is O
the O
standard O
surgical O
procedure O
for O
management O
of O
glaucoma O
. O

to O
compare O
the O
outcome O
of O
triangular O
and O
rectangular O
scleral O
flaps O
in O
trabeculectomy O
. O

this O
study O
was O
carried O
out O
in O
the O
Department O
ofOphthalmology O
, O
BPKIHS O
, O
Dharan O
, O
over O
a O
period O
of O
one O
year O
. O

A O
total O
of O
22 O
patients O
undergoing O
trabeculectomy O
were O
randomized O
to O
undergo O
either O
trabeculectomy O
with O
triangular O
scleral O
flap O
( O
Group O
A= O
11 O
eyes O
) O
or O
trabeculectomy O
with O
rectangular O
flap O
( O
Group O
B O
= O
11 O
eyes O
) O
. O

the O
parameters O
studied O
were O
intraocular O
pressure O
( O
IOP O
) O
, O
anterior O
chamber O
depth O
( O
ACD O
) O
, O
bleb O
characteristics O
and O
surgical O
complications O
. O

P O
value O
of O
< O
0.05 O
was O
considered O
significant O
. O

All O
calculations O
were O
executed O
using O
SPSS O
11.0 O
software O
program O
. O

the O
age O
ranged O
between O
40 O
to O
76 O
years O
with O
the O
mean O
of O
56.5 O
+/- O
9.25 O
years O
. O

The O
most O
common O
preoperative O
diagnosis O
was O
angle O
closure O
glaucoma O
. O

The B-Premise
postoperative I-Premise
percentage I-Premise
of I-Premise
IOP I-Premise
reduction I-Premise
( I-Premise
Group I-Premise
A I-Premise
68.9 I-Premise
% I-Premise
";" I-Premise
Group I-Premise
B I-Premise
66.51 I-Premise
% I-Premise
) I-Premise
was I-Premise
statically I-Premise
significant I-Premise
in I-Premise
both I-Premise
the I-Premise
groups I-Premise
( I-Premise
p=0.001 I-Premise
) I-Premise
. I-Premise

Trabeculectomy B-Premise
was I-Premise
almost I-Premise
equally I-Premise
effective I-Premise
with I-Premise
complete I-Premise
surgical I-Premise
success I-Premise
of I-Premise
91 I-Premise
% I-Premise
in I-Premise
group I-Premise
A I-Premise
, I-Premise
and I-Premise
82 I-Premise
% I-Premise
in I-Premise
group I-Premise
B I-Premise
( I-Premise
p=0.534 I-Premise
) I-Premise
. I-Premise

Final B-Premise
bleb I-Premise
scores I-Premise
were I-Premise
almost I-Premise
similar I-Premise
in I-Premise
both I-Premise
the I-Premise
groups I-Premise
with I-Premise
3.27 I-Premise
+/- I-Premise
1.5 I-Premise
in I-Premise
group I-Premise
A I-Premise
and I-Premise
3.36 I-Premise
+/- I-Premise
1.21 I-Premise
in I-Premise
group I-Premise
B I-Premise
( I-Premise
p=0.877 I-Premise
) I-Premise
. I-Premise

Hypotony B-Premise
with I-Premise
the I-Premise
IOP I-Premise
less I-Premise
than I-Premise
6 I-Premise
mmHg I-Premise
was I-Premise
found I-Premise
in I-Premise
the I-Premise
first I-Premise
post-operative I-Premise
day I-Premise
in I-Premise
2 I-Premise
patients I-Premise
in I-Premise
Group I-Premise
A I-Premise
and I-Premise
in I-Premise
1 I-Premise
in I-Premise
Group I-Premise
B I-Premise
. I-Premise

All O
of O
them O
improved O
spontaneously O
within O
a O
week O
. O

both B-Claim
triangular I-Claim
and I-Claim
rectangular I-Claim
scleral I-Claim
flaps I-Claim
in I-Claim
trabeculectomy I-Claim
are I-Claim
equally I-Claim
effective I-Claim
in I-Claim
terms I-Claim
of I-Claim
post I-Claim
surgical I-Claim
IOP I-Claim
control I-Claim
, I-Claim
bleb I-Claim
characteristics I-Claim
and I-Claim
complications I-Claim
. I-Claim

To O
compare O
the O
efficacy O
and O
safety O
of O
topical O
bimatoprost O
( O
LUMIGAN O
";" O
Allergan O
, O
Inc. O
, O
Irvine O
, O
CA O
) O
once O
daily O
with O
that O
of O
topical O
combined O
timolol O
and O
dorzolamide O
( O
Cosopt O
";" O
Merck O
and O
Co O
, O
Inc. O
, O
Whitehouse O
Station O
, O
NJ O
) O
twice O
daily O
. O

Prospective O
, O
randomized O
, O
double-masked O
, O
multicenter O
clinical O
trial O
. O

One O
hundred O
seventy-seven O
patients O
with O
a O
diagnosis O
of O
glaucoma O
or O
ocular O
hypertension O
and O
inadequate O
control O
of O
intraocular O
pressure O
( O
IOP O
) O
after O
at O
least O
2 O
weeks O
of O
topical O
timolol O
maleate O
0.5 O
% O
monotherapy O
. O

Patients O
were O
randomized O
to O
receive O
bimatoprost O
0.03 O
% O
once O
daily O
( O
n O
= O
90 O
) O
or O
combined O
timolol O
0.5 O
% O
and O
dorzolamide O
2 O
% O
twice O
daily O
( O
n O
= O
87 O
) O
over O
a O
3-month O
period O
. O

Intraocular O
pressure O
, O
the O
primary O
end O
point O
, O
was O
measured O
at O
8 O
AM O
and O
10 O
AM O
at O
baseline O
, O
week O
1 O
, O
and O
months O
1 O
, O
2 O
, O
and O
3 O
, O
and O
also O
at O
4 O
PM O
and O
8 O
PM O
at O
baseline O
and O
month O
3 O
. O

Bimatoprost B-Premise
provided I-Premise
significantly I-Premise
greater I-Premise
IOP I-Premise
lowering I-Premise
compared I-Premise
with I-Premise
combined I-Premise
timolol I-Premise
and I-Premise
dorzolamide I-Premise
. I-Premise

At B-Premise
the I-Premise
8 I-Premise
AM I-Premise
measurements I-Premise
, I-Premise
bimatoprost I-Premise
lowered I-Premise
mean I-Premise
IOP I-Premise
6.8 I-Premise
mmHg I-Premise
to I-Premise
7.6 I-Premise
mmHg I-Premise
from I-Premise
baseline I-Premise
, I-Premise
whereas I-Premise
combined I-Premise
timolol I-Premise
and I-Premise
dorzolamide I-Premise
lowered I-Premise
mean I-Premise
IOP I-Premise
4.4 I-Premise
to I-Premise
5.0 I-Premise
mmHg I-Premise
from I-Premise
baseline I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
the I-Premise
last I-Premise
follow-up I-Premise
, I-Premise
patients I-Premise
had I-Premise
better I-Premise
diurnal I-Premise
IOP I-Premise
control I-Premise
with I-Premise
bimatoprost I-Premise
than I-Premise
combined I-Premise
timolol I-Premise
and I-Premise
dorzolamide I-Premise
. I-Premise

At B-Premise
8 I-Premise
AM I-Premise
at I-Premise
the I-Premise
3-month I-Premise
visit I-Premise
, I-Premise
the I-Premise
percentages I-Premise
of I-Premise
patients I-Premise
achieving I-Premise
IOPs I-Premise
of I-Premise
< I-Premise
or I-Premise
13 I-Premise
mmHg I-Premise
, I-Premise
< I-Premise
or I-Premise
14 I-Premise
mmHg I-Premise
, I-Premise
< I-Premise
or I-Premise
15 I-Premise
mmHg I-Premise
, I-Premise
or I-Premise
< I-Premise
or I-Premise
16 I-Premise
mmHg I-Premise
were I-Premise
more I-Premise
than I-Premise
twice I-Premise
as I-Premise
high I-Premise
for I-Premise
bimatoprost I-Premise
than I-Premise
for I-Premise
combined I-Premise
timolol I-Premise
and I-Premise
dorzolamide I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
or I-Premise
=0.008 I-Premise
) I-Premise
. I-Premise

Taste B-Premise
perversion I-Premise
, I-Premise
ocular I-Premise
burning I-Premise
, I-Premise
and I-Premise
stinging I-Premise
with I-Premise
instillation I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
combined I-Premise
timolol I-Premise
and I-Premise
dorzolamide I-Premise
, I-Premise
whereas I-Premise
conjunctival I-Premise
hyperemia I-Premise
was I-Premise
more I-Premise
common I-Premise
with I-Premise
bimatoprost I-Premise
. I-Premise

In B-Claim
individuals I-Claim
with I-Claim
glaucoma I-Claim
or I-Claim
ocular I-Claim
hypertension I-Claim
, I-Claim
uncontrolled I-Claim
on I-Claim
a I-Claim
topical I-Claim
beta-blocker I-Claim
alone I-Claim
, I-Claim
bimatoprost I-Claim
lowered I-Claim
IOP I-Claim
more I-Claim
consistently I-Claim
than I-Claim
did I-Claim
combined I-Claim
timolol I-Claim
and I-Claim
dorzolamide I-Claim
. I-Claim

In O
a O
randomized O
clinical O
trial O
, O
the O
authors O
compared O
the O
use O
of O
postoperative O
subconjunctival O
injections O
of O
5-fluorouracil O
( O
5-FU O
) O
in O
19 O
eyes O
with O
a O
single O
intraoperative O
application O
of O
subconjunctival O
mitomycin O
( O
MMC O
) O
at O
the O
filtering O
site O
in O
20 O
eyes O
at O
high O
risk O
for O
failure O
of O
glaucoma O
filtering O
surgery O
. O

Six B-Premise
months I-Premise
after I-Premise
surgery I-Premise
, I-Premise
intraocular I-Premise
pressures I-Premise
averaged I-Premise
10.9 I-Premise
+/- I-Premise
5.3 I-Premise
mmHg I-Premise
( I-Premise
mean I-Premise
+/- I-Premise
standard I-Premise
deviation I-Premise
) I-Premise
in I-Premise
the I-Premise
MMC-treated I-Premise
eyes I-Premise
versus I-Premise
14.2 I-Premise
+/- I-Premise
5.5 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
5-FU-treated I-Premise
eyes I-Premise
( I-Premise
P I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
and I-Premise
were I-Premise
less I-Premise
than I-Premise
or I-Premise
equal I-Premise
to I-Premise
12 I-Premise
mmHg I-Premise
in I-Premise
60.0 I-Premise
% I-Premise
of I-Premise
MMC-treated I-Premise
eyes I-Premise
and I-Premise
21.1 I-Premise
% I-Premise
of I-Premise
5-FU-treated I-Premise
eyes I-Premise
( I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

Mitomycin-treated O
eyes O
were O
receiving O
an O
average O
of O
0.3 O
+/- O
0.5 O
medications O
for O
intraocular O
pressure O
control O
, O
and O
5-FU-treated O
eyes O
were O
receiving O
an O
average O
of O
1.1 O
+/- O
1.1 O
medications O
( O
P O
= O
0.01 O
) O
. O

Drug-induced B-Premise
corneal I-Premise
epithelial I-Premise
defects I-Premise
were I-Premise
seen I-Premise
in I-Premise
nine I-Premise
5-FU-treated I-Premise
eyes I-Premise
and I-Premise
in I-Premise
no I-Premise
MMC-treated I-Premise
eyes I-Premise
( I-Premise
P I-Premise
= I-Premise
0.0004 I-Premise
) I-Premise
. I-Premise

These B-Claim
results I-Claim
suggest I-Claim
that I-Claim
intraoperative I-Claim
MMC I-Claim
may I-Claim
be I-Claim
a I-Claim
viable I-Claim
alternative I-Claim
to I-Claim
postoperative I-Claim
5-FU I-Claim
, I-Claim
with I-Claim
lower I-Claim
overall I-Claim
intraocular I-Claim
pressures I-Claim
, I-Claim
decreased I-Claim
dependence I-Claim
on I-Claim
postoperative I-Claim
ocular I-Claim
antihypertensive I-Claim
medications I-Claim
, I-Claim
and I-Claim
decreased I-Claim
corneal I-Claim
toxicity I-Claim
. I-Claim

To O
compare O
the O
intraocular O
pressure O
( O
IOP O
) O
-reducing O
effect O
and O
side O
effects O
of O
0.005 O
% O
latanoprost O
administered O
once O
daily O
with O
0.5 O
% O
timolol O
administered O
twice O
daily O
in O
patients O
with O
open-angle O
glaucoma O
or O
ocular O
hypertension O
. O

This O
was O
a O
randomized O
, O
double-masked O
study O
with O
two O
parallel O
groups O
and O
a O
treatment O
period O
of O
6 O
months O
. O

The O
primary O
objective O
of O
the O
study O
is O
to O
compare O
the O
IOP-reducing O
effect O
of O
latanoprost O
with O
that O
of O
timolol O
at O
the O
end O
of O
the O
6-month O
treatment O
period O
. O

A O
total O
of O
294 O
patients O
were O
included O
: O
149 O
were O
in O
the O
latanoprost O
group O
and O
145 O
were O
in O
timolol O
group O
. O

Latanoprost O
was O
administered O
in O
the O
evening O
. O

Diurnal B-Premise
IOP I-Premise
( I-Premise
9:00 I-Premise
am I-Premise
, I-Premise
1:00 I-Premise
pm I-Premise
, I-Premise
5:00 I-Premise
pm I-Premise
) I-Premise
was I-Premise
reduced I-Premise
from I-Premise
25.2 I-Premise
to I-Premise
16.7 I-Premise
mmHg I-Premise
( I-Premise
33.7 I-Premise
% I-Premise
) I-Premise
with I-Premise
lantanoprost I-Premise
and I-Premise
from I-Premise
25.4 I-Premise
to I-Premise
17.1 I-Premise
mmHg I-Premise
( I-Premise
32.7 I-Premise
% I-Premise
) I-Premise
with I-Premise
timolol I-Premise
as I-Premise
determined I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
6-month I-Premise
treatment I-Premise
period I-Premise
. I-Premise

No O
upward O
drift O
in O
IOP O
occurred O
with O
either O
drug O
during O
the O
treatment O
period O
. O

Latanoprost B-Premise
caused I-Premise
a I-Premise
somewhat I-Premise
more I-Premise
conjunctival I-Premise
hyperemia I-Premise
than I-Premise
timolol I-Premise
and I-Premise
more I-Premise
corneal I-Premise
punctuate I-Premise
epithelial I-Premise
erosions I-Premise
. I-Premise

However O
, O
both B-Premise
drugs I-Premise
were I-Premise
generally I-Premise
well I-Premise
tolerated I-Premise
. I-Premise

The B-Premise
most I-Premise
significant I-Premise
side I-Premise
effect I-Premise
of I-Premise
latanoprost I-Premise
was I-Premise
increased I-Premise
pigmentation I-Premise
of I-Premise
the I-Premise
iris I-Premise
which I-Premise
was I-Premise
observed I-Premise
in I-Premise
15 I-Premise
patients I-Premise
( I-Premise
10.1 I-Premise
% I-Premise
) I-Premise
. I-Premise

Timolol B-Claim
caused I-Claim
more I-Claim
systemic I-Claim
side I-Claim
effects I-Claim
than I-Claim
latanoprost I-Claim
. I-Claim

Latanoprost B-Claim
0.005 I-Claim
% I-Claim
administered I-Claim
once I-Claim
daily I-Claim
in I-Claim
the I-Claim
evening I-Claim
reduced I-Claim
IOP I-Claim
at I-Claim
least I-Claim
as I-Claim
well I-Claim
as I-Claim
timolol I-Claim
0.5 I-Claim
% I-Claim
administered I-Claim
twice I-Claim
daily I-Claim
. I-Claim

Latanoprost B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
systemically I-Claim
and I-Claim
in I-Claim
the I-Claim
eye I-Claim
. I-Claim

However O
, O
the O
drug O
has O
an O
unusual O
side O
effect O
of O
increasing O
the O
pigmentation O
of O
the O
iris O
, O
particularly O
in O
individuals O
with O
green-brown O
or O
blue-brown O
eyes O
. O

To O
evaluate O
the O
long-term O
intraocular O
pressure O
( O
IOP O
) O
control O
of O
trabeculectomy O
and O
triple O
procedure O
( O
cataract O
extraction O
by O
phacoemulsification O
, O
intraocular O
lens O
implantation O
and O
trabeculectomy O
) O
, O
1,542 O
eyes O
of O
900 O
patients O
with O
primary O
open O
angle O
glaucoma O
( O
POAG O
) O
or O
chronic O
primary O
angle O
closure O
glaucoma O
( O
CPACG O
) O
were O
included O
. O

When O
success O
was O
defined O
as O
an O
IOP O
reduction O
of O
at O
least O
30 O
% O
from O
baseline O
, O
with O
or O
without O
antiglaucoma O
medications O
, O
the B-Premise
overall I-Premise
probability I-Premise
of I-Premise
success I-Premise
of I-Premise
trabeculectomy I-Premise
and I-Premise
triple I-Premise
procedure I-Premise
was I-Premise
0.613 I-Premise
and I-Premise
0.733 I-Premise
at I-Premise
15 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
success I-Premise
probability I-Premise
of I-Premise
trabeculectomy I-Premise
and I-Premise
triple I-Premise
procedure I-Premise
in I-Premise
reducing I-Premise
IOP I-Premise
below I-Premise
18 I-Premise
mm I-Premise
Hg I-Premise
was I-Premise
0.748 I-Premise
and I-Premise
0.825 I-Premise
at I-Premise
15 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Claim
POAG I-Claim
and I-Claim
CPACG I-Claim
patients I-Claim
, I-Claim
trabeculectomy I-Claim
and I-Claim
triple I-Claim
procedure I-Claim
were I-Claim
effective I-Claim
in I-Claim
reducing I-Claim
IOP I-Claim
for I-Claim
up I-Claim
to I-Claim
15 I-Claim
years I-Claim
after I-Claim
surgery I-Claim
. I-Claim

To O
determine O
the O
efficacy O
and O
safety O
of O
oral O
clonidine O
in O
decreasing O
the O
prevalence O
and O
intensity O
of O
postoperative O
intraocular O
pressure O
( O
IOP O
) O
rise O
in O
those O
undergoing O
phacoemulsification O
. O

This O
was O
a O
prospective O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
clinical O
trial O
including O
62 O
patients O
( O
each O
with O
1 O
affected O
aye O
) O
with O
senile O
cataract O
scheduled O
for O
phacoemulsification O
who O
were O
randomly O
assigned O
to O
receive O
preoperative O
oral O
clonidine O
( O
5g/kg O
, O
31 O
patients O
) O
or O
placebo O
( O
1 O
tablet O
, O
31 O
patients O
) O
. O

The O
IOP O
was O
measured O
preoperatively O
and O
at O
6 O
, O
12 O
, O
and O
24h O
postoperatively O
. O

The O
prevalence O
and O
intensity O
of O
the O
acute O
postoperative O
IOP O
rise O
was O
compared O
between O
and O
within O
the O
groups O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
2 I-Premise
study I-Premise
groups I-Premise
regarding I-Premise
the I-Premise
baseline I-Premise
characteristics I-Premise
and I-Premise
the I-Premise
baseline I-Premise
IOP I-Premise
( I-Premise
P=0.628 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
placebo I-Premise
as I-Premise
premedication I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
IOP I-Premise
at I-Premise
6 I-Premise
( I-Premise
17.96±5.49 I-Premise
vs I-Premise
13.61±4.09 I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
12 I-Premise
( I-Premise
16.90±4.11 I-Premise
vs I-Premise
13.96±3.25 I-Premise
";" I-Premise
P=0.003 I-Premise
) I-Premise
h I-Premise
postoperatively I-Premise
compared I-Premise
with I-Premise
those I-Premise
who I-Premise
received I-Premise
oral I-Premise
clonidine I-Premise
. I-Premise

However O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
2 I-Premise
groups I-Premise
regarding I-Premise
the I-Premise
IOP I-Premise
at I-Premise
24h I-Premise
after I-Premise
operation I-Premise
( I-Premise
15.41±3.96 I-Premise
vs I-Premise
16.01±3.41 I-Premise
";" I-Premise
P=0.0539 I-Premise
) I-Premise
. I-Premise

The B-Premise
prevalence I-Premise
of I-Premise
acute I-Premise
IOP I-Premise
rise I-Premise
( I-Premise
> I-Premise
21 I-Premise
mmHg I-Premise
) I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
placebo I-Premise
group I-Premise
compared I-Premise
with I-Premise
clonidine I-Premise
group I-Premise
( I-Premise
25.8 I-Premise
% I-Premise
vs I-Premise
9.6 I-Premise
% I-Premise
";" I-Premise
P=0.091 I-Premise
) I-Premise
. I-Premise

Administering B-Claim
preoperative I-Claim
oral I-Claim
clonidine I-Claim
in I-Claim
a I-Claim
dosage I-Claim
of I-Claim
5g/kg I-Claim
, I-Claim
2h I-Claim
before I-Claim
phacoemulsification I-Claim
, I-Claim
significantly I-Claim
decreases I-Claim
the I-Claim
prevalence I-Claim
and I-Claim
intensity I-Claim
of I-Claim
acute I-Claim
postoperative I-Claim
IOP I-Claim
rise I-Claim
in I-Claim
those I-Claim
undergoing I-Claim
general I-Claim
anesthesia I-Claim
. I-Claim

Oral B-Claim
clonidine I-Claim
is I-Claim
safe I-Claim
, I-Claim
cheap I-Claim
, I-Claim
and I-Claim
easily I-Claim
accessible I-Claim
and I-Claim
, I-Claim
thus I-Claim
, I-Claim
it I-Claim
is I-Claim
recommended I-Claim
for I-Claim
controlling I-Claim
the I-Claim
IOP I-Claim
after I-Claim
phacoemulsification I-Claim
, I-Claim
especially I-Claim
in I-Claim
high-risk I-Claim
patients I-Claim
. I-Claim

To O
compare O
the O
long-term O
efficacy O
and O
safety O
of O
combined O
trabeculectomy O
and O
cataract O
extraction O
versus O
trabeculectomy O
alone O
in O
primary O
angle-closure O
glaucoma O
( O
PACG O
) O
. O

Hospital O
files O
were O
retrospectively O
examined O
for O
99 O
Chinese O
PACG O
patients O
";" O
75 O
patients O
underwent O
combined O
surgery O
and O
24 O
underwent O
trabeculectomy O
alone O
. O

Success O
rates O
were O
assessed O
with O
the O
Kaplan-Meier O
survival O
analysis O
. O

The O
main O
outcome O
was O
the O
complete O
success O
rate O
defined O
as O
either O
a O
> O
20 O
% O
reduction O
in O
intraocular O
pressure O
( O
IOP O
) O
or O
an O
IOP O
that O
remained O
below O
15 O
mm O
Hg O
, O
with O
no O
medications O
required O
. O

Patients O
in O
the O
combined O
group O
and O
trabeculectomy O
group O
had O
a O
mean O
follow-up O
period O
of O
25.8 O
( O
SD O
10.8 O
) O
months O
and O
31.4 O
( O
8.9 O
) O
months O
, O
respectively O
. O

Survival O
analysis O
showed O
that O
the O
complete O
success O
rate O
at O
3 O
years O
was O
56 O
% O
in O
the O
combined O
group O
and O
54 O
% O
in O
the O
trabeculectomy O
group O
( O
p O
= O
0.903 O
) O
. O

There O
were O
no O
significant O
differences O
between O
groups O
in O
either O
IOP O
or O
the O
number O
of O
glaucoma O
medications O
throughout O
the O
3-year O
follow-up O
. O

The B-Premise
incidences I-Premise
of I-Premise
postoperative I-Premise
complications I-Premise
were I-Premise
similar I-Premise
between I-Premise
groups I-Premise
( I-Premise
p I-Premise
= I-Premise
0.232 I-Premise
) I-Premise
. I-Premise

No B-Premise
additional I-Premise
IOP-lowering I-Premise
surgical I-Premise
procedures I-Premise
were I-Premise
required I-Premise
in I-Premise
the I-Premise
combined I-Premise
group I-Premise
, I-Premise
while I-Premise
13 I-Premise
( I-Premise
54 I-Premise
% I-Premise
) I-Premise
eyes I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
required I-Premise
either I-Premise
cataract I-Premise
extraction I-Premise
or I-Premise
further I-Premise
IOP-lowering I-Premise
surgical I-Premise
procedures I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
PACG I-Claim
, I-Claim
the I-Claim
long-term I-Claim
IOP-lowering I-Claim
effect I-Claim
and I-Claim
surgical I-Claim
complications I-Claim
of I-Claim
combined I-Claim
trabeculectomy I-Claim
and I-Claim
cataract I-Claim
extraction I-Claim
are I-Claim
comparable I-Claim
with I-Claim
those I-Claim
of I-Claim
trabeculectomy I-Claim
alone I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
combined I-Claim
surgery I-Claim
incurred I-Claim
fewer I-Claim
subsequent I-Claim
surgical I-Claim
interventions I-Claim
. I-Claim

Carteolol O
is O
a O
beta-adrenoceptor O
antagonist O
with O
intrinsic O
sympathomimetic O
activity O
. O

Used O
topically O
to O
reduce O
intraocular O
pressure O
, O
it O
is O
typically O
applied O
twice O
daily O
. O

In O
an O
effort O
to O
provide O
a O
once-daily O
dosing O
regimen O
, O
carteolol O
was O
formulated O
with O
1 O
% O
alginic O
acid O
. O

Sodium O
alginate O
is O
a O
natural O
polymer O
product O
with O
bioadhesive O
properties O
providing O
increased O
corneal O
contact O
time O
and O
a O
better O
carteolol O
penetration O
through O
the O
cornea O
. O

The O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
long-acting O
1 O
% O
carteolol O
alginate O
solution O
compared O
to O
standard O
1 O
% O
carteolol O
solution O
. O

This O
was O
a O
double-masked O
, O
parallel O
group O
, O
multicentre O
study O
. O

Patients O
with O
ocular O
hypertension O
or O
open O
angle O
glaucoma O
( O
n=151 O
) O
were O
randomly O
assigned O
to O
receive O
either O
1 O
% O
carteolol O
alginate O
once O
daily O
( O
AM O
) O
or O
standard O
1 O
% O
carteolol O
solution O
twice O
daily O
for O
2 O
months O
. O

The O
masking O
was O
maintained O
through O
the O
use O
of O
a O
placebo O
in O
the O
evening O
for O
the O
alginate O
group O
. O

Entry O
into O
the O
study O
required O
unmedicated O
intraocular O
pressure O
( O
IOP O
) O
between O
23 O
mmHg O
and O
32 O
mmHg O
at O
9 O
AM O
and O
11 O
AM O
. O

Patients O
using O
ocular O
hypotensive O
medication O
were O
required O
to O
undergo O
a O
washout O
. O

All O
patients O
provided O
written O
informed O
consent O
. O

Excluded O
from O
the O
study O
were O
patients O
with O
angle O
closure O
, O
congenital O
, O
secondary O
glaucoma O
or O
advanced O
glaucoma O
";" O
any O
intraocular O
infection O
or O
inflammation O
, O
ocular O
trauma O
, O
ocular O
surgery O
or O
laser O
trabeculoplasty O
within O
the O
previous O
3 O
months O
";" O
contraindications O
to O
the O
use O
of O
beta O
adrenoceptor O
antagonists O
";" O
systemic O
medications O
likely O
to O
modify O
IOP O
prescribed O
or O
modified O
during O
the O
previous O
3 O
months O
";" O
ocular O
steroid O
use O
";" O
contact O
lens O
wear O
";" O
and O
pregnant O
and O
lactating O
women O
. O

Patients O
were O
evaluated O
at O
baseline O
, O
15 O
and O
60 O
days O
, O
with O
IOP O
measurements O
at O
9 O
AM O
and O
11 O
AM O
. O

At O
day O
15 O
and O
day O
60 O
, O
IOP O
was O
measured O
just O
before O
instillation O
of O
medication O
( O
9 O
AM O
) O
and O
2 O
hours O
after O
( O
11 O
AM O
) O
. O

Slit O
lamp O
examinations O
were O
performed O
at O
each O
follow-up O
examination O
, O
together O
with O
measurement O
of O
heart O
rate O
and O
blood O
pressure O
( O
10 O
AM O
) O
and O
ocular O
tolerance O
after O
medication O
( O
11 O
AM O
) O
. O

The O
primary O
efficacy O
criterion O
was O
the O
decrease O
in O
IOP O
from O
baseline O
at O
day O
60 O
for O
each O
measurement O
at O
9 O
AM O
and O
11 O
AM O
. O

The O
study O
eye O
was O
the O
eye O
with O
the O
higher O
IOP O
at O
day O
0 O
or O
, O
if O
equal O
, O
the O
right O
eye O
. O

Efficacy-of O
the O
151 O
patients O
included O
in O
the O
study O
, O
149 O
were O
evaluated O
( O
two O
patients O
were O
lost O
to O
follow-up O
after O
day O
0 O
) O
: O
74 O
in O
the O
alginate O
group O
and O
75 O
in O
the O
standard O
group O
. O

Both O
treatment O
groups O
were O
comparable O
at O
day O
0 O
except O
for O
sex O
, O
diastolic O
blood O
pressure O
, O
and O
IOP O
in O
the O
fellow O
eye O
. O

At B-Premise
09.00 I-Premise
hours I-Premise
( I-Premise
presumed I-Premise
trough I-Premise
) I-Premise
on I-Premise
day I-Premise
60 I-Premise
, I-Premise
mean I-Premise
reductions I-Premise
from I-Premise
baseline I-Premise
in I-Premise
intraocular I-Premise
pressure I-Premise
were I-Premise
6.32+/-2.87 I-Premise
and I-Premise
5.67+/-3.30 I-Premise
mmHg I-Premise
for I-Premise
the I-Premise
alginate I-Premise
carteolol I-Premise
and I-Premise
standard I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise

At B-Premise
11.00 I-Premise
hours I-Premise
( I-Premise
presumed I-Premise
peak I-Premise
) I-Premise
, I-Premise
mean I-Premise
reductions I-Premise
were I-Premise
6.70+/-2.81 I-Premise
and I-Premise
6.55+/-3.35 I-Premise
mmHg I-Premise
, I-Premise
respectively I-Premise
. I-Premise

At B-Premise
each I-Premise
evaluation I-Premise
time I-Premise
, I-Premise
the I-Premise
two I-Premise
unilateral I-Premise
t I-Premise
tests I-Premise
were I-Premise
highly I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0.005 I-Premise
) I-Premise
, I-Premise
confirming O
the O
equivalence O
of O
both O
treatments O
. O

Conclusions O
were O
not O
modified O
taking O
into O
account O
sex O
and O
diastolic O
blood O
pressure O
. O

Safety- B-Premise
Slight I-Premise
decreases I-Premise
in I-Premise
heart I-Premise
rate I-Premise
and I-Premise
blood I-Premise
pressure I-Premise
means I-Premise
were I-Premise
observed I-Premise
in I-Premise
both I-Premise
groups I-Premise
at I-Premise
follow-up I-Premise
visits I-Premise
with I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
groups I-Premise
. I-Premise

Subjective B-Premise
tolerance I-Premise
upon I-Premise
instillation I-Premise
was I-Premise
judged I-Premise
good I-Premise
or I-Premise
very I-Premise
good I-Premise
at I-Premise
day I-Premise
60 I-Premise
by I-Premise
100 I-Premise
% I-Premise
of I-Premise
alginate I-Premise
patients I-Premise
and I-Premise
by I-Premise
98.7 I-Premise
% I-Premise
of I-Premise
standard I-Premise
patients I-Premise
. I-Premise

Transient B-Premise
discomfort I-Premise
( I-Premise
mainly I-Premise
stinging I-Premise
or I-Premise
burning I-Premise
sensation I-Premise
) I-Premise
was I-Premise
reported I-Premise
by I-Premise
approximately I-Premise
4 I-Premise
% I-Premise
- I-Premise
6 I-Premise
% I-Premise
of I-Premise
patients I-Premise
in I-Premise
each I-Premise
treatment I-Premise
group I-Premise
at I-Premise
each I-Premise
visit I-Premise
. I-Premise

A B-Premise
blurred I-Premise
vision I-Premise
sensation I-Premise
was I-Premise
reported I-Premise
by I-Premise
2 I-Premise
out I-Premise
of I-Premise
74 I-Premise
patients I-Premise
of I-Premise
the I-Premise
alginate I-Premise
group I-Premise
. I-Premise

Among B-Premise
the I-Premise
17 I-Premise
reported I-Premise
adverse I-Premise
events I-Premise
, I-Premise
three I-Premise
were I-Premise
assessed I-Premise
as I-Premise
drug-related I-Premise
: I-Premise
one I-Premise
vertigo I-Premise
, I-Premise
one I-Premise
superficial I-Premise
punctate I-Premise
keratitis I-Premise
in I-Premise
the I-Premise
alginate I-Premise
group I-Premise
and I-Premise
one I-Premise
decrease I-Premise
in I-Premise
blood I-Premise
pressure I-Premise
in I-Premise
the I-Premise
standard I-Premise
group I-Premise
. I-Premise

No B-Premise
serious I-Premise
adverse I-Premise
events I-Premise
were I-Premise
reported I-Premise
. I-Premise

The B-Claim
new I-Claim
alginate I-Claim
formulation I-Claim
of I-Claim
long-acting I-Claim
carteolol I-Claim
1 I-Claim
% I-Claim
given I-Claim
once I-Claim
daily I-Claim
is I-Claim
as I-Claim
effective I-Claim
as I-Claim
standard I-Claim
1 I-Claim
% I-Claim
carteolol I-Claim
given I-Claim
twice I-Claim
daily I-Claim
, I-Claim
with I-Claim
no I-Claim
meaningful I-Claim
differences I-Claim
regarding I-Claim
safety I-Claim
. I-Claim

This O
efficacy O
wasy O
was O
verified O
at O
9 O
AM O
( O
24 O
hours O
after O
the O
last O
drop O
of O
long-acting O
carteolol O
or O
12 O
hours O
after O
that O
of O
standard O
carteolol O
) O
and O
at O
11 O
AM O
( O
2 O
hours O
after O
the O
morning O
drop O
) O
. O

The B-Claim
new I-Claim
alginate I-Claim
formulation I-Claim
of I-Claim
long-acting I-Claim
carteolol I-Claim
1 I-Claim
% I-Claim
given I-Claim
once I-Claim
a I-Claim
day I-Claim
is I-Claim
effective I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
glaucoma I-Claim
patients I-Claim
who I-Claim
require I-Claim
chronic I-Claim
treatment I-Claim
. I-Claim

To O
compare O
the O
postoperative O
intraocular O
pressure O
( O
IOP O
) O
and O
incidence O
of O
early O
complications O
after O
trabeculectomy O
with O
releasable O
suture O
to O
standard O
trabeculectomy O
in O
Chinese O
patients O
with O
primary O
angle-closure O
glaucoma O
. O

One O
hundred O
seventy-five O
patients O
diagnosed O
as O
primary O
angle-closure O
glaucoma O
with O
6 O
clock-hours O
or O
more O
of O
peripheral O
anterior O
synechia O
were O
randomly O
allocated O
to O
2 O
treatment O
groups O
: O
87 O
underwent O
standard O
trabeculectomy O
( O
S O
group O
: O
2 O
interrupted O
permanent O
sutures O
to O
the O
scleral O
flap O
) O
and O
88 O
received O
trabeculectomy O
with O
2 O
permanent O
and O
2 O
releasable O
sutures O
( O
R O
group O
) O
. O

The O
postoperative O
IOP O
and O
complications O
during O
the O
first O
3 O
months O
after O
surgery O
were O
compared O
. O

One O
hundred O
seventy-one O
patients O
( O
97.7 O
% O
) O
attended O
the O
3-month O
visit O
. O

The B-Premise
IOP I-Premise
in I-Premise
the I-Premise
first I-Premise
week I-Premise
after I-Premise
trabeculectomy I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
R I-Premise
group I-Premise
: I-Premise
day I-Premise
1 I-Premise
, I-Premise
17.3 I-Premise
± I-Premise
8.6 I-Premise
versus I-Premise
12.7 I-Premise
± I-Premise
6.0 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
";" I-Premise
day I-Premise
3 I-Premise
, I-Premise
18.0 I-Premise
± I-Premise
7.3 I-Premise
versus I-Premise
12.9 I-Premise
± I-Premise
6.3 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
";" I-Premise
day I-Premise
7 I-Premise
, I-Premise
14.8 I-Premise
± I-Premise
6.3 I-Premise
versus I-Premise
12.0 I-Premise
± I-Premise
4.9 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
P=0.001 I-Premise
) I-Premise
, I-Premise
but O
no B-Premise
difference I-Premise
was I-Premise
observed I-Premise
after I-Premise
the I-Premise
second I-Premise
week I-Premise
( I-Premise
P=0.659 I-Premise
to I-Premise
0.753 I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
transient I-Premise
hypotony I-Premise
was I-Premise
higher I-Premise
in I-Premise
S I-Premise
group I-Premise
( I-Premise
20.4 I-Premise
% I-Premise
) I-Premise
than I-Premise
the I-Premise
R I-Premise
group I-Premise
( I-Premise
9.1 I-Premise
% I-Premise
) I-Premise
( I-Premise
P=0.046 I-Premise
) I-Premise
";" I-Premise
hypotony B-Premise
recovered I-Premise
in I-Premise
80.8 I-Premise
% I-Premise
( I-Premise
21/26 I-Premise
) I-Premise
within I-Premise
1 I-Premise
week I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
shallow I-Premise
chamber I-Premise
, I-Premise
choroidal I-Premise
detachment I-Premise
, I-Premise
macular I-Premise
edema I-Premise
, I-Premise
additional I-Premise
surgery I-Premise
, I-Premise
or I-Premise
hyphema I-Premise
( I-Premise
P=0.56 I-Premise
to I-Premise
1.0 I-Premise
) I-Premise
. I-Premise

The B-Claim
technique I-Claim
of I-Claim
releasable I-Claim
sutures I-Claim
for I-Claim
trabeculectomy I-Claim
used I-Claim
in I-Claim
this I-Claim
study I-Claim
did I-Claim
not I-Claim
demonstrate I-Claim
significant I-Claim
advantages I-Claim
over I-Claim
standard I-Claim
trabeculectomy I-Claim
. I-Claim

Releasable B-Claim
sutures I-Claim
were I-Claim
associated I-Claim
with I-Claim
some I-Claim
decrease I-Claim
in I-Claim
visual I-Claim
acuity I-Claim
and I-Claim
increase I-Claim
in I-Claim
postoperative I-Claim
complaints I-Claim
. I-Claim

The O
objective O
of O
the O
study O
was O
to O
compare O
the O
long-term O
efficacy O
and O
safety O
of O
tafluprost O
0.0015 O
% O
with O
latanoprost O
0.005 O
% O
eye O
drops O
in O
patients O
with O
open-angle O
glaucoma O
or O
ocular O
hypertension O
. O

This O
double-masked O
, O
active-controlled O
, O
parallel-group O
, O
multinational O
, O
multicentre O
, O
phase O
III O
study O
was O
conducted O
at O
49 O
centres O
in O
8 O
countries O
. O

Eligible O
patients O
were O
assigned O
to O
treatment O
administered O
once O
daily O
at O
20:00 O
hrs O
for O
up O
to O
24 O
months O
. O

Change O
from O
baseline O
intraocular O
pressure O
( O
IOP O
) O
was O
the O
primary O
efficacy O
variable O
. O

Adverse O
events O
were O
recorded O
and O
ocular O
safety O
was O
evaluated O
. O

Both O
tafluprost O
and O
latanoprost O
were O
preserved O
with O
benzalkonium O
chloride O
. O

From O
533 O
patients O
randomized O
, O
402 O
patients O
completed O
24 O
months O
of O
therapy O
. O

Both B-Premise
treatments I-Premise
had I-Premise
a I-Premise
substantial I-Premise
IOP-lowering I-Premise
effect I-Premise
which I-Premise
persisted I-Premise
throughout I-Premise
the I-Premise
study I-Premise
( I-Premise
-7.1 I-Premise
mmHg I-Premise
for I-Premise
tafluprost I-Premise
and I-Premise
-7.7 I-Premise
mmHg I-Premise
for I-Premise
latanoprost I-Premise
at I-Premise
24 I-Premise
months I-Premise
) I-Premise
. I-Premise

Although O
the B-Claim
IOP-lowering I-Claim
effect I-Claim
during I-Claim
the I-Claim
study I-Claim
was I-Claim
slightly I-Claim
larger I-Claim
with I-Claim
latanoprost I-Claim
, I-Claim
this B-Premise
difference I-Premise
was I-Premise
clinically I-Premise
small I-Premise
and I-Premise
the I-Premise
noninferiority I-Premise
of I-Premise
tafluprost I-Premise
to I-Premise
latanoprost I-Premise
over I-Premise
all I-Premise
diurnal I-Premise
IOP I-Premise
measurements I-Premise
was I-Premise
shown I-Premise
with I-Premise
anova I-Premise
and I-Premise
almost I-Premise
reached I-Premise
with I-Premise
ancova I-Premise
( I-Premise
upper I-Premise
limits I-Premise
of I-Premise
the I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
intervals I-Premise
1.38 I-Premise
and I-Premise
1.52 I-Premise
for I-Premise
the I-Premise
overall I-Premise
period I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The O
noninferiority O
limit O
was O
1.5 O
mmHg O
. O

Tafluprost B-Claim
is I-Claim
a I-Claim
new I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
treatment I-Claim
for I-Claim
glaucoma I-Claim
and I-Claim
ocular I-Claim
hypertension I-Claim
. I-Claim

To O
compare O
the O
efficacy O
of O
bimatoprost O
and O
travoprost O
on O
intraocular O
pressure O
( O
IOP O
) O
reduction O
in O
an O
Egyptian O
population O
. O

Patients O
with O
primary O
open-angle O
glaucoma O
or O
ocular O
hypertension O
were O
randomized O
to O
receive O
either O
bimatoprost O
0.03 O
% O
or O
travoprost O
0.004 O
% O
once O
daily O
. O

IOPs O
were O
measured O
at O
baseline O
";" O
2 O
weeks O
";" O
and O
1 O
, O
2 O
, O
4 O
, O
and O
6 O
months O
using O
Goldman O
applanation O
tonometery O
. O

Seventy-two O
patients O
were O
included O
: O
34 O
and O
38 O
( O
P=0.142 O
) O
with O
a O
baseline O
mean O
IOP O
26.52 O
± O
5.185 O
and O
26.36 O
± O
1.605 O
mm O
Hg O
( O
P=0.629 O
) O
for O
bimatoprost O
and O
travoprost O
, O
respectively O
. O

Both B-Premise
drops I-Premise
provided I-Premise
statistically I-Premise
significant I-Premise
IOP I-Premise
reductions I-Premise
from I-Premise
baseline I-Premise
at I-Premise
all I-Premise
visits I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Bimatoprost B-Claim
provided I-Claim
greater I-Claim
( I-Claim
nonsignificant I-Claim
) I-Claim
mean I-Claim
IOP I-Claim
reductions I-Claim
from I-Claim
baseline I-Claim
than I-Claim
travoprost I-Claim
at I-Claim
each I-Claim
visit I-Claim
. I-Claim

Mean B-Premise
IOP I-Premise
reduction I-Premise
was I-Premise
8.77 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
33.39 I-Premise
% I-Premise
) I-Premise
and I-Premise
8.42 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
31.54 I-Premise
% I-Premise
) I-Premise
at I-Premise
2 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
= I-Premise
0.703 I-Premise
) I-Premise
, I-Premise
and I-Premise
8.47 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
31.61 I-Premise
% I-Premise
) I-Premise
and I-Premise
7.84 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
29.50 I-Premise
% I-Premise
) I-Premise
at I-Premise
6 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.536 I-Premise
) I-Premise
for I-Premise
bimatoprost I-Premise
and I-Premise
travoprost I-Premise
, I-Premise
respectively I-Premise
. I-Premise

IOPs B-Premise
at I-Premise
2 I-Premise
weeks I-Premise
were I-Premise
18 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
20 I-Premise
( I-Premise
58.8 I-Premise
% I-Premise
) I-Premise
versus I-Premise
19 I-Premise
( I-Premise
50 I-Premise
% I-Premise
) I-Premise
eyes I-Premise
( I-Premise
P I-Premise
= I-Premise
0.603 I-Premise
) I-Premise
, I-Premise
and I-Premise
16 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
12 I-Premise
( I-Premise
35 I-Premise
% I-Premise
) I-Premise
versus I-Premise
12 I-Premise
( I-Premise
32 I-Premise
% I-Premise
) I-Premise
eyes I-Premise
( I-Premise
P I-Premise
= I-Premise
0.456 I-Premise
) I-Premise
";" I-Premise
and I-Premise
at I-Premise
6 I-Premise
months I-Premise
18 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
22 I-Premise
( I-Premise
65 I-Premise
% I-Premise
) I-Premise
versus I-Premise
14 I-Premise
( I-Premise
37 I-Premise
% I-Premise
) I-Premise
eyes I-Premise
( I-Premise
P I-Premise
= I-Premise
0.045 I-Premise
) I-Premise
, I-Premise
and I-Premise
16 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
12 I-Premise
( I-Premise
35 I-Premise
% I-Premise
) I-Premise
versus I-Premise
7 I-Premise
( I-Premise
18 I-Premise
% I-Premise
) I-Premise
eyes I-Premise
( I-Premise
P I-Premise
= I-Premise
0.037 I-Premise
) I-Premise
for I-Premise
bimatoprost I-Premise
and I-Premise
travoprost I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Ocular B-Claim
adverse I-Claim
and I-Claim
clinical I-Claim
success I-Claim
occurred I-Claim
equally I-Claim
with I-Claim
both I-Claim
drops I-Claim
. I-Claim

Both B-Claim
drops I-Claim
lowered I-Claim
IOP I-Claim
effectively I-Claim
but B-Claim
bimatoprost I-Claim
showed I-Claim
a I-Claim
greater I-Claim
non-significant I-Claim
reductions I-Claim
in I-Claim
mean I-Claim
IOP I-Claim
from I-Claim
baseline I-Claim
. I-Claim

To O
compare O
the O
efficacy O
of O
bimatoprost/timolol O
( O
BTFC O
) O
or O
travoprost/timolol O
( O
TTFC O
) O
fixed O
combinations O
on O
intraocular O
pressure O
( O
IOP O
) O
reduction O
in O
an O
Egyptian O
population O
. O

Patients O
with O
primary O
open O
angle O
glaucoma O
were O
randomized O
to O
receive O
either O
BTFC O
or O
TTFC O
. O

IOPs O
were O
measured O
at O
baseline O
, O
2 O
weeks O
, O
and O
1 O
, O
2 O
, O
4 O
, O
and O
6 O
months O
. O

The O
primary O
outcome O
measure O
was O
the O
mean O
change O
in O
IOP O
from O
baseline O
at O
each O
visit O
. O

Secondary O
outcome O
measures O
included O
the O
incidence O
of O
adverse O
events O
. O

Eighty O
patients O
( O
80 O
eyes O
) O
were O
included O
finally O
: O
40 O
eyes O
in O
each O
group O
. O

Baseline O
mean O
IOPs O
were O
24.78±3.53 O
and O
25.26±3.51 O
mm O
Hg O
for O
BTFC O
and O
TTFC O
, O
respectively O
( O
P=0.344 O
) O
. O

Both B-Premise
drops I-Premise
provided I-Premise
statistically I-Premise
significant I-Premise
IOP I-Premise
reductions I-Premise
from I-Premise
baseline I-Premise
at I-Premise
all I-Premise
visits I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

BTFC B-Premise
provided I-Premise
greater I-Premise
significant I-Premise
mean I-Premise
IOP I-Premise
reductions I-Premise
from I-Premise
baseline I-Premise
than I-Premise
TTFC I-Premise
at I-Premise
each I-Premise
visit I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
IOP I-Premise
reductions I-Premise
were I-Premise
11.34 I-Premise
and I-Premise
6.42 I-Premise
mm I-Premise
Hg I-Premise
at I-Premise
2 I-Premise
weeks I-Premise
( I-Premise
P=0.000 I-Premise
) I-Premise
, I-Premise
and I-Premise
11.17 I-Premise
and I-Premise
7.89 I-Premise
mmHg I-Premise
at I-Premise
6 I-Premise
months I-Premise
( I-Premise
P=0.001 I-Premise
) I-Premise
for I-Premise
BTFC I-Premise
and I-Premise
TTFC I-Premise
, I-Premise
respectively I-Premise
. I-Premise

IOPs B-Premise
at I-Premise
2 I-Premise
weeks I-Premise
were I-Premise
18 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
36 I-Premise
( I-Premise
90.8 I-Premise
% I-Premise
) I-Premise
versus I-Premise
22 I-Premise
( I-Premise
55 I-Premise
% I-Premise
) I-Premise
eyes I-Premise
and I-Premise
16 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
28 I-Premise
( I-Premise
70 I-Premise
% I-Premise
) I-Premise
versus I-Premise
16 I-Premise
( I-Premise
40 I-Premise
% I-Premise
) I-Premise
eyes I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
at I-Premise
6 I-Premise
months I-Premise
, I-Premise
18 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
38 I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
versus I-Premise
28 I-Premise
( I-Premise
70 I-Premise
% I-Premise
) I-Premise
eyes I-Premise
and I-Premise
16 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
30 I-Premise
( I-Premise
75 I-Premise
% I-Premise
) I-Premise
versus I-Premise
18 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
eyes I-Premise
for I-Premise
BTFC I-Premise
and I-Premise
TTFC I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Both B-Claim
drops I-Claim
provided I-Claim
effective I-Claim
IOP I-Claim
reduction I-Claim
that I-Claim
was I-Claim
greater I-Claim
and O
patients B-Claim
were I-Claim
more I-Claim
likely I-Claim
to I-Claim
achieve I-Claim
lower I-Claim
target I-Claim
pressures I-Claim
with I-Claim
BTFC I-Claim
than I-Claim
with I-Claim
TTFC I-Claim
. I-Claim

To O
compare O
the O
efficacy O
and O
tolerability O
of O
a O
once-daily O
evening O
dose O
of O
bimatoprost/timolol O
fixed O
combination O
( O
BTFC O
) O
with O
that O
of O
a O
once-daily O
evening O
dose O
of O
latanoprost/timolol O
fixed O
combination O
( O
LTFC O
) O
in O
patients O
not O
controlled O
with O
prostaglandins O
analogues O
monotherapy O
. O

A O
total O
of O
82 O
patients O
on O
prostaglandin O
analogues O
monotherapy O
were O
enrolled O
in O
this O
prospective O
, O
multicenter O
, O
investigator O
masked O
, O
clinical O
study O
and O
were O
randomized O
to O
either O
BTFC O
( O
n=47 O
) O
or O
LTFC O
( O
n=35 O
) O
topical O
therapy O
once O
at O
night O
for O
12 O
weeks O
. O

The O
primary O
endpoint O
of O
the O
study O
was O
to O
compare O
the O
mean O
daily O
intraocular O
pressure O
( O
IOP O
) O
reduction O
from O
baseline O
between O
the O
two O
treatment O
arms O
. O

Secondary O
endpoints O
included O
the O
mean O
daily O
IOP O
at O
1 O
and O
3 O
months O
compared O
to O
baseline O
and O
the O
percentage O
of O
patients O
showing O
a O
mean O
IOP O
reduction O
from O
baseline O
greater O
than O
or O
equal O
to O
15 O
% O
or O
20 O
% O
. O

Mean O
IOP O
at O
baseline O
was O
22.7+/-2.0 O
and O
22.1+/-2.6 O
mmHg O
in O
the O
BTFC O
and O
LTFC O
groups O
, O
respectively O
( O
p=0.23 O
) O
. O

Both O
treatments O
were O
effective O
in O
reducing O
the O
IOP O
from O
baseline O
. O

The B-Premise
mean I-Premise
IOP I-Premise
reduction I-Premise
was I-Premise
significantly I-Premise
greater I-Premise
in I-Premise
the I-Premise
BTFC I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
LTFC I-Premise
group I-Premise
( I-Premise
-21.4 I-Premise
% I-Premise
vs I-Premise
-13.7 I-Premise
% I-Premise
, I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

A B-Premise
higher I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
BTFC I-Premise
group I-Premise
showed I-Premise
a I-Premise
mean I-Premise
IOP I-Premise
reduction I-Premise
from I-Premise
baseline I-Premise
> I-Premise
or=15 I-Premise
% I-Premise
( I-Premise
72.3 I-Premise
% I-Premise
vs I-Premise
40.0 I-Premise
% I-Premise
) I-Premise
and I-Premise
> I-Premise
or=20 I-Premise
% I-Premise
( I-Premise
61.7 I-Premise
% I-Premise
vs I-Premise
17.1 I-Premise
% I-Premise
) I-Premise
compared I-Premise
to I-Premise
patients I-Premise
in I-Premise
the I-Premise
LTFC I-Premise
group I-Premise
. I-Premise

Both B-Claim
BTFC I-Claim
and I-Claim
LTFC I-Claim
were I-Claim
more I-Claim
effective I-Claim
versus I-Claim
the I-Claim
monotherapy I-Claim
with I-Claim
prostaglandin I-Claim
analogues I-Claim
. I-Claim

BTFC B-Claim
demonstrated I-Claim
higher I-Claim
performance I-Claim
than I-Claim
LTFC I-Claim
in I-Claim
terms I-Claim
of I-Claim
relative I-Claim
IOP I-Claim
reduction I-Claim
. I-Claim

Oral B-Claim
carbonic I-Claim
anhydrase I-Claim
inhibitors I-Claim
used I-Claim
to I-Claim
treat I-Claim
glaucoma I-Claim
have I-Claim
significant I-Claim
systemic I-Claim
side I-Claim
effects I-Claim
. I-Claim

Brinzolamide O
1.0 O
% O
, O
a O
new O
topical O
ocular O
carbonic O
anhydrase O
inhibitor O
, O
is O
effective O
apparently O
without O
significant O
systemic O
side O
effects O
. O

This O
study O
was O
performed O
to O
establish O
the O
long-term O
safety O
and O
efficacy O
of O
brinzolamide O
1.0 O
% O
two O
and O
three O
times O
daily O
for O
primary O
open-angle O
glaucoma O
and O
ocular O
hypertension O
. O

An O
18-month O
, O
multicenter O
, O
double-masked O
, O
parallel O
, O
controlled O
study O
was O
conducted O
. O

Patients O
were O
randomized O
to O
brinzolamide O
two O
or O
three O
times O
daily O
or O
timolol O
0.5 O
% O
twice O
daily O
in O
a O
2:2:1 O
ratio O
( O
n O
= O
150 O
, O
153 O
, O
and O
75 O
, O
respectively O
) O
. O

Intraocular O
pressure O
was O
measured O
at O
8:00 O
AM O
at O
eligibility O
and O
months O
1 O
, O
3 O
, O
6 O
, O
9 O
, O
12 O
, O
15 O
, O
and O
18 O
. O

Efficacy O
was O
based O
on O
intraocular O
pressure O
reduction O
from O
baseline O
. O

Safety O
was O
also O
evaluated O
. O

All B-Premise
regimens I-Premise
produced I-Premise
clinically I-Premise
relevant I-Premise
and I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
intraocular I-Premise
pressure I-Premise
reductions I-Premise
from I-Premise
baseline I-Premise
. I-Premise

Mean B-Premise
changes I-Premise
in I-Premise
intraocular I-Premise
pressure I-Premise
trough I-Premise
measurements I-Premise
ranged I-Premise
from I-Premise
-2.7 I-Premise
to I-Premise
-3.9 I-Premise
mm I-Premise
Hg I-Premise
with I-Premise
brinzolamide I-Premise
twice-daily I-Premise
dosing I-Premise
and I-Premise
-2.8 I-Premise
to I-Premise
-3.8 I-Premise
mm I-Premise
Hg I-Premise
three I-Premise
times I-Premise
daily I-Premise
dosing I-Premise
compared I-Premise
with I-Premise
-4.7 I-Premise
to I-Premise
-5.6 I-Premise
mm I-Premise
Hg I-Premise
with I-Premise
timolol I-Premise
. I-Premise

The O
intraocular O
pressure O
reductions O
with O
brinzolamide O
two O
and O
three O
times O
daily O
were O
clinically O
and O
statistically O
equivalent O
. O

One O
hundred O
forty-four O
patients O
were O
discontinued O
from O
the O
study O
after O
randomization O
with O
the O
most O
common O
reasons O
being O
the O
occurrence O
of O
an O
adverse O
event O
( O
46 O
) O
, O
inadequate O
intraocular O
pressure O
control O
( O
23 O
) O
, O
patient O
decision O
unrelated O
to O
study O
medication O
( O
11 O
) O
, O
lost O
to O
follow-up O
( O
16 O
) O
, O
and O
noncompliance O
( O
9 O
) O
. O

Adverse B-Premise
events I-Premise
were I-Premise
nonserious I-Premise
and I-Premise
resolved I-Premise
without I-Premise
sequelae I-Premise
. I-Premise

There O
were O
no O
clinically O
relevant O
changes O
in O
safety O
parameters O
. O

Brinzolamide B-Claim
produced I-Claim
less I-Claim
ocular I-Claim
discomfort I-Claim
( I-Claim
burning/stinging I-Claim
) I-Claim
than I-Claim
timolol I-Claim
, I-Claim
and I-Claim
total I-Claim
carbonic I-Claim
anhydrase I-Claim
inhibition I-Claim
levels I-Claim
remained I-Claim
below I-Claim
that I-Claim
known I-Claim
to I-Claim
cause I-Claim
systemic I-Claim
side I-Claim
effects I-Claim
. I-Claim

Brinzolamide B-Claim
produced I-Claim
significant I-Claim
and I-Claim
equivalent I-Claim
reductions I-Claim
in I-Claim
intraocular I-Claim
pressure I-Claim
when I-Claim
dosed I-Claim
two I-Claim
and I-Claim
three I-Claim
times I-Claim
daily I-Claim
for I-Claim
18 I-Claim
months I-Claim
. I-Claim

Brinzolamide B-Claim
was I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
patients I-Claim
, I-Claim
with I-Claim
minimal I-Claim
ocular I-Claim
discomfort I-Claim
. I-Claim

To O
assess O
the O
safety O
and O
efficacy O
of O
the O
iStent O
trabecular O
micro-bypass O
stent O
( O
Glaukos O
Corporation O
, O
Laguna O
Hills O
, O
CA O
) O
in O
combination O
with O
cataract O
surgery O
in O
subjects O
with O
mild O
to O
moderate O
open-angle O
glaucoma O
. O

Prospective O
, O
randomized O
, O
open-label O
, O
controlled O
, O
multicenter O
clinical O
trial O
. O

A O
total O
of O
240 O
eyes O
with O
mild O
to O
moderate O
open-angle O
glaucoma O
with O
intraocular O
pressure O
( O
IOP O
) O
24 O
mmHg O
controlled O
on O
1 O
to O
3 O
medications O
were O
randomized O
to O
undergo O
cataract O
surgery O
with O
iStent O
implantation O
( O
treatment O
group O
) O
or O
cataract O
surgery O
only O
( O
control O
) O
. O

Fifty O
additional O
subjects O
were O
enrolled O
to O
undergo O
cataract O
surgery O
with O
iStent O
implantation O
under O
protocol O
expansion O
. O

Data O
in O
this O
report O
are O
based O
on O
the O
first O
240 O
eyes O
enrolled O
. O

Implantation O
of O
the O
iStent O
trabecular O
micro-bypass O
stent O
in O
conjunction O
with O
cataract O
surgery O
or O
cataract O
surgery O
only O
. O

The O
primary O
efficacy O
measure O
was O
unmedicated O
IOP O
<=21 O
mmHg O
at O
1 O
year O
. O

A O
secondary O
measure O
was O
unmedicated O
IOP O
reduction O
>=20 O
% O
at O
1 O
year O
. O

Safety O
measures O
included O
best-corrected O
visual O
acuity O
( O
BCVA O
) O
, O
slit-lamp O
observations O
, O
complications O
, O
and O
adverse O
events O
. O

The O
study O
met O
the O
primary O
outcome O
, O
with O
72 O
% O
of O
treatment O
eyes O
versus O
50 O
% O
of O
control O
eyes O
achieving O
the O
criterion O
( O
P O
< O
0.001 O
) O
. O

At B-Premise
1 I-Premise
year I-Premise
, I-Premise
IOP I-Premise
in I-Premise
both I-Premise
treatment I-Premise
groups I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
from I-Premise
baseline I-Premise
values I-Premise
. I-Premise

Sixty-six B-Premise
percent I-Premise
of I-Premise
treatment I-Premise
eyes I-Premise
versus I-Premise
48 I-Premise
% I-Premise
of I-Premise
control I-Premise
eyes I-Premise
achieved I-Premise
20 I-Premise
% I-Premise
IOP I-Premise
reduction I-Premise
without I-Premise
medication I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
incidence I-Premise
of I-Premise
adverse I-Premise
events I-Premise
was I-Premise
similar I-Premise
between I-Premise
groups I-Premise
with I-Premise
no I-Premise
unanticipated I-Premise
adverse I-Premise
device I-Premise
effects I-Premise
. I-Premise

Pressure B-Claim
reduction I-Claim
on I-Claim
fewer I-Claim
medications I-Claim
was I-Claim
clinically I-Claim
and I-Claim
statistically I-Claim
significantly I-Claim
better I-Claim
1 I-Claim
year I-Claim
after I-Claim
stent I-Claim
plus I-Claim
cataract I-Claim
surgery I-Claim
versus I-Claim
cataract I-Claim
surgery I-Claim
alone I-Claim
, I-Claim
with I-Claim
an I-Claim
overall I-Claim
safety I-Claim
profile I-Claim
similar I-Claim
to I-Claim
that I-Claim
of I-Claim
cataract I-Claim
surgery I-Claim
alone I-Claim
. I-Claim

Fixed B-Claim
combinations I-Claim
of I-Claim
0.2 I-Claim
% I-Claim
brimonidine-0.5 I-Claim
% I-Claim
timolol I-Claim
and I-Claim
2 I-Claim
% I-Claim
dorzolamide-0.5 I-Claim
% I-Claim
timolol I-Claim
are I-Claim
used I-Claim
to I-Claim
lower I-Claim
intraocular I-Claim
pressure I-Claim
( I-Claim
IOP I-Claim
) I-Claim
. I-Claim

The O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
IOP-lowering O
efficacy O
and O
ocular O
tolerability O
of O
brimonidine-timolol O
compared O
with O
dorzolamide-timolol O
when O
used O
as O
monotherapy O
or O
as O
adjunctive O
therapy O
to O
a O
prostaglandin O
analog O
( O
PGA O
) O
in O
patients O
with O
glaucoma O
or O
ocular O
hypertension O
. O

Pooled O
data O
analysis O
of O
two O
randomized O
, O
investigator-masked O
, O
3-month O
, O
parallel-group O
studies O
with O
identical O
protocols O
( O
ten O
sites O
) O
. O

In O
all O
, O
180 O
patients O
with O
open-angle O
glaucoma O
or O
ocular O
hypertension O
who O
were O
in O
need O
of O
lower O
IOP O
received O
topical O
brimonidine-timolol O
BID O
or O
dorzolamide-timolol O
BID O
as O
monotherapy O
( O
n O
= O
101 O
) O
or O
as O
adjunctive O
therapy O
to O
a O
PGA O
( O
latanoprost O
, O
bimatoprost O
, O
or O
travoprost O
) O
( O
n O
= O
79 O
) O
. O

IOP O
was O
measured O
at O
10 O
a.m. O
( O
peak O
effect O
) O
at O
baseline O
and O
at O
months O
1 O
and O
3 O
. O

Tolerability/comfort O
was O
evaluated O
using O
a O
patient O
questionnaire O
. O

There O
were O
no O
statistically O
significant O
between-group O
differences O
in O
patient O
demographics O
. O

Most O
patients O
were O
Caucasian O
, O
and O
the O
mean O
age O
was O
68 O
years O
. O

There O
were O
also O
no O
statistically O
significant O
differences O
between O
treatment O
groups O
in O
baseline O
IOP O
. O

At B-Premise
month I-Premise
3 I-Premise
, I-Premise
the I-Premise
mean I-Premise
( I-Premise
SD I-Premise
) I-Premise
reduction I-Premise
from I-Premise
baseline I-Premise
IOP I-Premise
for I-Premise
patients I-Premise
on I-Premise
fixed-combination I-Premise
monotherapy I-Premise
was I-Premise
7.7 I-Premise
( I-Premise
4.2 I-Premise
) I-Premise
mmHg I-Premise
( I-Premise
32.3 I-Premise
% I-Premise
) I-Premise
with I-Premise
brimonidine-timolol I-Premise
versus I-Premise
6.7 I-Premise
( I-Premise
5.0 I-Premise
) I-Premise
mmHg I-Premise
( I-Premise
26.1 I-Premise
% I-Premise
) I-Premise
with I-Premise
dorzolamide-timolol I-Premise
( I-Premise
p I-Premise
= I-Premise
0.040 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
reduction I-Premise
from I-Premise
PGA-treated I-Premise
baseline I-Premise
IOP I-Premise
for I-Premise
patients I-Premise
on I-Premise
fixed-combination I-Premise
adjunctive I-Premise
therapy I-Premise
was I-Premise
6.9 I-Premise
( I-Premise
4.8 I-Premise
) I-Premise
mmHg I-Premise
( I-Premise
29.3 I-Premise
% I-Premise
) I-Premise
with I-Premise
brimonidine-timolol I-Premise
versus I-Premise
5.2 I-Premise
( I-Premise
3.7 I-Premise
) I-Premise
mmHg I-Premise
( I-Premise
23.5 I-Premise
% I-Premise
) I-Premise
with I-Premise
dorzolamide-timolol I-Premise
( I-Premise
p I-Premise
= I-Premise
0.213 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
on I-Premise
brimonidine-timolol I-Premise
reported I-Premise
less I-Premise
burning I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
stinging I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
unusual I-Premise
taste I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
than I-Premise
patients I-Premise
on I-Premise
dorzolamide-timolol I-Premise
. I-Premise

Fixed-combination B-Claim
brimonidine-timolol I-Claim
provided I-Claim
the I-Claim
same I-Claim
or I-Claim
greater I-Claim
IOP I-Claim
lowering I-Claim
compared I-Claim
with I-Claim
fixed-combination I-Claim
dorzolamide-timolol I-Claim
. I-Claim

Both B-Claim
fixed-combination I-Claim
medications I-Claim
were I-Claim
safe I-Claim
and I-Claim
well-tolerated I-Claim
. I-Claim

Brimonidine-timolol O
received O
higher O
ratings O
of O
ocular O
comfort O
than O
dorzolamide-timolol O
. O

The O
duration O
of O
the O
studies O
was O
3 O
months O
, O
and O
additional O
studies O
will O
be O
needed O
to O
compare O
the O
efficacy O
and O
tolerability O
of O
brimonidine-timolol O
and O
dorzolamide-timolol O
during O
long-term O
treatment O
. O

To O
test O
the O
hypothesis O
that O
neodymium B-Claim
: I-Claim
yttrium-aluminum-garnet I-Claim
( I-Claim
Nd I-Claim
: I-Claim
YAG I-Claim
) I-Claim
laser I-Claim
peripheral I-Claim
iridotomy I-Claim
( I-Claim
LPI I-Claim
) I-Claim
significantly I-Claim
reduces I-Claim
the I-Claim
incidence I-Claim
of I-Claim
conversion I-Claim
from I-Claim
pigment I-Claim
dispersion I-Claim
syndrome I-Claim
( I-Claim
PDS I-Claim
) I-Claim
with I-Claim
ocular I-Claim
hypertension I-Claim
( I-Claim
OHT I-Claim
) I-Claim
to I-Claim
pigmentary I-Claim
glaucoma I-Claim
( I-Claim
PG I-Claim
) I-Claim
. I-Claim

Prospective O
, O
randomized O
, O
controlled O
3-year O
trial O
. O

One O
hundred O
sixteen O
eyes O
of O
116 O
patients O
with O
PDS O
and O
OHT O
. O

Patients O
were O
assigned O
randomly O
either O
to O
Nd O
: O
YAG O
LPI O
or O
to O
a O
control O
group O
( O
no O
laser O
) O
. O

The O
primary O
outcome O
measure O
was O
conversion O
to O
PG O
within O
3 O
years O
, O
based O
on O
full-threshold O
visual O
field O
( O
VF O
) O
analysis O
using O
the O
Ocular O
Hypertension O
Treatment O
Study O
criteria O
. O

Secondary O
outcome O
measures O
were O
whether O
eyes O
required O
topical O
antiglaucoma O
medications O
during O
the O
study O
period O
and O
the O
time O
to O
conversion O
or O
medication O
. O

Fifty-seven O
patients O
were O
randomized O
to O
undergo O
laser O
treatment O
and O
59 O
were O
randomized O
to O
no O
laser O
( O
controls O
) O
. O

Age O
, O
gender O
, O
spherical O
equivalent O
refraction O
, O
and O
intraocular O
pressure O
at O
baseline O
were O
similar O
between O
groups O
. O

Outcome O
data O
were O
available O
for O
105 O
( O
90 O
% O
) O
of O
recruited O
subjects O
, O
52 O
in O
the O
laser O
treatment O
group O
and O
53 O
in O
the O
no O
laser O
treatment O
group O
. O

Patients O
were O
followed O
up O
for O
a O
median O
of O
35.9 O
months O
( O
range O
, O
10-36 O
months O
) O
in O
the O
laser O
arm O
and O
35.9 O
months O
( O
range O
, O
1-36 O
months O
) O
in O
the O
control O
arm O
. O

Eight B-Premise
eyes I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
laser I-Premise
group I-Premise
and I-Premise
3 I-Premise
eyes I-Premise
( I-Premise
6 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
converted I-Premise
to I-Premise
glaucoma I-Premise
in I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

The B-Premise
proportion I-Premise
of I-Premise
eyes I-Premise
started I-Premise
on I-Premise
medical I-Premise
treatment I-Premise
was I-Premise
similar I-Premise
in I-Premise
the I-Premise
2 I-Premise
groups I-Premise
: I-Premise
8 I-Premise
eyes I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
laser I-Premise
group I-Premise
and I-Premise
9 I-Premise
eyes I-Premise
( I-Premise
17 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Survival B-Claim
analyses I-Claim
showed I-Claim
no I-Claim
evidence I-Claim
of I-Claim
any I-Claim
difference I-Claim
in I-Claim
time I-Claim
to I-Claim
VF I-Claim
progression I-Claim
or I-Claim
commencement I-Claim
of I-Claim
topical I-Claim
therapy I-Claim
between I-Claim
the I-Claim
2 I-Claim
groups I-Claim
. I-Claim

Cataract B-Premise
extraction I-Premise
was I-Premise
performed I-Premise
on I-Premise
1 I-Premise
patient I-Premise
in I-Premise
the I-Premise
laser I-Premise
group I-Premise
and I-Premise
in I-Premise
1 I-Premise
patient I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
during I-Premise
the I-Premise
study I-Premise
period I-Premise
( I-Premise
laser I-Premise
eye I-Premise
at I-Premise
18 I-Premise
months I-Premise
";" I-Premise
control I-Premise
eye I-Premise
at I-Premise
34 I-Premise
months I-Premise
) I-Premise
. I-Premise

This B-Claim
study I-Claim
suggests I-Claim
that I-Claim
there I-Claim
was I-Claim
no I-Claim
benefit I-Claim
of I-Claim
Nd I-Claim
: I-Claim
YAG I-Claim
LPI I-Claim
in I-Claim
preventing I-Claim
progression I-Claim
from I-Claim
PDS I-Claim
with I-Claim
OHT I-Claim
to I-Claim
PG I-Claim
within I-Claim
3 I-Claim
years I-Claim
of I-Claim
follow-up I-Claim
. I-Claim

To O
determine O
the O
analgesic O
effect O
of O
supplemental O
intracameral O
lidocaine O
1 O
% O
during O
phacoemulsification O
under O
topical O
anaesthesia O
, O
and O
to O
assess O
the O
risk O
factors O
associated O
with O
pain O
. O

In O
a O
double-masked O
, O
randomised O
, O
clinical O
trial O
, O
506 O
patients O
undergoing O
phacoemulsification O
under O
topical O
anaesthesia O
were O
randomised O
to O
receive O
a O
supplemental O
intracameral O
injection O
of O
either O
0.5 O
cc O
of O
1 O
% O
lidocaine O
( O
277 O
patients O
, O
54.7 O
% O
) O
or O
balanced O
salt O
solution O
( O
BSS O
) O
( O
229 O
patients O
, O
45.3 O
% O
) O
. O

Patients O
were O
interviewed O
by O
a O
trained O
interviewer O
using O
a O
standardised O
questionnaire O
. O

The O
main O
outcome O
measure O
was O
intraoperative O
pain O
, O
scored O
on O
a O
visual O
analogue O
scale O
of O
0-10 O
. O

Logistic O
regression O
was O
performed O
to O
assess O
ORs O
. O

125 B-Premise
of I-Premise
277 I-Premise
patients I-Premise
( I-Premise
45.1 I-Premise
% I-Premise
) I-Premise
experienced I-Premise
pain I-Premise
in I-Premise
the I-Premise
lidocaine I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
123 I-Premise
of I-Premise
229 I-Premise
patients I-Premise
( I-Premise
53.7 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
BSS I-Premise
group I-Premise
. I-Premise

The B-Claim
proportion I-Claim
of I-Claim
patients I-Claim
who I-Claim
experienced I-Claim
pain I-Claim
was I-Claim
significantly I-Claim
lower I-Claim
in I-Claim
the I-Claim
intracameral I-Claim
lidocaine I-Claim
group I-Claim
compared I-Claim
with I-Claim
the I-Claim
BSS I-Claim
group I-Claim
( I-Claim
multivariate I-Claim
OR I-Claim
0.68 I-Claim
, I-Claim
95 I-Claim
% I-Claim
CI I-Claim
0.47 I-Claim
to I-Claim
0.97 I-Claim
";" I-Claim
p=0.034 I-Claim
) I-Claim
. I-Claim

The B-Premise
median I-Premise
pain I-Premise
score I-Premise
( I-Premise
range I-Premise
) I-Premise
was I-Premise
0.0 I-Premise
for I-Premise
intracameral I-Premise
lidocaine I-Premise
group I-Premise
compared I-Premise
with I-Premise
1.0 I-Premise
for I-Premise
BSS I-Premise
group I-Premise
( I-Premise
p=0.039 I-Premise
) I-Premise
. I-Premise

Pain B-Premise
was I-Premise
more I-Premise
common I-Premise
in I-Premise
females I-Premise
( I-Premise
54.3 I-Premise
% I-Premise
vs I-Premise
43.6 I-Premise
% I-Premise
";" I-Premise
OR I-Premise
1.56 I-Premise
) I-Premise
, I-Premise
non-Chinese I-Premise
( I-Premise
62.3 I-Premise
% I-Premise
vs I-Premise
46.9 I-Premise
% I-Premise
";" I-Premise
OR I-Premise
2.13 I-Premise
) I-Premise
and I-Premise
those I-Premise
who I-Premise
had I-Premise
previous I-Premise
cataract I-Premise
surgery I-Premise
to I-Premise
the I-Premise
fellow I-Premise
eye I-Premise
( I-Premise
55.3 I-Premise
% I-Premise
vs I-Premise
44.7 I-Premise
% I-Premise
";" I-Premise
OR I-Premise
1.61 I-Premise
) I-Premise
. I-Premise

The B-Claim
use I-Claim
of I-Claim
0.5 I-Claim
cc I-Claim
of I-Claim
1 I-Claim
% I-Claim
intracameral I-Claim
lidocaine I-Claim
during I-Claim
phacoemulsification I-Claim
under I-Claim
topical I-Claim
anaesthesia I-Claim
significantly I-Claim
reduces I-Claim
pain I-Claim
experienced I-Claim
by I-Claim
patients I-Claim
. I-Claim

Risk B-Claim
factors I-Claim
for I-Claim
pain I-Claim
include I-Claim
females I-Claim
, I-Claim
non-Chinese I-Claim
and I-Claim
previous I-Claim
cataract I-Claim
surgery I-Claim
. I-Claim

Brimonidine O
is O
a O
highly O
selective O
alpha-2 O
adrenergic O
receptor O
agonist O
with O
intraocular O
pressure O
( O
IOP O
) O
reducing O
effect O
. O

We O
conducted O
this O
study O
in O
Taiwan O
to O
compare O
the O
safety O
and O
efficacy O
of O
brimonidine O
0.2 O
% O
with O
timolol O
0.5 O
% O
for O
the O
treatment O
of O
glaucoma O
. O

A O
prospective O
, O
randomized O
, O
single-masked O
, O
1-month O
clinical O
efficacy O
and O
safety O
trial O
was O
conducted O
from O
March O
to O
September O
2000 O
. O

Forty O
glaucoma O
patients O
were O
enrolled O
-- O
29 O
in O
the O
brimonidine O
group O
and O
11 O
in O
the O
timolol O
group O
. O

Patients O
instilled O
their O
study O
medications O
twice O
daily O
for O
4 O
weeks O
, O
and O
were O
followed O
at O
baseline O
visit O
, O
weeks O
2 O
and O
4 O
. O

Demographic O
data O
, O
reduction O
of O
IOP O
, O
safety O
and O
adverse O
events O
were O
obtained O
and O
analyzed O
. O

Both O
drugs O
showed O
sustained O
ocular O
hypotensive O
efficacy O
in O
the O
study O
period O
. O

At B-Premise
baseline I-Premise
, I-Premise
the I-Premise
mean I-Premise
IOP I-Premise
was I-Premise
24.48 I-Premise
+/- I-Premise
2.29 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
brimonidine I-Premise
group I-Premise
and I-Premise
23.32 I-Premise
+/- I-Premise
0.82 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
timolol I-Premise
group I-Premise
. I-Premise

The B-Premise
IOP I-Premise
readings I-Premise
after I-Premise
treatment I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
their I-Premise
baseline I-Premise
levels I-Premise
in I-Premise
both I-Premise
groups I-Premise
at I-Premise
all I-Premise
visits I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
peak I-Premise
, I-Premise
the I-Premise
mean I-Premise
decreases I-Premise
from I-Premise
the I-Premise
baseline I-Premise
IOP I-Premise
ranged I-Premise
from I-Premise
5.22 I-Premise
+/- I-Premise
0.30 I-Premise
mmHg I-Premise
to I-Premise
6.96 I-Premise
+/- I-Premise
0.33 I-Premise
mmHg I-Premise
for I-Premise
brimonidine I-Premise
and I-Premise
from I-Premise
4.55 I-Premise
+/- I-Premise
0.49 I-Premise
mmHg I-Premise
to I-Premise
6.64 I-Premise
+/- I-Premise
0.53 I-Premise
mmHg I-Premise
for I-Premise
timolol I-Premise
. I-Premise

At B-Premise
trough I-Premise
, I-Premise
the I-Premise
mean I-Premise
decreases I-Premise
from I-Premise
baseline I-Premise
ranged I-Premise
from I-Premise
3.72 I-Premise
+/- I-Premise
0.32 I-Premise
mmHg I-Premise
to I-Premise
4.55 I-Premise
+/- I-Premise
0.32 I-Premise
mmHg I-Premise
for I-Premise
brimonidine I-Premise
and I-Premise
3.82 I-Premise
+/- I-Premise
0.52 I-Premise
mmHg I-Premise
to I-Premise
4.27 I-Premise
+/- I-Premise
0.51 I-Premise
mmHg I-Premise
for I-Premise
timolol I-Premise
. I-Premise

No O
significant O
between-group O
differences O
were O
seen O
at O
peak O
or O
trough O
at O
all O
visits O
. O

The B-Premise
clinical I-Premise
success I-Premise
rate I-Premise
was I-Premise
86.2 I-Premise
% I-Premise
in I-Premise
the I-Premise
brimonidine I-Premise
group I-Premise
and I-Premise
81.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
timolol I-Premise
group I-Premise
, I-Premise
making I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
between I-Premise
them I-Premise
( I-Premise
p I-Premise
= I-Premise
0.817 I-Premise
) I-Premise
. I-Premise

17.2 B-Premise
% I-Premise
of I-Premise
patients I-Premise
in I-Premise
brimonidine I-Premise
group I-Premise
and I-Premise
9.0 I-Premise
% I-Premise
patients I-Premise
in I-Premise
timolol I-Premise
group I-Premise
reported I-Premise
mild I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Ocular B-Premise
allergy I-Premise
occurred I-Premise
in I-Premise
10.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
in I-Premise
brimonidine I-Premise
group I-Premise
. I-Premise

No B-Premise
significant I-Premise
changes I-Premise
in I-Premise
visual I-Premise
acuity I-Premise
, I-Premise
biomicroscopy I-Premise
or I-Premise
ophthalmoscopy I-Premise
were I-Premise
observed I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Mean B-Premise
systolic I-Premise
and I-Premise
diastolic I-Premise
blood I-Premise
pressure I-Premise
remained I-Premise
relatively I-Premise
stable I-Premise
in I-Premise
both I-Premise
groups I-Premise
except B-Premise
in I-Premise
week I-Premise
2 I-Premise
( I-Premise
p I-Premise
= I-Premise
0.016 I-Premise
) I-Premise
when I-Premise
brimonidine I-Premise
had I-Premise
lower I-Premise
systolic I-Premise
blood I-Premise
pressure I-Premise
. I-Premise

However O
, O
brimonidine O
showed O
no O
significant O
difference O
in O
week O
4 O
from O
baseline O
. O

The B-Premise
mean I-Premise
heart I-Premise
rate I-Premise
in I-Premise
the I-Premise
brimonidine I-Premise
group I-Premise
was I-Premise
relatively I-Premise
unchanged I-Premise
over I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
timolol I-Premise
experienced I-Premise
statistically I-Premise
significant I-Premise
mean I-Premise
heart I-Premise
rate I-Premise
decreases I-Premise
from I-Premise
baseline I-Premise
( I-Premise
p I-Premise
= I-Premise
0.020 I-Premise
) I-Premise
in I-Premise
week I-Premise
4 I-Premise
. I-Premise

Topically B-Claim
applied I-Claim
twice I-Claim
daily I-Claim
for I-Claim
one I-Claim
month I-Claim
, I-Claim
brimonidine I-Claim
tartrate I-Claim
0.2 I-Claim
% I-Claim
has I-Claim
clinical I-Claim
effectiveness I-Claim
equivalent I-Claim
to I-Claim
timolol I-Claim
0.5 I-Claim
% I-Claim
in I-Claim
Taiwanese I-Claim
patients I-Claim
with I-Claim
glaucoma I-Claim
. I-Claim

It B-Claim
has I-Claim
a I-Claim
safe I-Claim
systemic I-Claim
profile I-Claim
with I-Claim
minimum I-Claim
effect I-Claim
on I-Claim
the I-Claim
heart I-Claim
. I-Claim

To O
evaluate O
the O
efficacy O
and O
safety O
of O
intraoperative O
mitomycin O
C O
( O
MMC O
) O
in O
eyes O
undergoing O
Ahmed O
Glaucoma O
Valve O
implantation O
. O

Randomized O
controlled O
clinical O
trial O
. O

Sixty O
patients O
with O
refractory O
glaucoma O
. O

Sixty O
eyes O
of O
60 O
patients O
with O
refractory O
glaucoma O
were O
randomized O
to O
receive O
intraoperative O
MMC O
( O
0.5 O
mg/ml O
for O
5 O
minutes O
) O
( O
n O
= O
34 O
) O
or O
balanced O
salt O
solution O
( O
n O
= O
26 O
) O
during O
Ahmed O
Glaucoma O
Valve O
implantation O
. O

Surgical O
success O
was O
defined O
according O
to O
2 O
different O
criteria O
: O
( O
1 O
) O
postoperative O
intraocular O
pressure O
( O
IOP O
) O
between O
6 O
and O
21 O
mmHg O
, O
with O
or O
without O
antiglaucoma O
medications O
, O
and O
( O
2 O
) O
IOP O
reduction O
of O
at O
least O
30 O
% O
relative O
to O
preoperative O
values O
. O

Eyes O
requiring O
additional O
glaucoma O
surgery O
, O
developing O
phthisis O
, O
or O
showing O
loss O
of O
light O
perception O
were O
classified O
as O
failures O
. O

Success O
rates O
in O
both O
groups O
were O
compared O
using O
Kaplan-Meier O
survival O
curves O
and O
the O
log O
rank O
test O
. O

Other O
outcome O
measures O
were O
mean O
IOP O
, O
number O
of O
glaucoma O
medications O
, O
and O
complications O
. O

After B-Premise
a I-Premise
mean I-Premise
follow-up I-Premise
of I-Premise
12.3 I-Premise
months I-Premise
, I-Premise
Kaplan-Meier I-Premise
survival I-Premise
analysis I-Premise
showed I-Premise
a I-Premise
probability I-Premise
of I-Premise
success I-Premise
of I-Premise
59 I-Premise
% I-Premise
at I-Premise
18 I-Premise
months I-Premise
for I-Premise
the I-Premise
MMC I-Premise
group I-Premise
and I-Premise
61 I-Premise
% I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
when I-Premise
the I-Premise
first I-Premise
criterion I-Premise
for I-Premise
success I-Premise
was I-Premise
used I-Premise
( I-Premise
IOP I-Premise
between I-Premise
6 I-Premise
and I-Premise
21 I-Premise
mmHg I-Premise
) I-Premise
. I-Premise

When B-Premise
an I-Premise
IOP I-Premise
reduction I-Premise
of I-Premise
at I-Premise
least I-Premise
30 I-Premise
% I-Premise
was I-Premise
used I-Premise
as I-Premise
the I-Premise
criterion I-Premise
to I-Premise
define I-Premise
success I-Premise
, I-Premise
the I-Premise
Kaplan-Meier I-Premise
survival I-Premise
analysis I-Premise
demonstrated I-Premise
a I-Premise
probability I-Premise
of I-Premise
success I-Premise
at I-Premise
18 I-Premise
months I-Premise
of I-Premise
62 I-Premise
% I-Premise
for I-Premise
the I-Premise
MMC I-Premise
group I-Premise
and I-Premise
67 I-Premise
% I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
survival I-Premise
rates I-Premise
between I-Premise
the I-Premise
2 I-Premise
groups I-Premise
with I-Premise
either I-Premise
criterion I-Premise
( I-Premise
P I-Premise
= I-Premise
0.75 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.37 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

After B-Premise
15 I-Premise
days I-Premise
postoperatively I-Premise
, I-Premise
the I-Premise
mean I-Premise
IOP I-Premise
did I-Premise
not I-Premise
significantly I-Premise
differ I-Premise
for I-Premise
both I-Premise
MMC I-Premise
and I-Premise
control I-Premise
eyes I-Premise
. I-Premise

Mean B-Premise
numbers I-Premise
of I-Premise
postoperative I-Premise
antiglaucoma I-Premise
medications I-Premise
were I-Premise
similar I-Premise
in I-Premise
MMC-treated I-Premise
eyes I-Premise
and I-Premise
controls I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
incidences I-Premise
of I-Premise
postoperative I-Premise
complications I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Mitomycin B-Claim
C I-Claim
did I-Claim
not I-Claim
increase I-Claim
the I-Claim
short- I-Claim
or I-Claim
intermediate-term I-Claim
success I-Claim
rates I-Claim
of I-Claim
Ahmed I-Claim
Glaucoma I-Claim
Valve I-Claim
implantation I-Claim
. I-Claim

To O
compare O
the O
efficacy O
of O
the O
fixed O
dorzolamide O
2 O
% O
/timolol O
0.5 O
% O
combination O
( O
COSOPT O
) O
versus O
latanoprost O
0.005 O
% O
( O
XALATAN O
) O
. O

Two O
3-month O
, O
parallel O
group O
, O
randomized O
, O
observer-masked O
and O
patient-masked O
, O
multicentre O
, O
clinical O
trials O
were O
performed O
in O
patients O
with O
ocular O
hypertension O
or O
open-angle O
glaucoma O
. O

Study O
1 O
( O
n=256 O
) O
was O
conducted O
in O
the O
United O
States O
and O
Study O
2 O
( O
n=288 O
) O
was O
conducted O
in O
Europe/Israel O
. O

Patients O
could O
be O
included O
whether O
or O
not O
they O
were O
currently O
taking O
ocular O
hypotensive O
therapy O
, O
and O
regardless O
of O
the O
effectiveness O
of O
any O
previous O
therapy O
. O

Patients O
were O
washed O
out O
from O
their O
usual O
ocular O
hypotensive O
medications O
and O
then O
those O
with O
a O
baseline O
intraocular O
pressure O
( O
IOP O
) O
> O
/= O
24 O
mmHg O
were O
randomized O
to O
either O
the O
dorzolamide/timolol O
combination O
eye O
drops O
twice O
daily O
or O
latanoprost O
eye O
drops O
once O
daily O
in O
both O
eyes O
. O

Efficacy O
was O
assessed O
by O
daytime O
diurnal O
IOP O
( O
the O
mean O
of O
measurements O
made O
at O
800 O
, O
1000 O
, O
1400 O
and O
1600 O
h O
) O
. O

At B-Premise
baseline I-Premise
, I-Premise
the I-Premise
mean I-Premise
daytime I-Premise
diurnal I-Premise
IOP I-Premise
was I-Premise
26.1 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
dorzolamide/timolol I-Premise
combination I-Premise
group I-Premise
versus I-Premise
25.6 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
in I-Premise
Study I-Premise
1 I-Premise
, I-Premise
and I-Premise
25.3 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
dorzolamide/timolol I-Premise
combination I-Premise
group I-Premise
versus I-Premise
24.7 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
in I-Premise
Study I-Premise
2 I-Premise
. I-Premise

After B-Premise
3 I-Premise
months I-Premise
, I-Premise
the I-Premise
mean I-Premise
daytime I-Premise
diurnal I-Premise
IOP I-Premise
was I-Premise
18.9 I-Premise
mmHg I-Premise
for I-Premise
the I-Premise
dorzolamide/timolol I-Premise
combination I-Premise
versus I-Premise
18.4 I-Premise
mmHg I-Premise
for I-Premise
latanoprost I-Premise
in I-Premise
Study I-Premise
1 I-Premise
, I-Premise
and I-Premise
17.4 I-Premise
mmHg I-Premise
for I-Premise
the I-Premise
dorzolamide/timolol I-Premise
combination I-Premise
versus I-Premise
17.5 I-Premise
for I-Premise
latanoprost I-Premise
in I-Premise
Study I-Premise
2 I-Premise
. I-Premise

The B-Premise
difference I-Premise
between I-Premise
treatments I-Premise
in I-Premise
mean I-Premise
IOP I-Premise
change I-Premise
at I-Premise
3 I-Premise
months I-Premise
was I-Premise
-0.04 I-Premise
mmHg I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
-0.85 I-Premise
, I-Premise
0.77 I-Premise
] I-Premise
in I-Premise
Study I-Premise
1 I-Premise
, I-Premise
and I-Premise
-0.57 I-Premise
mmHg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-1.31 I-Premise
, I-Premise
0.16 I-Premise
) I-Premise
in I-Premise
Study I-Premise
2 I-Premise
. I-Premise

The B-Premise
probability I-Premise
that I-Premise
the I-Premise
TRUE I-Premise
difference I-Premise
lay I-Premise
between I-Premise
-1.5 I-Premise
and I-Premise
1.5 I-Premise
mmHg I-Premise
, I-Premise
the I-Premise
predefined I-Premise
bounds I-Premise
for I-Premise
equivalence I-Premise
, I-Premise
was I-Premise
> I-Premise
0.950 I-Premise
in I-Premise
both I-Premise
studies I-Premise
. I-Premise

Both B-Claim
treatments I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
over I-Claim
3 I-Claim
months I-Claim
, I-Claim
although B-Premise
ocular I-Premise
stinging I-Premise
occurred I-Premise
more I-Premise
frequently I-Premise
with I-Premise
the I-Premise
dorzolamide/timolol I-Premise
combination I-Premise
. I-Premise

The B-Claim
dorzolamide/timolol I-Claim
combination I-Claim
and I-Claim
latanoprost I-Claim
were I-Claim
equally I-Claim
effective I-Claim
at I-Claim
lowering I-Claim
IOP I-Claim
. I-Claim

To O
compare O
the O
safety O
and O
efficacy O
of O
intraoperative O
5-fluorouracil O
( O
5-FU O
) O
or O
Intraoperative O
mitomycin O
C O
( O
MMC O
) O
in O
eyes O
undergoing O
primary O
trabeculectomy O
. O

Prospective O
double-masked O
randomized O
clinical O
trial O
. O

One O
hundred O
fifteen O
eyes O
of O
103 O
patients O
with O
uncontrolled O
intraocular O
pressure O
( O
IOP O
) O
despite O
maximally O
tolerated O
medical O
therapy O
or O
laser O
were O
prospectively O
randomized O
in O
a O
double-masked O
fashion O
to O
one O
of O
two O
treatment O
groups O
in O
a O
single O
institution O
setting O
. O

Subject O
's O
eyes O
underwent O
primary O
trabeculectomy O
with O
either O
topical O
5-FU O
( O
50 O
mg/ml O
for O
5 O
minutes O
) O
or O
topical O
MMC O
( O
0.2 O
mg/ml O
for O
2 O
minutes O
) O
. O

Primary O
outcome O
measures O
included O
the O
number O
of O
eyes O
achieving O
target O
pressures O
of O
21 O
, O
18 O
, O
15 O
, O
and O
12 O
mm O
Hg O
at O
6 O
and O
12 O
months O
postoperatively O
. O

Secondary O
outcome O
measures O
included O
IOP O
, O
best-corrected O
visual O
acuity O
, O
complications O
, O
and O
interventions O
. O

Of O
the O
115 O
eyes O
, O
57 O
received O
5-FU O
while O
58 O
received O
MMC O
. O

A B-Premise
target I-Premise
IOP I-Premise
of I-Premise
21 I-Premise
mm I-Premise
Hg I-Premise
at I-Premise
6 I-Premise
months I-Premise
was I-Premise
achieved I-Premise
in I-Premise
53 I-Premise
of I-Premise
56 I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
eyes I-Premise
in I-Premise
the I-Premise
5-FU I-Premise
group I-Premise
and I-Premise
54 I-Premise
of I-Premise
57 I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
eyes I-Premise
in I-Premise
the I-Premise
MMC I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
1.00 I-Premise
) I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
45 I-Premise
of I-Premise
48 I-Premise
( I-Premise
94 I-Premise
% I-Premise
) I-Premise
eyes I-Premise
in I-Premise
the I-Premise
5-FU I-Premise
group I-Premise
met I-Premise
a I-Premise
target I-Premise
IOP I-Premise
of I-Premise
21 I-Premise
mm I-Premise
Hg I-Premise
while I-Premise
48 I-Premise
of I-Premise
54 I-Premise
( I-Premise
89 I-Premise
% I-Premise
) I-Premise
eyes I-Premise
in I-Premise
the I-Premise
MMC I-Premise
group I-Premise
did I-Premise
( I-Premise
P I-Premise
=.49 I-Premise
) I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
complications I-Premise
in I-Premise
each I-Premise
group I-Premise
were I-Premise
persistent I-Premise
choroidal I-Premise
effusions I-Premise
and I-Premise
bleb I-Premise
leak I-Premise
. I-Premise

Our B-Claim
study I-Claim
suggests I-Claim
that I-Claim
intraoperative I-Claim
topical I-Claim
5-FU I-Claim
is I-Claim
at I-Claim
least I-Claim
as I-Claim
effective I-Claim
as I-Claim
intraoperative I-Claim
topical I-Claim
MMC I-Claim
in I-Claim
reducing I-Claim
IOP I-Claim
of I-Claim
eyes I-Claim
undergoing I-Claim
primary I-Claim
trabeculectomy I-Claim
. I-Claim

The O
purpose O
of O
this O
randomized O
clinical O
trial O
was O
to O
compare O
the O
effectiveness O
and O
safety O
of O
viscocanalostomy O
( O
visco O
) O
with O
trabeculectomy O
( O
trab O
) O
in O
the O
management O
of O
primary O
open O
angle O
glaucoma O
( O
POAG O
) O
. O

Patients O
were O
randomized O
to O
have O
a O
viscocanalostomy O
( O
25 O
eyes O
) O
or O
a O
trabeculectomy O
( O
25 O
eyes O
) O
performed O
by O
one O
surgeon O
( O
TDM O
) O
and O
followed O
up O
prospectively O
. O

Patients O
were O
examined O
preoperatively O
, O
at O
day O
1 O
, O
day O
3 O
if O
required O
, O
day O
6 O
, O
week O
2 O
and O
thereafter O
as O
near O
as O
possible O
to O
1 O
, O
3 O
, O
6 O
, O
12 O
, O
18 O
, O
24 O
, O
30 O
, O
36 O
, O
48 O
, O
54 O
, O
and O
60 O
months O
. O

We O
recorded O
intraocular O
pressure O
( O
IOP O
) O
, O
presence O
or O
absence O
of O
any O
complications O
, O
presence O
and O
description O
of O
any O
bleb O
, O
visual O
acuity O
with O
glasses O
, O
and O
full O
examinations O
as O
routine O
to O
monitor O
any O
progression O
of O
the O
glaucoma O
. O

Bleb O
interventions O
including O
needling O
and O
antimetabolites O
were O
allowed O
and O
recorded O
in O
both O
groups O
. O

YAG O
laser O
goniopuncture O
was O
allowed O
in O
the O
viscocanalostomy O
group O
. O

Mean O
follow-up O
was O
40 O
months O
( O
SD O
15 O
) O
, O
with O
a O
range O
from O
6 O
to O
60 O
months O
. O

Forty-two B-Premise
percent I-Premise
( I-Premise
n=10 I-Premise
) I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
had I-Premise
a I-Premise
successful I-Premise
outcome I-Premise
( I-Premise
IOP I-Premise
< I-Premise
18 I-Premise
mm I-Premise
Hg I-Premise
with I-Premise
no I-Premise
treatment I-Premise
) I-Premise
at I-Premise
last I-Premise
follow-up I-Premise
visit I-Premise
, I-Premise
compared I-Premise
to I-Premise
21 I-Premise
% I-Premise
( I-Premise
n=5 I-Premise
) I-Premise
in I-Premise
the I-Premise
viscocanalostomy I-Premise
group I-Premise
. I-Premise

IOP B-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
trab I-Premise
group I-Premise
with I-Premise
differences I-Premise
in I-Premise
IOP I-Premise
being I-Premise
statistically I-Premise
significant I-Premise
at I-Premise
month I-Premise
12 I-Premise
( I-Premise
P= I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
24 I-Premise
( I-Premise
P= I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
30 I-Premise
( I-Premise
P=0.030 I-Premise
) I-Premise
, I-Premise
36 I-Premise
( I-Premise
P= I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
48 I-Premise
( I-Premise
P=0.018 I-Premise
) I-Premise
. I-Premise

The B-Premise
trabeculectomy I-Premise
group I-Premise
required I-Premise
less I-Premise
postoperative I-Premise
topical I-Premise
IOP-lowering I-Premise
medication I-Premise
( I-Premise
P=0.011 I-Premise
) I-Premise
. I-Premise

In O
this O
study O
, O
we B-Claim
found I-Claim
trabeculectomy I-Claim
to I-Claim
be I-Claim
more I-Claim
effective I-Claim
at I-Claim
lowering I-Claim
IOP I-Claim
than I-Claim
viscocanalostomy I-Claim
in I-Claim
POAG I-Claim
patients I-Claim
. I-Claim

To O
compare O
the O
effectiveness O
and O
safety O
of O
viscocanalostomy O
and O
trabeculectomy O
in O
adults O
with O
uncontrolled O
open-angle O
glaucoma O
. O

Single-masked O
, O
parallel-group O
, O
prospective O
, O
randomized O
24-month O
trial O
, O
with O
90 O
% O
power O
to O
detect O
a O
clinically O
important O
difference O
between O
groups O
. O

Fifty O
consecutive O
patients O
( O
50 O
eyes O
) O
with O
primary O
open-angle O
or O
pseudoexfoliative O
glaucoma O
. O

Eyes O
were O
assigned O
randomly O
to O
either O
viscocanalostomy O
( O
group O
1 O
) O
or O
trabeculectomy O
( O
group O
2 O
) O
with O
no O
intraoperative O
antifibrotics O
in O
the O
study O
eye O
. O

In O
group O
1 O
, O
no O
further O
intervention O
was O
allowed O
, O
whereas O
trabeculectomy O
eyes O
could O
receive O
subconjunctival O
5-fluorouracil O
( O
5-FU O
) O
injections O
or O
laser O
suture O
lysis O
after O
surgery O
. O

Success O
rate O
based O
on O
intraocular O
pressure O
( O
IOP O
) O
, O
visual O
acuity O
, O
discomfort O
, O
and O
other O
complications O
. O

At B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
24-month I-Premise
follow-up I-Premise
, I-Premise
IOP I-Premise
of I-Premise
21 I-Premise
mmHg I-Premise
or I-Premise
less I-Premise
and I-Premise
more I-Premise
than I-Premise
6 I-Premise
mmHg I-Premise
was I-Premise
achieved I-Premise
in I-Premise
76 I-Premise
% I-Premise
in I-Premise
group I-Premise
1 I-Premise
( I-Premise
n I-Premise
= I-Premise
19 I-Premise
) I-Premise
and I-Premise
in I-Premise
80 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
( I-Premise
n I-Premise
= I-Premise
20 I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
= I-Premise
0.60 I-Premise
) I-Premise
";" I-Premise
an B-Premise
IOP I-Premise
between I-Premise
6 I-Premise
and I-Premise
16 I-Premise
mmHg I-Premise
was I-Premise
obtained I-Premise
in I-Premise
56 I-Premise
% I-Premise
in I-Premise
group I-Premise
1 I-Premise
( I-Premise
n I-Premise
= I-Premise
14 I-Premise
) I-Premise
and I-Premise
in I-Premise
72 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
( I-Premise
n I-Premise
= I-Premise
18 I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
= I-Premise
0.17 I-Premise
";" I-Premise
Kaplan-Meier I-Premise
cumulative I-Premise
probability I-Premise
of I-Premise
success I-Premise
) I-Premise
. I-Premise

Complications B-Premise
of I-Premise
viscocanalostomy I-Premise
included I-Premise
one I-Premise
intraoperative I-Premise
conversion I-Premise
into I-Premise
trabeculectomy I-Premise
";" I-Premise
microruptures I-Premise
in I-Premise
Descemet I-Premise
's I-Premise
membrane I-Premise
in I-Premise
five I-Premise
eyes I-Premise
";" I-Premise
three I-Premise
cases I-Premise
of I-Premise
iris I-Premise
incarceration I-Premise
in I-Premise
the I-Premise
Decemet I-Premise
's I-Premise
window I-Premise
, I-Premise
two I-Premise
of I-Premise
which I-Premise
caused I-Premise
early I-Premise
failure I-Premise
of I-Premise
the I-Premise
procedure I-Premise
requiring I-Premise
reoperation I-Premise
";" I-Premise
and I-Premise
a I-Premise
1-mm I-Premise
to I-Premise
2-mm I-Premise
transient I-Premise
self-resolving I-Premise
hyphema I-Premise
in I-Premise
three I-Premise
cases I-Premise
. O

Complications B-Premise
of I-Premise
trabeculectomy I-Premise
included I-Premise
one I-Premise
case I-Premise
of I-Premise
postoperative I-Premise
bleb I-Premise
bleeding I-Premise
with I-Premise
early I-Premise
transient I-Premise
IOP I-Premise
spike I-Premise
";" I-Premise
one I-Premise
early I-Premise
hyphema I-Premise
";" I-Premise
five I-Premise
cases I-Premise
of I-Premise
postoperative I-Premise
hypotony I-Premise
, I-Premise
two I-Premise
of I-Premise
which I-Premise
had I-Premise
a I-Premise
positive I-Premise
Seidel I-Premise
test I-Premise
from I-Premise
the I-Premise
conjunctival I-Premise
suture I-Premise
";" I-Premise
three I-Premise
cases I-Premise
of I-Premise
transient I-Premise
choroidal I-Premise
detachment I-Premise
, I-Premise
two I-Premise
of I-Premise
which I-Premise
had I-Premise
shallow I-Premise
anterior I-Premise
chamber I-Premise
. I-Premise

No B-Premise
patient I-Premise
required I-Premise
reoperation I-Premise
. I-Premise

Two B-Premise
eyes I-Premise
required I-Premise
argon I-Premise
laser I-Premise
suture I-Premise
lysis I-Premise
, I-Premise
and I-Premise
nine I-Premise
underwent I-Premise
one I-Premise
or I-Premise
more I-Premise
5-FU I-Premise
injections I-Premise
, I-Premise
which I-Premise
caused I-Premise
punctate I-Premise
keratopathy I-Premise
in I-Premise
three I-Premise
eyes I-Premise
. I-Premise

Viscocanalostomy B-Claim
is I-Claim
an I-Claim
effective I-Claim
IOP-lowering I-Claim
procedure I-Claim
in I-Claim
white I-Claim
adults I-Claim
affected I-Claim
by I-Claim
open-angle I-Claim
glaucoma I-Claim
. I-Claim

Trabeculectomy B-Claim
with I-Claim
postoperative I-Claim
5-FU I-Claim
can I-Claim
probably I-Claim
provides I-Claim
lower I-Claim
IOPs I-Claim
but I-Claim
, I-Claim
with I-Claim
more I-Claim
numerous I-Claim
complications I-Claim
, I-Claim
greater I-Claim
discomfort I-Claim
, I-Claim
and I-Claim
more I-Claim
intensive I-Claim
postoperative I-Claim
management I-Claim
. I-Claim

To O
compare O
the O
efficacy O
of O
the O
Ahmed O
S2 O
Glaucoma O
Valve O
with O
the O
Baerveldt O
250-mm O
( O
2 O
) O
Glaucoma O
Implant O
in O
the O
treatment O
of O
adult O
glaucoma O
. O

Comparative O
case O
series O
. O

Fifty-nine O
eyes O
of O
59 O
patients O
who O
received O
the O
Ahmed O
S2 O
Glaucoma O
Valve O
and O
133 O
eyes O
of O
133 O
patients O
who O
received O
the O
Baerveldt O
250-mm O
( O
2 O
) O
Glaucoma O
Implant O
by O
the O
Indiana O
University O
Glaucoma O
Service O
from O
1996 O
to O
2003 O
. O

Eyes O
that O
had O
previous O
drainage O
implant O
procedures O
were O
excluded O
from O
both O
groups O
. O

If O
both O
eyes O
of O
a O
single O
patient O
received O
an O
implant O
, O
the O
second O
eye O
to O
undergo O
implantation O
was O
excluded O
from O
the O
study O
. O

Kaplan-Meier O
survival O
with O
success O
defined O
as O
intraocular O
pressure O
( O
IOP O
) O
> O
5 O
mmHg O
and O
< O
22 O
mmHg O
and O
at O
least O
20 O
% O
reduction O
from O
preoperative O
IOP O
( O
with O
or O
without O
antiglaucoma O
medications O
) O
and O
without O
loss O
of O
light O
perception O
. O

Secondary O
outcome O
measures O
included O
intraocular O
pressure O
, O
visual O
acuity O
, O
number O
of O
glaucoma O
medications O
, O
and O
surgical O
complications O
. O

The O
2 O
groups O
were O
similar O
with O
regards O
to O
age O
, O
gender O
, O
race O
, O
neovascular O
glaucoma O
diagnosis O
, O
number O
of O
prior O
ocular O
surgeries O
, O
preoperative O
IOP O
, O
and O
number O
of O
preoperative O
glaucoma O
medications O
. O

Mean O
durations O
of O
follow-up O
were O
20.0 O
months O
for O
Ahmed O
eyes O
and O
22.9 O
months O
for O
Baerveldt O
eyes O
. O

Cumulative B-Premise
successes I-Premise
in I-Premise
the I-Premise
Ahmed I-Premise
group I-Premise
were I-Premise
0.73 I-Premise
at I-Premise
1 I-Premise
year I-Premise
and I-Premise
0.62 I-Premise
at I-Premise
2 I-Premise
years I-Premise
, I-Premise
whereas I-Premise
cumulative I-Premise
successes I-Premise
in I-Premise
the I-Premise
Baerveldt I-Premise
group I-Premise
were I-Premise
0.92 I-Premise
at I-Premise
1 I-Premise
year I-Premise
and I-Premise
0.85 I-Premise
at I-Premise
2 I-Premise
years I-Premise
( I-Premise
Kaplan-Meier I-Premise
survival I-Premise
functions I-Premise
: I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
, I-Premise
log I-Premise
rank I-Premise
test I-Premise
) I-Premise
. I-Premise

Male B-Claim
gender I-Claim
, I-Claim
African I-Claim
descent I-Claim
, I-Claim
neovascular I-Claim
glaucoma I-Claim
, I-Claim
and I-Claim
Ahmed I-Claim
implantation I-Claim
were I-Claim
found I-Claim
to I-Claim
be I-Claim
significant I-Claim
predictors I-Claim
of I-Claim
failure I-Claim
. I-Claim

At B-Premise
last I-Premise
follow-up I-Premise
visit I-Premise
, I-Premise
eyes I-Premise
in I-Premise
the I-Premise
Ahmed I-Premise
group I-Premise
had I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
mean I-Premise
IOP I-Premise
( I-Premise
19.8+/-9.5 I-Premise
vs. I-Premise
15.8+/-7.9 I-Premise
mmHg I-Premise
, I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
, I-Premise
t I-Premise
test I-Premise
) I-Premise
and I-Premise
more I-Premise
antiglaucoma I-Premise
medications I-Premise
( I-Premise
1.4+/-1.2 I-Premise
vs. I-Premise
0.9+/-1.1 I-Premise
medications I-Premise
, I-Premise
P I-Premise
= I-Premise
0.008 I-Premise
, I-Premise
Mann-Whitney I-Premise
test I-Premise
) I-Premise
than I-Premise
eyes I-Premise
in I-Premise
the I-Premise
Baerveldt I-Premise
group I-Premise
. I-Premise

Two O
methods O
for O
avoiding O
hypotony O
after O
Baerveldt O
250-mm O
( O
2 O
) O
implantation O
had O
similar O
outcomes O
. O

Our B-Claim
study I-Claim
suggests I-Claim
that I-Claim
the I-Claim
Ahmed I-Claim
S2 I-Claim
Glaucoma I-Claim
Valve I-Claim
may I-Claim
be I-Claim
less I-Claim
effective I-Claim
at I-Claim
lowering I-Claim
IOP I-Claim
than I-Claim
the I-Claim
Baerveldt I-Claim
250-mm I-Claim
( I-Claim
2 I-Claim
) I-Claim
Glaucoma I-Claim
Implant I-Claim
. I-Claim

To O
evaluate O
the O
efficacy O
and O
safety O
of O
Baerveldt O
and O
Ahmed O
glaucoma O
drainage O
implants O
in O
Asian O
patients O
with O
refractory O
glaucoma O
. O

Retrospective O
nonrandomized O
study O
. O

Forty-one O
patients O
. O

The O
authors O
reviewed O
the O
insertion O
of O
18 O
Ahmed O
glaucoma O
valved O
( O
AGV-S2 O
) O
implants O
and O
24 O
350 O
mm O
( O
2 O
) O
Baerveldt O
glaucoma O
implants O
performed O
by O
a O
single O
surgeon O
at O
the O
Department O
of O
Ophthalmology O
, O
National O
University O
Hospital O
, O
Singapore O
, O
from O
January O
1 O
, O
2000 O
, O
to O
December O
31 O
, O
2000 O
. O

A O
total O
of O
42 O
glaucoma O
drainage O
implants O
was O
inserted O
into O
the O
eyes O
of O
41 O
patients O
. O

All O
patients O
had O
at O
least O
6 O
months O
of O
follow-up O
. O

Intraocular O
pressure O
( O
IOP O
) O
, O
visual O
acuity O
, O
and O
complications O
. O

Both B-Premise
drainage I-Premise
implants I-Premise
achieved I-Premise
remarkable I-Premise
reductions I-Premise
in I-Premise
IOP I-Premise
";" I-Premise
from I-Premise
pretreatment I-Premise
IOP I-Premise
of I-Premise
40.1+/-13.8 I-Premise
mmHg I-Premise
and I-Premise
43.7+/-9.3 I-Premise
mmHg I-Premise
to I-Premise
postoperative I-Premise
IOP I-Premise
of I-Premise
17.4+/-6.2 I-Premise
and I-Premise
14.9+/-5.5 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
Baerveldt I-Premise
and I-Premise
Ahmed I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise

A B-Premise
decrease I-Premise
in I-Premise
IOP I-Premise
of I-Premise
56.6 I-Premise
% I-Premise
and I-Premise
65.9 I-Premise
% I-Premise
had I-Premise
been I-Premise
achieved I-Premise
. I-Premise

Success B-Premise
rates I-Premise
were I-Premise
20 I-Premise
( I-Premise
83.3 I-Premise
% I-Premise
) I-Premise
for I-Premise
Baerveldt I-Premise
and I-Premise
12 I-Premise
( I-Premise
66.7 I-Premise
% I-Premise
) I-Premise
for I-Premise
Ahmed I-Premise
implants I-Premise
, I-Premise
whereas I-Premise
qualified I-Premise
success I-Premise
occurred I-Premise
in I-Premise
1 I-Premise
( I-Premise
4.2 I-Premise
% I-Premise
) I-Premise
Baerveldt I-Premise
and I-Premise
3 I-Premise
( I-Premise
16.7 I-Premise
% I-Premise
) I-Premise
Ahmed I-Premise
implants I-Premise
. I-Premise

Conversely B-Premise
, I-Premise
failure I-Premise
to I-Premise
control I-Premise
IOP I-Premise
occurred I-Premise
in I-Premise
3 I-Premise
( I-Premise
12.5 I-Premise
% I-Premise
) I-Premise
Baerveldt I-Premise
implants I-Premise
and I-Premise
3 I-Premise
( I-Premise
16.7 I-Premise
% I-Premise
) I-Premise
Ahmed I-Premise
implants I-Premise
. I-Premise

More B-Premise
than I-Premise
80 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
had I-Premise
maintained I-Premise
or I-Premise
improved I-Premise
visual I-Premise
function I-Premise
, I-Premise
whereas I-Premise
only I-Premise
4 I-Premise
( I-Premise
16.0 I-Premise
% I-Premise
) I-Premise
of I-Premise
the I-Premise
patients I-Premise
with I-Premise
Baerveldt I-Premise
implants I-Premise
and I-Premise
2 I-Premise
( I-Premise
16.7 I-Premise
% I-Premise
) I-Premise
patients I-Premise
with I-Premise
Ahmed I-Premise
implants I-Premise
had I-Premise
loss I-Premise
of I-Premise
more I-Premise
than I-Premise
1 I-Premise
Snellen I-Premise
line I-Premise
. I-Premise

Both B-Claim
Baerveldt I-Claim
and I-Claim
Ahmed I-Claim
glaucoma I-Claim
drainage I-Claim
implants I-Claim
performed I-Claim
well I-Claim
in I-Claim
terms I-Claim
of I-Claim
IOP I-Claim
control I-Claim
, I-Claim
preservation I-Claim
of I-Claim
visual I-Claim
function I-Claim
, I-Claim
and I-Claim
having I-Claim
low I-Claim
complication I-Claim
rates I-Claim
. I-Claim

To O
report O
the O
longer O
term O
results O
of O
a O
randomized O
, O
clinical O
trial O
comparing O
the O
350-mm2 O
and O
the O
500-mm2 O
Baerveldt O
glaucoma O
implants O
. O

Extended O
follow-up O
on O
a O
randomized O
, O
controlled O
trial O
. O

Between O
March O
1991 O
and O
April O
1993 O
, O
107 O
patients O
with O
uncontrolled O
intraocular O
pressure O
( O
IOP O
) O
due O
to O
non-neovascular O
glaucoma O
associated O
with O
aphakia O
, O
pseudophakia O
, O
or O
failed O
filters O
were O
randomly O
assigned O
for O
surgical O
placement O
of O
either O
the O
350-mm2 O
or O
the O
500-mm2 O
Baerveldt O
implant O
at O
the O
Doheny O
Eye O
Institute O
. O

A O
random-numbers O
table O
was O
used O
to O
assign O
each O
patient O
to O
one O
of O
the O
two O
groups O
. O

Preoperative O
IOPs O
and O
visual O
acuities O
were O
recorded O
. O

Clinical O
records O
were O
reviewed O
to O
ascertain O
postoperative O
IOPs O
, O
visual O
acuities O
, O
number O
of O
medications O
used O
, O
and O
implant-related O
complications O
that O
occurred O
throughout O
the O
follow-up O
period O
. O

Success O
was O
defined O
as O
IOP O
of O
6 O
mmHg O
or O
greater O
and O
of O
21 O
mmHg O
or O
less O
in O
two O
or O
more O
consecutive O
follow-up O
visits O
without O
further O
glaucoma O
surgery O
or O
loss O
of O
light O
perception O
attributable O
to O
glaucoma O
. O

The B-Premise
overall I-Premise
success I-Premise
rates I-Premise
were I-Premise
87 I-Premise
% I-Premise
for I-Premise
the I-Premise
350-mm2 I-Premise
group I-Premise
and I-Premise
70 I-Premise
% I-Premise
for I-Premise
the I-Premise
500-mm2 I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Average O
follow-up O
was O
37 O
months O
( O
range O
, O
1-76 O
months O
) O
for O
the O
350-mm2 O
group O
and O
34 O
months O
( O
range O
, O
5-77 O
months O
) O
for O
the O
500-mm2 O
group O
. O

The B-Premise
life-table I-Premise
success I-Premise
rates I-Premise
declined I-Premise
over I-Premise
time I-Premise
for I-Premise
both I-Premise
implant I-Premise
groups I-Premise
, I-Premise
from I-Premise
a I-Premise
high I-Premise
of I-Premise
98 I-Premise
% I-Premise
for I-Premise
the I-Premise
350-mm2 I-Premise
group I-Premise
and I-Premise
92 I-Premise
% I-Premise
for I-Premise
the I-Premise
500-mm2 I-Premise
group I-Premise
at I-Premise
1 I-Premise
year I-Premise
to I-Premise
a I-Premise
cumulative I-Premise
success I-Premise
rate I-Premise
of I-Premise
79 I-Premise
% I-Premise
for I-Premise
the I-Premise
350-mm2 I-Premise
group I-Premise
and I-Premise
66 I-Premise
% I-Premise
for I-Premise
the I-Premise
500-mm2 I-Premise
group I-Premise
at I-Premise
5 I-Premise
years I-Premise
. I-Premise

Visual B-Premise
acuities I-Premise
were I-Premise
better I-Premise
or I-Premise
remained I-Premise
the I-Premise
same I-Premise
in I-Premise
50 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
350-mm2 I-Premise
group I-Premise
and I-Premise
46 I-Premise
% I-Premise
of I-Premise
those I-Premise
in I-Premise
the I-Premise
500-mm2 I-Premise
group I-Premise
. I-Premise

Complications O
during O
the O
5-year O
follow-up O
were O
also O
statistically O
similar O
. O

The B-Claim
longer I-Claim
term I-Claim
results I-Claim
show I-Claim
that I-Claim
the I-Claim
350-mm2 I-Claim
Baerveldt I-Claim
implant I-Claim
is I-Claim
more I-Claim
successful I-Claim
than I-Claim
the I-Claim
500-mm2 I-Claim
implant I-Claim
for I-Claim
overall I-Claim
IOP I-Claim
control I-Claim
. I-Claim

Interval B-Claim
comparisons I-Claim
indicate I-Claim
a I-Claim
higher I-Claim
rate I-Claim
of I-Claim
success I-Claim
for I-Claim
the I-Claim
350-mm2 I-Claim
implant I-Claim
in I-Claim
the I-Claim
first I-Claim
, I-Claim
second I-Claim
, I-Claim
third I-Claim
, I-Claim
fourth I-Claim
, I-Claim
and I-Claim
fifth I-Claim
years I-Claim
of I-Claim
implantation I-Claim
. I-Claim

Visual O
acuities O
, O
implant-related O
complications O
, O
and O
average O
IOPs O
were O
statistically O
indistinguishable O
between O
the O
two O
groups O
. O

To O
determine O
whether O
treatment O
with O
betaxolol O
can O
delay O
or O
prevent O
the O
conversion O
from O
ocular O
hypertension O
to O
early O
glaucoma O
on O
the O
basis O
of O
visual O
field O
criteria O
, O
by O
means O
of O
a O
prospective O
, O
randomised O
, O
placebo-controlled O
trial O
. O

Three O
hundred O
and O
fifty-six O
ocular O
hypertensives O
were O
randomized O
to O
treatment O
with O
either O
betaxolol O
drops O
or O
placebo O
drops O
during O
the O
period O
1992-1996 O
. O

Each O
patient O
was O
followed O
prospectively O
with O
4-monthly O
visits O
. O

Examination O
at O
each O
visit O
included O
visual O
field O
testing O
, O
intra-ocular O
pressure O
( O
IOP O
) O
measurement O
and O
optic O
disc O
imaging O
. O

Conversion O
to O
early O
glaucoma O
was O
defined O
on O
the O
basis O
of O
visual O
field O
change O
by O
AGIS O
criteria O
. O

An O
intent-to-treat O
analysis O
compared O
visual O
field O
conversion O
after O
3 O
years O
in O
the O
treatment O
and O
placebo O
arms O
. O

Normal O
visual O
field O
survival O
analysis O
was O
also O
performed O
. O

The O
IOP O
characteristics O
of O
the O
two O
treatment O
groups O
were O
compared O
. O

Two O
hundred O
and O
fifty-five O
patients O
completed O
the O
study O
, O
which O
ended O
in O
1998 O
, O
with O
a O
range O
of O
follow-up O
of O
2-6 O
years O
. O

Sixteen B-Premise
( I-Premise
13.2 I-Premise
% I-Premise
) I-Premise
of I-Premise
121 I-Premise
patients I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
converted I-Premise
to I-Premise
glaucoma I-Premise
, I-Premise
compared I-Premise
with I-Premise
12 I-Premise
( I-Premise
9.0 I-Premise
% I-Premise
) I-Premise
of I-Premise
134 I-Premise
patients I-Premise
in I-Premise
the I-Premise
betaxolol I-Premise
group I-Premise
. I-Premise

The B-Premise
intent-to-treat I-Premise
analysis I-Premise
demonstrated I-Premise
no I-Premise
evidence I-Premise
of I-Premise
any I-Premise
difference I-Premise
in I-Premise
conversion I-Premise
rates I-Premise
between I-Premise
the I-Premise
betaxolol I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
after I-Premise
3 I-Premise
years I-Premise
. I-Premise

Visual B-Premise
field I-Premise
survival I-Premise
analysis I-Premise
demonstrated I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
betaxolol I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
. I-Premise

The B-Premise
betaxolol-treated I-Premise
group I-Premise
had I-Premise
significantly I-Premise
lower I-Premise
post-treatment I-Premise
IOP I-Premise
values I-Premise
. I-Premise

Converters B-Premise
had I-Premise
significantly I-Premise
higher I-Premise
pre- I-Premise
and I-Premise
post-treatment I-Premise
IOP I-Premise
values I-Premise
than I-Premise
non-converters I-Premise
. I-Premise

Betaxolol B-Premise
significantly I-Premise
lowered I-Premise
the I-Premise
IOP I-Premise
level I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
. I-Premise

Conversion B-Premise
to I-Premise
glaucoma I-Premise
was I-Premise
found I-Premise
to I-Premise
be I-Premise
related I-Premise
to I-Premise
both I-Premise
the I-Premise
baseline I-Premise
and I-Premise
post-treatment I-Premise
IOP I-Premise
levels I-Premise
. I-Premise

However O
the B-Claim
intent-to-treat I-Claim
analysis I-Claim
did I-Claim
not I-Claim
demonstrate I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
the I-Claim
conversion I-Claim
rate I-Claim
in I-Claim
the I-Claim
betaxolol-treated I-Claim
group I-Claim
. I-Claim

To O
compare O
phacoemulsification O
alone O
versus O
combined O
phacotrabeculectomy O
in O
medically O
uncontrolled O
chronic O
angle O
closure O
glaucoma O
( O
CACG O
) O
with O
coexisting O
cataract O
. O

Prospective O
randomized O
clinical O
trial O
. O

Fifty-one O
medically O
uncontrolled O
CACG O
eyes O
with O
coexisting O
cataract O
of O
51 O
patients O
. O

Recruited O
patients O
were O
randomized O
into O
group O
1 O
( O
phacoemulsification O
alone O
) O
or O
group O
2 O
( O
combined O
phacotrabeculectomy O
with O
adjunctive O
mitomycin O
C O
) O
. O

Postoperatively O
, O
patients O
were O
reviewed O
every O
3 O
months O
for O
2 O
years O
. O

Intraocular O
pressure O
( O
IOP O
) O
and O
requirement O
for O
topical O
glaucoma O
drugs O
. O

Twenty-seven O
CACG O
eyes O
were O
randomized O
into O
group O
1 O
, O
and O
24 O
CACG O
eyes O
were O
randomized O
into O
group O
2 O
. O

Combined B-Premise
phacotrabeculectomy I-Premise
resulted I-Premise
in I-Premise
lower I-Premise
mean I-Premise
postoperative I-Premise
IOP I-Premise
than I-Premise
phacoemulsification I-Premise
alone I-Premise
at I-Premise
3 I-Premise
months I-Premise
( I-Premise
14.0 I-Premise
vs I-Premise
17.0 I-Premise
mmHg I-Premise
, I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
15 I-Premise
months I-Premise
( I-Premise
13.2 I-Premise
vs I-Premise
15.4 I-Premise
mmHg I-Premise
, I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
and I-Premise
18 I-Premise
months I-Premise
( I-Premise
13.6 I-Premise
vs I-Premise
15.9 I-Premise
mmHg I-Premise
, I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Combined B-Premise
phacotrabeculectomy I-Premise
resulted I-Premise
in I-Premise
1.25 I-Premise
fewer I-Premise
topical I-Premise
glaucoma I-Premise
drugs I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
in I-Premise
the I-Premise
24-month I-Premise
postoperative I-Premise
period I-Premise
, I-Premise
compared I-Premise
with I-Premise
phacoemulsification I-Premise
alone I-Premise
. I-Premise

Combined B-Premise
surgery I-Premise
was I-Premise
associated I-Premise
with I-Premise
more I-Premise
postoperative I-Premise
complications I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
more I-Premise
progression I-Premise
of I-Premise
optic I-Premise
neuropathy I-Premise
( I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
compared I-Premise
with I-Premise
phacoemulsification I-Premise
alone I-Premise
. I-Premise

Combined B-Claim
phacotrabeculectomy I-Claim
with I-Claim
adjunctive I-Claim
mitomycin I-Claim
C I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
phacoemulsification I-Claim
alone I-Claim
in I-Claim
controlling I-Claim
IOP I-Claim
in I-Claim
medically I-Claim
uncontrolled I-Claim
CACG I-Claim
eyes I-Claim
with I-Claim
coexisting I-Claim
cataract I-Claim
. I-Claim

Combined B-Claim
phacotrabeculectomy I-Claim
is I-Claim
associated I-Claim
with I-Claim
more I-Claim
postoperative I-Claim
complications I-Claim
. I-Claim

To O
compare O
the O
additional O
intraocular O
pressure-lowering O
effect O
of O
latanoprost O
0.005 O
% O
administered O
once O
daily O
with O
that O
of O
pilocarpine O
2 O
% O
administered O
three O
times O
daily O
in O
patients O
with O
primary O
open-angle O
glaucoma O
or O
ocular O
hypertension O
currently O
on O
monotherapy O
with O
timolol O
0.5 O
% O
twice O
daily O
. O

In O
a O
6-month O
, O
multicenter O
, O
randomized O
, O
open-label O
study O
242 O
patients O
with O
POAG O
or O
OH O
whose O
IOP O
was O
not O
controlled O
with O
timolol O
0.5 O
% O
b.i.d O
. O

were O
enrolled O
. O

Eyes O
had O
not O
been O
treated O
with O
pilocarpine O
and O
latanoprost O
for O
at O
least O
2 O
years O
. O

An O
analysis O
of O
covariance O
with O
diurnal O
IOP O
change O
from O
baseline O
to O
month O
6 O
for O
study O
eyes O
was O
performed O
. O

Four O
patients O
on O
latanoprost O
0.005 O
% O
and O
35 O
on O
pilocarpine O
2 O
% O
did O
not O
complete O
the O
study O
( O
P O
< O
0.001 O
) O
. O

Two O
hundred O
and O
forty O
patients O
were O
included O
in O
the O
intent-to-treat O
analysis O
. O

For B-Premise
both I-Premise
treatments I-Premise
the I-Premise
diurnal I-Premise
IOP I-Premise
reduction I-Premise
after I-Premise
6 I-Premise
months I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

IOP B-Premise
( I-Premise
mean+/-SD I-Premise
) I-Premise
was I-Premise
reduced I-Premise
from I-Premise
23.3+/-2.8 I-Premise
to I-Premise
17.8+/-2.8 I-Premise
( I-Premise
-5.6 I-Premise
) I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
latanoprost I-Premise
0.005 I-Premise
% I-Premise
group I-Premise
and I-Premise
from I-Premise
23.0+/-3.2 I-Premise
to I-Premise
18.5+/-2.4 I-Premise
( I-Premise
-4.8 I-Premise
) I-Premise
mmHg I-Premise
in I-Premise
pilocarpine I-Premise
2 I-Premise
% I-Premise
t.i.d.-treated I-Premise
eyes I-Premise
. I-Premise

The B-Premise
mean I-Premise
difference I-Premise
of I-Premise
-0.8 I-Premise
mmHg I-Premise
( I-Premise
per I-Premise
protocol I-Premise
, I-Premise
PP I-Premise
) I-Premise
and I-Premise
-1.6 I-Premise
mmHg I-Premise
( I-Premise
intend-to-treat I-Premise
, I-Premise
ITT I-Premise
) I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.04 I-Premise
, I-Premise
PP I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
, I-Premise
ITT I-Premise
) I-Premise
in I-Premise
favor I-Premise
of I-Premise
latanoprost I-Premise
0.005 I-Premise
% I-Premise
. I-Premise

Two B-Premise
eyes I-Premise
treated I-Premise
with I-Premise
latanoprost I-Premise
showed I-Premise
an I-Premise
iris I-Premise
color I-Premise
change I-Premise
. I-Premise

Thirty-six B-Premise
patients I-Premise
in I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
and I-Premise
106 I-Premise
in I-Premise
the I-Premise
pilocarpine I-Premise
2 I-Premise
% I-Premise
group I-Premise
reported I-Premise
ocular I-Premise
adverse I-Premise
events I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

From B-Claim
the I-Claim
data I-Claim
we I-Claim
conclude I-Claim
that I-Claim
the I-Claim
additivity I-Claim
of I-Claim
latanoprost I-Claim
0.005 I-Claim
% I-Claim
is I-Claim
at I-Claim
least I-Claim
as I-Claim
effective I-Claim
as I-Claim
pilocarpine I-Claim
2 I-Claim
% I-Claim
t.i.d I-Claim
. I-Claim
in I-Claim
reducing I-Claim
IOP I-Claim
when I-Claim
added I-Claim
to I-Claim
eyes I-Claim
currently I-Claim
on I-Claim
monotherapy I-Claim
with I-Claim
timolol I-Claim
0.5 I-Claim
% I-Claim
b.i.d I-Claim
. I-Claim

Latanoprost B-Claim
was I-Claim
better I-Claim
tolerated I-Claim
than I-Claim
pilocarpine I-Claim
2 I-Claim
% I-Claim
eye I-Claim
drops I-Claim
in I-Claim
this I-Claim
study I-Claim
. I-Claim

The B-Claim
increase I-Claim
in I-Claim
iris I-Claim
pigmentation I-Claim
requires I-Claim
further I-Claim
investigation I-Claim
. I-Claim

The O
Baerveldt O
glaucoma O
implant O
is O
a O
large O
equatorial O
aqueous O
shunting O
device O
that O
is O
installed O
through O
a O
single-quadrant O
conjunctival O
incision O
. O

The O
intermediate-term O
results O
of O
a O
randomized O
study O
comparing O
the O
-350 O
and O
500-mm2 O
Baerveldt O
implants O
are O
reported O
. O

Seventy-three O
patients O
with O
medically O
uncontrollable O
, O
nonneovascular O
glaucomas O
associated O
with O
aphakia O
, O
pseudophakia O
, O
or O
failed O
filters O
were O
enrolled O
in O
a O
randomized O
, O
prospective O
study O
comparing O
-350 O
and O
500-mm2 O
Baerveldt O
implants O
. O

Surgical O
success O
was O
defined O
as O
6 O
mmHg O
< O
or O
= O
final O
intraocular O
pressure O
< O
or O
= O
21 O
mmHg O
without O
glaucoma O
reoperation O
or O
devastating O
complication O
. O

Of B-Premise
patients I-Premise
with I-Premise
-350 I-Premise
and I-Premise
500-mm2 I-Premise
implants I-Premise
, I-Premise
93 I-Premise
% I-Premise
and I-Premise
88 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
achieved I-Premise
surgical I-Premise
success I-Premise
( I-Premise
18-month I-Premise
life-table I-Premise
analysis I-Premise
, I-Premise
P I-Premise
= I-Premise
0.93 I-Premise
) I-Premise
. I-Premise

The B-Premise
500-mm2 I-Premise
implants I-Premise
afforded I-Premise
intraocular I-Premise
pressure I-Premise
control I-Premise
with I-Premise
significantly I-Premise
fewer I-Premise
medications I-Premise
( I-Premise
0.7 I-Premise
versus I-Premise
1.3 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
. I-Premise

The B-Premise
postoperative I-Premise
visual I-Premise
acuities I-Premise
remained I-Premise
within I-Premise
one I-Premise
line I-Premise
of I-Premise
the I-Premise
preoperative I-Premise
visual I-Premise
acuities I-Premise
or I-Premise
improved I-Premise
in I-Premise
62 I-Premise
% I-Premise
and I-Premise
66 I-Premise
% I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
-350 I-Premise
and I-Premise
500-mm2 I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
0.93 I-Premise
) I-Premise
. I-Premise

Complication B-Claim
rates I-Claim
were I-Claim
statistically I-Claim
similar I-Claim
. I-Claim

The B-Premise
most I-Premise
frequent I-Premise
ones I-Premise
in I-Premise
the I-Premise
-350 I-Premise
and I-Premise
500-mm2 I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
, I-Premise
were I-Premise
serous I-Premise
choroidal I-Premise
effusion I-Premise
( I-Premise
16 I-Premise
% I-Premise
and I-Premise
32 I-Premise
% I-Premise
) I-Premise
, I-Premise
strabismus I-Premise
( I-Premise
16 I-Premise
% I-Premise
and I-Premise
19 I-Premise
% I-Premise
) I-Premise
, I-Premise
anterior I-Premise
uveitis I-Premise
( I-Premise
14 I-Premise
% I-Premise
and I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
corneal I-Premise
or I-Premise
corneal I-Premise
graft I-Premise
edema I-Premise
( I-Premise
11 I-Premise
% I-Premise
each I-Premise
) I-Premise
. I-Premise

The B-Claim
intermediate-term I-Claim
results I-Claim
of I-Claim
the I-Claim
-350 I-Claim
and I-Claim
500-mm2 I-Claim
Baerveldt I-Claim
implants I-Claim
were I-Claim
statistically I-Claim
comparable I-Claim
with I-Claim
respect I-Claim
to I-Claim
surgical I-Claim
and I-Claim
visual I-Claim
outcomes I-Claim
, I-Claim
as I-Claim
well I-Claim
as I-Claim
complications I-Claim
, O
although B-Claim
the I-Claim
larger I-Claim
implant I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
higher I-Claim
rate I-Claim
of I-Claim
some I-Claim
complications I-Claim
. I-Claim

However O
, O
the B-Claim
500-mm2 I-Claim
Baerveldt I-Claim
implant I-Claim
afforded I-Claim
intraocular I-Claim
pressure I-Claim
control I-Claim
with I-Claim
fewer I-Claim
medications I-Claim
than I-Claim
the I-Claim
350-mm2 I-Claim
implant I-Claim
. I-Claim

To O
evaluate O
the O
additive O
intraocular O
pressure O
( O
IOP O
) O
-lowering O
efficacy O
and O
safety O
of O
fixed O
combination O
brimonidine O
0.2 O
% O
/timolol O
0.5 O
% O
compared O
with O
timolol O
0.5 O
% O
at O
peak O
and O
trough O
effect O
when O
used O
as O
therapy O
adjunctive O
to O
latanoprost O
0.005 O
% O
in O
patients O
with O
glaucoma O
or O
ocular O
hypertension O
who O
require O
additional O
IOP O
lowering O
. O

In O
this O
prospective O
, O
randomized O
, O
multicenter O
, O
investigator-masked O
, O
parallel-group O
study O
, O
patients O
were O
treated O
with O
latanoprost O
monotherapy O
for O
at O
least O
four O
weeks O
prior O
to O
baseline O
. O

At O
baseline O
on O
latanoprost O
, O
patients O
with O
IOP O
21 O
mmHg O
in O
at O
least O
one O
eye O
were O
randomized O
to O
twice-daily O
fixed O
brimonidine-timolol O
( O
n O
= O
102 O
) O
or O
timolol O
( O
n O
= O
102 O
) O
, O
each O
adjunctive O
to O
latanoprost O
for O
12 O
weeks O
. O

IOP O
was O
measured O
at O
8 O
am O
and O
10 O
am O
at O
baseline O
, O
week O
6 O
, O
and O
week O
12 O
and O
evaluated O
in O
the O
per O
protocol O
population O
. O

The O
primary O
efficacy O
endpoint O
was O
peak O
IOP O
lowering O
at O
10 O
am O
, O
week O
12 O
. O

Safety O
measures O
included O
adverse O
events O
. O

Baseline O
mean O
IOP O
was O
similar O
at O
10 O
am O
in O
the O
treatment O
groups O
( O
brimonidine-timolol O
23.4 O
mmHg O
";" O
timolol O
23.0 O
mmHg O
) O
. O

The B-Premise
mean I-Premise
additional I-Premise
reduction I-Premise
from I-Premise
latanoprost-treated I-Premise
baseline I-Premise
IOP I-Premise
was I-Premise
8.3 I-Premise
mmHg I-Premise
( I-Premise
35.5 I-Premise
% I-Premise
) I-Premise
with I-Premise
fixed I-Premise
brimonidine-timolol I-Premise
and I-Premise
6.2 I-Premise
mmHg I-Premise
( I-Premise
27.0 I-Premise
% I-Premise
) I-Premise
with I-Premise
timolol I-Premise
at I-Premise
10 I-Premise
am I-Premise
, I-Premise
week I-Premise
12 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
fixed I-Premise
brimonidine-timolol I-Premise
adjunctive I-Premise
to I-Premise
latanoprost I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
than I-Premise
patients I-Premise
treated I-Premise
with I-Premise
adjunctive I-Premise
timolol I-Premise
to I-Premise
achieve I-Premise
an I-Premise
IOP I-Premise
< I-Premise
18 I-Premise
mmHg I-Premise
( I-Premise
P I-Premise
= I-Premise
0.028 I-Premise
) I-Premise
and I-Premise
a I-Premise
20 I-Premise
% I-Premise
reduction I-Premise
in I-Premise
IOP I-Premise
from I-Premise
baseline I-Premise
( I-Premise
P I-Premise
= I-Premise
0.047 I-Premise
) I-Premise
at I-Premise
both I-Premise
8 I-Premise
am I-Premise
and I-Premise
10 I-Premise
am I-Premise
in I-Premise
week I-Premise
12 I-Premise
. I-Premise

Adverse B-Premise
events I-Premise
occurred I-Premise
in I-Premise
14.7 I-Premise
% I-Premise
of I-Premise
fixed I-Premise
brimonidine-timolol I-Premise
patients I-Premise
and I-Premise
12.7 I-Premise
% I-Premise
of I-Premise
timolol I-Premise
patients I-Premise
. I-Premise

Biomicroscopy B-Premise
findings I-Premise
were I-Premise
similar I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
after I-Premise
12 I-Premise
weeks I-Premise
of I-Premise
treatment I-Premise
. I-Premise

Fixed-combination B-Claim
brimonidine-timolol I-Claim
reduced I-Claim
IOP I-Claim
significantly I-Claim
more I-Claim
effectively I-Claim
than I-Claim
timolol I-Claim
when I-Claim
used I-Claim
as I-Claim
adjunctive I-Claim
therapy I-Claim
to I-Claim
latanoprost I-Claim
in I-Claim
patients I-Claim
with I-Claim
glaucoma I-Claim
and I-Claim
ocular I-Claim
hypertension I-Claim
. I-Claim

Both B-Claim
fixed I-Claim
brimonidine-timolol I-Claim
and I-Claim
timolol I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
as I-Claim
agents I-Claim
adjunctive I-Claim
to I-Claim
latanoprost I-Claim
. I-Claim

To O
evaluate O
the O
intraocular O
pressure O
( O
IOP O
) O
-lowering O
efficacy O
and O
safety O
of O
fixed-combination O
brimonidine O
0.2 O
% O
-timolol O
0.5 O
% O
compared O
with O
latanoprost O
0.005 O
% O
in O
patients O
with O
glaucoma O
or O
ocular O
hypertension O
. O

This O
was O
a O
prospective O
, O
randomized O
, O
multicenter O
, O
investigator-masked O
clinical O
trial O
. O

After O
washout O
of O
any O
previous O
IOP-lowering O
medications O
, O
patients O
with O
IOP O
of O
24 O
mmHg O
or O
higher O
were O
randomized O
to O
twice-daily O
fixed-combination O
brimonidine O
0.2 O
% O
-timolol O
0.5 O
% O
( O
n O
= O
73 O
) O
or O
once-daily O
latanoprost O
0.005 O
% O
( O
n O
= O
75 O
, O
dosed O
in O
the O
evening O
, O
with O
vehicle O
control O
in O
the O
morning O
to O
maintain O
masking O
) O
for O
12 O
weeks O
. O

IOP O
was O
measured O
at O
8 O
a.m. O
( O
before O
dosing O
) O
, O
10 O
a.m. O
, O
and O
3 O
p.m. O
at O
baseline O
, O
week O
6 O
, O
and O
week O
12 O
. O

The O
primary O
efficacy O
endpoint O
was O
diurnal O
IOP O
( O
averaged O
over O
8 O
a.m. O
, O
10 O
a.m. O
, O
and O
3 O
p.m. O
) O
at O
week O
12 O
. O

Safety O
measures O
included O
biomicroscopy O
. O

There O
was O
no O
statistically O
significant O
difference O
between O
the O
treatment O
groups O
in O
mean O
diurnal O
IOP O
at O
baseline O
( O
p O
= O
0.118 O
) O
. O

At B-Premise
week I-Premise
12 I-Premise
, I-Premise
the I-Premise
mean I-Premise
( I-Premise
SD I-Premise
) I-Premise
diurnal I-Premise
IOP I-Premise
was I-Premise
17.8 I-Premise
( I-Premise
2.9 I-Premise
) I-Premise
mmHg I-Premise
with I-Premise
brimonidine-timolol I-Premise
and I-Premise
17.9 I-Premise
( I-Premise
3.9 I-Premise
) I-Premise
mmHg I-Premise
with I-Premise
latanoprost I-Premise
( I-Premise
p I-Premise
= I-Premise
0.794 I-Premise
) I-Premise
. I-Premise

The B-Premise
percentage I-Premise
of I-Premise
patients I-Premise
achieving I-Premise
at I-Premise
least I-Premise
a I-Premise
20 I-Premise
% I-Premise
decrease I-Premise
from I-Premise
baseline I-Premise
diurnal I-Premise
IOP I-Premise
at I-Premise
week I-Premise
12 I-Premise
was I-Premise
87.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
brimonidine-timolol I-Premise
group I-Premise
and I-Premise
77.3 I-Premise
% I-Premise
in I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.131 I-Premise
) I-Premise
. I-Premise

Measured B-Premise
biomicroscopic I-Premise
changes I-Premise
from I-Premise
baseline I-Premise
to I-Premise
week I-Premise
12 I-Premise
were I-Premise
infrequent I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Fixed-combination B-Claim
brimonidine-timolol I-Claim
was I-Claim
as I-Claim
effective I-Claim
as I-Claim
latanoprost I-Claim
in I-Claim
reducing I-Claim
IOP I-Claim
in I-Claim
patients I-Claim
with I-Claim
glaucoma I-Claim
or I-Claim
ocular I-Claim
hypertension I-Claim
. I-Claim

Both B-Claim
treatments I-Claim
demonstrated I-Claim
favorable I-Claim
ocular I-Claim
tolerability I-Claim
. I-Claim

The O
duration O
of O
the O
study O
was O
12 O
weeks O
, O
and O
additional O
studies O
will O
be O
needed O
to O
compare O
the O
efficacy O
and O
safety O
of O
fixed-combination O
brimonidine-timolol O
and O
latanoprost O
during O
long-term O
treatment O
. O

To O
compare O
the O
efficacy O
of O
intraocular O
pressure O
( O
IOP O
) O
control O
of O
the O
Baerveldt-350 O
implant O
with O
tube O
ligature O
and O
the O
Ahmed O
valve O
in O
patients O
with O
refractory O
glaucoma O
. O

Four O
hundred O
seventy O
glaucoma O
drainage O
device O
procedures O
from O
July O
1995 O
to O
July O
2001 O
( O
6 O
years O
) O
were O
reviewed O
retrospectively O
. O

Thirty-two O
cases O
of O
Baerveldt-350 O
implantation O
performed O
in O
patients O
with O
glaucoma O
refractory O
to O
medical O
treatment O
and O
filtering O
procedures O
, O
without O
previous O
drainage O
device O
or O
cyclodestructive O
procedures O
, O
and O
with O
a O
minimum O
of O
1-year O
follow-up O
were O
identified O
. O

Thirty-two O
cases O
of O
Ahmed O
valve O
implantation O
were O
matched O
case O
by O
case O
with O
32 O
Baerveldt-350 O
cases O
for O
age O
, O
race O
, O
gender O
, O
glaucoma O
subtype O
, O
previous O
ocular O
history O
, O
preoperative O
IOP O
, O
and O
surgeon O
who O
performed O
the O
implantation O
. O

The O
two O
groups O
were O
compared O
for O
IOP O
control O
, O
visual O
outcome O
, O
complication O
rate O
, O
and O
surgical O
success O
rate O
. O

Surgical B-Premise
success I-Premise
rate I-Premise
was I-Premise
defined I-Premise
as I-Premise
an I-Premise
IOP I-Premise
reduction I-Premise
greater I-Premise
than I-Premise
or I-Premise
equal I-Premise
to I-Premise
30 I-Premise
% I-Premise
and I-Premise
final I-Premise
IOP I-Premise
more I-Premise
than I-Premise
5 I-Premise
mm I-Premise
Hg I-Premise
and I-Premise
less I-Premise
than I-Premise
22 I-Premise
mm I-Premise
Hg I-Premise
, I-Premise
without I-Premise
devastating I-Premise
complications I-Premise
. I-Premise

Over B-Premise
a I-Premise
follow-up I-Premise
period I-Premise
of I-Premise
1 I-Premise
year I-Premise
, I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
were I-Premise
detected I-Premise
between I-Premise
the I-Premise
Baerveldt-350 I-Premise
implant I-Premise
versus I-Premise
Ahmed I-Premise
valve I-Premise
for I-Premise
IOP I-Premise
control I-Premise
( I-Premise
12.1 I-Premise
+/- I-Premise
5.3 I-Premise
mm I-Premise
Hg I-Premise
vs I-Premise
13.6 I-Premise
+/- I-Premise
5.6 I-Premise
mm I-Premise
Hg I-Premise
respectively I-Premise
, I-Premise
at I-Premise
a I-Premise
power I-Premise
of I-Premise
90 I-Premise
% I-Premise
to I-Premise
detect I-Premise
a I-Premise
difference I-Premise
of I-Premise
3.2 I-Premise
mm I-Premise
Hg I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
and I-Premise
P I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
surgical I-Premise
success I-Premise
rate I-Premise
( I-Premise
65.6 I-Premise
% I-Premise
vs. I-Premise
65.6 I-Premise
% I-Premise
respectively I-Premise
, I-Premise
complete I-Premise
and I-Premise
qualified I-Premise
combined I-Premise
) I-Premise
, I-Premise
postoperative I-Premise
hypotony I-Premise
rate I-Premise
( I-Premise
37.5 I-Premise
% I-Premise
vs. I-Premise
34.4 I-Premise
% I-Premise
respectively I-Premise
) I-Premise
, I-Premise
and I-Premise
visual I-Premise
acuity I-Premise
changes I-Premise
of I-Premise
more I-Premise
than I-Premise
1 I-Premise
line I-Premise
in I-Premise
Snellen I-Premise
visual I-Premise
acuity I-Premise
( I-Premise
43.3 I-Premise
% I-Premise
vs. I-Premise
29.0 I-Premise
% I-Premise
respectively I-Premise
) I-Premise
. I-Premise

In B-Claim
a I-Claim
case-controlled I-Claim
comparison I-Claim
, I-Claim
the I-Claim
Baerveldt-350 I-Claim
implant I-Claim
and I-Claim
the I-Claim
Ahmed I-Claim
valve I-Claim
had I-Claim
similar I-Claim
IOP I-Claim
control I-Claim
and I-Claim
surgical I-Claim
outcomes I-Claim
in I-Claim
patients I-Claim
with I-Claim
refractory I-Claim
glaucoma I-Claim
at I-Claim
1-year I-Claim
follow-up I-Claim
. I-Claim

To O
compare O
the O
IOP-lowering O
efficacy O
of O
a.m.-dosed O
travoprost O
and O
latanoprost O
at O
24-h O
post-dose O
. O

Open-angle O
glaucoma O
patients O
not O
naïve O
to O
prostaglandin O
therapy O
and O
currently O
controlled O
on O
p.m.-dosed O
( O
2100 O
) O
latanoprost O
( O
n O
= O
21 O
) O
or O
travoprost O
( O
n O
= O
30 O
) O
had O
baseline O
IOPs O
measured O
at O
900 O
. O

In O
a O
randomized O
, O
single-masked O
, O
crossover O
design O
, O
patients O
received O
travoprost O
( O
Travatan O
† O
) O
or O
latanoprost O
( O
Xalatan O
‡ O
) O
at O
900 O
for O
4 O
weeks O
, O
then O
were O
crossed O
over O
to O
receive O
the O
second O
prostaglandin O
for O
another O
4 O
weeks O
. O

Treatment O
IOP O
was O
measured O
at O
900 O
prior O
to O
morning O
dose O
at O
both O
4 O
and O
8 O
week O
visits O
. O

Patient O
dosing O
preference O
( O
a.m./p.m O
. O
) O

was O
surveyed O
on O
exit O
. O

Main O
outcome O
measure O
: O
Intraocular O
pressure O
( O
IOP O
) O
. O

† O
Travatan O
is O
a O
registered O
trade O
name O
of O
Alcon O
Laboratories O
, O
Inc. O
, O
Fort O
Worth O
, O
TX O
, O
USA O
‡ O
Xalatan O
is O
a O
registered O
trade O
name O
of O
Pfizer O
, O
New O
York O
, O
NY O
, O
USA O
. O

The B-Premise
mean I-Premise
IOP I-Premise
in I-Premise
the I-Premise
first I-Premise
period I-Premise
when I-Premise
all I-Premise
patients I-Premise
were I-Premise
dosed I-Premise
in I-Premise
the I-Premise
evening I-Premise
was I-Premise
assessed I-Premise
12 I-Premise
h I-Premise
after I-Premise
dosing I-Premise
at I-Premise
09:00 I-Premise
and I-Premise
it I-Premise
was I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
mean I-Premise
+/- I-Premise
standard I-Premise
deviation I-Premise
: I-Premise
17.9 I-Premise
+/- I-Premise
2.7 I-Premise
mmHg I-Premise
for I-Premise
travoprost I-Premise
versus I-Premise
17.7 I-Premise
+/- I-Premise
2.5 I-Premise
mmHg I-Premise
for I-Premise
latanoprost I-Premise
, I-Premise
p I-Premise
= I-Premise
0.812 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
a.m.-dosing I-Premise
crossover I-Premise
comparison I-Premise
, I-Premise
the I-Premise
24-h I-Premise
post-dose I-Premise
IOP I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
on I-Premise
travoprost I-Premise
( I-Premise
16.9 I-Premise
+/- I-Premise
3.1 I-Premise
mmHg I-Premise
) I-Premise
compared I-Premise
to I-Premise
latanoprost I-Premise
( I-Premise
18.6 I-Premise
+/- I-Premise
3.3 I-Premise
mmHg I-Premise
) I-Premise
. I-Premise

In O
the O
exit O
survey O
, O
51 O
% O
of O
patients O
preferred O
a.m.-dosing O
. O

a.m.-dosed B-Claim
travoprost I-Claim
is I-Claim
superior I-Claim
to I-Claim
a.m.-dosed I-Claim
latanoprost I-Claim
by I-Claim
1.7 I-Claim
mmHg I-Claim
at I-Claim
24-h I-Claim
post-dose I-Claim
. I-Claim

To O
assess O
the O
efficacy O
and O
safety O
of O
fixed-combination O
latanoprost-timolol O
( O
FCLT O
) O
vs O
latanoprost O
or O
timolol O
monotherapy O
. O

This O
12-week O
, O
randomized O
, O
double-masked O
, O
parallel-group O
study O
included O
patients O
with O
open-angle O
glaucoma O
or O
ocular O
hypertension O
treated O
with O
a O
beta-blocker O
and O
with O
baseline O
intraocular O
pressure O
( O
IOP O
) O
of O
26 O
through O
36 O
mm O
Hg O
. O

Following O
washout O
, O
eligible O
patients O
were O
randomized O
to O
once-daily O
FCLT O
in O
the O
evening O
, O
latanoprost O
in O
the O
evening O
, O
or O
timolol O
in O
the O
morning O
. O

Postbaseline O
IOP O
assessments O
at O
8 O
am O
, O
10 O
am O
, O
and O
4 O
pm O
at O
weeks O
2 O
, O
6 O
, O
and O
12 O
";" O
statistical O
superiority O
of O
FCLT O
for O
the O
18 O
pairwise O
comparisons O
between O
FCLT O
and O
the O
2 O
monotherapies O
, O
using O
analysis O
of O
variance O
. O

All O
therapies O
resulted O
in O
significant O
IOP O
reductions O
from O
baseline O
. O

Pairwise O
comparisons O
favored O
FCLT O
at O
all O
time O
points O
. O

When O
the O
18 O
comparisons O
were O
tested O
simultaneously O
, O
FCLT B-Premise
was I-Premise
statistically I-Premise
superior I-Premise
to I-Premise
latanoprost I-Premise
at I-Premise
7 I-Premise
of I-Premise
9 I-Premise
time I-Premise
points I-Premise
and I-Premise
at I-Premise
all I-Premise
9 I-Premise
time I-Premise
points I-Premise
when I-Premise
compared I-Premise
with I-Premise
timolol I-Premise
. I-Premise

In O
addition O
, O
FCLT B-Premise
was I-Premise
associated I-Premise
with I-Premise
greater I-Premise
percentage I-Premise
reductions I-Premise
in I-Premise
diurnal I-Premise
IOP I-Premise
levels I-Premise
and I-Premise
a I-Premise
greater I-Premise
likelihood I-Premise
of I-Premise
achieving I-Premise
lower I-Premise
mean I-Premise
diurnal I-Premise
IOP I-Premise
levels I-Premise
. I-Premise

Diurnal B-Premise
IOP I-Premise
reductions I-Premise
of I-Premise
30 I-Premise
% I-Premise
or I-Premise
more I-Premise
from I-Premise
baseline I-Premise
to I-Premise
week I-Premise
12 I-Premise
were I-Premise
achieved I-Premise
by I-Premise
73.5 I-Premise
% I-Premise
, I-Premise
57.5 I-Premise
% I-Premise
, I-Premise
and I-Premise
32.8 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
with I-Premise
FCLT I-Premise
, I-Premise
latanoprost I-Premise
, I-Premise
and I-Premise
timolol I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.007 I-Premise
for I-Premise
FCLT I-Premise
vs I-Premise
timolol I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
for I-Premise
FCLT I-Premise
vs I-Premise
latanoprost I-Premise
) I-Premise
. I-Premise

All B-Claim
therapies I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Fixed-combination B-Claim
latanoprost-timolol I-Claim
therapy I-Claim
is I-Claim
as I-Claim
safe I-Claim
and I-Claim
effective I-Claim
in I-Claim
lowering I-Claim
IOP I-Claim
in I-Claim
patients I-Claim
with I-Claim
either I-Claim
ocular I-Claim
hypertension I-Claim
or I-Claim
glaucoma I-Claim
as I-Claim
monotherapy I-Claim
with I-Claim
latanoprost I-Claim
or I-Claim
timolol I-Claim
. I-Claim

Combination B-Claim
therapy I-Claim
can I-Claim
be I-Claim
used I-Claim
to I-Claim
treat I-Claim
patients I-Claim
for I-Claim
whom I-Claim
monotherapy I-Claim
does I-Claim
not I-Claim
provide I-Claim
sufficient I-Claim
IOP I-Claim
reduction I-Claim
. I-Claim

The B-Claim
simplicity I-Claim
, I-Claim
efficacy I-Claim
, I-Claim
and I-Claim
tolerability I-Claim
of I-Claim
FCLT I-Claim
contribute I-Claim
to I-Claim
its I-Claim
utility I-Claim
in I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

To O
determine O
the O
effect O
of O
scleral O
flap O
size O
on O
the O
medium-term O
intraocular O
pressure O
control O
and O
complication O
rates O
after O
augmented O
trabeculectomy O
. O

Prospective O
randomized O
clinical O
trial O
. O

Glaucoma O
patients O
undergoing O
primary O
trabeculectomy O
. O

Exclusion O
criteria O
included O
previous O
ocular O
surgery O
apart O
from O
cataract O
surgery O
, O
secondary O
glaucoma O
and O
age O
under O
18 O
. O

Patients O
were O
randomized O
to O
either O
standard O
trabeculectomy O
( O
4 O
× O
4 O
mm O
scleral O
flap O
) O
or O
microtrabeculectomy O
( O
2 O
× O
2 O
mm O
scleral O
flap O
) O
, O
both O
with O
adjustable O
sutures O
and O
antimetabolites O
. O

Bleb O
needling O
was O
performed O
as O
required O
. O

Patients O
were O
evaluated O
at O
day O
1 O
, O
weeks O
1 O
, O
3 O
, O
6 O
and O
months O
3 O
, O
6 O
, O
12 O
, O
18 O
and O
24 O
postoperatively O
. O

Vision O
, O
intraocular O
pressure O
, O
complications O
and O
failure O
( O
intraocular O
pressure O
>= O
21 O
mmHg O
or O
not O
reduced O
by O
>=20 O
% O
from O
baseline O
, O
intraocular O
pressure O
<= O
5 O
mmHg O
, O
repeat O
glaucoma O
surgery O
and O
no O
light O
perception O
vision O
) O
. O

Forty-one O
patients O
were O
recruited O
";" O
20 O
had O
standard O
trabeculectomy O
, O
and O
21 O
had O
microtrabeculectomy O
. O

At B-Premise
2 I-Premise
years I-Premise
, I-Premise
the I-Premise
mean I-Premise
intraocular I-Premise
pressure I-Premise
and I-Premise
cumulative I-Premise
probability I-Premise
of I-Premise
failure I-Premise
was I-Premise
12.4 I-Premise
± I-Premise
4.6 I-Premise
mmHg I-Premise
and I-Premise
0.28 I-Premise
for I-Premise
standard I-Premise
trabeculectomy I-Premise
, I-Premise
and I-Premise
11.5 I-Premise
± I-Premise
3.6 I-Premise
mmHg I-Premise
and I-Premise
0.27 I-Premise
for I-Premise
microtrabeculectomy I-Premise
( I-Premise
P I-Premise
= I-Premise
0.50 I-Premise
and I-Premise
0.89 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

One B-Premise
patient I-Premise
in I-Premise
each I-Premise
group I-Premise
required I-Premise
Baerveldt I-Premise
device I-Premise
implantation I-Premise
. I-Premise

Vision B-Premise
reduced I-Premise
>=2 I-Premise
Snellen I-Premise
lines I-Premise
in I-Premise
15 I-Premise
% I-Premise
in I-Premise
the I-Premise
standard I-Premise
trabeculectomy I-Premise
group I-Premise
and I-Premise
25 I-Premise
% I-Premise
in I-Premise
the I-Premise
microtrabeculectomy I-Premise
group I-Premise
, I-Premise
mainly I-Premise
from I-Premise
cataract I-Premise
( I-Premise
P I-Premise
= I-Premise
0.48 I-Premise
) I-Premise
. I-Premise

Both B-Claim
trabeculectomy I-Claim
techniques I-Claim
achieved I-Claim
good I-Claim
intraocular I-Claim
pressure I-Claim
reduction I-Claim
and I-Claim
had I-Claim
similar I-Claim
complication I-Claim
rates I-Claim
. I-Claim

Scleral B-Claim
flap I-Claim
size I-Claim
had I-Claim
no I-Claim
significant I-Claim
effect I-Claim
on I-Claim
medium-term I-Claim
intraocular I-Claim
pressure I-Claim
control I-Claim
and I-Claim
complication I-Claim
profile I-Claim
. I-Claim

To O
compare O
the O
efficacy O
and O
safety O
of O
tafluprost O
, O
a O
preservative-free O
( O
PF O
) O
prostaglandin O
analogue O
, O
with O
PF O
timolol O
in O
patients O
with O
open-angle O
glaucoma O
or O
ocular O
hypertension O
. O

Randomized O
, O
double-masked O
, O
multicenter O
clinical O
trial O
. O

After O
discontinuation O
and O
washout O
of O
existing O
ocular O
hypotensive O
treatment O
, O
patients O
who O
had O
intraocular O
pressure O
( O
IOP O
) O
23 O
and O
36 O
mm O
Hg O
in O
at O
least O
1 O
eye O
at O
the O
08:00 O
hour O
time O
point O
were O
randomized O
1:1 O
to O
12 O
weeks O
of O
treatment O
with O
either O
PF O
tafluprost O
0.0015 O
% O
or O
PF O
timolol O
0.5 O
% O
. O

IOP O
was O
measured O
3 O
times O
during O
the O
day O
( O
08:00 O
, O
10:00 O
, O
16:00 O
hours O
) O
at O
baseline O
and O
at O
weeks O
2 O
, O
6 O
, O
and O
12 O
. O

It O
was O
hypothesized O
that O
PF O
tafluprost O
would O
be O
noninferior O
to O
PF O
timolol O
over O
12 O
weeks O
with O
regard O
to O
change O
from O
baseline O
IOP O
. O

The O
trial O
was O
powered O
for O
a O
noninferiority O
margin O
of O
1.5 O
mm O
Hg O
at O
each O
of O
the O
9 O
time O
points O
assessed O
. O

A O
total O
of O
643 O
patients O
were O
randomized O
and O
618 O
completed O
( O
PF O
tafluprost O
= O
306 O
, O
PF O
timolol O
= O
312 O
) O
. O

IOPs B-Premise
at I-Premise
the I-Premise
3 I-Premise
time I-Premise
points I-Premise
assessed I-Premise
during I-Premise
the I-Premise
baseline I-Premise
visit I-Premise
ranged I-Premise
from I-Premise
23.8 I-Premise
to I-Premise
26.1 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
PF I-Premise
tafluprost I-Premise
group I-Premise
and I-Premise
23.5 I-Premise
to I-Premise
26.0 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
PF I-Premise
timolol I-Premise
group I-Premise
. I-Premise

IOPs B-Premise
at I-Premise
the I-Premise
3 I-Premise
time I-Premise
points I-Premise
assessed I-Premise
during I-Premise
the I-Premise
12-week I-Premise
visit I-Premise
ranged I-Premise
from I-Premise
17.4 I-Premise
to I-Premise
18.6 I-Premise
mm I-Premise
Hg I-Premise
for I-Premise
PF I-Premise
tafluprost I-Premise
and I-Premise
17.9 I-Premise
to I-Premise
18.5 I-Premise
mm I-Premise
Hg I-Premise
for I-Premise
PF I-Premise
timolol I-Premise
. I-Premise

At O
all O
9 O
time O
points O
, O
the O
upper O
limits O
of O
the O
2-sided O
95 O
% O
confidence O
intervals O
for O
the O
difference O
between O
treatments O
in O
IOP O
lowering O
were O
less O
than O
the O
prespecified O
noninferiority O
margin O
. O

Similar B-Premise
percentages I-Premise
of I-Premise
PF I-Premise
tafluprost I-Premise
and I-Premise
PF I-Premise
timolol I-Premise
patients I-Premise
reported I-Premise
ocular I-Premise
pain/stinging/irritation I-Premise
( I-Premise
4.4 I-Premise
% I-Premise
vs I-Premise
4.6 I-Premise
% I-Premise
) I-Premise
and I-Premise
pruritus I-Premise
( I-Premise
2.5 I-Premise
% I-Premise
vs I-Premise
1.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
percentages I-Premise
of I-Premise
PF I-Premise
tafluprost I-Premise
and I-Premise
PF I-Premise
timolol I-Premise
patients I-Premise
reporting I-Premise
conjunctival I-Premise
hyperemia I-Premise
were I-Premise
4.4 I-Premise
% I-Premise
vs I-Premise
1.2 I-Premise
% I-Premise
( I-Premise
nominal I-Premise
P I-Premise
= I-Premise
.016 I-Premise
) I-Premise
. I-Premise

The B-Claim
IOP-lowering I-Claim
effect I-Claim
of I-Claim
PF I-Claim
tafluprost I-Claim
was I-Claim
noninferior I-Claim
to I-Claim
that I-Claim
of I-Claim
PF I-Claim
timolol I-Claim
. I-Claim

PF B-Claim
tafluprost I-Claim
is I-Claim
an I-Claim
efficacious I-Claim
and I-Claim
generally I-Claim
well-tolerated I-Claim
ocular I-Claim
hypotensive I-Claim
agent I-Claim
. I-Claim

To O
report O
one-year O
results O
of O
the O
Tube O
Versus O
Trabeculectomy O
( O
TVT O
) O
Study O
. O

Multicenter O
randomized O
clinical O
trial O
. O

Setting O
: O
17 O
Clinical O
Centers O
. O

Study O
Population O
: O
Patients O
18 O
to O
85 O
years O
of O
age O
who O
had O
previous O
trabeculectomy O
and/or O
cataract O
extraction O
with O
intraocular O
lens O
implantation O
and O
uncontrolled O
glaucoma O
with O
intraocular O
pressure O
( O
IOP O
) O
> O
or O
18 O
mm O
Hg O
and O
< O
or O
40 O
mm O
Hg O
on O
maximum O
tolerated O
medical O
therapy O
. O

Interventions O
: O
350 O
mm O
( O
2 O
) O
Baerveldt O
glaucoma O
implant O
or O
trabeculectomy O
with O
mitomycin O
C O
( O
MMC O
) O
. O

Main O
Outcome O
Measures O
: O
IOP O
, O
visual O
acuity O
, O
and O
reoperation O
for O
glaucoma O
. O

A O
total O
of O
212 O
eyes O
of O
212 O
patients O
were O
enrolled O
, O
including O
107 O
in O
the O
tube O
group O
and O
105 O
in O
the O
trabeculectomy O
group O
. O

At O
one O
year O
, O
IOP O
( O
mean O
+/- O
SD O
) O
was O
12.4 O
+/- O
3.9 O
mm O
Hg O
in O
the O
tube O
group O
and O
12.7 O
+/- O
5.8 O
mm O
Hg O
in O
the O
trabeculectomy O
group O
( O
P O
= O
.73 O
) O
. O

The B-Premise
number I-Premise
of I-Premise
glaucoma I-Premise
medications I-Premise
( I-Premise
mean I-Premise
+/- I-Premise
SD I-Premise
) I-Premise
was I-Premise
1.3 I-Premise
+/- I-Premise
1.3 I-Premise
in I-Premise
the I-Premise
tube I-Premise
group I-Premise
and I-Premise
0.5 I-Premise
+/- I-Premise
0.9 I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
cumulative I-Premise
probability I-Premise
of I-Premise
failure I-Premise
during I-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
was I-Premise
3.9 I-Premise
% I-Premise
in I-Premise
the I-Premise
tube I-Premise
group I-Premise
and I-Premise
13.5 I-Premise
% I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
.017 I-Premise
) I-Premise
. I-Premise

Nonvalved B-Premise
tube I-Premise
shunt I-Premise
surgery I-Premise
was I-Premise
more I-Premise
likely I-Premise
to I-Premise
maintain I-Premise
IOP I-Premise
control I-Premise
and I-Premise
avoid I-Premise
persistent I-Premise
hypotony I-Premise
or I-Premise
reoperation I-Premise
for I-Premise
glaucoma I-Premise
than I-Premise
trabeculectomy I-Premise
with I-Premise
MMC I-Premise
during I-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
in I-Premise
the I-Premise
TVT I-Premise
Study I-Premise
. I-Premise

Both B-Claim
surgical I-Claim
procedures I-Claim
produced I-Claim
similar I-Claim
IOP I-Claim
reduction I-Claim
at I-Claim
one I-Claim
year I-Claim
, O
but O
there B-Claim
was I-Claim
less I-Claim
need I-Claim
for I-Claim
supplemental I-Claim
medical I-Claim
therapy I-Claim
following I-Claim
trabeculectomy I-Claim
with I-Claim
MMC I-Claim
. I-Claim

The O
aim O
of O
this O
study O
is O
to O
assess O
the O
efficacy O
and O
complications O
of O
trabeculectomy O
with O
a O
biodegradable O
implant O
( O
ologen O
implant O
) O
vs O
trabeculectomy O
using O
mitomycin O
C O
( O
MMC O
) O
in O
patients O
with O
medically O
uncontrolled O
open-angle O
glaucoma O
in O
a O
prospective O
randomised O
clinical O
trial O
. O

In O
the O
MMC O
group O
( O
10 O
patients O
) O
, O
trabeculectomy O
was O
performed O
according O
to O
standard O
protocols O
. O

In O
the O
ologen O
group O
( O
10 O
patients O
) O
after O
standard O
trabeculectomy O
the O
implant O
was O
positioned O
on O
top O
of O
the O
scleral O
flap O
and O
no O
MMC O
was O
applied O
. O

Follow-up O
was O
continued O
for O
12 O
months O
after O
surgery O
and O
included O
testing O
of O
intraocular O
pressure O
( O
IOP O
) O
, O
visual O
acuity O
, O
visual O
field O
, O
ultrasound O
biomicroscopy O
, O
and O
filtering O
bleb O
score O
. O

The O
mean O
preoperative O
IOP O
was O
24.8+/-8.9 O
mm O
Hg O
for O
all O
patients O
enrolled O
. O

At B-Premise
1 I-Premise
year I-Premise
after I-Premise
surgery I-Premise
, I-Premise
the I-Premise
mean I-Premise
IOP I-Premise
was I-Premise
15.6+/-2.4mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
ologen I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
, I-Premise
43 I-Premise
% I-Premise
reduction I-Premise
) I-Premise
and I-Premise
11.5+/-4.1 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
MMC I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
, I-Premise
50 I-Premise
% I-Premise
reduction I-Premise
) I-Premise
. I-Premise

No B-Premise
anti-glaucomatous I-Premise
medication I-Premise
was I-Premise
necessary I-Premise
in I-Premise
the I-Premise
MMC I-Premise
group I-Premise
in I-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
whereas I-Premise
five I-Premise
patients I-Premise
in I-Premise
the I-Premise
ologen I-Premise
group I-Premise
required I-Premise
topical I-Premise
treatment I-Premise
. I-Premise

The B-Premise
absolute I-Premise
success I-Premise
rate I-Premise
was I-Premise
100 I-Premise
% I-Premise
in I-Premise
the I-Premise
MMC I-Premise
group I-Premise
and I-Premise
50 I-Premise
% I-Premise
in I-Premise
the I-Premise
ologen I-Premise
group I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
. I-Premise

After B-Premise
1 I-Premise
year I-Premise
, I-Premise
filtering I-Premise
blebs I-Premise
developed I-Premise
significantly I-Premise
more I-Premise
avascular I-Premise
areas I-Premise
in I-Premise
the I-Premise
MMC I-Premise
group I-Premise
( I-Premise
score=1.4 I-Premise
) I-Premise
than I-Premise
in I-Premise
the I-Premise
ologen I-Premise
group I-Premise
( I-Premise
score=2.8 I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Claim
complete I-Claim
success I-Claim
rate I-Claim
using I-Claim
trabeculectomy I-Claim
with I-Claim
the I-Claim
ologen I-Claim
implant I-Claim
is I-Claim
lower I-Claim
than I-Claim
that I-Claim
achieved I-Claim
by I-Claim
trabeculectomy I-Claim
with I-Claim
MMC I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
bleb I-Claim
morphology I-Claim
caused I-Claim
more I-Claim
problems I-Claim
in I-Claim
the I-Claim
MMC I-Claim
group I-Claim
( I-Claim
avascularity I-Claim
score I-Claim
) I-Claim
. I-Claim

To O
compare O
the O
effect O
on O
intraocular O
pressure O
of O
latanoprost O
versus O
timolol O
plus O
dorzolamide O
in O
open-angle O
glaucoma O
. O

Thirty-five O
patients O
with O
open-angle O
glaucoma O
were O
randomized O
, O
18 O
to O
latanoprost O
once O
daily O
and O
17 O
to O
timolol O
plus O
dorzolamide O
twice O
daily O
. O

Intraocular O
pressure O
and O
ocular O
side O
effects O
were O
recorded O
at O
baseline O
, O
and O
after O
2 O
weeks O
and O
3 O
months O
of O
treatment O
. O

Latanoprost B-Premise
reduced I-Premise
the I-Premise
intraocular I-Premise
pressure I-Premise
1.09 I-Premise
and I-Premise
1.58 I-Premise
mm I-Premise
Hg I-Premise
more I-Premise
than I-Premise
timolol I-Premise
plus I-Premise
dorzolamide I-Premise
after I-Premise
2 I-Premise
weeks I-Premise
and I-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
, I-Premise
respectively I-Premise
. I-Premise

These B-Premise
differences I-Premise
were I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
study I-Premise
. I-Premise

After B-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
, I-Premise
32.3 I-Premise
% I-Premise
of I-Premise
the I-Premise
eyes I-Premise
in I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
reduced I-Premise
the I-Premise
intraocular I-Premise
pressure I-Premise
in I-Premise
30 I-Premise
% I-Premise
or I-Premise
more I-Premise
with I-Premise
respect I-Premise
to I-Premise
baseline I-Premise
, I-Premise
while I-Premise
15.6 I-Premise
% I-Premise
of I-Premise
the I-Premise
eyes I-Premise
in I-Premise
the I-Premise
timolol I-Premise
plus I-Premise
dorzolamide I-Premise
group I-Premise
achieved I-Premise
this I-Premise
reduction I-Premise
. I-Premise

Latanoprost B-Claim
administered I-Claim
once I-Claim
daily I-Claim
reduced I-Claim
the I-Claim
intraocular I-Claim
pressure I-Claim
at I-Claim
least I-Claim
as I-Claim
well I-Claim
as I-Claim
timolol I-Claim
plus I-Claim
dorzolamide I-Claim
twice I-Claim
daily I-Claim
in I-Claim
patients I-Claim
with I-Claim
open-angle I-Claim
glaucoma I-Claim
. I-Claim

To O
compare O
intraocular O
pressure O
( O
IOP O
) O
control O
and O
other O
clinical O
outcomes O
after O
1-site O
fornix-based O
and O
2-site O
limbus-based O
phacotrabeculectomy O
. O

Prospective O
randomized O
controlled O
trial O
. O

A O
total O
of O
90 O
eyes O
of O
76 O
patients O
with O
cataract O
and O
glaucoma O
were O
treated O
. O

Forty-four O
eyes O
were O
assigned O
randomly O
to O
receive O
a O
1-site O
phacotrabeculectomy O
with O
a O
fornix-based O
conjunctival O
flap O
, O
and O
46 O
eyes O
were O
assigned O
randomly O
to O
receive O
a O
2-site O
phacotrabeculectomy O
with O
a O
limbus-based O
conjunctival O
flap O
. O

All O
operations O
were O
performed O
with O
mitomycin O
C O
. O

Intraocular O
pressure O
and O
number O
of O
antiglaucoma O
medications O
were O
recorded O
at O
baseline O
and O
during O
a O
3-year O
follow-up O
period O
. O

Mean B-Premise
preoperative I-Premise
IOP I-Premise
was I-Premise
20.1+/-3.8 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
1-site I-Premise
group I-Premise
and I-Premise
19.5+/-5.3 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
2-site I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.56 I-Premise
) I-Premise
using I-Premise
a I-Premise
mean I-Premise
of I-Premise
2.3+/-0.9 I-Premise
and I-Premise
2.5+/-0.9 I-Premise
antiglaucoma I-Premise
medications I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
0.27 I-Premise
) I-Premise
. I-Premise

After B-Premise
3 I-Premise
years I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
the I-Premise
mean I-Premise
IOP I-Premise
was I-Premise
12.6+/-4.8 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
1-site I-Premise
group I-Premise
and I-Premise
11.7+/-4.0 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
2-site I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.40 I-Premise
) I-Premise
, I-Premise
receiving I-Premise
a I-Premise
mean I-Premise
of I-Premise
0.3+/-0.7 I-Premise
and I-Premise
0.4+/-0.9 I-Premise
medications I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
0.59 I-Premise
) I-Premise
. I-Premise

At B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
study I-Premise
, I-Premise
73 I-Premise
% I-Premise
of I-Premise
1-site I-Premise
eyes I-Premise
and I-Premise
78.4 I-Premise
% I-Premise
of I-Premise
2-site I-Premise
eyes I-Premise
had I-Premise
IOPs I-Premise
of I-Premise
less I-Premise
than I-Premise
18 I-Premise
mmHg I-Premise
while I-Premise
receiving I-Premise
no I-Premise
antiglaucoma I-Premise
medications I-Premise
( I-Premise
P I-Premise
= I-Premise
0.59 I-Premise
) I-Premise
. I-Premise

Visual B-Premise
acuity I-Premise
was I-Premise
similar I-Premise
for I-Premise
both I-Premise
groups I-Premise
at I-Premise
3 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
the I-Premise
need I-Premise
for I-Premise
digital I-Premise
pressure I-Premise
, I-Premise
postoperative I-Premise
bleb I-Premise
needling I-Premise
with I-Premise
5-fluorouracil I-Premise
, I-Premise
or I-Premise
number I-Premise
of I-Premise
postoperative I-Premise
visits I-Premise
. I-Premise

There O
were O
2 O
major O
complications O
in O
each O
group O
during O
follow-up O
. O

Early B-Premise
leaks I-Premise
of I-Premise
the I-Premise
conjunctival I-Premise
wound I-Premise
closure I-Premise
occurred I-Premise
in I-Premise
6 I-Premise
eyes I-Premise
in I-Premise
the I-Premise
1-site I-Premise
group I-Premise
and I-Premise
in I-Premise
0 I-Premise
eyes I-Premise
in I-Premise
the I-Premise
2-site I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

Operating O
time O
( O
in O
minutes O
) O
was O
less O
in O
the O
1-site O
surgery O
group O
( O
P O
< O
0.0001 O
) O
. O

Day O
one O
postoperative O
IOP O
was O
higher O
in O
the O
2-site O
group O
( O
P O
= O
0.0.01 O
) O
. O

One-site B-Claim
fornix-based I-Claim
and I-Claim
2-site I-Claim
limbus-based I-Claim
phacotrabeculectomy I-Claim
were I-Claim
similarly I-Claim
effective I-Claim
in I-Claim
lowering I-Claim
IOP I-Claim
and I-Claim
reducing I-Claim
the I-Claim
need I-Claim
for I-Claim
antiglaucoma I-Claim
medications I-Claim
over I-Claim
a I-Claim
3-year I-Claim
follow-up I-Claim
period I-Claim
. I-Claim

To O
evaluate O
the O
efficacy O
and O
tolerability O
of O
brimonidine O
purite O
0.1 O
% O
in O
comparison O
to O
brinzolamide O
1 O
% O
when O
used O
as O
adjunctive O
therapy O
to O
latanoprost O
0.005 O
% O
in O
patients O
with O
glaucoma O
or O
ocular O
hypertension O
. O

Randomized O
, O
single-center O
, O
investigator-masked O
, O
parallel-group O
clinical O
study O
. O

Patients O
with O
IOP O
> O
or= O
18 O
mmHg O
while O
on O
once-daily O
latanoprost O
were O
randomized O
to O
adjunctive O
treatment O
with O
brimonidine O
purite O
TID O
( O
n O
= O
20 O
) O
or O
brinzolamide O
TID O
( O
n O
= O
20 O
) O
for O
3 O
months O
. O

Intraocular O
pressure O
( O
IOP O
) O
was O
measured O
at O
8 O
a.m. O
, O
10 O
a.m. O
, O
and O
4 O
p.m. O
at O
latanoprost-treated O
baseline O
and O
after O
1 O
and O
3 O
months O
of O
latanoprost O
and O
adjunctive O
therapy O
. O

A O
patient O
questionnaire O
was O
administered O
to O
evaluate O
the O
tolerability O
of O
eye O
drop O
instillation O
. O

Baseline B-Premise
mean I-Premise
diurnal I-Premise
IOP I-Premise
( I-Premise
+/- I-Premise
standard I-Premise
deviation I-Premise
, I-Premise
mmHg I-Premise
) I-Premise
on I-Premise
latanoprost I-Premise
was I-Premise
comparable I-Premise
between I-Premise
groups I-Premise
( I-Premise
brimonidine I-Premise
purite I-Premise
: I-Premise
19.6 I-Premise
+/- I-Premise
2.94 I-Premise
";" I-Premise
brinzolamide I-Premise
: I-Premise
19.8 I-Premise
+/- I-Premise
3.25 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.846 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
diurnal I-Premise
IOP I-Premise
at I-Premise
Month I-Premise
3 I-Premise
was I-Premise
16.3 I-Premise
+/- I-Premise
2.63 I-Premise
mmHg I-Premise
with I-Premise
brimonidine I-Premise
purite I-Premise
and I-Premise
17.8 I-Premise
+/- I-Premise
2.19 I-Premise
mmHg I-Premise
with I-Premise
brinzolamide I-Premise
( I-Premise
p I-Premise
= I-Premise
0.028 I-Premise
) I-Premise
. I-Premise

Adjunctive B-Premise
use I-Premise
of I-Premise
brimonidine I-Premise
purite I-Premise
provided I-Premise
greater I-Premise
IOP I-Premise
lowering I-Premise
than I-Premise
brinzolamide I-Premise
at I-Premise
10 I-Premise
a.m. I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
4 I-Premise
p.m. I-Premise
( I-Premise
p I-Premise
= I-Premise
0.050 I-Premise
) I-Premise
and I-Premise
equivalent I-Premise
IOP I-Premise
lowering I-Premise
to I-Premise
brinzolamide I-Premise
at I-Premise
8 I-Premise
a.m. I-Premise
( I-Premise
p I-Premise
= I-Premise
0.716 I-Premise
) I-Premise
. I-Premise

Blurred B-Premise
vision I-Premise
at I-Premise
Month I-Premise
1 I-Premise
and I-Premise
bitter I-Premise
taste I-Premise
at I-Premise
Months I-Premise
1 I-Premise
and I-Premise
3 I-Premise
were I-Premise
more I-Premise
common I-Premise
upon I-Premise
instillation I-Premise
of I-Premise
brinzolamide I-Premise
eye I-Premise
drops I-Premise
. I-Premise

Brimonidine B-Claim
purite I-Claim
0.1 I-Claim
% I-Claim
provided I-Claim
significantly I-Claim
lower I-Claim
IOP I-Claim
compared I-Claim
with I-Claim
brinzolamide I-Claim
1 I-Claim
% I-Claim
when I-Claim
used I-Claim
as I-Claim
adjunctive I-Claim
therapy I-Claim
to I-Claim
latanoprost I-Claim
. I-Claim

Both B-Claim
adjunctive I-Claim
therapies I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Limitations B-Premise
of I-Premise
this I-Premise
study I-Premise
include I-Premise
the I-Premise
use I-Premise
of I-Premise
a I-Premise
single I-Premise
site I-Premise
and I-Premise
the I-Premise
sample I-Premise
size I-Premise
. I-Premise

Additional B-Claim
studies I-Claim
are I-Claim
needed I-Claim
to I-Claim
further I-Claim
evaluate I-Claim
these I-Claim
drugs I-Claim
as I-Claim
adjunctive I-Claim
therapy I-Claim
to I-Claim
prostaglandin I-Claim
analogs I-Claim
. I-Claim

Ocular O
blood O
flow O
dysregulation O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
glaucoma O
. O

Whereas O
the O
effect O
of O
single O
antiglaucoma O
substances O
on O
ocular O
blood O
flow O
has O
been O
addressed O
in O
various O
experiments O
, O
evidence O
for O
fixed O
combinations O
is O
sparse O
. O

In O
the O
present O
study O
, O
we O
set O
out O
to O
compare O
the O
effects O
of O
latanoprost O
0.005 O
% O
/timolol O
0.5 O
% O
( O
LT O
) O
fixed O
combination O
and O
brimonidine O
0.2 O
% O
/timolol O
0.5 O
% O
( O
BT O
) O
fixed O
combination O
on O
intraocular O
pressure O
( O
IOP O
) O
and O
ocular O
blood O
flow O
. O

In O
the O
present O
study O
, O
which O
followed O
a O
randomized O
, O
double-masked O
2-way O
crossover O
design O
, O
16 O
patients O
with O
primary O
open-angle O
glaucoma O
and O
2 O
patients O
with O
ocular O
hypertension O
were O
included O
. O

The O
patients O
underwent O
a O
6-week O
treatment O
with O
LT O
and O
a O
6-week O
treatment O
with O
BT O
after O
a O
washout O
for O
previous O
antiglaucoma O
medication O
. O

Optic O
nerve O
head O
blood O
flow O
( O
ONHBF O
) O
was O
measured O
using O
laser O
Doppler O
flowmetry O
";" O
retrobulbar O
flow O
velocities O
were O
measured O
using O
color O
Doppler O
imaging O
in O
the O
ophthalmic O
artery O
, O
the O
central O
retinal O
artery O
, O
and O
the O
posterior O
ciliary O
arteries O
. O

IOP O
was O
measured O
at O
8 O
AM O
, O
12 O
PM O
, O
and O
4 O
PM O
. O

The O
mean O
baseline O
IOP O
was O
25.3 O
±2.8 O
mmHg O
. O

Both B-Premise
drugs I-Premise
were I-Premise
equally I-Premise
effective I-Premise
in I-Premise
reducing I-Premise
IOP I-Premise
( I-Premise
LT I-Premise
: I-Premise
-35.0 I-Premise
% I-Premise
±10.0 I-Premise
% I-Premise
";" I-Premise
BT I-Premise
: I-Premise
-33.6 I-Premise
% I-Premise
±8.8 I-Premise
% I-Premise
, I-Premise
P=0.463 I-Premise
between I-Premise
groups I-Premise
) I-Premise
. I-Premise

In O
addition O
, O
no B-Premise
difference I-Premise
in I-Premise
ocular I-Premise
perfusion I-Premise
pressure I-Premise
was I-Premise
observed I-Premise
between I-Premise
the I-Premise
2 I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
P=0.1 I-Premise
, I-Premise
between I-Premise
groups I-Premise
) I-Premise
. I-Premise

Neither B-Premise
LT I-Premise
nor I-Premise
BT I-Premise
altered I-Premise
ONHBF I-Premise
( I-Premise
P=0.4 I-Premise
, I-Premise
baseline I-Premise
vs. I-Premise
treatment I-Premise
) I-Premise
and O
no B-Premise
effect I-Premise
on I-Premise
flow I-Premise
velocities I-Premise
in I-Premise
the I-Premise
retrobulbar I-Premise
vessels I-Premise
was I-Premise
seen I-Premise
with I-Premise
either I-Premise
of I-Premise
the I-Premise
2 I-Premise
treatments I-Premise
. I-Premise

In O
the O
present O
study O
, O
a B-Claim
6-week I-Claim
treatment I-Claim
with I-Claim
LT I-Claim
or I-Claim
BT I-Claim
was I-Claim
equally I-Claim
effective I-Claim
in I-Claim
reducing I-Claim
IOP I-Claim
. I-Claim

In O
addition O
, O
none B-Claim
of I-Claim
the I-Claim
administered I-Claim
drugs I-Claim
induced I-Claim
a I-Claim
significant I-Claim
effect I-Claim
on I-Claim
ocular I-Claim
blood I-Claim
flow I-Claim
parameters I-Claim
. I-Claim

Bimatoprost O
and O
the O
fixed O
combination O
of O
latanoprost O
with O
timolol O
maleate O
are O
2 O
medications O
widely O
used O
to O
treat O
glaucoma O
and O
ocular O
hypertension O
( O
OHT O
) O
. O

The O
aim O
of O
the O
study O
is O
to O
compare O
the O
efficacy O
of O
these O
2 O
drugs O
in O
reducing O
intraocular O
pressure O
( O
IOP O
) O
after O
8 O
weeks O
of O
treatment O
in O
patients O
with O
primary O
open O
angle O
glaucoma O
( O
POAG O
) O
or O
OHT O
. O

In O
this O
randomized O
, O
open-label O
trial O
, O
44 O
patients O
with O
POAG O
or O
OHT O
were O
allocated O
to O
receive O
either O
bimatoprost O
( O
1 O
drop O
QD O
) O
or O
latanoprost/timolol O
( O
1 O
drop O
QD O
) O
. O

Primary O
outcome O
was O
the O
mean O
diurnal O
IOP O
measurement O
at O
the O
8th O
week O
, O
calculated O
as O
the O
mean O
IOP O
measurements O
taken O
at O
8:00 O
am O
, O
10:00 O
am O
, O
and O
12:00 O
pm O
Secondary O
outcomes O
included O
the O
baseline O
change O
in O
IOP O
measured O
3 O
times O
a O
day O
, O
after O
the O
water-drinking O
test O
( O
performed O
after O
the O
last O
IOP O
measurement O
) O
, O
and O
the O
assessment O
of O
side O
effects O
of O
each O
therapy O
. O

The B-Premise
mean I-Premise
IOP I-Premise
levels I-Premise
of I-Premise
latanoprost/timolol I-Premise
( I-Premise
13.83 I-Premise
, I-Premise
SD I-Premise
= I-Premise
2.54 I-Premise
) I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
of I-Premise
bimatoprost I-Premise
( I-Premise
16.16 I-Premise
, I-Premise
SD I-Premise
= I-Premise
3.28 I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
at I-Premise
week I-Premise
8 I-Premise
. I-Premise

Also O
, O
the B-Premise
change I-Premise
in I-Premise
mean I-Premise
IOP I-Premise
values I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
latanoprost/timolol I-Premise
group I-Premise
at I-Premise
10:00 I-Premise
am I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
and I-Premise
12:00 I-Premise
pm I-Premise
( I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
but I-Premise
not I-Premise
at I-Premise
8:00 I-Premise
am I-Premise
( I-Premise
P I-Premise
= I-Premise
ns I-Premise
) I-Premise
. I-Premise

During O
the O
water-drinking O
test O
, O
there O
was O
no O
significant O
difference O
in O
IOP O
increase O
( O
absolute O
and O
percentage O
) O
between O
groups O
";" O
however O
, O
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
mean I-Premise
heart I-Premise
rate I-Premise
in I-Premise
the I-Premise
latanoprost/timolol I-Premise
group I-Premise
. O

Finally O
, O
no B-Premise
significant I-Premise
changes I-Premise
in I-Premise
blood I-Premise
pressure I-Premise
and I-Premise
lung I-Premise
spirometry I-Premise
were I-Premise
observed I-Premise
in I-Premise
either I-Premise
groups I-Premise
. I-Premise

The B-Claim
fixed I-Claim
combination I-Claim
of I-Claim
latanoprost/timolol I-Claim
was I-Claim
significantly I-Claim
superior I-Claim
to I-Claim
bimatoprost I-Claim
alone I-Claim
in I-Claim
reducing I-Claim
IOP I-Claim
in I-Claim
patients I-Claim
with I-Claim
POAG I-Claim
or I-Claim
OHT I-Claim
. I-Claim

Further B-Claim
studies I-Claim
with I-Claim
large I-Claim
sample I-Claim
sizes I-Claim
should I-Claim
be I-Claim
taken I-Claim
to I-Claim
support I-Claim
the I-Claim
superior I-Claim
efficacy I-Claim
of I-Claim
latanoprost/timolol I-Claim
, I-Claim
as I-Claim
well I-Claim
as I-Claim
to I-Claim
better I-Claim
assess I-Claim
its I-Claim
profile I-Claim
of I-Claim
side I-Claim
effects I-Claim
. I-Claim

To O
compare O
the O
efficacy O
and O
safety O
of O
laser O
peripheral O
iridotomy O
with O
or O
without O
laser O
peripheral O
iridoplasty O
in O
the O
treatment O
of O
eyes O
with O
synechial O
primary O
angle-closure O
or O
primary O
angle-closure O
glaucoma O
. O

Randomized O
, O
controlled O
clinical O
trial O
. O

Consecutive O
patients O
older O
than O
40 O
years O
with O
synechial O
primary O
angle-closure O
or O
primary O
angle O
closure O
glaucoma O
were O
recruited O
. O

Eligible O
patients O
were O
randomized O
to O
1 O
of O
2 O
treatment O
options O
, O
iridotomy O
or O
iridotomy O
plus O
iridoplasty O
, O
and O
were O
followed O
up O
for O
1 O
year O
. O

Main O
outcome O
measures O
were O
intraocular O
pressure O
( O
IOP O
) O
, O
peripheral O
anterior O
synechiae O
, O
corneal O
endothelial O
cell O
count O
, O
and O
complications O
. O

Seventy-seven O
eyes O
( O
77 O
patients O
) O
were O
randomized O
to O
the O
iridotomy O
group O
, O
and O
81 O
eyes O
( O
81 O
patients O
) O
were O
randomized O
to O
the O
iridotomy O
plus O
iridoplasty O
group O
. O

Sixty-one O
patients O
( O
79.2 O
% O
) O
in O
the O
iridotomy O
and O
65 O
patients O
( O
80.2 O
% O
) O
from O
the O
iridotomy O
plus O
iridoplasty O
groups O
completed O
1 O
year O
of O
follow-up O
. O

There O
were O
no O
significant O
differences O
between O
the O
groups O
in O
the O
baseline O
data O
. O

IOP B-Premise
was I-Premise
reduced I-Premise
from I-Premise
24.66 I-Premise
+/- I-Premise
13.76 I-Premise
mm I-Premise
Hg I-Premise
to I-Premise
19.03 I-Premise
+/- I-Premise
6.21 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
iridotomy I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
from I-Premise
27.96 I-Premise
+/- I-Premise
13.06 I-Premise
mm I-Premise
Hg I-Premise
to I-Premise
20.45 I-Premise
+/- I-Premise
7.26 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
iridotomy I-Premise
plus I-Premise
iridoplasty I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Extent B-Premise
of I-Premise
peripheral I-Premise
anterior I-Premise
synechiae I-Premise
was I-Premise
decreased I-Premise
by I-Premise
1 I-Premise
more I-Premise
clock-hour I-Premise
after I-Premise
iridoplasty I-Premise
compared I-Premise
with I-Premise
that I-Premise
after I-Premise
iridotomy I-Premise
in I-Premise
the I-Premise
iridotomy I-Premise
plus I-Premise
iridoplasty I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
IOP I-Premise
, I-Premise
medications I-Premise
, I-Premise
need I-Premise
for I-Premise
surgery I-Premise
, I-Premise
or I-Premise
visual I-Premise
function I-Premise
between I-Premise
groups I-Premise
at I-Premise
the I-Premise
1-year I-Premise
visit I-Premise
. I-Premise

In B-Claim
eyes I-Claim
with I-Claim
synechial I-Claim
primary I-Claim
angle-closure I-Claim
or I-Claim
primary I-Claim
angle-closure I-Claim
glaucoma I-Claim
, I-Claim
both I-Claim
iridotomy I-Claim
alone I-Claim
or I-Claim
combined I-Claim
with I-Claim
iridoplasty I-Claim
provide I-Claim
a I-Claim
significant I-Claim
and I-Claim
equivalent I-Claim
reduction I-Claim
in I-Claim
IOP I-Claim
. I-Claim

There B-Claim
is I-Claim
also I-Claim
a I-Claim
possible I-Claim
reduction I-Claim
in I-Claim
peripheral I-Claim
anterior I-Claim
synechiae I-Claim
, I-Claim
more I-Claim
so I-Claim
in I-Claim
the I-Claim
iridoplasty I-Claim
group I-Claim
. I-Claim

To O
compare O
efficacy O
( O
intraocular O
pressure O
( O
IOP O
) O
reduction O
) O
and O
safety O
of O
preservative-free O
latanoprost O
( O
T2345 O
) O
to O
benzalkonium O
chloride O
( O
BAK O
) O
-preserved O
latanoprost O
( O
BPL O
";" O
Xalatan O
) O
in O
ocular O
hypertension O
( O
OHT O
) O
or O
primary O
open O
angle O
glaucoma O
( O
POAG O
) O
patients O
. O

Prospective O
, O
international O
, O
multicentre O
, O
randomised O
, O
investigator-masked O
, O
parallel-group O
trial O
. O

After O
a O
wash-out O
period O
, O
POAG O
or O
OHT O
patients O
, O
previously O
managed O
by O
BPL O
monotherapy O
, O
randomly O
received O
T2345 O
or O
BPL O
( O
one O
drop O
into O
the O
affected O
eye O
( O
s O
) O
) O
once O
daily O
from O
D0 O
to O
D84 O
. O

Change O
in O
IOP O
was O
measured O
at O
09:00 O
( O
±1 O
h O
) O
from O
D0 O
to O
D84 O
in O
the O
worse O
eye O
. O

Mean B-Premise
IOP I-Premise
reduction I-Premise
( I-Premise
D0-D84 I-Premise
) I-Premise
was I-Premise
-8.6 I-Premise
±2.6 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
-36 I-Premise
% I-Premise
) I-Premise
on I-Premise
T2345 I-Premise
and I-Premise
-9.0 I-Premise
±2.4 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
-38 I-Premise
% I-Premise
) I-Premise
on I-Premise
BPL I-Premise
, I-Premise
confirming I-Premise
non-inferiority I-Premise
of I-Premise
T2345 I-Premise
to I-Premise
BPL I-Premise
. I-Premise

Non-inferiority O
of O
T2345 O
was O
observed O
from O
D15 O
. O

The B-Premise
most I-Premise
frequent I-Premise
ocular I-Premise
adverse I-Premise
event I-Premise
, I-Premise
drug I-Premise
intolerance I-Premise
, I-Premise
was I-Premise
reported I-Premise
in I-Premise
1 I-Premise
( I-Premise
0.5 I-Premise
% I-Premise
) I-Premise
patient I-Premise
on I-Premise
T2345 I-Premise
versus I-Premise
4 I-Premise
( I-Premise
2.1 I-Premise
% I-Premise
) I-Premise
patients I-Premise
on I-Premise
BPL I-Premise
. I-Premise

Moderate B-Premise
to I-Premise
severe I-Premise
conjunctival I-Premise
hyperaemia I-Premise
was I-Premise
less I-Premise
frequent I-Premise
on I-Premise
T2345 I-Premise
than I-Premise
on I-Premise
BPL I-Premise
at I-Premise
D42 I-Premise
( I-Premise
20.2 I-Premise
% I-Premise
vs I-Premise
30.6 I-Premise
% I-Premise
";" I-Premise
p=0.003 I-Premise
) I-Premise
and I-Premise
D84 I-Premise
( I-Premise
21.4 I-Premise
% I-Premise
vs I-Premise
29.1 I-Premise
% I-Premise
";" I-Premise
p=0.02 I-Premise
) I-Premise
. I-Premise

Upon B-Premise
instillation I-Premise
, I-Premise
the I-Premise
global I-Premise
subjective I-Premise
ocular I-Premise
symptom I-Premise
score I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
on I-Premise
T2345 I-Premise
than I-Premise
BPL I-Premise
on I-Premise
D42 I-Premise
( I-Premise
0.15 I-Premise
vs I-Premise
0.41 I-Premise
";" I-Premise
p=0.001 I-Premise
) I-Premise
and I-Premise
D84 I-Premise
( I-Premise
0.18 I-Premise
vs I-Premise
0.46 I-Premise
";" I-Premise
p=0.001 I-Premise
) I-Premise
. I-Premise

Preservative-free B-Claim
latanoprost I-Claim
has I-Claim
the I-Claim
same I-Claim
efficacy I-Claim
as I-Claim
BPL I-Claim
, I-Claim
with I-Claim
improved I-Claim
local I-Claim
tolerance I-Claim
. I-Claim

To O
compare O
the O
effect O
on O
intraocular O
pressure O
( O
IOP O
) O
of O
the O
silicone O
Ahmed O
glaucoma O
valve O
with O
and O
without O
an O
intravitreal O
injection O
of O
triamcinolone O
acetonide O
. O

Forty-nine O
patients O
with O
clinically O
uncontrolled O
neovascular O
glaucoma O
were O
included O
in O
the O
study O
";" O
22 O
were O
randomly O
assigned O
to O
the O
study O
group O
( O
silicone O
Ahmed O
glaucoma O
valve O
implant O
with O
intravitreal O
triamcinolone O
acetonide O
) O
and O
27 O
to O
the O
control O
group O
( O
silicone O
Ahmed O
glaucoma O
valve O
) O
. O

IOP O
was O
the O
primary O
outcome O
measure O
in O
this O
study O
. O

The O
secondary O
outcome O
measure O
was O
success O
, O
defined O
by O
IOP O
lower O
than O
22 O
mm O
Hg O
and O
higher O
than O
5 O
mm O
Hg O
, O
and O
no O
serious O
complications O
. O

Success O
rates O
in O
both O
the O
groups O
were O
compared O
using O
Kaplan-Meier O
survival O
curves O
and O
the O
log-rank O
test O
. O

IOP O
levels O
were O
compared O
using O
mixed O
linear O
model O
analysis O
to O
correct O
for O
repeated O
measures O
correlation O
. O

Forty-three O
patients O
, O
18 O
in O
the O
study O
group O
and O
25 O
in O
the O
control O
group O
, O
completed O
the O
study O
( O
follow-up O
of O
12 O
mo O
) O
. O

The B-Premise
mean I-Premise
IOP I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
after I-Premise
1 I-Premise
year I-Premise
in I-Premise
both I-Premise
the I-Premise
groups I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
IOP I-Premise
in I-Premise
the I-Premise
first I-Premise
month I-Premise
of I-Premise
follow-up I-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
study I-Premise
group I-Premise
( I-Premise
control I-Premise
";" I-Premise
20.4±9.7 I-Premise
, I-Premise
study I-Premise
";" I-Premise
13.6±6.5 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
success I-Premise
rate I-Premise
at I-Premise
1 I-Premise
year I-Premise
was I-Premise
78 I-Premise
% I-Premise
for I-Premise
the I-Premise
study I-Premise
group I-Premise
and I-Premise
76 I-Premise
% I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P=0.82 I-Premise
) I-Premise
. I-Premise

Complication B-Premise
rates I-Premise
were I-Premise
not I-Premise
different I-Premise
between I-Premise
the I-Premise
groups I-Premise
. I-Premise

Intravitreal B-Claim
injection I-Claim
of I-Claim
triamcinolone I-Claim
acetonide I-Claim
in I-Claim
neovascular I-Claim
glaucoma I-Claim
did I-Claim
not I-Claim
affect I-Claim
the I-Claim
intermediate-term I-Claim
success I-Claim
of I-Claim
the I-Claim
silicone I-Claim
Ahmed I-Claim
valve I-Claim
nor I-Claim
reduce I-Claim
the I-Claim
incidence I-Claim
of I-Claim
complications I-Claim
. I-Claim

The B-Premise
mean I-Premise
IOP I-Premise
spike I-Premise
in I-Premise
the I-Premise
first I-Premise
month I-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
triamcinolone I-Premise
group I-Premise
. I-Premise

To O
compare O
the O
intraocular O
pressure O
( O
IOP O
) O
-lowering O
effect O
of O
combined O
viscocanalostomy O
and O
phacoemulsification O
and O
combined O
trabeculectomy O
and O
phacoemulsification O
with O
mitomycin O
C O
in O
eyes O
with O
primary O
open-angle O
glaucoma O
. O

Prospective O
randomized O
1-year O
trial O
. O

Forty O
consecutive O
patients O
( O
40 O
eyes O
) O
with O
primary O
open-angle O
glaucoma O
and O
cataract O
. O

Eyes O
were O
assigned O
randomly O
either O
to O
trabeculectomy O
with O
mitomycin O
C O
or O
to O
viscocanalostomy O
in O
combination O
with O
phacoemulsification O
and O
intraocular O
lens O
implantation O
. O

Success O
rate O
based O
on O
IOP O
. O

Mean B-Premise
baseline I-Premise
IOP I-Premise
was I-Premise
24.0+/-2.0 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
viscocanalostomy I-Premise
group I-Premise
and I-Premise
23.7+/-2.6 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.7 I-Premise
) I-Premise
. I-Premise
Mean I-Premise
postoperative I-Premise
IOP I-Premise
was I-Premise
13.7+/-2.2 I-Premise
mmHg I-Premise
at I-Premise
3 I-Premise
months I-Premise
, I-Premise
14.8+/-3.3 I-Premise
mmHg I-Premise
at I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
14.9+/-3.0 I-Premise
mmHg I-Premise
at I-Premise
12 I-Premise
months I-Premise
in I-Premise
the I-Premise
viscocanalostomy I-Premise
group I-Premise
and I-Premise
12.1+/-4.0 I-Premise
mmHg I-Premise
at I-Premise
3 I-Premise
months I-Premise
, I-Premise
13.8+/-4.7 I-Premise
mmHg I-Premise
at I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
14.1+/-4.4 I-Premise
mmHg I-Premise
at I-Premise
12 I-Premise
months I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
. I-Premise

There O
was O
no O
significant O
difference O
in O
the O
mean O
IOP O
between O
the O
groups O
at O
any O
time O
. O

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
17 I-Premise
patients I-Premise
( I-Premise
85 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
viscocanalostomy I-Premise
group I-Premise
and I-Premise
16 I-Premise
patients I-Premise
( I-Premise
80 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
achieved I-Premise
an I-Premise
IOP I-Premise
of I-Premise
20 I-Premise
mmHg I-Premise
or I-Premise
less I-Premise
without I-Premise
medication I-Premise
( I-Premise
P I-Premise
= I-Premise
0.7 I-Premise
) I-Premise
. I-Premise

Complications O
included O
2 O
cases O
( O
10 O
% O
) O
of O
flat/shallow O
anterior O
chamber O
and O
4 O
cases O
( O
20 O
% O
) O
of O
hypotony O
in O
the O
trabeculectomy O
group O
, O
whereas O
intraoperative O
microperforation O
of O
Descemet O
's O
membrane O
occurred O
in O
3 O
cases O
( O
15 O
% O
) O
in O
the O
viscocanalostomy O
group O
. O

There B-Claim
was I-Claim
no I-Claim
significant I-Claim
difference I-Claim
in I-Claim
IOP I-Claim
reduction I-Claim
between I-Claim
viscocanalostomy I-Claim
and I-Claim
trabeculectomy I-Claim
with I-Claim
mitomycin I-Claim
C I-Claim
in I-Claim
combination I-Claim
with I-Claim
phacoemulsification I-Claim
and I-Claim
intraocular I-Claim
lens I-Claim
implantation I-Claim
in I-Claim
patients I-Claim
with I-Claim
primary I-Claim
open-angle I-Claim
glaucoma I-Claim
. I-Claim

To O
compare O
intraocular O
pressure O
( O
IOP O
) O
over O
time O
after O
standard O
trabeculectomy O
vs O
Ex-PRESS O
implantation O
in O
patients O
with O
bilateral O
primary O
open-angle O
glaucoma O
( O
POAG O
) O
. O

Prospective O
, O
randomised O
study O
. O

This O
study O
included O
adult O
patients O
with O
bilateral O
POAG O
necessitating O
surgery O
. O

Each O
patient O
underwent O
trabeculectomy O
in O
one O
eye O
and O
Ex-PRESS O
implantation O
under O
a O
scleral O
flap O
in O
the O
other O
eye O
according O
to O
randomised O
contralateral O
allocations O
. O

Efficacy O
was O
assessed O
by O
IOP O
values O
and O
success O
rates O
( O
IOP O
threshold O
and/or O
need O
for O
topical O
glaucoma O
medication O
) O
during O
30 O
months O
. O

Statistical O
analysis O
included O
Generalised O
Estimate O
Equation O
and O
Cox O
Survival O
models O
, O
and O
paired O
t-tests O
. O

Thirty O
eyes O
of O
15 O
patients O
were O
studied O
for O
a O
mean O
of O
23.6 O
months O
( O
SD O
, O
± O
6.9 O
) O
. O

At B-Premise
the I-Premise
last I-Premise
follow-up I-Premise
visit I-Premise
, I-Premise
mean I-Premise
pre-operative I-Premise
IOP I-Premise
decreased I-Premise
from I-Premise
31.1 I-Premise
( I-Premise
± I-Premise
14.2 I-Premise
) I-Premise
to I-Premise
16.2 I-Premise
( I-Premise
± I-Premise
1.5 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
after I-Premise
trabeculectomy I-Premise
, I-Premise
and I-Premise
from I-Premise
28.1 I-Premise
( I-Premise
± I-Premise
9.0 I-Premise
) I-Premise
to I-Premise
15.7 I-Premise
( I-Premise
± I-Premise
1.8 I-Premise
) I-Premise
mm I-Premise
Hg I-Premise
after I-Premise
Ex-PRESS I-Premise
implantation I-Premise
( I-Premise
P=0.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
number I-Premise
of I-Premise
anti-glaucoma I-Premise
medicines I-Premise
prescribed I-Premise
at I-Premise
the I-Premise
last I-Premise
follow-up I-Premise
decreased I-Premise
from I-Premise
3.7 I-Premise
pre-operatively I-Premise
( I-Premise
both I-Premise
groups I-Premise
) I-Premise
to I-Premise
0.9 I-Premise
after I-Premise
trabeculectomy I-Premise
vs I-Premise
0.3 I-Premise
after I-Premise
Ex-PRESS I-Premise
implantation I-Premise
( I-Premise
P=0.001 I-Premise
) I-Premise
. I-Premise

Complete B-Premise
success I-Premise
rates I-Premise
( I-Premise
5 I-Premise
< I-Premise
IOP I-Premise
< I-Premise
18 I-Premise
mm I-Premise
Hg I-Premise
without I-Premise
medications I-Premise
) I-Premise
were I-Premise
higher I-Premise
with I-Premise
Ex-PRESS I-Premise
compared I-Premise
with I-Premise
trabeculectomy I-Premise
( I-Premise
P=0.0024 I-Premise
) I-Premise
. I-Premise

Postoperative B-Premise
complications I-Premise
were I-Premise
more I-Premise
frequent I-Premise
after I-Premise
trabeculectomy I-Premise
( I-Premise
33 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
Ex-PRESS I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
, I-Premise
with I-Premise
four I-Premise
trabeculectomy I-Premise
eyes I-Premise
( I-Premise
27 I-Premise
% I-Premise
) I-Premise
needing I-Premise
postoperative I-Premise
interventions I-Premise
, I-Premise
compared I-Premise
with I-Premise
none I-Premise
with I-Premise
Ex-PRESS I-Premise
. I-Premise

Trabeculectomy B-Claim
and I-Claim
Ex-PRESS I-Claim
implantation I-Claim
provided I-Claim
similar I-Claim
IOP I-Claim
control I-Claim
, I-Claim
but O
the B-Claim
Ex-PRESS I-Claim
group I-Claim
had I-Claim
a I-Claim
lower I-Claim
rate I-Claim
of I-Claim
complications I-Claim
, I-Claim
fewer I-Claim
postoperative I-Claim
interventions I-Claim
, I-Claim
and I-Claim
needed I-Claim
less I-Claim
glaucoma I-Claim
medications I-Claim
. I-Claim

To O
compare O
the O
ocular O
hypotensive O
efficacy O
and O
safety O
of O
topical O
bimatoprost O
and O
timolol-dorzolamide O
combination O
in O
patients O
with O
primary O
open-angle O
glaucoma O
( O
POAG O
) O
or O
ocular O
hypertension O
during O
6 O
months O
of O
treatment O
. O

A O
sample O
of O
65 O
patients O
with O
a O
diagnosis O
of O
POAG O
or O
ocular O
hypertension O
were O
randomized O
to O
receive O
either O
bimatoprost O
0.03 O
% O
once O
daily O
or O
timolol-dorzolamide O
combination O
twice O
daily O
. O

Study O
visits O
occurred O
at O
baseline O
and O
after O
2 O
weeks O
and O
1 O
, O
3 O
and O
6 O
months O
of O
therapy O
. O

Intraocular O
pressure O
( O
IOP O
) O
measurements O
were O
performed O
at O
12.00 O
hours O
at O
all O
study O
visits O
and O
also O
at O
08.00 O
hours O
and O
16.00 O
hours O
at O
baseline O
and O
6-month O
visits O
. O

At O
each O
visit O
, O
local O
and O
systemic O
side-effects O
that O
occurred O
during O
the O
treatment O
period O
were O
recorded O
. O

Student O
's O
t-test O
was O
used O
to O
compare O
the O
differences O
between O
IOP O
values O
. O

Differences O
in O
IOP O
between O
the O
bimatoprost O
and O
timolol-dorzolamide O
groups O
were O
statistically O
insignificant O
at O
all O
study O
visits O
( O
p O
> O
0.05 O
) O
. O

In B-Premise
the I-Premise
bimatoprost-treated I-Premise
group I-Premise
, I-Premise
the I-Premise
IOP I-Premise
reduction I-Premise
was I-Premise
6.2 I-Premise
+/- I-Premise
1.8 I-Premise
mmHg I-Premise
, I-Premise
whereas I-Premise
it I-Premise
was I-Premise
6.5 I-Premise
+/- I-Premise
2.3 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
timolol-dorzolamide I-Premise
group I-Premise
after I-Premise
6 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
. I-Premise

The B-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
p I-Premise
= I-Premise
0.48 I-Premise
) I-Premise
. I-Premise

The B-Premise
IOP-lowering I-Premise
efficacies I-Premise
of I-Premise
bimatoprost I-Premise
and I-Premise
timolol-dorzolamide I-Premise
combination I-Premise
were I-Premise
similar I-Premise
over I-Premise
a I-Premise
6-month I-Premise
follow-up I-Premise
. I-Premise

Both B-Claim
bimatoprost I-Claim
and I-Claim
the I-Claim
timolol-dorzolamide I-Claim
combination I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Bimatoprost B-Claim
can I-Claim
be I-Claim
used I-Claim
as I-Claim
a I-Claim
longterm I-Claim
monotherapy I-Claim
agent I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
POAG I-Claim
and I-Claim
ocular I-Claim
hypertension I-Claim
. I-Claim

To O
compare O
the O
efficacy O
and O
side O
effects O
and O
the O
effect O
on O
aqueous O
humor O
dynamics O
of O
0.005 O
% O
latanoprost O
applied O
topically O
once O
daily O
with O
0.5 O
% O
timolol O
given O
twice O
daily O
for O
12 O
months O
to O
patients O
with O
pigmentary O
glaucoma O
. O

Prospective O
, O
randomized O
, O
double-masked O
, O
clinical O
study O
. O

Thirty-six O
patients O
affected O
with O
bilateral O
pigmentary O
glaucoma O
controlled O
with O
no O
more O
than O
a O
single O
hypotensive O
medication O
were O
enrolled O
in O
the O
study O
. O

The O
sample O
population O
was O
randomly O
divided O
into O
2 O
age- O
and O
gender-matched O
groups O
each O
of O
18 O
patients O
. O

Group O
1 O
received O
0.005 O
% O
latanoprost O
eyedrops O
once O
daily O
and O
the O
vehicle O
( O
placebo O
) O
once O
daily O
";" O
group O
2 O
was O
assigned O
to O
timolol O
0.5 O
% O
eyedrops O
twice O
daily O
. O

Diurnal O
curves O
of O
intraocular O
pressure O
( O
IOP O
) O
were O
performed O
on O
the O
baseline O
day O
and O
after O
0.5 O
, O
3 O
, O
6 O
, O
and O
12 O
months O
of O
treatment O
. O

The O
IOP O
measurements O
were O
performed O
at O
8:00 O
AM O
, O
12:00 O
noon O
, O
4:00 O
PM O
, O
and O
8:00 O
PM O
. O

Outflow O
facility O
( O
C O
) O
was O
measured O
on O
the O
baseline O
day O
and O
on O
the O
last O
day O
of O
the O
study O
with O
a O
Schiotz O
electronic O
tonometer O
. O

A O
two-tailed O
Student O
's O
t O
test O
for O
paired O
or O
unpaired O
data O
was O
used O
for O
statistical O
evaluation O
of O
differences O
between O
treatment O
and O
baseline O
values O
or O
between O
the O
latanoprost O
and O
timolol O
group O
. O

Diurnal O
IOP O
measurements O
were O
compared O
hour O
by O
hour O
. O

Mean O
values O
of O
the O
two O
eyes O
IOP O
and O
C O
were O
used O
for O
analysis O
. O

Compared B-Premise
with I-Premise
baseline I-Premise
measurements I-Premise
, I-Premise
both I-Premise
latanoprost I-Premise
and I-Premise
timolol I-Premise
caused I-Premise
a I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
reduction I-Premise
of I-Premise
IOP I-Premise
at I-Premise
each I-Premise
hour I-Premise
of I-Premise
diurnal I-Premise
curve I-Premise
throughout I-Premise
the I-Premise
duration I-Premise
of I-Premise
therapy I-Premise
. I-Premise

Reduction B-Premise
of I-Premise
IOP I-Premise
was I-Premise
6.0 I-Premise
+/- I-Premise
4.5 I-Premise
and I-Premise
5.9 I-Premise
+/- I-Premise
4.6 I-Premise
with I-Premise
latanoprost I-Premise
and I-Premise
4.8 I-Premise
+/- I-Premise
3.0 I-Premise
and I-Premise
4.6 I-Premise
+/- I-Premise
3.1 I-Premise
with I-Premise
timolol I-Premise
after I-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Comparison B-Premise
of I-Premise
mean I-Premise
diurnal I-Premise
measurements I-Premise
with I-Premise
latanoprost I-Premise
and I-Premise
timolol I-Premise
showed I-Premise
a I-Premise
statistical I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
difference I-Premise
at I-Premise
3 I-Premise
, I-Premise
6 I-Premise
, I-Premise
and I-Premise
12 I-Premise
months I-Premise
. I-Premise

Mean B-Premise
C I-Premise
was I-Premise
found I-Premise
to I-Premise
be I-Premise
significantly I-Premise
enhanced I-Premise
( I-Premise
30 I-Premise
% I-Premise
) I-Premise
only I-Premise
in I-Premise
the I-Premise
latanoprost-treated I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
baseline I-Premise
( I-Premise
P I-Premise
= I-Premise
0.017 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
conjunctival I-Premise
hyperemia I-Premise
was I-Premise
graded I-Premise
at I-Premise
0.3 I-Premise
in I-Premise
latanoprost-treated I-Premise
eyes I-Premise
and I-Premise
0.2 I-Premise
in I-Premise
timolol-treated I-Premise
eyes I-Premise
. I-Premise

A B-Premise
remarkable I-Premise
change I-Premise
in I-Premise
iris I-Premise
color I-Premise
was I-Premise
observed I-Premise
in I-Premise
both I-Premise
eyes I-Premise
of I-Premise
1 I-Premise
of I-Premise
the I-Premise
18 I-Premise
patients I-Premise
treated I-Premise
with I-Premise
latanoprost I-Premise
and I-Premise
none I-Premise
of I-Premise
the I-Premise
18 I-Premise
patients I-Premise
who I-Premise
received I-Premise
timolol I-Premise
. I-Premise

Darkening O
of O
the O
peripheral O
iris O
stroma O
was O
suspected O
in O
two O
patients O
treated O
with O
latanoprost O
. O

In B-Premise
the I-Premise
timolol I-Premise
group I-Premise
, I-Premise
heart I-Premise
rate I-Premise
was I-Premise
significantly I-Premise
reduced I-Premise
from I-Premise
72 I-Premise
+/- I-Premise
9 I-Premise
at I-Premise
baseline I-Premise
to I-Premise
67 I-Premise
+/- I-Premise
10 I-Premise
beats I-Premise
per I-Premise
minute I-Premise
at I-Premise
12 I-Premise
months I-Premise
. I-Premise

Although O
further B-Claim
studies I-Claim
may I-Claim
need I-Claim
to I-Claim
confirm I-Claim
these I-Claim
data I-Claim
on I-Claim
a I-Claim
larger I-Claim
sample I-Claim
and I-Claim
to I-Claim
evaluate I-Claim
the I-Claim
side I-Claim
effect I-Claim
of I-Claim
increased I-Claim
iris I-Claim
pigmentation I-Claim
on I-Claim
long-term I-Claim
follow-up I-Claim
, I-Claim
in B-Claim
patients I-Claim
with I-Claim
pigmentary I-Claim
glaucoma I-Claim
, I-Claim
0.005 I-Claim
% I-Claim
latanoprost I-Claim
taken I-Claim
once I-Claim
daily I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
more I-Claim
effective I-Claim
in I-Claim
reducing I-Claim
IOP I-Claim
than I-Claim
0.5 I-Claim
% I-Claim
timolol I-Claim
taken I-Claim
twice I-Claim
daily I-Claim
. I-Claim

Increased B-Claim
intraocular I-Claim
pressure I-Claim
( I-Claim
IOP I-Claim
) I-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
one I-Claim
of I-Claim
the I-Claim
most I-Claim
important I-Claim
risk I-Claim
factors I-Claim
for I-Claim
developing I-Claim
glaucoma I-Claim
. I-Claim

Yet O
it O
has O
not O
been O
clearly O
demonstrated O
that O
IOP-lowering O
treatment O
can O
reduce O
the O
incidence O
of O
glaucoma O
damage O
in O
patients O
with O
ocular O
hypertension O
. O

The O
aim O
of O
the O
current O
paper O
was O
to O
report O
the O
results O
of O
a O
long-term O
study O
addressing O
this O
very O
problem O
. O

We O
conducted O
a O
randomised O
, O
double-masked O
study O
comparing O
timolol O
and O
placebo O
treatment O
in O
90 O
patients O
with O
ocular O
hypertension O
plus O
some O
additional O
risk O
factor O
. O

Patients O
were O
followed O
at O
3-month O
intervals O
prospectively O
for O
10 O
years O
or O
until O
glaucomatous O
field O
loss O
could O
be O
demonstrated O
with O
computerised O
perimetry O
. O

A O
post-study O
analysis O
was O
performed O
including O
all O
available O
data O
, O
thus O
extending O
maximum O
follow-up O
to O
17 O
years O
. O

After B-Premise
5 I-Premise
years I-Premise
of I-Premise
follow-up I-Premise
eight I-Premise
patients I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
and I-Premise
five I-Premise
patients I-Premise
in I-Premise
the I-Premise
timolol I-Premise
group I-Premise
had I-Premise
developed I-Premise
glaucomatous I-Premise
field I-Premise
loss I-Premise
( I-Premise
NS I-Premise
) I-Premise
";" I-Premise
the B-Premise
corresponding I-Premise
figures I-Premise
after I-Premise
10 I-Premise
years I-Premise
were I-Premise
15 I-Premise
patients I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
and I-Premise
seven I-Premise
patients I-Premise
in I-Premise
the I-Premise
timolol I-Premise
group I-Premise
. I-Premise

Survival B-Premise
analysis I-Premise
showed I-Premise
a I-Premise
tendency I-Premise
but I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
P I-Premise
= I-Premise
0.07 I-Premise
) I-Premise
. I-Premise

Study B-Premise
attrition I-Premise
was I-Premise
large I-Premise
. I-Premise

Eighteen B-Premise
patients I-Premise
in I-Premise
each I-Premise
group I-Premise
had I-Premise
developed I-Premise
glaucomatous I-Premise
field I-Premise
loss I-Premise
when I-Premise
also I-Premise
post-study I-Premise
data I-Premise
were I-Premise
included I-Premise
. I-Premise

IOP B-Premise
reduction I-Premise
was I-Premise
greater I-Premise
in I-Premise
eyes I-Premise
passing I-Premise
the I-Premise
10-year I-Premise
visit I-Premise
without I-Premise
field I-Premise
loss I-Premise
( I-Premise
5.7 I-Premise
mmHg I-Premise
) I-Premise
, I-Premise
than I-Premise
in I-Premise
those I-Premise
that I-Premise
reached I-Premise
an I-Premise
end-point I-Premise
( I-Premise
2.3 I-Premise
mmHg I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.0002 I-Premise
) I-Premise
. I-Premise

In B-Claim
this I-Claim
long-term I-Claim
study I-Claim
we I-Claim
found I-Claim
a I-Claim
tendency I-Claim
but I-Claim
failed I-Claim
to I-Claim
prove I-Claim
a I-Claim
beneficial I-Claim
effect I-Claim
of I-Claim
topical I-Claim
timolol I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
elevated I-Claim
IOP I-Claim
, I-Claim
normal I-Claim
visual I-Claim
fields I-Claim
and I-Claim
some I-Claim
additional I-Claim
risk I-Claim
factor I-Claim
. I-Claim

The B-Premise
intent-to-treat I-Premise
analysis I-Premise
showed I-Premise
no I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

The B-Premise
high I-Premise
attrition I-Premise
shows I-Premise
the I-Premise
difficulties I-Premise
associated I-Premise
with I-Premise
very I-Premise
long I-Premise
follow-up I-Premise
. I-Premise

Trabeculectomy O
is O
a O
commonly O
used O
surgical O
treatment O
for O
glaucoma O
. O

To O
evaluate O
the O
effectiveness O
of O
combination O
of O
permanent O
and O
releasable O
scleral O
flap O
sutures O
to O
minimize O
the O
immediate O
postoperative O
complications O
of O
trabeculectomy O
. O

This O
study O
was O
carried O
out O
in O
Department O
of O
Ophthalmology O
, O
B O
P O
Koirala O
Institute O
of O
Health O
Sciences O
, O
Dharan O
, O
Nepal O
. O

Forty O
one O
eyes O
of O
34 O
patients O
undergoing O
trabeculectomy O
were O
randomized O
to O
undergo O
either O
conventional O
trabeculectomy O
( O
Group O
A= O
20 O
eyes O
) O
or O
trabeculectomy O
with O
combination O
of O
permanent O
and O
releasable O
scleral O
flap O
sutures O
( O
Group O
B O
21 O
eyes O
) O
. O

The O
parameters O
studied O
were O
intraocular O
pressure O
( O
IOP O
) O
, O
anterior O
chamber O
depth O
( O
ACD O
) O
and O
surgical O
complications O
over O
a O
period O
of O
6 O
weeks O
. O

Significantly B-Premise
higher I-Premise
number I-Premise
of I-Premise
eyes I-Premise
belonging I-Premise
to I-Premise
group I-Premise
A I-Premise
( I-Premise
14 I-Premise
eyes I-Premise
) I-Premise
had I-Premise
shallower I-Premise
anterior I-Premise
chamber I-Premise
than I-Premise
group I-Premise
B I-Premise
( I-Premise
7 I-Premise
eyes I-Premise
) I-Premise
on I-Premise
first I-Premise
post I-Premise
operative I-Premise
day I-Premise
( I-Premise
p=0.042 I-Premise
) I-Premise
. I-Premise

Six B-Premise
eyes I-Premise
( I-Premise
30 I-Premise
% I-Premise
) I-Premise
in I-Premise
group I-Premise
A I-Premise
had I-Premise
peripheral I-Premise
or I-Premise
central I-Premise
irido-corneal I-Premise
touch I-Premise
in I-Premise
early I-Premise
postoperative I-Premise
period I-Premise
as I-Premise
compared I-Premise
to I-Premise
only I-Premise
one I-Premise
in I-Premise
Group I-Premise
B. I-Premise
Hypotony B-Premise
was I-Premise
noted I-Premise
in I-Premise
3 I-Premise
eyes I-Premise
in I-Premise
each I-Premise
group I-Premise
. I-Premise

Two O
patients O
in O
group O
A O
required O
reformation O
of O
anterior O
chamber O
. O

Other O
surgical O
complications O
in O
the O
two O
groups O
were O
similar O
. O

Both B-Claim
the I-Claim
groups I-Claim
had I-Claim
a I-Claim
significant I-Claim
drop I-Claim
in I-Claim
IOP I-Claim
following I-Claim
surgery I-Claim
. O

However O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
IOP I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
after I-Premise
6 I-Premise
weeks I-Premise
( I-Premise
Group I-Premise
A I-Premise
: I-Premise
10.95 I-Premise
+/- I-Premise
3.03 I-Premise
mmHg I-Premise
vs. I-Premise
Group I-Premise
B I-Premise
: I-Premise
12.29 I-Premise
+/- I-Premise
4.67 I-Premise
mmHg I-Premise
";" I-Premise
p=0.87 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
drop I-Premise
in I-Premise
IOP I-Premise
following I-Premise
removal I-Premise
of I-Premise
sutures I-Premise
( I-Premise
15.19 I-Premise
+/- I-Premise
6.15 I-Premise
mmHg I-Premise
to I-Premise
13.19 I-Premise
+/- I-Premise
6.13 I-Premise
mmHg I-Premise
";" I-Premise
p=006 I-Premise
) I-Premise
in I-Premise
group I-Premise
B I-Premise
. I-Premise

Use B-Claim
of I-Claim
combination I-Claim
of I-Claim
permanent I-Claim
and I-Claim
releasable I-Claim
scleral I-Claim
flap I-Claim
sutures I-Claim
is I-Claim
a I-Claim
safe I-Claim
technique I-Claim
that I-Claim
significantly I-Claim
reduces I-Claim
the I-Claim
incidence I-Claim
of I-Claim
immediate I-Claim
postoperative I-Claim
shallow I-Claim
anterior I-Claim
chamber I-Claim
after I-Claim
trabeculectomy I-Claim
. I-Claim

To O
compare O
the O
effect O
of O
selective O
laser O
trabeculoplasty O
( O
SLT O
) O
and O
travoprost O
on O
24-hour O
IOP O
fluctuations O
in O
primary O
open-angle O
glaucoma O
( O
POAG O
) O
and O
normal-tension O
glaucoma O
( O
NTG O
) O
. O

Sixty O
eyes O
were O
included O
. O

Sixteen O
and O
14 O
eyes O
of O
POAG O
patients O
were O
randomized O
to O
receive O
360° O
SLT O
or O
0.004 O
% O
travoprost O
, O
respectively O
. O

Fourteen O
and O
16 O
eyes O
of O
NTG O
patients O
were O
randomized O
to O
receive O
either O
SLT O
or O
travoprost O
, O
respectively O
. O

The O
24-hour O
IOP O
data O
were O
collected O
before O
treatment O
and O
6 O
to O
8 O
weeks O
after O
treatment O
. O

IOP O
was O
measured O
at O
2 O
hours O
intervals O
in O
the O
sitting O
position O
during O
daytime O
( O
9 O
AM O
to O
7 O
PM O
) O
and O
in O
the O
supine O
position O
during O
nighttime O
( O
9 O
PM O
to O
7 O
AM O
) O
. O

Main O
outcome O
measure O
was O
the O
percentage O
of O
eyes O
that O
achieved O
posttreatment O
24-hour O
IOP O
fluctuations O
< O
3 O
mm O
Hg O
. O

Success O
in O
fluctuation O
reduction O
was O
defined O
as O
at O
least O
a O
50 O
% O
reduction O
in O
these O
fluctuations O
. O

Fifty-eight O
eyes O
were O
analyzed O
. O

Overall O
, O
eyes B-Premise
in I-Premise
the I-Premise
SLT I-Premise
and I-Premise
the I-Premise
travoprost I-Premise
groups I-Premise
achieved I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
IOP I-Premise
compared I-Premise
with I-Premise
the I-Premise
baseline I-Premise
IOP I-Premise
values I-Premise
( I-Premise
-3.7 I-Premise
mm I-Premise
Hg I-Premise
[ I-Premise
P I-Premise
= I-Premise
0.002 I-Premise
] I-Premise
vs I-Premise
-4.1 I-Premise
mm I-Premise
Hg I-Premise
[ I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
] I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

There O
was O
no O
significant O
difference O
in O
IOP O
reduction O
in O
both O
groups O
according O
to O
type O
of O
glaucoma O
. O

During O
the O
diurnal O
period O
, O
100 O
% O
of O
POAG O
eyes O
in O
the O
travoprost O
group O
achieved O
posttreatment O
IOP O
fluctuations O
< O
3 O
mm O
Hg O
, O
and O
87 O
% O
of O
eyes O
in O
the O
SLT O
group O
achieved O
the O
same O
level O
of O
fluctuations O
( O
P O
< O
0.001 O
) O
. O

Ninety-six B-Premise
percent I-Premise
of I-Premise
NTG I-Premise
eyes I-Premise
in I-Premise
the I-Premise
travoprost I-Premise
group I-Premise
, I-Premise
and I-Premise
82 I-Premise
% I-Premise
of I-Premise
eyes I-Premise
in I-Premise
the I-Premise
SLT I-Premise
group I-Premise
had I-Premise
IOP I-Premise
fluctuations I-Premise
< I-Premise
3 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Success B-Premise
in I-Premise
fluctuation I-Premise
reduction I-Premise
was I-Premise
75 I-Premise
% I-Premise
and I-Premise
92 I-Premise
% I-Premise
for I-Premise
the I-Premise
SLT I-Premise
and I-Premise
travoprost I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
. I-Premise

The B-Claim
effect I-Claim
of I-Claim
travoprost I-Claim
on I-Claim
IOP I-Claim
reduction I-Claim
in I-Claim
POAG I-Claim
and I-Claim
NTG I-Claim
patients I-Claim
was I-Claim
significant I-Claim
both I-Claim
during I-Claim
the I-Claim
daytime I-Claim
and I-Claim
the I-Claim
nighttime I-Claim
, I-Claim
while O
the B-Claim
SLT I-Claim
's I-Claim
effect I-Claim
was I-Claim
significant I-Claim
only I-Claim
during I-Claim
the I-Claim
nighttime I-Claim
. I-Claim

Both B-Claim
travoprost I-Claim
and I-Claim
SLT I-Claim
can I-Claim
significantly I-Claim
reduce I-Claim
the I-Claim
IOP I-Claim
in I-Claim
patients I-Claim
with I-Claim
POAG I-Claim
and I-Claim
NTG I-Claim
. I-Claim

Based O
on O
habitual O
positions O
, O
travoprost B-Claim
better I-Claim
controls I-Claim
IOP I-Claim
fluctuations I-Claim
than I-Claim
SLT I-Claim
, I-Claim
especially I-Claim
during I-Claim
the I-Claim
daytime I-Claim
. I-Claim

To O
compare O
selective O
laser O
trabeculoplasty O
( O
SLT O
) O
and O
argon O
laser O
trabeculoplasty O
( O
ALT O
) O
, O
in O
terms O
of O
intraocular O
pressure O
( O
IOP O
) O
lowering O
, O
in O
patients O
with O
open-angle O
glaucoma O
. O

176 O
eyes O
of O
152 O
patients O
were O
enrolled O
in O
this O
study O
, O
89 O
in O
the O
SLT O
and O
87 O
in O
the O
ALT O
groups O
. O

Patients O
were O
randomised O
to O
receive O
either O
SLT O
or O
ALT O
treatment O
to O
180 O
degrees O
of O
the O
trabecular O
meshwork O
. O

Patients O
were O
followed O
up O
to O
12 O
months O
after O
treatment O
. O

The O
main O
outcome O
measured O
was O
IOP O
lowering O
at O
12 O
months O
after O
treatment O
, O
compared O
between O
the O
SLT O
and O
ALT O
groups O
. O

No B-Premise
significant I-Premise
difference I-Premise
( I-Premise
p I-Premise
= I-Premise
0.846 I-Premise
) I-Premise
was I-Premise
found I-Premise
in I-Premise
mean I-Premise
decrease I-Premise
in I-Premise
IOP I-Premise
between I-Premise
the I-Premise
SLT I-Premise
( I-Premise
5.86 I-Premise
mm I-Premise
Hg I-Premise
) I-Premise
and I-Premise
ALT I-Premise
( I-Premise
6.04 I-Premise
mm I-Premise
Hg I-Premise
) I-Premise
groups I-Premise
at I-Premise
1 I-Premise
year I-Premise
or I-Premise
at I-Premise
any I-Premise
other I-Premise
time I-Premise
points I-Premise
, I-Premise
nor I-Premise
were I-Premise
there I-Premise
any I-Premise
significant I-Premise
differences I-Premise
in I-Premise
the I-Premise
rate I-Premise
of I-Premise
early I-Premise
or I-Premise
late I-Premise
complications I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

SLT B-Claim
is I-Claim
equivalent I-Claim
to I-Claim
ALT I-Claim
in I-Claim
terms I-Claim
of I-Claim
IOP I-Claim
lowering I-Claim
at I-Claim
1 I-Claim
year I-Claim
, I-Claim
and I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
procedure I-Claim
for I-Claim
patients I-Claim
with I-Claim
open-angle I-Claim
glaucoma I-Claim
. I-Claim

Many O
physicians O
recommend O
either O
brimonidine O
or O
latanoprost O
as O
firstline O
therapy O
for O
chronic O
open-angle O
glaucoma O
or O
ocular O
hypertension O
. O

However O
, O
a O
search O
of O
MEDLINE O
indicates O
that O
there O
have O
been O
few O
head-to-head O
comparisons O
of O
the O
2 O
monotherapies O
in O
a O
clinical O
setting O
. O

This O
study O
compared O
the O
clinical O
efficacy O
and O
tolerability O
of O
brimonidine O
0.2 O
% O
twice O
daily O
with O
those O
of O
latanoprost O
0.005 O
% O
once O
daily O
as O
monotherapy O
in O
patients O
with O
open-angle O
glaucoma O
or O
ocular O
hypertension O
. O

In O
this O
3-month O
, O
multicenter O
, O
double-masked O
, O
parallel-group O
, O
4-visit O
study O
, O
treatment-naive O
and O
previously O
treated O
patients O
with O
open-angle O
glaucoma O
or O
ocular O
hypertension O
and O
bilateral O
intraocular O
pressure O
( O
IOP O
) O
after O
washout O
of O
between O
22 O
and O
34 O
mm O
Hg O
were O
randomized O
to O
receive O
either O
brimonidine O
or O
latanoprost O
. O

Patients O
who O
had O
received O
previous O
treatment O
with O
either O
study O
drug O
were O
excluded O
from O
the O
study O
. O

The O
primary O
outcome O
measure O
was O
response O
rate O
, O
defined O
as O
the O
percentage O
of O
patients O
achieving O
> O
or O
= O
20 O
% O
reduction O
in O
IOP O
from O
baseline O
to O
month O
3 O
. O

Secondary O
outcome O
measures O
were O
mean O
IOP O
reduction O
from O
baseline O
to O
month O
3 O
and O
clinical O
success O
, O
defined O
as O
the O
investigator O
's O
recommendation O
that O
the O
patient O
continue O
using O
the O
assigned O
study O
medication O
. O

A O
total O
of O
127 O
patients O
( O
55 O
treatment O
naive O
) O
were O
enrolled O
, O
66 O
in O
the O
brimonidine O
group O
and O
61 O
in O
the O
latanoprost O
group O
. O

After B-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
, I-Premise
80 I-Premise
% I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
brimonidine I-Premise
group I-Premise
and I-Premise
74 I-Premise
% I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
had I-Premise
achieved I-Premise
> I-Premise
or I-Premise
= I-Premise
20 I-Premise
% I-Premise
reduction I-Premise
in I-Premise
IOP I-Premise
from I-Premise
baseline I-Premise
. I-Premise

The B-Premise
mean I-Premise
reduction I-Premise
in I-Premise
IOP I-Premise
from I-Premise
baseline I-Premise
at I-Premise
month I-Premise
3 I-Premise
was I-Premise
6.8 I-Premise
mm I-Premise
Hg I-Premise
with I-Premise
brimonidine I-Premise
and I-Premise
6.5 I-Premise
mm I-Premise
Hg I-Premise
with I-Premise
latanoprost I-Premise
( I-Premise
27.8 I-Premise
% I-Premise
vs I-Premise
27.0 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Among B-Premise
treatment-naive I-Premise
patients I-Premise
, I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
percentage I-Premise
of I-Premise
brimonidine-treated I-Premise
patients I-Premise
achieved I-Premise
> I-Premise
or I-Premise
= I-Premise
20 I-Premise
% I-Premise
decrease I-Premise
in I-Premise
IOP I-Premise
compared I-Premise
with I-Premise
latanoprost-treated I-Premise
patients I-Premise
( I-Premise
88 I-Premise
% I-Premise
vs I-Premise
59 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

In B-Premise
previously I-Premise
treated I-Premise
patients I-Premise
, I-Premise
a I-Premise
higher I-Premise
percentage I-Premise
of I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
achieved I-Premise
> I-Premise
or I-Premise
= I-Premise
20 I-Premise
% I-Premise
reduction I-Premise
in I-Premise
IOP I-Premise
compared I-Premise
with I-Premise
the I-Premise
brimonidine I-Premise
group I-Premise
( I-Premise
88 I-Premise
% I-Premise
vs I-Premise
74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
";" I-Premise
however B-Premise
, I-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

Significantly B-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
brimonidine I-Premise
group I-Premise
achieved I-Premise
clinical I-Premise
success I-Premise
at I-Premise
month I-Premise
3 I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
latanoprost I-Premise
group I-Premise
( I-Premise
91 I-Premise
% I-Premise
vs I-Premise
74 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

At B-Premise
peak I-Premise
effect I-Premise
, I-Premise
brimonidine I-Premise
twice I-Premise
daily I-Premise
was I-Premise
as I-Premise
effective I-Premise
as I-Premise
latanoprost I-Premise
once I-Premise
daily I-Premise
in I-Premise
lowering I-Premise
IOP I-Premise
. I-Premise

In B-Premise
treatment-naive I-Premise
patients I-Premise
, I-Premise
latanoprost I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
rate I-Premise
of I-Premise
nonresponse I-Premise
after I-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
compared I-Premise
with I-Premise
brimonidine I-Premise
. I-Premise

This B-Claim
suggests I-Claim
that I-Claim
brimonidine I-Claim
may I-Claim
be I-Claim
the I-Claim
more I-Claim
reliable I-Claim
choice I-Claim
for I-Claim
first-line I-Claim
therapy I-Claim
of I-Claim
newly I-Claim
diagnosed I-Claim
open-angle I-Claim
glaucoma I-Claim
or I-Claim
ocular I-Claim
hypertension I-Claim
. I-Claim

In B-Premise
previously I-Premise
treated I-Premise
patients I-Premise
, I-Premise
however I-Premise
, I-Premise
latanoprost I-Premise
provided I-Premise
greater I-Premise
mean I-Premise
IOP I-Premise
reduction I-Premise
than I-Premise
did I-Premise
brimonidine I-Premise
. I-Premise

Significantly B-Claim
more I-Claim
patients I-Claim
achieved I-Claim
clinical I-Claim
success I-Claim
with I-Claim
brimonidine I-Claim
monotherapy I-Claim
than I-Claim
with I-Claim
latanoprost I-Claim
monotherapy I-Claim
. I-Claim

To O
assess O
the O
long-term O
safety O
and O
efficacy O
of O
a O
single O
trabecular O
micro-bypass O
stent O
with O
concomitant O
cataract O
surgery O
versus O
cataract O
surgery O
alone O
for O
mild O
to O
moderate O
open-angle O
glaucoma O
. O

Twenty-nine O
investigational O
sites O
, O
United O
States O
. O

Prospective O
randomized O
controlled O
multicenter O
clinical O
trial O
. O

Eyes O
with O
mild O
to O
moderate O
glaucoma O
with O
an O
unmedicated O
intraocular O
pressure O
( O
IOP O
) O
of O
22 O
mm O
Hg O
or O
higher O
and O
36 O
mm O
Hg O
or O
lower O
were O
randomly O
assigned O
to O
have O
cataract O
surgery O
with O
iStent O
trabecular O
micro-bypass O
stent O
implantation O
( O
stent O
group O
) O
or O
cataract O
surgery O
alone O
( O
control O
group O
) O
. O

Patients O
were O
followed O
for O
24 O
months O
postoperatively O
. O

The B-Premise
incidence I-Premise
of I-Premise
adverse I-Premise
events I-Premise
was I-Premise
low I-Premise
in I-Premise
both I-Premise
groups I-Premise
through I-Premise
24 I-Premise
months I-Premise
of I-Premise
follow-up I-Premise
. I-Premise

At B-Premise
24 I-Premise
months I-Premise
, I-Premise
the I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
with I-Premise
an I-Premise
IOP I-Premise
of I-Premise
21 I-Premise
mm I-Premise
Hg I-Premise
or I-Premise
lower I-Premise
without I-Premise
ocular I-Premise
hypotensive I-Premise
medications I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
stent I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P=.036 I-Premise
) I-Premise
. I-Premise

Overall O
, O
the B-Premise
mean I-Premise
IOP I-Premise
was I-Premise
stable I-Premise
between I-Premise
12 I-Premise
months I-Premise
and I-Premise
24 I-Premise
months I-Premise
( I-Premise
17.0 I-Premise
mm I-Premise
Hg I-Premise
± I-Premise
2.8 I-Premise
[ I-Premise
SD I-Premise
] I-Premise
and I-Premise
17.1 I-Premise
± I-Premise
2.9 I-Premise
mm I-Premise
Hg I-Premise
, I-Premise
respectively I-Premise
) I-Premise
in I-Premise
the I-Premise
stent I-Premise
group I-Premise
but I-Premise
increased I-Premise
( I-Premise
17.0 I-Premise
± I-Premise
3.1 I-Premise
mm I-Premise
Hg I-Premise
to I-Premise
17.8 I-Premise
± I-Premise
3.3 I-Premise
mm I-Premise
Hg I-Premise
, I-Premise
respectively I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Ocular B-Premise
hypotensive I-Premise
medication I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
stent I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
";" I-Premise
it I-Premise
was I-Premise
also I-Premise
lower I-Premise
at I-Premise
24 I-Premise
months I-Premise
, I-Premise
although I-Premise
the I-Premise
difference I-Premise
was I-Premise
no I-Premise
longer I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

Patients B-Claim
with I-Claim
combined I-Claim
single I-Claim
trabecular I-Claim
micro-bypass I-Claim
stent I-Claim
and I-Claim
cataract I-Claim
surgery I-Claim
had I-Claim
significantly I-Claim
better I-Claim
IOP I-Claim
control I-Claim
on I-Claim
no I-Claim
medication I-Claim
through I-Claim
24 I-Claim
months I-Claim
than I-Claim
patients I-Claim
having I-Claim
cataract I-Claim
surgery I-Claim
alone I-Claim
. I-Claim

Both B-Claim
groups I-Claim
had I-Claim
a I-Claim
similar I-Claim
favorable I-Claim
long-term I-Claim
safety I-Claim
profile I-Claim
. I-Claim

To O
determine O
if O
postoperative O
topical O
cyclosporine O
0.05 O
% O
has O
any O
beneficial O
effect O
following O
trabeculectomy O
. O

This O
was O
an O
interventional O
, O
randomized O
, O
prospective O
, O
double-masked O
clinical O
trial O
of O
44 O
consecutive O
patients O
with O
uncontrolled O
glaucoma O
requiring O
filtration O
surgery O
. O

Ocular O
surface O
disease O
index O
questionnaire O
and O
comprehensive O
ocular O
exam O
, O
including O
Schirmer O
's O
tear O
test O
1 O
, O
were O
performed O
. O

Patients O
underwent O
routine O
trabeculectomy O
, O
with O
or O
without O
phacoemulsification O
. O

The O
study O
group O
( O
n O
= O
22 O
) O
received O
cyclosporine O
0.05 O
% O
, O
and O
the O
control O
group O
( O
n O
= O
22 O
) O
received O
artificial O
tears O
. O

Patients O
were O
evaluated O
at O
1 O
and O
6 O
months O
post O
surgery O
. O

Outcome O
measures O
were O
intraocular O
pressure O
, O
success O
rate O
, O
bleb O
appearance O
, O
ocular O
surface O
disease O
index O
, O
Schirmer O
's O
tear O
test O
1 O
and O
conjunctival O
inflammation O
. O

Thirty-nine O
patients O
completed O
the O
study O
( O
19 O
in O
the O
study O
group O
, O
20 O
in O
the O
control O
group O
) O
. O

The B-Premise
mean I-Premise
baseline I-Premise
intraocular I-Premise
pressure I-Premise
was I-Premise
23.8 I-Premise
+/- I-Premise
12.6 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
study I-Premise
group I-Premise
and I-Premise
25.9 I-Premise
+/- I-Premise
10.6 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.513 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
intraocular I-Premise
pressure I-Premise
at I-Premise
postoperative I-Premise
month I-Premise
6 I-Premise
was I-Premise
14.88 I-Premise
+/- I-Premise
6.2 I-Premise
and I-Premise
14.62 I-Premise
+/- I-Premise
5.46 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
study I-Premise
group I-Premise
and I-Premise
control I-Premise
group I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
0.837 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
mean I-Premise
values I-Premise
of I-Premise
Schirmer I-Premise
's I-Premise
tear I-Premise
test I-Premise
1 I-Premise
and I-Premise
the I-Premise
level I-Premise
of I-Premise
conjunctival I-Premise
hyperaemia I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
at I-Premise
baseline I-Premise
, I-Premise
months I-Premise
1 I-Premise
and I-Premise
6 I-Premise
post I-Premise
surgery I-Premise
. I-Premise

The B-Premise
treatment I-Premise
group I-Premise
had I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
ocular I-Premise
surface I-Premise
disease I-Premise
index I-Premise
score I-Premise
at I-Premise
6 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
, I-Premise
indicating I-Premise
less I-Premise
severity I-Premise
of I-Premise
dry I-Premise
eye I-Premise
symptoms I-Premise
and I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
ocular I-Premise
pain I-Premise
. I-Premise

Topical B-Claim
cyclosporine I-Claim
0.05 I-Claim
% I-Claim
had I-Claim
no I-Claim
effect I-Claim
on I-Claim
postoperative I-Claim
bleb I-Claim
function I-Claim
and I-Claim
intraocular I-Claim
pressure I-Claim
following I-Claim
trabeculectomy I-Claim
, I-Claim
but I-Claim
improved I-Claim
subjective I-Claim
ocular I-Claim
surface I-Claim
symptoms I-Claim
in I-Claim
these I-Claim
patients I-Claim
. I-Claim

To O
compare O
the O
efficacy O
and O
safety O
of O
0.0015 O
% O
tafluprost O
ophthalmic O
solution O
( O
Tafluprost O
) O
with O
Placebo O
ophthalmic O
solution O
( O
Placebo O
) O
in O
normal O
tension O
glaucoma O
( O
NTG O
) O
. O

Total O
of O
94 O
patients O
enrolled O
in O
a O
randomized O
, O
double-blind O
, O
parallel-group O
and O
multicenter O
study O
. O

Patients O
with O
NTG O
were O
randomly O
assigned O
to O
either O
Tafluprost O
or O
Placebo O
. O

Both O
ophthalmic O
solutions O
were O
instilled O
once O
a O
day O
in O
the O
morning O
for O
4 O
weeks O
. O

Mean B-Premise
intraocular I-Premise
pressure I-Premise
( I-Premise
IOP I-Premise
) I-Premise
changes I-Premise
from I-Premise
baseline I-Premise
were I-Premise
-4.0 I-Premise
+/- I-Premise
1.7 I-Premise
mmHg I-Premise
in I-Premise
Tafluprost I-Premise
administered I-Premise
patients I-Premise
and I-Premise
-1.4 I-Premise
+/- I-Premise
1.8 I-Premise
mmHg I-Premise
in I-Premise
Placebo I-Premise
administered I-Premise
patients I-Premise
at I-Premise
4 I-Premise
weeks I-Premise
, I-Premise
with I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

IOP B-Premise
change I-Premise
at I-Premise
4 I-Premise
weeks I-Premise
, I-Premise
% I-Premise
IOP I-Premise
reduction I-Premise
at I-Premise
2 I-Premise
and I-Premise
4 I-Premise
weeks I-Premise
were I-Premise
also I-Premise
significantly I-Premise
greater I-Premise
in I-Premise
Tafluprost I-Premise
than I-Premise
in I-Premise
Placebo I-Premise
. I-Premise

A B-Premise
total I-Premise
of I-Premise
51.0 I-Premise
% I-Premise
in I-Premise
Tafluprost I-Premise
treated I-Premise
group I-Premise
and I-Premise
8.9 I-Premise
% I-Premise
in I-Premise
Placebo I-Premise
treated I-Premise
group I-Premise
reported I-Premise
adverse I-Premise
drug I-Premise
reactions I-Premise
. I-Premise

These B-Claim
results I-Claim
indicate I-Claim
that I-Claim
Tafluprost I-Claim
is I-Claim
clinically I-Claim
useful I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
NTG I-Claim
. I-Claim

To O
compare O
the O
intraocular O
pressure O
( O
IOP O
) O
-lowering O
effect O
and O
safety O
of O
topical O
brimonidine O
to O
that O
of O
timolol O
, O
and O
to O
study O
the O
additive O
effect O
of O
topical O
brimonidine O
to O
topical O
prostaglandin O
( O
PG O
) O
analogues O
in O
475 O
patients O
with O
either O
ocular O
hypertension O
or O
primary O
open O
angle O
glaucoma O
. O

The O
primary O
endpoint O
was O
the O
mean O
IOP O
change O
from O
the O
baseline O
at O
0 O
and O
2 O
hours O
at O
week O
4 O
. O

The B-Premise
mean I-Premise
changes I-Premise
were I-Premise
-4.7 I-Premise
+/- I-Premise
2.1 I-Premise
( I-Premise
S. I-Premise
D. I-Premise
) I-Premise
in I-Premise
the I-Premise
timolol I-Premise
and I-Premise
-4.0 I-Premise
+/- I-Premise
2.0 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
brimonidine I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0138 I-Premise
) I-Premise
. I-Premise

The B-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
of I-Premise
the I-Premise
inter-group I-Premise
difference I-Premise
was I-Premise
greater I-Premise
than I-Premise
the I-Premise
pre-determined I-Premise
criterion I-Premise
of I-Premise
non-inferiority I-Premise
of I-Premise
brimonidine I-Premise
to I-Premise
timolol I-Premise
. I-Premise

When B-Premise
added I-Premise
to I-Premise
PG I-Premise
analogues I-Premise
, I-Premise
the I-Premise
IOP-lowering I-Premise
effect I-Premise
of I-Premise
brimonidine I-Premise
( I-Premise
-2.9 I-Premise
+/- I-Premise
1.8 I-Premise
mmHg I-Premise
) I-Premise
was I-Premise
greater I-Premise
than I-Premise
that I-Premise
of I-Premise
the I-Premise
placebo I-Premise
( I-Premise
-2.1 I-Premise
+/- I-Premise
1.8 I-Premise
mmHg I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0010 I-Premise
) I-Premise
. I-Premise

No O
appreciable O
adverse O
side O
effects O
were O
encountered O
. O

Topical B-Claim
brimonidine I-Claim
showed I-Claim
an I-Claim
additive I-Claim
IOP-lowering I-Claim
effect I-Claim
to I-Claim
topical I-Claim
PG I-Claim
analogues I-Claim
, I-Claim
although B-Claim
its I-Claim
IOP-lowering I-Claim
effect I-Claim
was I-Claim
inferior I-Claim
to I-Claim
topical I-Claim
timolol I-Claim
as I-Claim
monotherapy I-Claim
. I-Claim

To O
evaluate O
the O
intraocular O
pressure-lowering O
efficacy O
and O
safety O
of O
travoprost O
0.0015 O
% O
and O
0.004 O
% O
, O
dosed O
daily O
in O
the O
evening O
compared O
with O
vehicle O
, O
in O
patients O
with O
open-angle O
glaucoma O
or O
ocular O
hypertension O
, O
whose O
intraocular O
pressure O
was O
not O
adequately O
controlled O
on O
timolol O
0.5 O
% O
twice O
daily O
( O
twice O
daily O
) O
. O

Subjects O
who O
qualified O
at O
screening O
began O
a O
run-in O
period O
dosing O
timolol O
twice O
daily O
for O
3 O
weeks O
. O

If O
the O
subjects O
had O
an O
intraocular O
pressure O
of O
24 O
to O
36 O
mm O
Hg O
at O
8 O
AM O
and O
21 O
to O
36 O
mm O
Hg O
at O
10 O
AM O
and O
4 O
pm O
in O
at O
least O
one O
eye O
on O
timolol O
, O
they O
were O
randomized O
to O
one O
of O
two O
concentrations O
of O
travoprost O
( O
0.0015 O
% O
or O
0.004 O
% O
) O
or O
vehicle O
solution O
every O
day O
and O
were O
followed O
for O
6 O
months O
. O

Four O
hundred O
twenty-six O
subjects O
were O
randomized O
. O

The O
mean O
intraocular O
pressure O
at O
8 O
AM O
, O
10 O
AM O
, O
and O
4 O
PM O
in O
the O
patient O
's O
eye O
with O
the O
higher O
intraocular O
pressure O
was O
used O
for O
the O
analysis O
. O

Mean B-Premise
baseline I-Premise
values I-Premise
( I-Premise
25 I-Premise
mm I-Premise
Hg I-Premise
) I-Premise
for I-Premise
subjects I-Premise
at I-Premise
eligibility I-Premise
( I-Premise
while I-Premise
maintained I-Premise
on I-Premise
timolol I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
among I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

The B-Premise
intraocular I-Premise
pressure I-Premise
was I-Premise
lowered I-Premise
an I-Premise
additional I-Premise
-5.7 I-Premise
to I-Premise
-7.2 I-Premise
mm I-Premise
Hg I-Premise
and I-Premise
-5.1 I-Premise
to I-Premise
-6.7 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
travoprost I-Premise
0.004 I-Premise
% I-Premise
and I-Premise
0.0015 I-Premise
% I-Premise
concentrations I-Premise
, I-Premise
respectively I-Premise
. I-Premise

These B-Premise
changes I-Premise
were I-Premise
significantly I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
=.0001 I-Premise
) I-Premise
different I-Premise
from I-Premise
the I-Premise
vehicle I-Premise
group I-Premise
( I-Premise
-1.3 I-Premise
to I-Premise
-2.8 I-Premise
mm I-Premise
Hg I-Premise
) I-Premise
. I-Premise

The B-Premise
intraocular I-Premise
pressure I-Premise
range I-Premise
on I-Premise
treatment I-Premise
at I-Premise
all I-Premise
visit I-Premise
times I-Premise
over I-Premise
the I-Premise
6-month I-Premise
treatment I-Premise
period I-Premise
ranged I-Premise
from I-Premise
17.9 I-Premise
to I-Premise
19.2 I-Premise
mm I-Premise
Hg I-Premise
for I-Premise
travoprost I-Premise
0.004 I-Premise
% I-Premise
and I-Premise
18.3 I-Premise
to I-Premise
20.1 I-Premise
mm I-Premise
Hg I-Premise
for I-Premise
travoprost I-Premise
0.0015 I-Premise
% I-Premise
compared I-Premise
with I-Premise
22.4 I-Premise
to I-Premise
24.1 I-Premise
mm I-Premise
Hg I-Premise
for I-Premise
vehicle I-Premise
. I-Premise

Average B-Premise
hyperemia I-Premise
scores I-Premise
ranged I-Premise
from I-Premise
trace I-Premise
to I-Premise
mild I-Premise
( I-Premise
mean I-Premise
0.5 I-Premise
on I-Premise
a I-Premise
scale I-Premise
of I-Premise
0 I-Premise
= I-Premise
none/trace I-Premise
";" I-Premise
1= I-Premise
mild I-Premise
";" I-Premise
2 I-Premise
= I-Premise
moderate I-Premise
";" I-Premise
3 I-Premise
= I-Premise
severe I-Premise
) I-Premise
for I-Premise
all I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

No B-Premise
iris I-Premise
pigmentation I-Premise
changes I-Premise
were I-Premise
observed I-Premise
in I-Premise
any I-Premise
patient I-Premise
during I-Premise
this I-Premise
study I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
clinically I-Premise
or I-Premise
statistically I-Premise
significant I-Premise
changes I-Premise
from I-Premise
baseline I-Premise
in I-Premise
visual I-Premise
acuity I-Premise
, I-Premise
ocular I-Premise
cells I-Premise
and I-Premise
flare I-Premise
, I-Premise
fundus I-Premise
parameter I-Premise
, I-Premise
cup-to-disk I-Premise
ratio I-Premise
and I-Premise
visual I-Premise
field I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
reported I-Premise
for I-Premise
any I-Premise
treatment I-Premise
group I-Premise
. I-Premise

Travoprost B-Claim
produced I-Claim
clinically I-Claim
relevant I-Claim
and I-Claim
statistically I-Claim
significant I-Claim
additional I-Claim
intraocular I-Claim
pressure I-Claim
reductions I-Claim
from I-Claim
baseline I-Claim
when I-Claim
used I-Claim
adjunctively I-Claim
with I-Claim
timolol I-Claim
in I-Claim
subjects I-Claim
with I-Claim
open-angle I-Claim
glaucoma I-Claim
or I-Claim
ocular I-Claim
hypertension I-Claim
. I-Claim

To O
compare O
the O
short- O
and O
intermediate-term O
results O
of O
two O
commonly O
used O
glaucoma O
surgical O
procedures O
, O
trabeculectomy O
and O
Ahmed O
glaucoma O
valve O
implant O
. O

A O
randomized O
clinical O
trial O
was O
performed O
at O
two O
international O
centers O
. O

One O
eye O
each O
of O
consecutive O
patients O
requiring O
glaucoma O
surgery O
for O
intraocular O
pressure O
control O
was O
randomized O
to O
receive O
either O
trabeculectomy O
or O
the O
Ahmed O
implant O
. O

Of O
the O
117 O
patients O
, O
62 O
were O
randomized O
to O
trabeculectomy O
and O
55 O
to O
the O
Ahmed O
implant O
. O

With B-Premise
a I-Premise
mean I-Premise
follow-up I-Premise
of I-Premise
9.7 I-Premise
months I-Premise
, I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
had I-Premise
statistically I-Premise
lower I-Premise
intraocular I-Premise
pressures I-Premise
at I-Premise
weeks I-Premise
6 I-Premise
to I-Premise
15 I-Premise
( I-Premise
12.6 I-Premise
mm I-Premise
Hg I-Premise
vs I-Premise
16.4 I-Premise
mm I-Premise
Hg I-Premise
) I-Premise
and I-Premise
months I-Premise
11 I-Premise
to I-Premise
13 I-Premise
( I-Premise
11.4 I-Premise
mm I-Premise
Hg I-Premise
vs I-Premise
17.2 I-Premise
mm I-Premise
Hg I-Premise
) I-Premise
than I-Premise
the I-Premise
Ahmed I-Premise
implant I-Premise
group I-Premise
. I-Premise

Compared B-Premise
with I-Premise
preoperative I-Premise
status I-Premise
, I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
were I-Premise
noted I-Premise
for I-Premise
visual I-Premise
acuity I-Premise
, I-Premise
visual I-Premise
field I-Premise
, I-Premise
lens I-Premise
status I-Premise
, I-Premise
and I-Premise
final I-Premise
anterior I-Premise
chamber I-Premise
depth I-Premise
. I-Premise

The B-Premise
cumulative I-Premise
probabilities I-Premise
of I-Premise
success I-Premise
( I-Premise
intraocular I-Premise
pressure I-Premise
< I-Premise
21 I-Premise
mm I-Premise
Hg I-Premise
and I-Premise
at I-Premise
least I-Premise
15 I-Premise
% I-Premise
reduction I-Premise
in I-Premise
intraocular I-Premise
pressure I-Premise
from I-Premise
preoperative I-Premise
level I-Premise
) I-Premise
were I-Premise
83.6 I-Premise
% I-Premise
for I-Premise
trabeculectomy I-Premise
and I-Premise
88.1 I-Premise
% I-Premise
for I-Premise
Ahmed I-Premise
implant I-Premise
( I-Premise
P I-Premise
=.43 I-Premise
) I-Premise
. I-Premise

However O
, O
the B-Premise
Ahmed I-Premise
implant I-Premise
group I-Premise
had I-Premise
a I-Premise
greater I-Premise
adjunctive I-Premise
medication I-Premise
requirement I-Premise
. I-Premise

On B-Premise
the I-Premise
last I-Premise
visit I-Premise
, I-Premise
10 I-Premise
of I-Premise
the I-Premise
trabeculectomy I-Premise
eyes I-Premise
and I-Premise
19 I-Premise
of I-Premise
the I-Premise
Ahmed I-Premise
implant I-Premise
eyes I-Premise
required I-Premise
at I-Premise
least I-Premise
one I-Premise
topical I-Premise
medication I-Premise
( I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
rate I-Premise
of I-Premise
complications I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

Lower B-Premise
mean I-Premise
intraocular I-Premise
pressures I-Premise
were I-Premise
noted I-Premise
for I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
. I-Premise

All B-Premise
other I-Premise
results I-Premise
, I-Premise
including I-Premise
success I-Premise
( I-Premise
as I-Premise
defined I-Premise
in I-Premise
this I-Premise
study I-Premise
) I-Premise
and I-Premise
frequency I-Premise
of I-Premise
complications I-Premise
, I-Premise
were I-Premise
comparable I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

To O
compare O
the O
intraocular O
pressure O
( O
IOP O
) O
reducing O
effect O
and O
safety O
of O
latanoprost O
0.005 O
% O
once O
daily O
with O
unoprostone O
0.12 O
% O
twice O
daily O
in O
patients O
with O
primary O
open-angle O
glaucoma O
( O
POAG O
) O
or O
ocular O
hypertension O
( O
OH O
) O
. O

An O
8-week O
, O
double-masked O
, O
randomized O
, O
parallel-group O
, O
single-center O
clinical O
trial O
. O

A O
total O
of O
108 O
patients O
with O
POAG O
or O
OH O
were O
enrolled O
. O

After O
completing O
a O
wash-out O
of O
ocular O
hypotensive O
medications O
, O
patients O
were O
randomized O
to O
receive O
either O
latanoprost O
once O
daily O
in O
the O
evening O
plus O
placebo O
once O
daily O
in O
the O
morning O
, O
or O
unoprostone O
twice O
daily O
( O
morning O
and O
evening O
) O
. O

IOP O
was O
measured O
at O
10:00 O
AM O
and O
at O
5:00 O
PM O
at O
baseline O
and O
at O
week O
8 O
, O
and O
before O
12:00 O
noon O
at O
week O
2 O
. O

Ocular O
and O
systemic O
safety O
assessments O
were O
performed O
. O

From B-Premise
an I-Premise
overall I-Premise
baseline I-Premise
of I-Premise
24.1 I-Premise
mmHg I-Premise
, I-Premise
latanoprost I-Premise
reduced I-Premise
IOP I-Premise
by I-Premise
6.7 I-Premise
mmHg I-Premise
( I-Premise
28 I-Premise
% I-Premise
) I-Premise
and I-Premise
unoprostone I-Premise
reduced I-Premise
IOP I-Premise
by I-Premise
3.3 I-Premise
mmHg I-Premise
( I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
difference I-Premise
between I-Premise
the I-Premise
groups I-Premise
of I-Premise
3.4 I-Premise
mmHg I-Premise
was I-Premise
significant I-Premise
( I-Premise
P I-Premise
: I-Premise
< I-Premise
0.001 I-Premise
, I-Premise
analysis I-Premise
of I-Premise
covariance I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
: I-Premise
-4.7 I-Premise
to I-Premise
-2.1 I-Premise
) I-Premise
in I-Premise
favor I-Premise
of I-Premise
latanoprost I-Premise
. I-Premise

A B-Premise
> I-Premise
/=30 I-Premise
% I-Premise
reduction I-Premise
in I-Premise
mean I-Premise
IOP I-Premise
from I-Premise
baseline I-Premise
was I-Premise
achieved I-Premise
by I-Premise
44 I-Premise
% I-Premise
of I-Premise
latanoprost-treated I-Premise
patients I-Premise
compared I-Premise
with I-Premise
8 I-Premise
% I-Premise
of I-Premise
unoprostone-treated I-Premise
patients I-Premise
. I-Premise

The O
incidence O
of O
adverse O
events O
was O
low O
and O
comparable O
between O
the O
groups O
. O

Latanoprost B-Claim
administered I-Claim
once I-Claim
daily I-Claim
was I-Claim
significantly I-Claim
more I-Claim
effective I-Claim
in I-Claim
reducing I-Claim
IOP I-Claim
compared I-Claim
with I-Claim
unoprostone I-Claim
administered I-Claim
twice I-Claim
daily I-Claim
in I-Claim
patients I-Claim
with I-Claim
POAG I-Claim
and I-Claim
OH I-Claim
. I-Claim

To O
compare O
the O
efficacy O
and O
safety O
of O
latanoprost O
versus O
timolol O
in O
pediatric O
patients O
with O
glaucoma O
. O

Prospective O
, O
randomized O
, O
double-masked O
, O
12-week O
, O
multicenter O
study O
. O

Individuals O
aged O
< O
18 O
years O
with O
glaucoma O
. O

Stratified O
by O
age O
, O
diagnosis O
, O
and O
intraocular O
pressure O
( O
IOP O
) O
level O
, O
subjects O
were O
randomized O
( O
1:1 O
) O
to O
latanoprost O
vehicle O
at O
8 O
am O
and O
latanoprost O
0.005 O
% O
at O
8 O
pm O
or O
timolol O
0.5 O
% O
( O
0.25 O
% O
for O
those O
aged O
< O
3 O
years O
) O
twice O
daily O
( O
8 O
am O
, O
8 O
pm O
) O
. O

At O
baseline O
and O
weeks O
1 O
, O
4 O
, O
and O
12 O
, O
IOP O
and O
ocular O
safety O
were O
assessed O
and O
adverse O
events O
were O
recorded O
. O

Therapy O
was O
switched O
to O
open-label O
latanoprost O
pm O
and O
timolol O
am O
and O
pm O
for O
uncontrolled O
IOP O
. O

Mean O
IOP O
reduction O
from O
baseline O
to O
week O
12 O
. O

Latanoprost O
was O
considered O
noninferior O
to O
timolol O
if O
the O
lower O
limit O
of O
the O
95 O
% O
confidence O
interval O
( O
CI O
) O
of O
the O
difference O
was O
> O
-3 O
mmHg O
. O

A O
proportion O
of O
responders O
( O
subjects O
with O
15 O
% O
IOP O
reduction O
at O
weeks O
4 O
and O
12 O
) O
were O
evaluated O
. O

Analyses O
were O
performed O
in O
diagnosis O
subgroups O
: O
primary O
congenital O
glaucoma O
( O
PCG O
) O
and O
non-PCG O
. O

In O
total O
, O
137 O
subjects O
were O
treated O
( O
safety O
population O
";" O
12-18 O
years O
, O
n=48 O
";" O
-3 O
< O
12 O
years O
, O
n=55 O
";" O
0 O
< O
3 O
years O
, O
n=34 O
) O
. O

Mean O
age O
was O
8.8±5.5 O
years O
, O
and O
mean O
baseline O
IOP O
was O
27.7±6.17 O
mmHg O
";" O
125 O
subjects O
completed O
the O
study O
, O
and O
107 O
subjects O
were O
in O
the O
per O
protocol O
population O
. O

Mean B-Premise
IOP I-Premise
reductions I-Premise
for I-Premise
latanoprost I-Premise
and I-Premise
timolol I-Premise
at I-Premise
week I-Premise
12 I-Premise
were I-Premise
7.2 I-Premise
and I-Premise
5.7 I-Premise
mmHg I-Premise
, I-Premise
respectively I-Premise
, I-Premise
with I-Premise
a I-Premise
difference I-Premise
of I-Premise
1.5 I-Premise
mmHg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-0.8 I-Premise
to I-Premise
3.7 I-Premise
";" I-Premise
P=0.21 I-Premise
) I-Premise
. I-Premise

Responder B-Premise
rates I-Premise
were I-Premise
60 I-Premise
% I-Premise
for I-Premise
latanoprost I-Premise
and I-Premise
52 I-Premise
% I-Premise
for I-Premise
timolol I-Premise
( I-Premise
P=0.33 I-Premise
) I-Premise
. I-Premise

Between-treatment B-Premise
differences I-Premise
in I-Premise
mean I-Premise
IOP I-Premise
reduction I-Premise
for I-Premise
PCG I-Premise
and I-Premise
non-PCG I-Premise
subgroups I-Premise
were I-Premise
0.6 I-Premise
mmHg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-2.3 I-Premise
to I-Premise
3.4 I-Premise
) I-Premise
and I-Premise
2.6 I-Premise
mmHg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-0.8 I-Premise
to I-Premise
6.1 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Responder B-Premise
rates I-Premise
for I-Premise
latanoprost I-Premise
versus I-Premise
timolol I-Premise
were I-Premise
50 I-Premise
% I-Premise
versus I-Premise
46 I-Premise
% I-Premise
for I-Premise
the I-Premise
PCG I-Premise
group I-Premise
and I-Premise
72 I-Premise
% I-Premise
versus I-Premise
57 I-Premise
% I-Premise
for I-Premise
the I-Premise
non-PCG I-Premise
group I-Premise
. I-Premise

Both B-Claim
therapies I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Latanoprost B-Claim
0.005 I-Claim
% I-Claim
is I-Claim
not I-Claim
inferior I-Claim
( I-Claim
i.e. I-Claim
, I-Claim
is I-Claim
either I-Claim
more I-Claim
or I-Claim
similarly I-Claim
effective I-Claim
) I-Claim
to I-Claim
timolol I-Claim
and I-Claim
produces I-Claim
clinically I-Claim
relevant I-Claim
IOP I-Claim
reductions I-Claim
across I-Claim
pediatric I-Claim
patients I-Claim
with I-Claim
and I-Claim
without I-Claim
PCG I-Claim
. I-Claim

Both B-Claim
latanoprost I-Claim
and I-Claim
timolol I-Claim
had I-Claim
favorable I-Claim
safety I-Claim
profiles I-Claim
over I-Claim
the I-Claim
duration I-Claim
of I-Claim
this I-Claim
3-month I-Claim
trial I-Claim
. I-Claim

The O
purpose O
of O
this O
study O
is O
to O
compare O
the O
safety O
and O
intraocular O
pressure O
( O
IOP O
) O
-lowering O
efficacy O
of O
travoprost/timolol O
in O
a O
benzalkonium O
chloride O
( O
BAK O
) O
-free O
fixed O
combination O
preserved O
with O
polyquaternium-1 O
( O
TRA/TIM O
BAK-free O
) O
, O
with O
travoprost/timolol-fixed O
combination O
preserved O
with O
BAK O
( O
TRA/TIM O
) O
, O
in O
patients O
with O
open-angle O
glaucoma O
or O
ocular O
hypertension O
. O

In O
this O
prospective O
randomized O
controlled O
trial O
, O
subjects O
with O
IOP O
of O
at O
least O
22 O
mm O
Hg O
in O
one O
or O
both O
eyes O
at O
900 O
h O
, O
and O
IOP O
of O
at O
least O
21 O
mm O
Hg O
in O
one O
or O
both O
eyes O
at O
1100 O
h O
and O
1600 O
h O
at O
two O
eligibility O
visits O
were O
randomly O
assigned O
to O
receive O
either O
TRA/TIM O
BAK-free O
( O
n=195 O
) O
or O
TRA/TIM O
( O
n=193 O
) O
, O
dosed O
once O
daily O
in O
the O
morning O
( O
900 O
h O
) O
for O
6 O
weeks O
. O

IOP O
was O
assessed O
at O
900 O
h O
, O
1100 O
h O
, O
and O
1600 O
h O
at O
each O
scheduled O
visit O
( O
baseline O
, O
2 O
and O
6 O
weeks O
after O
randomization O
) O
. O

Mean B-Premise
IOP I-Premise
reduction I-Premise
across I-Premise
all I-Premise
visits I-Premise
and I-Premise
time I-Premise
points I-Premise
was I-Premise
8.0 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
TRA/TIM I-Premise
BAK-free I-Premise
group I-Premise
and I-Premise
8.4 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
TRA/TIM I-Premise
group I-Premise
( I-Premise
P=0.0943 I-Premise
) I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
mean I-Premise
IOP I-Premise
between I-Premise
groups I-Premise
ranged I-Premise
from I-Premise
0.2 I-Premise
to I-Premise
0.7 I-Premise
mm I-Premise
Hg I-Premise
across I-Premise
visits I-Premise
and I-Premise
time I-Premise
points I-Premise
, I-Premise
with I-Premise
a I-Premise
mean I-Premise
pooled I-Premise
difference I-Premise
of I-Premise
0.4 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
-0.1 I-Premise
to I-Premise
0.8 I-Premise
) I-Premise
, I-Premise
demonstrating O
equivalence O
of O
the O
two O
formulations O
. O

The B-Premise
most I-Premise
common I-Premise
drug-related I-Premise
adverse I-Premise
event I-Premise
was I-Premise
hyperemia I-Premise
of I-Premise
the I-Premise
eye I-Premise
( I-Premise
ocular I-Premise
hyperemia I-Premise
and I-Premise
conjunctival I-Premise
hyperemia I-Premise
combined I-Premise
) I-Premise
, I-Premise
occurring I-Premise
in I-Premise
11.8 I-Premise
% I-Premise
of I-Premise
the I-Premise
TRA/TIM I-Premise
BAK-free I-Premise
group I-Premise
and I-Premise
13.0 I-Premise
% I-Premise
of I-Premise
the I-Premise
TRA/TIM I-Premise
group I-Premise
. I-Premise

Travoprost/timolol B-Claim
BAK-free I-Claim
demonstrated I-Claim
equivalence I-Claim
to I-Claim
travoprost/timolol I-Claim
preserved I-Claim
with I-Claim
BAK I-Claim
in I-Claim
efficacy I-Claim
. I-Claim

No B-Claim
clinically I-Claim
relevant I-Claim
differences I-Claim
in I-Claim
the I-Claim
safety I-Claim
profiles I-Claim
of I-Claim
travoprost/timolol I-Claim
BAK-free I-Claim
and I-Claim
travoprost/timolol I-Claim
preserved I-Claim
with I-Claim
BAK I-Claim
were I-Claim
identified I-Claim
. I-Claim

To O
compare O
the O
effect O
of O
treatment O
with O
latanoprost O
or O
brimonidine O
on O
intraocular O
pressure O
in O
patients O
with O
glaucoma O
or O
ocular O
hypertension O
and O
intraocular O
pressure O
inadequately O
controlled O
by O
monotherapy O
or O
dual O
therapy O
. O

Three O
hundred O
seventy-nine O
patients O
with O
primary O
open-angle O
glaucoma O
or O
ocular O
hypertension O
were O
recruited O
for O
this O
6-month O
prospective O
, O
randomized O
, O
observer-masked O
multicenter O
study O
involving O
30 O
eye O
clinics O
. O

All O
patients O
were O
receiving O
monotherapy O
or O
dual O
therapy O
that O
did O
not O
adequately O
control O
intraocular O
pressure O
. O

After O
appropriate O
washout O
periods O
, O
patients O
were O
randomized O
to O
treatment O
with O
latanoprost O
once O
daily O
or O
brimonidine O
twice O
daily O
. O

The O
main O
outcome O
measure O
was O
change O
in O
mean O
diurnal O
intraocular O
pressure O
after O
6 O
months O
of O
treatment O
compared O
with O
baseline O
. O

Of O
the O
379 O
randomized O
patients O
, O
375 O
were O
included O
in O
the O
intent-to-treat O
analysis O
. O

From B-Premise
an I-Premise
overall I-Premise
baseline I-Premise
mean I-Premise
intraocular I-Premise
pressure I-Premise
of I-Premise
25.0 I-Premise
mm I-Premise
Hg I-Premise
, I-Premise
latanoprost I-Premise
monotherapy I-Premise
reduced I-Premise
mean I-Premise
diurnal I-Premise
intraocular I-Premise
pressure I-Premise
by I-Premise
7.1 I-Premise
+/- I-Premise
3.3 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
mean I-Premise
+/- I-Premise
SD I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
whereas I-Premise
brimonidine I-Premise
monotherapy I-Premise
yielded I-Premise
an I-Premise
intraocular-pressure I-Premise
reduction I-Premise
of I-Premise
5.2 I-Premise
+/- I-Premise
3.5 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

This B-Premise
1.9 I-Premise
mm I-Premise
Hg I-Premise
difference I-Premise
in I-Premise
intraocular-pressure I-Premise
reduction I-Premise
was I-Premise
significantly I-Premise
in I-Premise
favor I-Premise
of I-Premise
latanoprost I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Ocular B-Premise
allergy I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
systemic I-Premise
side I-Premise
effects I-Premise
( I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
were I-Premise
reported I-Premise
significantly I-Premise
less I-Premise
frequently I-Premise
by I-Premise
latanoprost-treated I-Premise
patients I-Premise
compared I-Premise
with I-Premise
brimonidine-treated I-Premise
patients I-Premise
. I-Premise

Both B-Claim
latanoprost I-Claim
and I-Claim
brimonidine I-Claim
reduced I-Claim
intraocular I-Claim
pressure I-Claim
in I-Claim
patients I-Claim
with I-Claim
glaucoma I-Claim
or I-Claim
ocular I-Claim
hypertension I-Claim
after I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
. I-Claim

However B-Claim
, I-Claim
latanoprost I-Claim
once I-Claim
daily I-Claim
was I-Claim
significantly I-Claim
more I-Claim
effective I-Claim
than I-Claim
brimonidine I-Claim
twice I-Claim
daily I-Claim
in I-Claim
reducing I-Claim
mean I-Claim
diurnal I-Claim
intraocular I-Claim
pressure I-Claim
. I-Claim

Latanoprost B-Claim
was I-Claim
better I-Claim
tolerated I-Claim
with I-Claim
less I-Claim
frequently I-Claim
occurring I-Claim
ocular I-Claim
allergy I-Claim
and I-Claim
systemic I-Claim
side I-Claim
effects I-Claim
. I-Claim

To O
assess O
the O
intraocular O
pressure-lowering O
efficacy O
and O
the O
postoperative O
complication O
profile O
of O
viscocanalostomy O
versus O
trabeculectomy O
. O

Sixty O
eyes O
of O
60 O
patients O
with O
medically O
uncontrolled O
open-angle O
glaucoma O
were O
randomized O
either O
to O
the O
viscocanalostomy O
or O
to O
the O
trabeculectomy O
group O
of O
the O
trial O
. O

Viscocanalostomy O
was O
performed O
according O
to O
Stegmann O
's O
technique O
using O
high-molecular-weight O
sodium O
hyaluronate O
to O
fill O
the O
ostia O
of O
the O
Schlemm O
canal O
. O

For O
trabeculectomy O
, O
a O
modified O
Cairns-trabeculectomy O
was O
performed O
. O

Examinations O
were O
performed O
before O
surgery O
and O
postoperatively O
daily O
for O
1 O
week O
. O

Follow-up O
visits O
were O
scheduled O
1 O
, O
6 O
, O
and O
12 O
months O
after O
surgery O
. O

The O
mean O
( O
SD O
) O
preoperative O
intraocular O
pressure O
was O
27.1 O
( O
7.1 O
) O
mm O
Hg O
for O
all O
patients O
enrolled O
. O

One B-Premise
day I-Premise
after I-Premise
surgery I-Premise
, I-Premise
mean I-Premise
( I-Premise
SD I-Premise
) I-Premise
intraocular I-Premise
pressure I-Premise
was I-Premise
15.9 I-Premise
( I-Premise
5.2 I-Premise
) I-Premise
for I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
15.7 I-Premise
( I-Premise
3.6 I-Premise
) I-Premise
for I-Premise
the I-Premise
viscocanalostomy I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
success I-Premise
rate I-Premise
, I-Premise
defined I-Premise
as I-Premise
an I-Premise
intraocular I-Premise
pressure I-Premise
lower I-Premise
than I-Premise
22 I-Premise
mm I-Premise
Hg I-Premise
without I-Premise
medication I-Premise
, I-Premise
was I-Premise
56.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
and I-Premise
30 I-Premise
% I-Premise
in I-Premise
the I-Premise
viscocanalostomy I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
postoperatively I-Premise
( I-Premise
P I-Premise
= I-Premise
0.041 I-Premise
) I-Premise
. I-Premise

The B-Premise
number I-Premise
of I-Premise
postoperative I-Premise
complications I-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
viscocanalostomy I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
. I-Premise

In B-Claim
eyes I-Claim
with I-Claim
open-angle I-Claim
glaucoma I-Claim
, I-Claim
viscocanalostomy I-Claim
is I-Claim
less I-Claim
effective I-Claim
in I-Claim
reducing I-Claim
intraocular I-Claim
pressure I-Claim
than I-Claim
standard I-Claim
filtering I-Claim
surgery I-Claim
. I-Claim

However O
, O
postoperative B-Claim
complications I-Claim
are I-Claim
more I-Claim
frequent I-Claim
after I-Claim
filtering I-Claim
surgery I-Claim
. I-Claim

To O
compare O
the O
intraocular O
pressure O
( O
IOP O
) O
-lowering O
effect O
and O
safety O
of O
latanoprost O
0.005 O
% O
once O
daily O
with O
that O
of O
unoprostone O
0.15 O
% O
twice O
daily O
for O
patients O
with O
primary O
open-angle O
glaucoma O
or O
ocular O
hypertension O
. O

Randomized O
clinical O
trial O
. O

In O
a O
prospective O
, O
8-week O
, O
investigator-masked O
, O
parallel-group O
study O
conducted O
at O
numerous O
centers O
in O
the O
United O
States O
, O
165 O
previously O
treated O
patients O
with O
IOP O
> O
or= O
25 O
mm O
Hg O
in O
one O
or O
both O
eyes O
after O
washout O
were O
randomly O
assigned O
to O
receive O
either O
latanoprost O
0.005 O
% O
once O
daily O
in O
the O
evening O
or O
unoprostone O
0.15 O
% O
twice O
daily O
. O

Observations O
procedures O
were O
Goldmann O
applanation O
tonometry O
, O
best-corrected O
visual O
acuity O
, O
slit O
lamp O
biomicroscopy O
, O
and O
ophthalmoscopy O
. O

The O
main O
outcome O
measure O
was O
change O
in O
the O
mean O
of O
the O
IOPs O
measured O
at O
8:00 O
AM O
, O
12 O
noon O
, O
and O
4:00 O
PM O
between O
baseline O
( O
before O
treatment O
) O
and O
after O
8 O
weeks O
of O
treatment O
. O

The B-Premise
change I-Premise
in I-Premise
the I-Premise
mean I-Premise
+/- I-Premise
SD I-Premise
of I-Premise
the I-Premise
IOPs I-Premise
measured I-Premise
at I-Premise
8:00 I-Premise
AM I-Premise
, I-Premise
12 I-Premise
noon I-Premise
, I-Premise
and I-Premise
4:00 I-Premise
PM I-Premise
was I-Premise
-7.2 I-Premise
+/- I-Premise
3.2 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
28 I-Premise
% I-Premise
) I-Premise
for I-Premise
latanoprost I-Premise
( I-Premise
25.3 I-Premise
+/- I-Premise
2.8 I-Premise
mm I-Premise
Hg I-Premise
at I-Premise
baseline I-Premise
to I-Premise
18.2 I-Premise
+/- I-Premise
2.8 I-Premise
mm I-Premise
Hg I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
) I-Premise
and I-Premise
-3.9 I-Premise
+/- I-Premise
2.6 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
for I-Premise
unoprostone I-Premise
( I-Premise
25.5 I-Premise
+/- I-Premise
3.3 I-Premise
mm I-Premise
Hg I-Premise
at I-Premise
baseline I-Premise
to I-Premise
21.6 I-Premise
+/- I-Premise
4.0 I-Premise
mm I-Premise
Hg I-Premise
";" I-Premise
P I-Premise
< I-Premise
or=.001 I-Premise
. I-Premise

No B-Premise
serious I-Premise
adverse I-Premise
event I-Premise
related I-Premise
to I-Premise
either I-Premise
medication I-Premise
was I-Premise
reported I-Premise
. I-Premise

Over B-Claim
an I-Claim
8-week I-Claim
period I-Claim
, I-Claim
latanoprost I-Claim
0.005 I-Claim
% I-Claim
once I-Claim
daily I-Claim
lowered I-Claim
IOP I-Claim
more I-Claim
than I-Claim
unoprostone I-Claim
0.15 I-Claim
% I-Claim
twice I-Claim
daily I-Claim
in I-Claim
patients I-Claim
with I-Claim
elevated I-Claim
IOP I-Claim
. I-Claim

Both B-Claim
agents I-Claim
were I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

To O
compare O
viscocanalostomy O
, O
a O
nonpenetrating O
procedure O
for O
glaucoma O
treatment O
, O
with O
trabeculectomy O
. O

Randomized O
controlled O
trial O
. O

Twenty O
white O
subjects O
( O
20 O
eyes O
) O
with O
open-angle O
glaucoma O
with O
no O
history O
of O
surgery O
were O
enrolled O
. O

Ten O
subjects O
were O
randomly O
assigned O
to O
viscocanalostomy O
according O
to O
Stegmann O
's O
technique O
and O
10 O
subjects O
to O
a O
modified O
Cairns O
trabeculectomy O
. O

A O
complete O
ophthalmologic O
examination O
was O
performed O
the O
day O
before O
surgery O
and O
postoperatively O
. O

Further O
visits O
were O
scheduled O
monthly O
for O
6 O
to O
8 O
months O
after O
surgery O
. O

Success O
was O
defined O
as O
intraocular O
pressure O
( O
IOP O
) O
between O
7 O
and O
20 O
mmHg O
, O
with O
no O
medication O
. O

After B-Premise
a I-Premise
mean I-Premise
follow-up I-Premise
of I-Premise
6 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
6-8 I-Premise
months I-Premise
) I-Premise
, I-Premise
success I-Premise
was I-Premise
obtained I-Premise
in I-Premise
5 I-Premise
of I-Premise
10 I-Premise
cases I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
and I-Premise
in I-Premise
0 I-Premise
of I-Premise
10 I-Premise
case I-Premise
in I-Premise
the I-Premise
viscocanalostomy I-Premise
group I-Premise
. I-Premise

With B-Premise
Kaplan-Meier I-Premise
's I-Premise
method I-Premise
, I-Premise
subjects I-Premise
with I-Premise
viscocanalostomy I-Premise
showed I-Premise
shorter I-Premise
postoperative I-Premise
IOP-reduction I-Premise
periods I-Premise
than I-Premise
subjects I-Premise
undergoing I-Premise
trabeculectomy I-Premise
. I-Premise

According B-Claim
to I-Claim
the I-Claim
results I-Claim
of I-Claim
this I-Claim
short-term I-Claim
study I-Claim
, I-Claim
trabeculectomy I-Claim
was I-Claim
more I-Claim
effective I-Claim
than I-Claim
viscocanalostomy I-Claim
in I-Claim
lowering I-Claim
IOP I-Claim
in I-Claim
glaucomatous I-Claim
eyes I-Claim
of I-Claim
white I-Claim
patients I-Claim
. I-Claim

To O
compare O
outcomes O
of O
selective O
laser O
trabeculoplasty O
( O
SLT O
) O
with O
drug O
therapy O
for O
glaucoma O
patients O
in O
a O
prospective O
randomized O
clinical O
trial O
. O

Sixty-nine O
patients O
( O
127 O
eyes O
) O
with O
open-angle O
glaucoma O
or O
ocular O
hypertension O
were O
randomized O
to O
SLT O
or O
medical O
therapy O
. O

Target O
intraocular O
pressure O
( O
IOP O
) O
was O
determined O
using O
the O
Collaborative O
Initial O
Glaucoma O
Treatment O
Study O
formula O
. O

Patients O
were O
treated O
with O
SLT O
( O
100 O
applications O
360 O
degrees O
) O
or O
medical O
therapy O
( O
prostaglandin O
analog O
) O
. O

Six O
visits O
over O
1 O
year O
followed O
initial O
treatment O
. O

If O
target O
IOP O
range O
was O
not O
attained O
with O
SLT O
, O
additional O
SLT O
was O
the O
next O
step O
, O
or O
in O
the O
medical O
arm O
additional O
medications O
were O
added O
. O

Primary O
outcome O
: O
IOP O
";" O
secondary O
: O
number O
of O
steps O
. O

Sixty-nine O
patients O
were O
treated O
. O

Data O
collection O
terminated O
with O
54 O
patients O
reaching O
9 O
to O
12-months O
follow-up O
. O

Twenty-nine O
patients O
were O
in O
the O
SLT O
group O
, O
25 O
patients O
in O
the O
medical O
group O
. O

Baseline B-Premise
mean I-Premise
IOP I-Premise
for I-Premise
all I-Premise
eyes I-Premise
was I-Premise
24.5 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
SLT I-Premise
group I-Premise
, I-Premise
24.7 I-Premise
mm I-Premise
Hg I-Premise
in I-Premise
the I-Premise
medical I-Premise
group I-Premise
. I-Premise
Mean I-Premise
IOP I-Premise
( I-Premise
both I-Premise
eyes I-Premise
) I-Premise
at I-Premise
last I-Premise
follow-up I-Premise
was I-Premise
18.2 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
6.3 I-Premise
mm I-Premise
Hg I-Premise
reduction I-Premise
) I-Premise
in I-Premise
the I-Premise
SLT I-Premise
arm I-Premise
, I-Premise
17.7 I-Premise
mm I-Premise
Hg I-Premise
( I-Premise
7.0 I-Premise
mm I-Premise
Hg I-Premise
reduction I-Premise
) I-Premise
in I-Premise
the I-Premise
medical I-Premise
arm I-Premise
. I-Premise

By B-Premise
last I-Premise
follow-up I-Premise
, I-Premise
11 I-Premise
% I-Premise
of I-Premise
eyes I-Premise
received I-Premise
additional I-Premise
SLT I-Premise
, I-Premise
27 I-Premise
% I-Premise
required I-Premise
additional I-Premise
medication I-Premise
. I-Premise

There B-Premise
was I-Premise
not I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
SLT I-Premise
and I-Premise
medication I-Premise
groups I-Premise
. I-Premise

IOP B-Premise
reduction I-Premise
was I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
after I-Premise
9 I-Premise
to I-Premise
12-months I-Premise
follow-up I-Premise
. I-Premise

More O
treatment O
steps O
were O
necessary O
to O
maintain O
target O
IOP O
in O
the O
medication O
group O
, O
although O
there O
was O
not O
a O
statistically O
significant O
difference O
between O
groups O
. O

These B-Claim
results I-Claim
support I-Claim
the I-Claim
option I-Claim
of I-Claim
SLT I-Claim
as I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
initial I-Claim
therapy I-Claim
in I-Claim
open-angle I-Claim
glaucoma I-Claim
or I-Claim
ocular I-Claim
hypertension I-Claim
. I-Claim

To O
compare O
the O
efficacy O
and O
safety O
of O
viscocanalostomy O
and O
trabeculectomy O
in O
patients O
with O
primary O
open-angle O
glaucoma O
( O
POAG O
) O
. O

Department O
of O
Ophthalmology O
, O
Ankara O
Education O
and O
Research O
Hospital O
, O
Ankara O
, O
Turkey O
. O

In O
this O
prospective O
randomized O
trial O
, O
50 O
eyes O
of O
50 O
patients O
with O
medically O
uncontrolled O
POAG O
were O
randomized O
to O
have O
a O
trabeculectomy O
( O
25 O
eyes O
) O
or O
a O
viscocanalostomy O
( O
25 O
eyes O
) O
. O

Visual O
acuity O
, O
intraocular O
pressure O
( O
IOP O
) O
, O
and O
slitlamp O
examinations O
were O
performed O
before O
surgery O
and O
1 O
day O
, O
1 O
week O
, O
1 O
, O
3 O
, O
and O
6 O
months O
, O
and O
1 O
, O
2 O
, O
and O
3 O
years O
postoperatively O
. O

At B-Premise
3 I-Premise
years I-Premise
, I-Premise
the I-Premise
mean I-Premise
IOP I-Premise
was I-Premise
16.0 I-Premise
mmHg I-Premise
+/- I-Premise
7.07 I-Premise
( I-Premise
SD I-Premise
) I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
and I-Premise
17.8 I-Premise
+/- I-Premise
4.6 I-Premise
mmHg I-Premise
in I-Premise
the I-Premise
viscocanalostomy I-Premise
group I-Premise
( I-Premise
P=.694 I-Premise
) I-Premise
. I-Premise

Complete B-Premise
success I-Premise
( I-Premise
IOP I-Premise
6 I-Premise
to I-Premise
21 I-Premise
mm I-Premise
Hg I-Premise
without I-Premise
medication I-Premise
) I-Premise
was I-Premise
achieved I-Premise
in I-Premise
66.2 I-Premise
% I-Premise
of I-Premise
eyes I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
55.1 I-Premise
% I-Premise
at I-Premise
3 I-Premise
years I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
and I-Premise
in I-Premise
52.9 I-Premise
% I-Premise
and I-Premise
35.3 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
the I-Premise
viscocanalostomy I-Premise
group I-Premise
( I-Premise
P I-Premise
> I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Qualified B-Premise
success I-Premise
( I-Premise
IOP I-Premise
6 I-Premise
to I-Premise
21 I-Premise
mmHg I-Premise
with I-Premise
medication I-Premise
) I-Premise
was I-Premise
achieved I-Premise
in I-Premise
95.8 I-Premise
% I-Premise
of I-Premise
eyes I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
79.2 I-Premise
% I-Premise
at I-Premise
3 I-Premise
years I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
and I-Premise
in I-Premise
90.7 I-Premise
% I-Premise
and I-Premise
73.9 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
the I-Premise
viscocanalostomy I-Premise
group I-Premise
( I-Premise
P I-Premise
> I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Postoperative B-Premise
hypotony I-Premise
and I-Premise
cataract I-Premise
formation I-Premise
occurred I-Premise
more I-Premise
frequently I-Premise
in I-Premise
the I-Premise
trabeculectomy I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
viscocanalostomy I-Premise
group I-Premise
( I-Premise
P=.002 I-Premise
) I-Premise
. I-Premise

Primary B-Claim
trabeculectomy I-Claim
lowered I-Claim
IOP I-Claim
more I-Claim
than I-Claim
viscocanalostomy I-Claim
in I-Claim
POAG I-Claim
patients I-Claim
. I-Claim

However O
, O
the B-Claim
complication I-Claim
rate I-Claim
was I-Claim
lower I-Claim
in I-Claim
the I-Claim
viscocanalostomy I-Claim
group I-Claim
. I-Claim

To O
investigate O
risk O
factors O
associated O
with O
visual O
field O
progression O
in O
the O
Low-pressure O
Glaucoma O
Treatment O
Study O
, O
a O
prospective O
trial O
designed O
to O
compare O
the O
effects O
of O
the O
alpha2-adrenergic O
agonist O
brimonidine O
tartrate O
0.2 O
% O
to O
the O
beta-adrenergic O
antagonist O
timolol O
maleate O
0.5 O
% O
on O
visual O
function O
in O
low-pressure O
glaucoma O
. O

Prospective O
cohort O
study O
. O

Low-pressure O
Glaucoma O
Treatment O
Study O
patients O
with O
>=5 O
visual O
field O
tests O
during O
follow-up O
were O
included O
. O

Progression O
was O
determined O
using O
pointwise O
linear O
regression O
analysis O
, O
defined O
as O
the O
same O
3 O
or O
more O
visual O
field O
locations O
with O
a O
slope O
more O
negative O
than O
-1.0 O
dB/year O
at O
P O
< O
5 O
% O
, O
on O
3 O
consecutive O
tests O
. O

Ocular O
and O
systemic O
risk O
factors O
were O
analyzed O
using O
Cox O
proportional O
hazards O
model O
and O
further O
tested O
for O
independence O
in O
a O
multivariate O
model O
. O

A O
total O
of O
253 O
eyes O
of O
127 O
subjects O
( O
mean O
age O
, O
64.7 O
10.9 O
years O
";" O
mean O
follow-up O
, O
40.6 O
12 O
months O
) O
were O
analyzed O
. O

Eyes B-Premise
randomized I-Premise
to I-Premise
timolol I-Premise
progressed I-Premise
faster I-Premise
than I-Premise
those I-Premise
randomized I-Premise
to I-Premise
brimonidine I-Premise
( I-Premise
mean I-Premise
rates I-Premise
of I-Premise
progression I-Premise
, I-Premise
-0.38 I-Premise
0.9 I-Premise
vs I-Premise
0.02 I-Premise
0.7 I-Premise
dB/y I-Premise
, I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

In O
the O
final O
multivariate O
model O
adjusting O
for O
all O
tested O
covariates O
, O
older B-Premise
age I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
1.41/decade I-Premise
older I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
1.05 I-Premise
to I-Premise
1.90 I-Premise
, I-Premise
P I-Premise
= I-Premise
.022 I-Premise
) I-Premise
, I-Premise
use I-Premise
of I-Premise
systemic I-Premise
antihypertensives I-Premise
( I-Premise
HR I-Premise
= I-Premise
2.53 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1.32 I-Premise
to I-Premise
4.87 I-Premise
, I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
, I-Premise
and I-Premise
mean I-Premise
ocular I-Premise
perfusion I-Premise
pressure I-Premise
( I-Premise
HR I-Premise
= I-Premise
1.21/mm I-Premise
Hg I-Premise
lower I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1.12 I-Premise
to I-Premise
1.31 I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
were I-Premise
associated I-Premise
with I-Premise
progression I-Premise
whereas O
randomization B-Premise
to I-Premise
brimonidine I-Premise
revealed I-Premise
a I-Premise
protective I-Premise
effect I-Premise
( I-Premise
HR I-Premise
= I-Premise
0.26 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.12 I-Premise
to I-Premise
0.55 I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

While O
randomization B-Premise
to I-Premise
brimonidine I-Premise
0.2 I-Premise
% I-Premise
was I-Premise
protective I-Premise
compared I-Premise
to I-Premise
timolol I-Premise
0.5 I-Premise
% I-Premise
, I-Premise
lower B-Premise
mean I-Premise
ocular I-Premise
perfusion I-Premise
pressure I-Premise
increased I-Premise
the I-Premise
risk I-Premise
for I-Premise
reaching I-Premise
a I-Premise
progression I-Premise
outcome I-Premise
in I-Premise
the I-Premise
Low-pressure I-Premise
Glaucoma I-Premise
Treatment I-Premise
Study I-Premise
. I-Premise

This B-Claim
suggests I-Claim
that I-Claim
the I-Claim
beneficial I-Claim
effect I-Claim
of I-Claim
randomization I-Claim
to I-Claim
the I-Claim
brimonidine I-Claim
arm I-Claim
was I-Claim
independent I-Claim
of I-Claim
possible I-Claim
differences I-Claim
in I-Claim
ocular I-Claim
perfusion I-Claim
pressures I-Claim
between I-Claim
the I-Claim
2 I-Claim
treatment I-Claim
arms I-Claim
. I-Claim

The B-Claim
current I-Claim
results I-Claim
and I-Claim
large I-Claim
number I-Claim
of I-Claim
drop-outs I-Claim
in I-Claim
the I-Claim
brimonidine I-Claim
0.2 I-Claim
% I-Claim
arm I-Claim
suggest I-Claim
that I-Claim
more I-Claim
research I-Claim
is I-Claim
necessary I-Claim
before I-Claim
altering I-Claim
clinical I-Claim
practice I-Claim
paradigms I-Claim
. I-Claim

To O
compare O
the O
effect O
of O
time O
on O
therapy O
, O
efficacy O
, O
tolerability O
and O
resource O
utilization O
of O
latanoprost O
or O
non-prostaglandin O
analogues O
( O
non-PGs O
) O
in O
patients O
who O
required O
a O
change O
in O
intraocular O
pressure O
( O
IOP O
) O
-lowering O
monotherapy O
. O

This O
open-label O
, O
multicentre O
study O
( O
Sweden O
, O
19 O
sites O
";" O
Finland O
, O
seven O
sites O
) O
included O
adults O
with O
glaucoma O
or O
ocular O
hypertension O
with O
mean O
diurnal O
IOP O
> O
or O
= O
21 O
mmHg O
on O
ocular O
hypotensive O
monotherapy O
. O

Patients O
were O
randomized O
to O
latanoprost O
monotherapy O
or O
non-PG O
therapy O
( O
commercially O
available O
therapy O
other O
than O
a O
PG O
) O
and O
followed O
for O
36 O
months O
. O

End-points O
included O
: O
time O
to O
treatment O
failure O
( O
baseline O
to O
visit O
with O
a O
change O
in/addition O
to O
treatment O
) O
";" O
diurnal O
IOP O
( O
mean O
of O
08.00 O
, O
12.00 O
and O
16:00 O
hr O
measurements O
) O
at O
months O
6 O
, O
12 O
, O
24 O
and O
36 O
";" O
tolerability O
";" O
and O
resource O
utilization O
, O
where O
analyses O
used O
Swedish O
and O
Finnish O
2006 O
unit O
costs O
. O

Three O
hundred O
and O
twenty-six O
patients O
received O
> O
or O
= O
1 O
dose O
of O
latanoprost O
( O
n O
= O
162 O
) O
or O
non-PGs O
( O
n O
= O
164 O
) O
. O

Median O
time O
to O
treatment O
failure O
was O
longer O
for O
latanoprost O
( O
36 O
months O
) O
than O
for O
non-PGs O
( O
12 O
months O
";" O
p O
< O
0.001 O
) O
";" O
51 O
% O
and O
24 O
% O
of O
patients O
remained O
on O
randomized O
therapy O
after O
36 O
months O
, O
respectively O
( O
p O
< O
0.001 O
) O
. O

Decreases B-Premise
in I-Premise
mean I-Premise
diurnal I-Premise
IOP I-Premise
from I-Premise
baseline I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
for I-Premise
latanoprost I-Premise
than I-Premise
for I-Premise
non-PGs I-Premise
at I-Premise
months I-Premise
6 I-Premise
and I-Premise
12 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

No B-Premise
serious I-Premise
adverse I-Premise
events I-Premise
were I-Premise
judged I-Premise
to I-Premise
be I-Premise
treatment-related I-Premise
. O

Mean B-Premise
total I-Premise
36-month I-Premise
direct I-Premise
costs I-Premise
were I-Premise
similar I-Premise
in I-Premise
patients I-Premise
initiated I-Premise
with I-Premise
latanoprost I-Premise
and I-Premise
non-PGs I-Premise
. I-Premise

Patients B-Premise
who I-Premise
failed I-Premise
previous I-Premise
monotherapy I-Premise
remained I-Premise
on I-Premise
therapy I-Premise
longer I-Premise
when I-Premise
switched I-Premise
to I-Premise
latanoprost I-Premise
. I-Premise

The B-Claim
IOP-reducing I-Claim
effect I-Claim
of I-Claim
latanoprost I-Claim
and I-Claim
tolerability I-Claim
were I-Claim
sustained I-Claim
over I-Claim
the I-Claim
long I-Claim
term I-Claim
. I-Claim

Resource B-Claim
utilization I-Claim
and I-Claim
costs I-Claim
were I-Claim
generally I-Claim
similar I-Claim
in I-Claim
those I-Claim
initiating I-Claim
latanoprost I-Claim
or I-Claim
non-PG I-Claim
therapy I-Claim
. I-Claim

